/*! For license information please see main.3b845206.js.LICENSE.txt */
!function(){var e={76:function(e,t,n){"use strict";n.d(t,{Z:function(){return ae}});var r=function(){function e(e){var t=this;this._insertTag=function(e){var n;n=0===t.tags.length?t.insertionPoint?t.insertionPoint.nextSibling:t.prepend?t.container.firstChild:t.before:t.tags[t.tags.length-1].nextSibling,t.container.insertBefore(e,n),t.tags.push(e)},this.isSpeedy=void 0===e.speedy||e.speedy,this.tags=[],this.ctr=0,this.nonce=e.nonce,this.key=e.key,this.container=e.container,this.prepend=e.prepend,this.insertionPoint=e.insertionPoint,this.before=null}var t=e.prototype;return t.hydrate=function(e){e.forEach(this._insertTag)},t.insert=function(e){this.ctr%(this.isSpeedy?65e3:1)===0&&this._insertTag(function(e){var t=document.createElement("style");return t.setAttribute("data-emotion",e.key),void 0!==e.nonce&&t.setAttribute("nonce",e.nonce),t.appendChild(document.createTextNode("")),t.setAttribute("data-s",""),t}(this));var t=this.tags[this.tags.length-1];if(this.isSpeedy){var n=function(e){if(e.sheet)return e.sheet;for(var t=0;t<document.styleSheets.length;t++)if(document.styleSheets[t].ownerNode===e)return document.styleSheets[t]}(t);try{n.insertRule(e,n.cssRules.length)}catch(r){0}}else t.appendChild(document.createTextNode(e));this.ctr++},t.flush=function(){this.tags.forEach((function(e){return e.parentNode&&e.parentNode.removeChild(e)})),this.tags=[],this.ctr=0},e}(),a=Math.abs,o=String.fromCharCode,i=Object.assign;function s(e){return e.trim()}function l(e,t,n){return e.replace(t,n)}function u(e,t){return e.indexOf(t)}function c(e,t){return 0|e.charCodeAt(t)}function d(e,t,n){return e.slice(t,n)}function p(e){return e.length}function f(e){return e.length}function m(e,t){return t.push(e),e}var h=1,v=1,y=0,b=0,g=0,_="";function w(e,t,n,r,a,o,i){return{value:e,root:t,parent:n,type:r,props:a,children:o,line:h,column:v,length:i,return:""}}function S(e,t){return i(w("",null,null,"",null,null,0),e,{length:-e.length},t)}function T(){return g=b>0?c(_,--b):0,v--,10===g&&(v=1,h--),g}function C(){return g=b<y?c(_,b++):0,v++,10===g&&(v=1,h++),g}function k(){return c(_,b)}function A(){return b}function x(e,t){return d(_,e,t)}function F(e){switch(e){case 0:case 9:case 10:case 13:case 32:return 5;case 33:case 43:case 44:case 47:case 62:case 64:case 126:case 59:case 123:case 125:return 4;case 58:return 3;case 34:case 39:case 40:case 91:return 2;case 41:case 93:return 1}return 0}function R(e){return h=v=1,y=p(_=e),b=0,[]}function P(e){return _="",e}function E(e){return s(x(b-1,I(91===e?e+2:40===e?e+1:e)))}function O(e){for(;(g=k())&&g<33;)C();return F(e)>2||F(g)>3?"":" "}function N(e,t){for(;--t&&C()&&!(g<48||g>102||g>57&&g<65||g>70&&g<97););return x(e,A()+(t<6&&32==k()&&32==C()))}function I(e){for(;C();)switch(g){case e:return b;case 34:case 39:34!==e&&39!==e&&I(g);break;case 40:41===e&&I(e);break;case 92:C()}return b}function M(e,t){for(;C()&&e+g!==57&&(e+g!==84||47!==k()););return"/*"+x(t,b-1)+"*"+o(47===e?e:C())}function z(e){for(;!F(k());)C();return x(e,b)}var D="-ms-",L="-moz-",Z="-webkit-",j="comm",B="rule",W="decl",J="@keyframes";function U(e,t){for(var n="",r=f(e),a=0;a<r;a++)n+=t(e[a],a,e,t)||"";return n}function V(e,t,n,r){switch(e.type){case"@import":case W:return e.return=e.return||e.value;case j:return"";case J:return e.return=e.value+"{"+U(e.children,r)+"}";case B:e.value=e.props.join(",")}return p(n=U(e.children,r))?e.return=e.value+"{"+n+"}":""}function $(e,t){switch(function(e,t){return(((t<<2^c(e,0))<<2^c(e,1))<<2^c(e,2))<<2^c(e,3)}(e,t)){case 5103:return Z+"print-"+e+e;case 5737:case 4201:case 3177:case 3433:case 1641:case 4457:case 2921:case 5572:case 6356:case 5844:case 3191:case 6645:case 3005:case 6391:case 5879:case 5623:case 6135:case 4599:case 4855:case 4215:case 6389:case 5109:case 5365:case 5621:case 3829:return Z+e+e;case 5349:case 4246:case 4810:case 6968:case 2756:return Z+e+L+e+D+e+e;case 6828:case 4268:return Z+e+D+e+e;case 6165:return Z+e+D+"flex-"+e+e;case 5187:return Z+e+l(e,/(\w+).+(:[^]+)/,"-webkit-box-$1$2-ms-flex-$1$2")+e;case 5443:return Z+e+D+"flex-item-"+l(e,/flex-|-self/,"")+e;case 4675:return Z+e+D+"flex-line-pack"+l(e,/align-content|flex-|-self/,"")+e;case 5548:return Z+e+D+l(e,"shrink","negative")+e;case 5292:return Z+e+D+l(e,"basis","preferred-size")+e;case 6060:return Z+"box-"+l(e,"-grow","")+Z+e+D+l(e,"grow","positive")+e;case 4554:return Z+l(e,/([^-])(transform)/g,"$1-webkit-$2")+e;case 6187:return l(l(l(e,/(zoom-|grab)/,Z+"$1"),/(image-set)/,Z+"$1"),e,"")+e;case 5495:case 3959:return l(e,/(image-set\([^]*)/,Z+"$1$`$1");case 4968:return l(l(e,/(.+:)(flex-)?(.*)/,"-webkit-box-pack:$3-ms-flex-pack:$3"),/s.+-b[^;]+/,"justify")+Z+e+e;case 4095:case 3583:case 4068:case 2532:return l(e,/(.+)-inline(.+)/,Z+"$1$2")+e;case 8116:case 7059:case 5753:case 5535:case 5445:case 5701:case 4933:case 4677:case 5533:case 5789:case 5021:case 4765:if(p(e)-1-t>6)switch(c(e,t+1)){case 109:if(45!==c(e,t+4))break;case 102:return l(e,/(.+:)(.+)-([^]+)/,"$1-webkit-$2-$3$1"+L+(108==c(e,t+3)?"$3":"$2-$3"))+e;case 115:return~u(e,"stretch")?$(l(e,"stretch","fill-available"),t)+e:e}break;case 4949:if(115!==c(e,t+1))break;case 6444:switch(c(e,p(e)-3-(~u(e,"!important")&&10))){case 107:return l(e,":",":"+Z)+e;case 101:return l(e,/(.+:)([^;!]+)(;|!.+)?/,"$1"+Z+(45===c(e,14)?"inline-":"")+"box$3$1"+Z+"$2$3$1"+D+"$2box$3")+e}break;case 5936:switch(c(e,t+11)){case 114:return Z+e+D+l(e,/[svh]\w+-[tblr]{2}/,"tb")+e;case 108:return Z+e+D+l(e,/[svh]\w+-[tblr]{2}/,"tb-rl")+e;case 45:return Z+e+D+l(e,/[svh]\w+-[tblr]{2}/,"lr")+e}return Z+e+D+e+e}return e}function H(e){return P(G("",null,null,null,[""],e=R(e),0,[0],e))}function G(e,t,n,r,a,i,s,c,d){for(var f=0,h=0,v=s,y=0,b=0,g=0,_=1,w=1,S=1,x=0,F="",R=a,P=i,I=r,D=F;w;)switch(g=x,x=C()){case 40:if(108!=g&&58==D.charCodeAt(v-1)){-1!=u(D+=l(E(x),"&","&\f"),"&\f")&&(S=-1);break}case 34:case 39:case 91:D+=E(x);break;case 9:case 10:case 13:case 32:D+=O(g);break;case 92:D+=N(A()-1,7);continue;case 47:switch(k()){case 42:case 47:m(K(M(C(),A()),t,n),d);break;default:D+="/"}break;case 123*_:c[f++]=p(D)*S;case 125*_:case 59:case 0:switch(x){case 0:case 125:w=0;case 59+h:b>0&&p(D)-v&&m(b>32?Q(D+";",r,n,v-1):Q(l(D," ","")+";",r,n,v-2),d);break;case 59:D+=";";default:if(m(I=q(D,t,n,f,h,a,c,F,R=[],P=[],v),i),123===x)if(0===h)G(D,t,I,I,R,i,v,c,P);else switch(y){case 100:case 109:case 115:G(e,I,I,r&&m(q(e,I,I,0,0,a,c,F,a,R=[],v),P),a,P,v,c,r?R:P);break;default:G(D,I,I,I,[""],P,0,c,P)}}f=h=b=0,_=S=1,F=D="",v=s;break;case 58:v=1+p(D),b=g;default:if(_<1)if(123==x)--_;else if(125==x&&0==_++&&125==T())continue;switch(D+=o(x),x*_){case 38:S=h>0?1:(D+="\f",-1);break;case 44:c[f++]=(p(D)-1)*S,S=1;break;case 64:45===k()&&(D+=E(C())),y=k(),h=v=p(F=D+=z(A())),x++;break;case 45:45===g&&2==p(D)&&(_=0)}}return i}function q(e,t,n,r,o,i,u,c,p,m,h){for(var v=o-1,y=0===o?i:[""],b=f(y),g=0,_=0,S=0;g<r;++g)for(var T=0,C=d(e,v+1,v=a(_=u[g])),k=e;T<b;++T)(k=s(_>0?y[T]+" "+C:l(C,/&\f/g,y[T])))&&(p[S++]=k);return w(e,t,n,0===o?B:c,p,m,h)}function K(e,t,n){return w(e,t,n,j,o(g),d(e,2,-2),0)}function Q(e,t,n,r){return w(e,t,n,W,d(e,0,r),d(e,r+1,-1),r)}var X=function(e,t,n){for(var r=0,a=0;r=a,a=k(),38===r&&12===a&&(t[n]=1),!F(a);)C();return x(e,b)},Y=function(e,t){return P(function(e,t){var n=-1,r=44;do{switch(F(r)){case 0:38===r&&12===k()&&(t[n]=1),e[n]+=X(b-1,t,n);break;case 2:e[n]+=E(r);break;case 4:if(44===r){e[++n]=58===k()?"&\f":"",t[n]=e[n].length;break}default:e[n]+=o(r)}}while(r=C());return e}(R(e),t))},ee=new WeakMap,te=function(e){if("rule"===e.type&&e.parent&&!(e.length<1)){for(var t=e.value,n=e.parent,r=e.column===n.column&&e.line===n.line;"rule"!==n.type;)if(!(n=n.parent))return;if((1!==e.props.length||58===t.charCodeAt(0)||ee.get(n))&&!r){ee.set(e,!0);for(var a=[],o=Y(t,a),i=n.props,s=0,l=0;s<o.length;s++)for(var u=0;u<i.length;u++,l++)e.props[l]=a[s]?o[s].replace(/&\f/g,i[u]):i[u]+" "+o[s]}}},ne=function(e){if("decl"===e.type){var t=e.value;108===t.charCodeAt(0)&&98===t.charCodeAt(2)&&(e.return="",e.value="")}},re=[function(e,t,n,r){if(e.length>-1&&!e.return)switch(e.type){case W:e.return=$(e.value,e.length);break;case J:return U([S(e,{value:l(e.value,"@","@"+Z)})],r);case B:if(e.length)return function(e,t){return e.map(t).join("")}(e.props,(function(t){switch(function(e,t){return(e=t.exec(e))?e[0]:e}(t,/(::plac\w+|:read-\w+)/)){case":read-only":case":read-write":return U([S(e,{props:[l(t,/:(read-\w+)/,":-moz-$1")]})],r);case"::placeholder":return U([S(e,{props:[l(t,/:(plac\w+)/,":-webkit-input-$1")]}),S(e,{props:[l(t,/:(plac\w+)/,":-moz-$1")]}),S(e,{props:[l(t,/:(plac\w+)/,D+"input-$1")]})],r)}return""}))}}],ae=function(e){var t=e.key;if("css"===t){var n=document.querySelectorAll("style[data-emotion]:not([data-s])");Array.prototype.forEach.call(n,(function(e){-1!==e.getAttribute("data-emotion").indexOf(" ")&&(document.head.appendChild(e),e.setAttribute("data-s",""))}))}var a=e.stylisPlugins||re;var o,i,s={},l=[];o=e.container||document.head,Array.prototype.forEach.call(document.querySelectorAll('style[data-emotion^="'+t+' "]'),(function(e){for(var t=e.getAttribute("data-emotion").split(" "),n=1;n<t.length;n++)s[t[n]]=!0;l.push(e)}));var u,c,d=[V,(c=function(e){u.insert(e)},function(e){e.root||(e=e.return)&&c(e)})],p=function(e){var t=f(e);return function(n,r,a,o){for(var i="",s=0;s<t;s++)i+=e[s](n,r,a,o)||"";return i}}([te,ne].concat(a,d));i=function(e,t,n,r){u=n,U(H(e?e+"{"+t.styles+"}":t.styles),p),r&&(m.inserted[t.name]=!0)};var m={key:t,sheet:new r({key:t,container:o,nonce:e.nonce,speedy:e.speedy,prepend:e.prepend,insertionPoint:e.insertionPoint}),nonce:e.nonce,inserted:s,registered:{},insert:i};return m.sheet.hydrate(l),m}},9797:function(e,t){"use strict";t.Z=function(e){var t=Object.create(null);return function(n){return void 0===t[n]&&(t[n]=e(n)),t[n]}}},9886:function(e,t,n){"use strict";n.d(t,{T:function(){return s},w:function(){return i}});var r=n(2791),a=n(76),o=(n(9140),n(2561),(0,r.createContext)("undefined"!==typeof HTMLElement?(0,a.Z)({key:"css"}):null));o.Provider;var i=function(e){return(0,r.forwardRef)((function(t,n){var a=(0,r.useContext)(o);return e(t,a,n)}))},s=(0,r.createContext)({})},9140:function(e,t,n){"use strict";n.d(t,{O:function(){return h}});var r=function(e){for(var t,n=0,r=0,a=e.length;a>=4;++r,a-=4)t=1540483477*(65535&(t=255&e.charCodeAt(r)|(255&e.charCodeAt(++r))<<8|(255&e.charCodeAt(++r))<<16|(255&e.charCodeAt(++r))<<24))+(59797*(t>>>16)<<16),n=1540483477*(65535&(t^=t>>>24))+(59797*(t>>>16)<<16)^1540483477*(65535&n)+(59797*(n>>>16)<<16);switch(a){case 3:n^=(255&e.charCodeAt(r+2))<<16;case 2:n^=(255&e.charCodeAt(r+1))<<8;case 1:n=1540483477*(65535&(n^=255&e.charCodeAt(r)))+(59797*(n>>>16)<<16)}return(((n=1540483477*(65535&(n^=n>>>13))+(59797*(n>>>16)<<16))^n>>>15)>>>0).toString(36)},a={animationIterationCount:1,borderImageOutset:1,borderImageSlice:1,borderImageWidth:1,boxFlex:1,boxFlexGroup:1,boxOrdinalGroup:1,columnCount:1,columns:1,flex:1,flexGrow:1,flexPositive:1,flexShrink:1,flexNegative:1,flexOrder:1,gridRow:1,gridRowEnd:1,gridRowSpan:1,gridRowStart:1,gridColumn:1,gridColumnEnd:1,gridColumnSpan:1,gridColumnStart:1,msGridRow:1,msGridRowSpan:1,msGridColumn:1,msGridColumnSpan:1,fontWeight:1,lineHeight:1,opacity:1,order:1,orphans:1,tabSize:1,widows:1,zIndex:1,zoom:1,WebkitLineClamp:1,fillOpacity:1,floodOpacity:1,stopOpacity:1,strokeDasharray:1,strokeDashoffset:1,strokeMiterlimit:1,strokeOpacity:1,strokeWidth:1},o=n(9797),i=/[A-Z]|^ms/g,s=/_EMO_([^_]+?)_([^]*?)_EMO_/g,l=function(e){return 45===e.charCodeAt(1)},u=function(e){return null!=e&&"boolean"!==typeof e},c=(0,o.Z)((function(e){return l(e)?e:e.replace(i,"-$&").toLowerCase()})),d=function(e,t){switch(e){case"animation":case"animationName":if("string"===typeof t)return t.replace(s,(function(e,t,n){return f={name:t,styles:n,next:f},t}))}return 1===a[e]||l(e)||"number"!==typeof t||0===t?t:t+"px"};function p(e,t,n){if(null==n)return"";if(void 0!==n.__emotion_styles)return n;switch(typeof n){case"boolean":return"";case"object":if(1===n.anim)return f={name:n.name,styles:n.styles,next:f},n.name;if(void 0!==n.styles){var r=n.next;if(void 0!==r)for(;void 0!==r;)f={name:r.name,styles:r.styles,next:f},r=r.next;return n.styles+";"}return function(e,t,n){var r="";if(Array.isArray(n))for(var a=0;a<n.length;a++)r+=p(e,t,n[a])+";";else for(var o in n){var i=n[o];if("object"!==typeof i)null!=t&&void 0!==t[i]?r+=o+"{"+t[i]+"}":u(i)&&(r+=c(o)+":"+d(o,i)+";");else if(!Array.isArray(i)||"string"!==typeof i[0]||null!=t&&void 0!==t[i[0]]){var s=p(e,t,i);switch(o){case"animation":case"animationName":r+=c(o)+":"+s+";";break;default:r+=o+"{"+s+"}"}}else for(var l=0;l<i.length;l++)u(i[l])&&(r+=c(o)+":"+d(o,i[l])+";")}return r}(e,t,n);case"function":if(void 0!==e){var a=f,o=n(e);return f=a,p(e,t,o)}}if(null==t)return n;var i=t[n];return void 0!==i?i:n}var f,m=/label:\s*([^\s;\n{]+)\s*(;|$)/g;var h=function(e,t,n){if(1===e.length&&"object"===typeof e[0]&&null!==e[0]&&void 0!==e[0].styles)return e[0];var a=!0,o="";f=void 0;var i=e[0];null==i||void 0===i.raw?(a=!1,o+=p(n,t,i)):o+=i[0];for(var s=1;s<e.length;s++)o+=p(n,t,e[s]),a&&(o+=i[s]);m.lastIndex=0;for(var l,u="";null!==(l=m.exec(o));)u+="-"+l[1];return{name:r(o)+u,styles:o,next:f}}},2561:function(e,t,n){"use strict";var r;n.d(t,{L:function(){return i},j:function(){return s}});var a=n(2791),o=!!(r||(r=n.t(a,2))).useInsertionEffect&&(r||(r=n.t(a,2))).useInsertionEffect,i=o||function(e){return e()},s=o||a.useLayoutEffect},5438:function(e,t,n){"use strict";n.d(t,{My:function(){return o},fp:function(){return r},hC:function(){return a}});function r(e,t,n){var r="";return n.split(" ").forEach((function(n){void 0!==e[n]?t.push(e[n]+";"):r+=n+" "})),r}var a=function(e,t,n){var r=e.key+"-"+t.name;!1===n&&void 0===e.registered[r]&&(e.registered[r]=t.styles)},o=function(e,t,n){a(e,t,n);var r=e.key+"-"+t.name;if(void 0===e.inserted[t.name]){var o=t;do{e.insert(t===o?"."+r:"",o,e.sheet,!0);o=o.next}while(void 0!==o)}}},2156:function(e,t,n){"use strict";var r=n(4836);t.Z=void 0;var a=r(n(5649)),o=n(184),i=(0,a.default)((0,o.jsx)("path",{d:"M15.41 7.41 14 6l-6 6 6 6 1.41-1.41L10.83 12z"}),"NavigateBefore");t.Z=i},5129:function(e,t,n){"use strict";var r=n(4836);t.Z=void 0;var a=r(n(5649)),o=n(184),i=(0,a.default)((0,o.jsx)("path",{d:"M10 6 8.59 7.41 13.17 12l-4.58 4.59L10 18l6-6z"}),"NavigateNext");t.Z=i},5649:function(e,t,n){"use strict";Object.defineProperty(t,"__esModule",{value:!0}),Object.defineProperty(t,"default",{enumerable:!0,get:function(){return r.createSvgIcon}});var r=n(3111)},4360:function(e,t,n){"use strict";n.d(t,{Z:function(){return Z}});var r=n(7462),a=n(3366),o=n(6189),i=n(2466),s=n(5080),l=n(4942);function u(e,t){var n;return(0,r.Z)({toolbar:(n={minHeight:56},(0,l.Z)(n,e.up("xs"),{"@media (orientation: landscape)":{minHeight:48}}),(0,l.Z)(n,e.up("sm"),{minHeight:64}),n)},t)}var c=n(2065),d={black:"#000",white:"#fff"},p={50:"#fafafa",100:"#f5f5f5",200:"#eeeeee",300:"#e0e0e0",400:"#bdbdbd",500:"#9e9e9e",600:"#757575",700:"#616161",800:"#424242",900:"#212121",A100:"#f5f5f5",A200:"#eeeeee",A400:"#bdbdbd",A700:"#616161"},f={50:"#f3e5f5",100:"#e1bee7",200:"#ce93d8",300:"#ba68c8",400:"#ab47bc",500:"#9c27b0",600:"#8e24aa",700:"#7b1fa2",800:"#6a1b9a",900:"#4a148c",A100:"#ea80fc",A200:"#e040fb",A400:"#d500f9",A700:"#aa00ff"},m={50:"#ffebee",100:"#ffcdd2",200:"#ef9a9a",300:"#e57373",400:"#ef5350",500:"#f44336",600:"#e53935",700:"#d32f2f",800:"#c62828",900:"#b71c1c",A100:"#ff8a80",A200:"#ff5252",A400:"#ff1744",A700:"#d50000"},h={50:"#fff3e0",100:"#ffe0b2",200:"#ffcc80",300:"#ffb74d",400:"#ffa726",500:"#ff9800",600:"#fb8c00",700:"#f57c00",800:"#ef6c00",900:"#e65100",A100:"#ffd180",A200:"#ffab40",A400:"#ff9100",A700:"#ff6d00"},v={50:"#e3f2fd",100:"#bbdefb",200:"#90caf9",300:"#64b5f6",400:"#42a5f5",500:"#2196f3",600:"#1e88e5",700:"#1976d2",800:"#1565c0",900:"#0d47a1",A100:"#82b1ff",A200:"#448aff",A400:"#2979ff",A700:"#2962ff"},y={50:"#e1f5fe",100:"#b3e5fc",200:"#81d4fa",300:"#4fc3f7",400:"#29b6f6",500:"#03a9f4",600:"#039be5",700:"#0288d1",800:"#0277bd",900:"#01579b",A100:"#80d8ff",A200:"#40c4ff",A400:"#00b0ff",A700:"#0091ea"},b={50:"#e8f5e9",100:"#c8e6c9",200:"#a5d6a7",300:"#81c784",400:"#66bb6a",500:"#4caf50",600:"#43a047",700:"#388e3c",800:"#2e7d32",900:"#1b5e20",A100:"#b9f6ca",A200:"#69f0ae",A400:"#00e676",A700:"#00c853"},g=["mode","contrastThreshold","tonalOffset"],_={text:{primary:"rgba(0, 0, 0, 0.87)",secondary:"rgba(0, 0, 0, 0.6)",disabled:"rgba(0, 0, 0, 0.38)"},divider:"rgba(0, 0, 0, 0.12)",background:{paper:d.white,default:d.white},action:{active:"rgba(0, 0, 0, 0.54)",hover:"rgba(0, 0, 0, 0.04)",hoverOpacity:.04,selected:"rgba(0, 0, 0, 0.08)",selectedOpacity:.08,disabled:"rgba(0, 0, 0, 0.26)",disabledBackground:"rgba(0, 0, 0, 0.12)",disabledOpacity:.38,focus:"rgba(0, 0, 0, 0.12)",focusOpacity:.12,activatedOpacity:.12}},w={text:{primary:d.white,secondary:"rgba(255, 255, 255, 0.7)",disabled:"rgba(255, 255, 255, 0.5)",icon:"rgba(255, 255, 255, 0.5)"},divider:"rgba(255, 255, 255, 0.12)",background:{paper:"#121212",default:"#121212"},action:{active:d.white,hover:"rgba(255, 255, 255, 0.08)",hoverOpacity:.08,selected:"rgba(255, 255, 255, 0.16)",selectedOpacity:.16,disabled:"rgba(255, 255, 255, 0.3)",disabledBackground:"rgba(255, 255, 255, 0.12)",disabledOpacity:.38,focus:"rgba(255, 255, 255, 0.12)",focusOpacity:.12,activatedOpacity:.24}};function S(e,t,n,r){var a=r.light||r,o=r.dark||1.5*r;e[t]||(e.hasOwnProperty(n)?e[t]=e[n]:"light"===t?e.light=(0,c.$n)(e.main,a):"dark"===t&&(e.dark=(0,c._j)(e.main,o)))}function T(e){var t=e.mode,n=void 0===t?"light":t,s=e.contrastThreshold,l=void 0===s?3:s,u=e.tonalOffset,T=void 0===u?.2:u,C=(0,a.Z)(e,g),k=e.primary||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:v[200],light:v[50],dark:v[400]}:{main:v[700],light:v[400],dark:v[800]}}(n),A=e.secondary||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:f[200],light:f[50],dark:f[400]}:{main:f[500],light:f[300],dark:f[700]}}(n),x=e.error||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:m[500],light:m[300],dark:m[700]}:{main:m[700],light:m[400],dark:m[800]}}(n),F=e.info||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:y[400],light:y[300],dark:y[700]}:{main:y[700],light:y[500],dark:y[900]}}(n),R=e.success||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:b[400],light:b[300],dark:b[700]}:{main:b[800],light:b[500],dark:b[900]}}(n),P=e.warning||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:h[400],light:h[300],dark:h[700]}:{main:"#ed6c02",light:h[500],dark:h[900]}}(n);function E(e){return(0,c.mi)(e,w.text.primary)>=l?w.text.primary:_.text.primary}var O=function(e){var t=e.color,n=e.name,a=e.mainShade,i=void 0===a?500:a,s=e.lightShade,l=void 0===s?300:s,u=e.darkShade,c=void 0===u?700:u;if(!(t=(0,r.Z)({},t)).main&&t[i]&&(t.main=t[i]),!t.hasOwnProperty("main"))throw new Error((0,o.Z)(11,n?" (".concat(n,")"):"",i));if("string"!==typeof t.main)throw new Error((0,o.Z)(12,n?" (".concat(n,")"):"",JSON.stringify(t.main)));return S(t,"light",l,T),S(t,"dark",c,T),t.contrastText||(t.contrastText=E(t.main)),t},N={dark:w,light:_};return(0,i.Z)((0,r.Z)({common:(0,r.Z)({},d),mode:n,primary:O({color:k,name:"primary"}),secondary:O({color:A,name:"secondary",mainShade:"A400",lightShade:"A200",darkShade:"A700"}),error:O({color:x,name:"error"}),warning:O({color:P,name:"warning"}),info:O({color:F,name:"info"}),success:O({color:R,name:"success"}),grey:p,contrastThreshold:l,getContrastText:E,augmentColor:O,tonalOffset:T},N[n]),C)}var C=["fontFamily","fontSize","fontWeightLight","fontWeightRegular","fontWeightMedium","fontWeightBold","htmlFontSize","allVariants","pxToRem"];var k={textTransform:"uppercase"},A='"Roboto", "Helvetica", "Arial", sans-serif';function x(e,t){var n="function"===typeof t?t(e):t,o=n.fontFamily,s=void 0===o?A:o,l=n.fontSize,u=void 0===l?14:l,c=n.fontWeightLight,d=void 0===c?300:c,p=n.fontWeightRegular,f=void 0===p?400:p,m=n.fontWeightMedium,h=void 0===m?500:m,v=n.fontWeightBold,y=void 0===v?700:v,b=n.htmlFontSize,g=void 0===b?16:b,_=n.allVariants,w=n.pxToRem,S=(0,a.Z)(n,C);var T=u/14,x=w||function(e){return"".concat(e/g*T,"rem")},F=function(e,t,n,a,o){return(0,r.Z)({fontFamily:s,fontWeight:e,fontSize:x(t),lineHeight:n},s===A?{letterSpacing:"".concat((i=a/t,Math.round(1e5*i)/1e5),"em")}:{},o,_);var i},R={h1:F(d,96,1.167,-1.5),h2:F(d,60,1.2,-.5),h3:F(f,48,1.167,0),h4:F(f,34,1.235,.25),h5:F(f,24,1.334,0),h6:F(h,20,1.6,.15),subtitle1:F(f,16,1.75,.15),subtitle2:F(h,14,1.57,.1),body1:F(f,16,1.5,.15),body2:F(f,14,1.43,.15),button:F(h,14,1.75,.4,k),caption:F(f,12,1.66,.4),overline:F(f,12,2.66,1,k)};return(0,i.Z)((0,r.Z)({htmlFontSize:g,pxToRem:x,fontFamily:s,fontSize:u,fontWeightLight:d,fontWeightRegular:f,fontWeightMedium:h,fontWeightBold:y},R),S,{clone:!1})}function F(){return["".concat(arguments.length<=0?void 0:arguments[0],"px ").concat(arguments.length<=1?void 0:arguments[1],"px ").concat(arguments.length<=2?void 0:arguments[2],"px ").concat(arguments.length<=3?void 0:arguments[3],"px rgba(0,0,0,").concat(.2,")"),"".concat(arguments.length<=4?void 0:arguments[4],"px ").concat(arguments.length<=5?void 0:arguments[5],"px ").concat(arguments.length<=6?void 0:arguments[6],"px ").concat(arguments.length<=7?void 0:arguments[7],"px rgba(0,0,0,").concat(.14,")"),"".concat(arguments.length<=8?void 0:arguments[8],"px ").concat(arguments.length<=9?void 0:arguments[9],"px ").concat(arguments.length<=10?void 0:arguments[10],"px ").concat(arguments.length<=11?void 0:arguments[11],"px rgba(0,0,0,").concat(.12,")")].join(",")}var R=["none",F(0,2,1,-1,0,1,1,0,0,1,3,0),F(0,3,1,-2,0,2,2,0,0,1,5,0),F(0,3,3,-2,0,3,4,0,0,1,8,0),F(0,2,4,-1,0,4,5,0,0,1,10,0),F(0,3,5,-1,0,5,8,0,0,1,14,0),F(0,3,5,-1,0,6,10,0,0,1,18,0),F(0,4,5,-2,0,7,10,1,0,2,16,1),F(0,5,5,-3,0,8,10,1,0,3,14,2),F(0,5,6,-3,0,9,12,1,0,3,16,2),F(0,6,6,-3,0,10,14,1,0,4,18,3),F(0,6,7,-4,0,11,15,1,0,4,20,3),F(0,7,8,-4,0,12,17,2,0,5,22,4),F(0,7,8,-4,0,13,19,2,0,5,24,4),F(0,7,9,-4,0,14,21,2,0,5,26,4),F(0,8,9,-5,0,15,22,2,0,6,28,5),F(0,8,10,-5,0,16,24,2,0,6,30,5),F(0,8,11,-5,0,17,26,2,0,6,32,5),F(0,9,11,-5,0,18,28,2,0,7,34,6),F(0,9,12,-6,0,19,29,2,0,7,36,6),F(0,10,13,-6,0,20,31,3,0,8,38,7),F(0,10,13,-6,0,21,33,3,0,8,40,7),F(0,10,14,-6,0,22,35,3,0,8,42,7),F(0,11,14,-7,0,23,36,3,0,9,44,8),F(0,11,15,-7,0,24,38,3,0,9,46,8)],P=["duration","easing","delay"],E={easeInOut:"cubic-bezier(0.4, 0, 0.2, 1)",easeOut:"cubic-bezier(0.0, 0, 0.2, 1)",easeIn:"cubic-bezier(0.4, 0, 1, 1)",sharp:"cubic-bezier(0.4, 0, 0.6, 1)"},O={shortest:150,shorter:200,short:250,standard:300,complex:375,enteringScreen:225,leavingScreen:195};function N(e){return"".concat(Math.round(e),"ms")}function I(e){if(!e)return 0;var t=e/36;return Math.round(10*(4+15*Math.pow(t,.25)+t/5))}function M(e){var t=(0,r.Z)({},E,e.easing),n=(0,r.Z)({},O,e.duration);return(0,r.Z)({getAutoHeightDuration:I,create:function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:["all"],r=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},o=r.duration,i=void 0===o?n.standard:o,s=r.easing,l=void 0===s?t.easeInOut:s,u=r.delay,c=void 0===u?0:u;(0,a.Z)(r,P);return(Array.isArray(e)?e:[e]).map((function(e){return"".concat(e," ").concat("string"===typeof i?i:N(i)," ").concat(l," ").concat("string"===typeof c?c:N(c))})).join(",")}},e,{easing:t,duration:n})}var z={mobileStepper:1e3,fab:1050,speedDial:1050,appBar:1100,drawer:1200,modal:1300,snackbar:1400,tooltip:1500},D=["breakpoints","mixins","spacing","palette","transitions","typography","shape"];function L(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},t=e.mixins,n=void 0===t?{}:t,l=e.palette,c=void 0===l?{}:l,d=e.transitions,p=void 0===d?{}:d,f=e.typography,m=void 0===f?{}:f,h=(0,a.Z)(e,D);if(e.vars)throw new Error((0,o.Z)(18));var v=T(c),y=(0,s.Z)(e),b=(0,i.Z)(y,{mixins:u(y.breakpoints,n),palette:v,shadows:R.slice(),typography:x(v,m),transitions:M(p),zIndex:(0,r.Z)({},z)});b=(0,i.Z)(b,h);for(var g=arguments.length,_=new Array(g>1?g-1:0),w=1;w<g;w++)_[w-1]=arguments[w];return b=_.reduce((function(e,t){return(0,i.Z)(e,t)}),b)}var Z=L},4205:function(e,t,n){"use strict";var r=(0,n(4360).Z)();t.Z=r},277:function(e,t,n){"use strict";var r=n(4046),a=n(4205),o=(0,r.ZP)({defaultTheme:a.Z,rootShouldForwardProp:function(e){return(0,r.x9)(e)&&"classes"!==e}});t.ZP=o},5513:function(e,t,n){"use strict";n.d(t,{Z:function(){return o}});var r=n(8691),a=n(4205);function o(e){var t=e.props,n=e.name;return(0,r.Z)({props:t,name:n,defaultTheme:a.Z})}},9853:function(e,t,n){"use strict";var r=n(7312);t.Z=r.Z},3111:function(e,t,n){"use strict";n.r(t),n.d(t,{capitalize:function(){return a.Z},createChainedFunction:function(){return o},createSvgIcon:function(){return w},debounce:function(){return S},deprecatedPropType:function(){return T},isMuiElement:function(){return C},ownerDocument:function(){return A},ownerWindow:function(){return x},requirePropFactory:function(){return F},setRef:function(){return R},unstable_ClassNameGenerator:function(){return j},unstable_useEnhancedEffect:function(){return P},unstable_useId:function(){return I},unsupportedProp:function(){return M},useControlled:function(){return z},useEventCallback:function(){return D.Z},useForkRef:function(){return L.Z},useIsFocusVisible:function(){return Z.Z}});var r=n(5902),a=n(9853);var o=function(){for(var e=arguments.length,t=new Array(e),n=0;n<e;n++)t[n]=arguments[n];return t.reduce((function(e,t){return null==t?e:function(){for(var n=arguments.length,r=new Array(n),a=0;a<n;a++)r[a]=arguments[a];e.apply(this,r),t.apply(this,r)}}),(function(){}))},i=n(7462),s=n(2791),l=n.t(s,2),u=n(3366),c=n(8182),d=n(4419),p=n(5513),f=n(277),m=n(1217);function h(e){return(0,m.Z)("MuiSvgIcon",e)}(0,n(5878).Z)("MuiSvgIcon",["root","colorPrimary","colorSecondary","colorAction","colorError","colorDisabled","fontSizeInherit","fontSizeSmall","fontSizeMedium","fontSizeLarge"]);var v=n(184),y=["children","className","color","component","fontSize","htmlColor","inheritViewBox","titleAccess","viewBox"],b=(0,f.ZP)("svg",{name:"MuiSvgIcon",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,"inherit"!==n.color&&t["color".concat((0,a.Z)(n.color))],t["fontSize".concat((0,a.Z)(n.fontSize))]]}})((function(e){var t,n,r,a,o,i,s,l,u,c,d,p,f,m,h,v,y,b=e.theme,g=e.ownerState;return{userSelect:"none",width:"1em",height:"1em",display:"inline-block",fill:"currentColor",flexShrink:0,transition:null==(t=b.transitions)||null==(n=t.create)?void 0:n.call(t,"fill",{duration:null==(r=b.transitions)||null==(a=r.duration)?void 0:a.shorter}),fontSize:{inherit:"inherit",small:(null==(o=b.typography)||null==(i=o.pxToRem)?void 0:i.call(o,20))||"1.25rem",medium:(null==(s=b.typography)||null==(l=s.pxToRem)?void 0:l.call(s,24))||"1.5rem",large:(null==(u=b.typography)||null==(c=u.pxToRem)?void 0:c.call(u,35))||"2.1875rem"}[g.fontSize],color:null!=(d=null==(p=(b.vars||b).palette)||null==(f=p[g.color])?void 0:f.main)?d:{action:null==(m=(b.vars||b).palette)||null==(h=m.action)?void 0:h.active,disabled:null==(v=(b.vars||b).palette)||null==(y=v.action)?void 0:y.disabled,inherit:void 0}[g.color]}})),g=s.forwardRef((function(e,t){var n=(0,p.Z)({props:e,name:"MuiSvgIcon"}),r=n.children,o=n.className,s=n.color,l=void 0===s?"inherit":s,f=n.component,m=void 0===f?"svg":f,g=n.fontSize,_=void 0===g?"medium":g,w=n.htmlColor,S=n.inheritViewBox,T=void 0!==S&&S,C=n.titleAccess,k=n.viewBox,A=void 0===k?"0 0 24 24":k,x=(0,u.Z)(n,y),F=(0,i.Z)({},n,{color:l,component:m,fontSize:_,instanceFontSize:e.fontSize,inheritViewBox:T,viewBox:A}),R={};T||(R.viewBox=A);var P=function(e){var t=e.color,n=e.fontSize,r=e.classes,o={root:["root","inherit"!==t&&"color".concat((0,a.Z)(t)),"fontSize".concat((0,a.Z)(n))]};return(0,d.Z)(o,h,r)}(F);return(0,v.jsxs)(b,(0,i.Z)({as:m,className:(0,c.Z)(P.root,o),focusable:"false",color:w,"aria-hidden":!C||void 0,role:C?"img":void 0,ref:t},R,x,{ownerState:F,children:[r,C?(0,v.jsx)("title",{children:C}):null]}))}));g.muiName="SvgIcon";var _=g;function w(e,t){var n=function(n,r){return(0,v.jsx)(_,(0,i.Z)({"data-testid":"".concat(t,"Icon"),ref:r},n,{children:e}))};return n.muiName=_.muiName,s.memo(s.forwardRef(n))}var S=function(e){var t,n=arguments.length>1&&void 0!==arguments[1]?arguments[1]:166;function r(){for(var r=this,a=arguments.length,o=new Array(a),i=0;i<a;i++)o[i]=arguments[i];var s=function(){e.apply(r,o)};clearTimeout(t),t=setTimeout(s,n)}return r.clear=function(){clearTimeout(t)},r};var T=function(e,t){return function(){return null}};var C=function(e,t){return s.isValidElement(e)&&-1!==t.indexOf(e.type.muiName)};function k(e){return e&&e.ownerDocument||document}var A=k;var x=function(e){return k(e).defaultView||window};var F=function(e,t){return function(){return null}},R=n(2971).Z,P=n(5721).Z,E=n(885),O=0;var N=l.useId;var I=function(e){if(void 0!==N){var t=N();return null!=e?e:t}return function(e){var t=s.useState(e),n=(0,E.Z)(t,2),r=n[0],a=n[1],o=e||r;return s.useEffect((function(){null==r&&a("mui-".concat(O+=1))}),[r]),o}(e)};var M=function(e,t,n,r,a){return null};var z=function(e){var t=e.controlled,n=e.default,r=(e.name,e.state,s.useRef(void 0!==t).current),a=s.useState(n),o=(0,E.Z)(a,2),i=o[0],l=o[1];return[r?t:i,s.useCallback((function(e){r||l(e)}),[])]},D=n(6702),L=n(792),Z=n(2763),j={configure:function(e){console.warn(["MUI: `ClassNameGenerator` import from `@mui/material/utils` is outdated and might cause unexpected issues.","","You should use `import { unstable_ClassNameGenerator } from '@mui/material/className'` instead","","The detail of the issue: https://github.com/mui/material-ui/issues/30011#issuecomment-1024993401","","The updated documentation: https://mui.com/guides/classname-generator/"].join("\n")),r.Z.configure(e)}}},6702:function(e,t,n){"use strict";n.d(t,{Z:function(){return o}});var r=n(2791),a=n(5721);var o=function(e){var t=r.useRef(e);return(0,a.Z)((function(){t.current=e})),r.useCallback((function(){return t.current.apply(void 0,arguments)}),[])}},792:function(e,t,n){"use strict";n.d(t,{Z:function(){return o}});var r=n(2791),a=n(2971);var o=function(e,t){return r.useMemo((function(){return null==e&&null==t?null:function(n){(0,a.Z)(e,n),(0,a.Z)(t,n)}}),[e,t])}},2763:function(e,t,n){"use strict";n.d(t,{Z:function(){return p}});var r,a=n(2791),o=!0,i=!1,s={text:!0,search:!0,url:!0,tel:!0,email:!0,password:!0,number:!0,date:!0,month:!0,week:!0,time:!0,datetime:!0,"datetime-local":!0};function l(e){e.metaKey||e.altKey||e.ctrlKey||(o=!0)}function u(){o=!1}function c(){"hidden"===this.visibilityState&&i&&(o=!0)}function d(e){var t=e.target;try{return t.matches(":focus-visible")}catch(n){}return o||function(e){var t=e.type,n=e.tagName;return!("INPUT"!==n||!s[t]||e.readOnly)||"TEXTAREA"===n&&!e.readOnly||!!e.isContentEditable}(t)}var p=function(){var e=a.useCallback((function(e){var t;null!=e&&((t=e.ownerDocument).addEventListener("keydown",l,!0),t.addEventListener("mousedown",u,!0),t.addEventListener("pointerdown",u,!0),t.addEventListener("touchstart",u,!0),t.addEventListener("visibilitychange",c,!0))}),[]),t=a.useRef(!1);return{isFocusVisibleRef:t,onFocus:function(e){return!!d(e)&&(t.current=!0,!0)},onBlur:function(){return!!t.current&&(i=!0,window.clearTimeout(r),r=window.setTimeout((function(){i=!1}),100),t.current=!1,!0)},ref:e}}},2421:function(e,t,n){"use strict";n.d(t,{ZP:function(){return _},Co:function(){return w}});var r=n(2791),a=n(7462),o=n(9797),i=/^((children|dangerouslySetInnerHTML|key|ref|autoFocus|defaultValue|defaultChecked|innerHTML|suppressContentEditableWarning|suppressHydrationWarning|valueLink|abbr|accept|acceptCharset|accessKey|action|allow|allowUserMedia|allowPaymentRequest|allowFullScreen|allowTransparency|alt|async|autoComplete|autoPlay|capture|cellPadding|cellSpacing|challenge|charSet|checked|cite|classID|className|cols|colSpan|content|contentEditable|contextMenu|controls|controlsList|coords|crossOrigin|data|dateTime|decoding|default|defer|dir|disabled|disablePictureInPicture|download|draggable|encType|enterKeyHint|form|formAction|formEncType|formMethod|formNoValidate|formTarget|frameBorder|headers|height|hidden|high|href|hrefLang|htmlFor|httpEquiv|id|inputMode|integrity|is|keyParams|keyType|kind|label|lang|list|loading|loop|low|marginHeight|marginWidth|max|maxLength|media|mediaGroup|method|min|minLength|multiple|muted|name|nonce|noValidate|open|optimum|pattern|placeholder|playsInline|poster|preload|profile|radioGroup|readOnly|referrerPolicy|rel|required|reversed|role|rows|rowSpan|sandbox|scope|scoped|scrolling|seamless|selected|shape|size|sizes|slot|span|spellCheck|src|srcDoc|srcLang|srcSet|start|step|style|summary|tabIndex|target|title|translate|type|useMap|value|width|wmode|wrap|about|datatype|inlist|prefix|property|resource|typeof|vocab|autoCapitalize|autoCorrect|autoSave|color|incremental|fallback|inert|itemProp|itemScope|itemType|itemID|itemRef|on|option|results|security|unselectable|accentHeight|accumulate|additive|alignmentBaseline|allowReorder|alphabetic|amplitude|arabicForm|ascent|attributeName|attributeType|autoReverse|azimuth|baseFrequency|baselineShift|baseProfile|bbox|begin|bias|by|calcMode|capHeight|clip|clipPathUnits|clipPath|clipRule|colorInterpolation|colorInterpolationFilters|colorProfile|colorRendering|contentScriptType|contentStyleType|cursor|cx|cy|d|decelerate|descent|diffuseConstant|direction|display|divisor|dominantBaseline|dur|dx|dy|edgeMode|elevation|enableBackground|end|exponent|externalResourcesRequired|fill|fillOpacity|fillRule|filter|filterRes|filterUnits|floodColor|floodOpacity|focusable|fontFamily|fontSize|fontSizeAdjust|fontStretch|fontStyle|fontVariant|fontWeight|format|from|fr|fx|fy|g1|g2|glyphName|glyphOrientationHorizontal|glyphOrientationVertical|glyphRef|gradientTransform|gradientUnits|hanging|horizAdvX|horizOriginX|ideographic|imageRendering|in|in2|intercept|k|k1|k2|k3|k4|kernelMatrix|kernelUnitLength|kerning|keyPoints|keySplines|keyTimes|lengthAdjust|letterSpacing|lightingColor|limitingConeAngle|local|markerEnd|markerMid|markerStart|markerHeight|markerUnits|markerWidth|mask|maskContentUnits|maskUnits|mathematical|mode|numOctaves|offset|opacity|operator|order|orient|orientation|origin|overflow|overlinePosition|overlineThickness|panose1|paintOrder|pathLength|patternContentUnits|patternTransform|patternUnits|pointerEvents|points|pointsAtX|pointsAtY|pointsAtZ|preserveAlpha|preserveAspectRatio|primitiveUnits|r|radius|refX|refY|renderingIntent|repeatCount|repeatDur|requiredExtensions|requiredFeatures|restart|result|rotate|rx|ry|scale|seed|shapeRendering|slope|spacing|specularConstant|specularExponent|speed|spreadMethod|startOffset|stdDeviation|stemh|stemv|stitchTiles|stopColor|stopOpacity|strikethroughPosition|strikethroughThickness|string|stroke|strokeDasharray|strokeDashoffset|strokeLinecap|strokeLinejoin|strokeMiterlimit|strokeOpacity|strokeWidth|surfaceScale|systemLanguage|tableValues|targetX|targetY|textAnchor|textDecoration|textRendering|textLength|to|transform|u1|u2|underlinePosition|underlineThickness|unicode|unicodeBidi|unicodeRange|unitsPerEm|vAlphabetic|vHanging|vIdeographic|vMathematical|values|vectorEffect|version|vertAdvY|vertOriginX|vertOriginY|viewBox|viewTarget|visibility|widths|wordSpacing|writingMode|x|xHeight|x1|x2|xChannelSelector|xlinkActuate|xlinkArcrole|xlinkHref|xlinkRole|xlinkShow|xlinkTitle|xlinkType|xmlBase|xmlns|xmlnsXlink|xmlLang|xmlSpace|y|y1|y2|yChannelSelector|z|zoomAndPan|for|class|autofocus)|(([Dd][Aa][Tt][Aa]|[Aa][Rr][Ii][Aa]|x)-.*))$/,s=(0,o.Z)((function(e){return i.test(e)||111===e.charCodeAt(0)&&110===e.charCodeAt(1)&&e.charCodeAt(2)<91})),l=n(9886),u=n(5438),c=n(9140),d=n(2561),p=s,f=function(e){return"theme"!==e},m=function(e){return"string"===typeof e&&e.charCodeAt(0)>96?p:f},h=function(e,t,n){var r;if(t){var a=t.shouldForwardProp;r=e.__emotion_forwardProp&&a?function(t){return e.__emotion_forwardProp(t)&&a(t)}:a}return"function"!==typeof r&&n&&(r=e.__emotion_forwardProp),r},v=function(e){var t=e.cache,n=e.serialized,r=e.isStringTag;(0,u.hC)(t,n,r);(0,d.L)((function(){return(0,u.My)(t,n,r)}));return null},y=function e(t,n){var o,i,s=t.__emotion_real===t,d=s&&t.__emotion_base||t;void 0!==n&&(o=n.label,i=n.target);var p=h(t,n,s),f=p||m(d),y=!f("as");return function(){var b=arguments,g=s&&void 0!==t.__emotion_styles?t.__emotion_styles.slice(0):[];if(void 0!==o&&g.push("label:"+o+";"),null==b[0]||void 0===b[0].raw)g.push.apply(g,b);else{0,g.push(b[0][0]);for(var _=b.length,w=1;w<_;w++)g.push(b[w],b[0][w])}var S=(0,l.w)((function(e,t,n){var a=y&&e.as||d,o="",s=[],h=e;if(null==e.theme){for(var b in h={},e)h[b]=e[b];h.theme=(0,r.useContext)(l.T)}"string"===typeof e.className?o=(0,u.fp)(t.registered,s,e.className):null!=e.className&&(o=e.className+" ");var _=(0,c.O)(g.concat(s),t.registered,h);o+=t.key+"-"+_.name,void 0!==i&&(o+=" "+i);var w=y&&void 0===p?m(a):f,S={};for(var T in e)y&&"as"===T||w(T)&&(S[T]=e[T]);return S.className=o,S.ref=n,(0,r.createElement)(r.Fragment,null,(0,r.createElement)(v,{cache:t,serialized:_,isStringTag:"string"===typeof a}),(0,r.createElement)(a,S))}));return S.displayName=void 0!==o?o:"Styled("+("string"===typeof d?d:d.displayName||d.name||"Component")+")",S.defaultProps=t.defaultProps,S.__emotion_real=S,S.__emotion_base=d,S.__emotion_styles=g,S.__emotion_forwardProp=p,Object.defineProperty(S,"toString",{value:function(){return"."+i}}),S.withComponent=function(t,r){return e(t,(0,a.Z)({},n,r,{shouldForwardProp:h(S,r,!0)})).apply(void 0,g)},S}},b=y.bind();["a","abbr","address","area","article","aside","audio","b","base","bdi","bdo","big","blockquote","body","br","button","canvas","caption","cite","code","col","colgroup","data","datalist","dd","del","details","dfn","dialog","div","dl","dt","em","embed","fieldset","figcaption","figure","footer","form","h1","h2","h3","h4","h5","h6","head","header","hgroup","hr","html","i","iframe","img","input","ins","kbd","keygen","label","legend","li","link","main","map","mark","marquee","menu","menuitem","meta","meter","nav","noscript","object","ol","optgroup","option","output","p","param","picture","pre","progress","q","rp","rt","ruby","s","samp","script","section","select","small","source","span","strong","style","sub","summary","sup","table","tbody","td","textarea","tfoot","th","thead","time","title","tr","track","u","ul","var","video","wbr","circle","clipPath","defs","ellipse","foreignObject","g","image","line","linearGradient","mask","path","pattern","polygon","polyline","radialGradient","rect","stop","svg","text","tspan"].forEach((function(e){b[e]=b(e)}));var g=b;function _(e,t){return g(e,t)}var w=function(e,t){Array.isArray(e.__emotion_styles)&&(e.__emotion_styles=t(e.__emotion_styles))}},1184:function(e,t,n){"use strict";n.d(t,{L7:function(){return l},P$:function(){return c},VO:function(){return a},W8:function(){return s},dt:function(){return u},k9:function(){return i}});var r=n(2466),a={xs:0,sm:600,md:900,lg:1200,xl:1536},o={keys:["xs","sm","md","lg","xl"],up:function(e){return"@media (min-width:".concat(a[e],"px)")}};function i(e,t,n){var r=e.theme||{};if(Array.isArray(t)){var i=r.breakpoints||o;return t.reduce((function(e,r,a){return e[i.up(i.keys[a])]=n(t[a]),e}),{})}if("object"===typeof t){var s=r.breakpoints||o;return Object.keys(t).reduce((function(e,r){if(-1!==Object.keys(s.values||a).indexOf(r)){e[s.up(r)]=n(t[r],r)}else{var o=r;e[o]=t[o]}return e}),{})}return n(t)}function s(){var e,t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},n=null==(e=t.keys)?void 0:e.reduce((function(e,n){return e[t.up(n)]={},e}),{});return n||{}}function l(e,t){return e.reduce((function(e,t){var n=e[t];return(!n||0===Object.keys(n).length)&&delete e[t],e}),t)}function u(e){for(var t=s(e),n=arguments.length,a=new Array(n>1?n-1:0),o=1;o<n;o++)a[o-1]=arguments[o];var i=[t].concat(a).reduce((function(e,t){return(0,r.Z)(e,t)}),{});return l(Object.keys(t),i)}function c(e){var t,n=e.values,r=e.breakpoints,a=e.base||function(e,t){if("object"!==typeof e)return{};var n={},r=Object.keys(t);return Array.isArray(e)?r.forEach((function(t,r){r<e.length&&(n[t]=!0)})):r.forEach((function(t){null!=e[t]&&(n[t]=!0)})),n}(n,r),o=Object.keys(a);return 0===o.length?n:o.reduce((function(e,r,a){return Array.isArray(n)?(e[r]=null!=n[a]?n[a]:n[t],t=a):"object"===typeof n?(e[r]=null!=n[r]?n[r]:n[t],t=r):e[r]=n,e}),{})}},2065:function(e,t,n){"use strict";n.d(t,{$n:function(){return d},Fq:function(){return u},_j:function(){return c},mi:function(){return l}});var r=n(6189);function a(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:0,n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:1;return Math.min(Math.max(t,e),n)}function o(e){if(e.type)return e;if("#"===e.charAt(0))return o(function(e){e=e.slice(1);var t=new RegExp(".{1,".concat(e.length>=6?2:1,"}"),"g"),n=e.match(t);return n&&1===n[0].length&&(n=n.map((function(e){return e+e}))),n?"rgb".concat(4===n.length?"a":"","(").concat(n.map((function(e,t){return t<3?parseInt(e,16):Math.round(parseInt(e,16)/255*1e3)/1e3})).join(", "),")"):""}(e));var t=e.indexOf("("),n=e.substring(0,t);if(-1===["rgb","rgba","hsl","hsla","color"].indexOf(n))throw new Error((0,r.Z)(9,e));var a,i=e.substring(t+1,e.length-1);if("color"===n){if(a=(i=i.split(" ")).shift(),4===i.length&&"/"===i[3].charAt(0)&&(i[3]=i[3].slice(1)),-1===["srgb","display-p3","a98-rgb","prophoto-rgb","rec-2020"].indexOf(a))throw new Error((0,r.Z)(10,a))}else i=i.split(",");return{type:n,values:i=i.map((function(e){return parseFloat(e)})),colorSpace:a}}function i(e){var t=e.type,n=e.colorSpace,r=e.values;return-1!==t.indexOf("rgb")?r=r.map((function(e,t){return t<3?parseInt(e,10):e})):-1!==t.indexOf("hsl")&&(r[1]="".concat(r[1],"%"),r[2]="".concat(r[2],"%")),r=-1!==t.indexOf("color")?"".concat(n," ").concat(r.join(" ")):"".concat(r.join(", ")),"".concat(t,"(").concat(r,")")}function s(e){var t="hsl"===(e=o(e)).type||"hsla"===e.type?o(function(e){var t=(e=o(e)).values,n=t[0],r=t[1]/100,a=t[2]/100,s=r*Math.min(a,1-a),l=function(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:(e+n/30)%12;return a-s*Math.max(Math.min(t-3,9-t,1),-1)},u="rgb",c=[Math.round(255*l(0)),Math.round(255*l(8)),Math.round(255*l(4))];return"hsla"===e.type&&(u+="a",c.push(t[3])),i({type:u,values:c})}(e)).values:e.values;return t=t.map((function(t){return"color"!==e.type&&(t/=255),t<=.03928?t/12.92:Math.pow((t+.055)/1.055,2.4)})),Number((.2126*t[0]+.7152*t[1]+.0722*t[2]).toFixed(3))}function l(e,t){var n=s(e),r=s(t);return(Math.max(n,r)+.05)/(Math.min(n,r)+.05)}function u(e,t){return e=o(e),t=a(t),"rgb"!==e.type&&"hsl"!==e.type||(e.type+="a"),"color"===e.type?e.values[3]="/".concat(t):e.values[3]=t,i(e)}function c(e,t){if(e=o(e),t=a(t),-1!==e.type.indexOf("hsl"))e.values[2]*=1-t;else if(-1!==e.type.indexOf("rgb")||-1!==e.type.indexOf("color"))for(var n=0;n<3;n+=1)e.values[n]*=1-t;return i(e)}function d(e,t){if(e=o(e),t=a(t),-1!==e.type.indexOf("hsl"))e.values[2]+=(100-e.values[2])*t;else if(-1!==e.type.indexOf("rgb"))for(var n=0;n<3;n+=1)e.values[n]+=(255-e.values[n])*t;else if(-1!==e.type.indexOf("color"))for(var r=0;r<3;r+=1)e.values[r]+=(1-e.values[r])*t;return i(e)}},4046:function(e,t,n){"use strict";n.d(t,{ZP:function(){return C},x9:function(){return S}});var r=n(2982),a=n(885),o=n(3366),i=n(7462),s=n(2421),l=n(5080),u=n(7312),c=["variant"];function d(e){return 0===e.length}function p(e){var t=e.variant,n=(0,o.Z)(e,c),r=t||"";return Object.keys(n).sort().forEach((function(t){r+="color"===t?d(r)?e[t]:(0,u.Z)(e[t]):"".concat(d(r)?t:(0,u.Z)(t)).concat((0,u.Z)(e[t].toString()))})),r}var f=n(104),m=["name","slot","skipVariantsResolver","skipSx","overridesResolver"],h=["theme"],v=["theme"];function y(e){return 0===Object.keys(e).length}function b(e){return"string"===typeof e&&e.charCodeAt(0)>96}var g=function(e,t){return t.components&&t.components[e]&&t.components[e].styleOverrides?t.components[e].styleOverrides:null},_=function(e,t){var n=[];t&&t.components&&t.components[e]&&t.components[e].variants&&(n=t.components[e].variants);var r={};return n.forEach((function(e){var t=p(e.props);r[t]=e.style})),r},w=function(e,t,n,r){var a,o,i=e.ownerState,s=void 0===i?{}:i,l=[],u=null==n||null==(a=n.components)||null==(o=a[r])?void 0:o.variants;return u&&u.forEach((function(n){var r=!0;Object.keys(n.props).forEach((function(t){s[t]!==n.props[t]&&e[t]!==n.props[t]&&(r=!1)})),r&&l.push(t[p(n.props)])})),l};function S(e){return"ownerState"!==e&&"theme"!==e&&"sx"!==e&&"as"!==e}var T=(0,l.Z)();function C(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},t=e.defaultTheme,n=void 0===t?T:t,l=e.rootShouldForwardProp,u=void 0===l?S:l,c=e.slotShouldForwardProp,d=void 0===c?S:c,p=e.styleFunctionSx,C=void 0===p?f.Z:p,k=function(e){var t=y(e.theme)?n:e.theme;return C((0,i.Z)({},e,{theme:t}))};return k.__mui_systemSx=!0,function(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{};(0,s.Co)(e,(function(e){return e.filter((function(e){return!(null!=e&&e.__mui_systemSx)}))}));var l,c=t.name,p=t.slot,f=t.skipVariantsResolver,T=t.skipSx,C=t.overridesResolver,A=(0,o.Z)(t,m),x=void 0!==f?f:p&&"Root"!==p||!1,F=T||!1;var R=S;"Root"===p?R=u:p?R=d:b(e)&&(R=void 0);var P=(0,s.ZP)(e,(0,i.Z)({shouldForwardProp:R,label:l},A)),E=function(e){for(var t=arguments.length,s=new Array(t>1?t-1:0),l=1;l<t;l++)s[l-1]=arguments[l];var u=s?s.map((function(e){return"function"===typeof e&&e.__emotion_real!==e?function(t){var r=t.theme,a=(0,o.Z)(t,h);return e((0,i.Z)({theme:y(r)?n:r},a))}:e})):[],d=e;c&&C&&u.push((function(e){var t=y(e.theme)?n:e.theme,r=g(c,t);if(r){var o={};return Object.entries(r).forEach((function(n){var r=(0,a.Z)(n,2),s=r[0],l=r[1];o[s]="function"===typeof l?l((0,i.Z)({},e,{theme:t})):l})),C(e,o)}return null})),c&&!x&&u.push((function(e){var t=y(e.theme)?n:e.theme;return w(e,_(c,t),t,c)})),F||u.push(k);var p=u.length-s.length;if(Array.isArray(e)&&p>0){var f=new Array(p).fill("");(d=[].concat((0,r.Z)(e),(0,r.Z)(f))).raw=[].concat((0,r.Z)(e.raw),(0,r.Z)(f))}else"function"===typeof e&&e.__emotion_real!==e&&(d=function(t){var r=t.theme,a=(0,o.Z)(t,v);return e((0,i.Z)({theme:y(r)?n:r},a))});var m=P.apply(void 0,[d].concat((0,r.Z)(u)));return m};return P.withConfig&&(E.withConfig=P.withConfig),E}}},5080:function(e,t,n){"use strict";n.d(t,{Z:function(){return f}});var r=n(7462),a=n(3366),o=n(2466),i=n(4942),s=["values","unit","step"];function l(e){var t=e.values,n=void 0===t?{xs:0,sm:600,md:900,lg:1200,xl:1536}:t,o=e.unit,l=void 0===o?"px":o,u=e.step,c=void 0===u?5:u,d=(0,a.Z)(e,s),p=function(e){var t=Object.keys(e).map((function(t){return{key:t,val:e[t]}}))||[];return t.sort((function(e,t){return e.val-t.val})),t.reduce((function(e,t){return(0,r.Z)({},e,(0,i.Z)({},t.key,t.val))}),{})}(n),f=Object.keys(p);function m(e){var t="number"===typeof n[e]?n[e]:e;return"@media (min-width:".concat(t).concat(l,")")}function h(e){var t="number"===typeof n[e]?n[e]:e;return"@media (max-width:".concat(t-c/100).concat(l,")")}function v(e,t){var r=f.indexOf(t);return"@media (min-width:".concat("number"===typeof n[e]?n[e]:e).concat(l,") and ")+"(max-width:".concat((-1!==r&&"number"===typeof n[f[r]]?n[f[r]]:t)-c/100).concat(l,")")}return(0,r.Z)({keys:f,values:p,up:m,down:h,between:v,only:function(e){return f.indexOf(e)+1<f.length?v(e,f[f.indexOf(e)+1]):m(e)},not:function(e){var t=f.indexOf(e);return 0===t?m(f[1]):t===f.length-1?h(f[t]):v(e,f[f.indexOf(e)+1]).replace("@media","@media not all and")},unit:l},d)}var u={borderRadius:4},c=n(5682);function d(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:8;if(e.mui)return e;var t=(0,c.hB)({spacing:e}),n=function(){for(var e=arguments.length,n=new Array(e),r=0;r<e;r++)n[r]=arguments[r];var a=0===n.length?[1]:n;return a.map((function(e){var n=t(e);return"number"===typeof n?"".concat(n,"px"):n})).join(" ")};return n.mui=!0,n}var p=["breakpoints","palette","spacing","shape"];var f=function(){for(var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},t=e.breakpoints,n=void 0===t?{}:t,i=e.palette,s=void 0===i?{}:i,c=e.spacing,f=e.shape,m=void 0===f?{}:f,h=(0,a.Z)(e,p),v=l(n),y=d(c),b=(0,o.Z)({breakpoints:v,direction:"ltr",components:{},palette:(0,r.Z)({mode:"light"},s),spacing:y,shape:(0,r.Z)({},u,m)},h),g=arguments.length,_=new Array(g>1?g-1:0),w=1;w<g;w++)_[w-1]=arguments[w];return b=_.reduce((function(e,t){return(0,o.Z)(e,t)}),b)}},114:function(e,t,n){"use strict";n.d(t,{Gc:function(){return q},G$:function(){return G}});var r=n(8529),a=n(8247);var o=function(){for(var e=arguments.length,t=new Array(e),n=0;n<e;n++)t[n]=arguments[n];var r=t.reduce((function(e,t){return t.filterProps.forEach((function(n){e[n]=t})),e}),{}),o=function(e){return Object.keys(e).reduce((function(t,n){return r[n]?(0,a.Z)(t,r[n](e)):t}),{})};return o.propTypes={},o.filterProps=t.reduce((function(e,t){return e.concat(t.filterProps)}),[]),o},i=n(5682),s=n(1184);function l(e){return"number"!==typeof e?e:"".concat(e,"px solid")}var u=(0,r.Z)({prop:"border",themeKey:"borders",transform:l}),c=(0,r.Z)({prop:"borderTop",themeKey:"borders",transform:l}),d=(0,r.Z)({prop:"borderRight",themeKey:"borders",transform:l}),p=(0,r.Z)({prop:"borderBottom",themeKey:"borders",transform:l}),f=(0,r.Z)({prop:"borderLeft",themeKey:"borders",transform:l}),m=(0,r.Z)({prop:"borderColor",themeKey:"palette"}),h=(0,r.Z)({prop:"borderTopColor",themeKey:"palette"}),v=(0,r.Z)({prop:"borderRightColor",themeKey:"palette"}),y=(0,r.Z)({prop:"borderBottomColor",themeKey:"palette"}),b=(0,r.Z)({prop:"borderLeftColor",themeKey:"palette"}),g=function(e){if(void 0!==e.borderRadius&&null!==e.borderRadius){var t=(0,i.eI)(e.theme,"shape.borderRadius",4,"borderRadius");return(0,s.k9)(e,e.borderRadius,(function(e){return{borderRadius:(0,i.NA)(t,e)}}))}return null};g.propTypes={},g.filterProps=["borderRadius"];var _=o(u,c,d,p,f,m,h,v,y,b,g),w=o((0,r.Z)({prop:"displayPrint",cssProperty:!1,transform:function(e){return{"@media print":{display:e}}}}),(0,r.Z)({prop:"display"}),(0,r.Z)({prop:"overflow"}),(0,r.Z)({prop:"textOverflow"}),(0,r.Z)({prop:"visibility"}),(0,r.Z)({prop:"whiteSpace"})),S=o((0,r.Z)({prop:"flexBasis"}),(0,r.Z)({prop:"flexDirection"}),(0,r.Z)({prop:"flexWrap"}),(0,r.Z)({prop:"justifyContent"}),(0,r.Z)({prop:"alignItems"}),(0,r.Z)({prop:"alignContent"}),(0,r.Z)({prop:"order"}),(0,r.Z)({prop:"flex"}),(0,r.Z)({prop:"flexGrow"}),(0,r.Z)({prop:"flexShrink"}),(0,r.Z)({prop:"alignSelf"}),(0,r.Z)({prop:"justifyItems"}),(0,r.Z)({prop:"justifySelf"})),T=function(e){if(void 0!==e.gap&&null!==e.gap){var t=(0,i.eI)(e.theme,"spacing",8,"gap");return(0,s.k9)(e,e.gap,(function(e){return{gap:(0,i.NA)(t,e)}}))}return null};T.propTypes={},T.filterProps=["gap"];var C=function(e){if(void 0!==e.columnGap&&null!==e.columnGap){var t=(0,i.eI)(e.theme,"spacing",8,"columnGap");return(0,s.k9)(e,e.columnGap,(function(e){return{columnGap:(0,i.NA)(t,e)}}))}return null};C.propTypes={},C.filterProps=["columnGap"];var k=function(e){if(void 0!==e.rowGap&&null!==e.rowGap){var t=(0,i.eI)(e.theme,"spacing",8,"rowGap");return(0,s.k9)(e,e.rowGap,(function(e){return{rowGap:(0,i.NA)(t,e)}}))}return null};k.propTypes={},k.filterProps=["rowGap"];var A=o(T,C,k,(0,r.Z)({prop:"gridColumn"}),(0,r.Z)({prop:"gridRow"}),(0,r.Z)({prop:"gridAutoFlow"}),(0,r.Z)({prop:"gridAutoColumns"}),(0,r.Z)({prop:"gridAutoRows"}),(0,r.Z)({prop:"gridTemplateColumns"}),(0,r.Z)({prop:"gridTemplateRows"}),(0,r.Z)({prop:"gridTemplateAreas"}),(0,r.Z)({prop:"gridArea"})),x=o((0,r.Z)({prop:"position"}),(0,r.Z)({prop:"zIndex",themeKey:"zIndex"}),(0,r.Z)({prop:"top"}),(0,r.Z)({prop:"right"}),(0,r.Z)({prop:"bottom"}),(0,r.Z)({prop:"left"})),F=o((0,r.Z)({prop:"color",themeKey:"palette"}),(0,r.Z)({prop:"bgcolor",cssProperty:"backgroundColor",themeKey:"palette"}),(0,r.Z)({prop:"backgroundColor",themeKey:"palette"})),R=(0,r.Z)({prop:"boxShadow",themeKey:"shadows"});function P(e){return e<=1&&0!==e?"".concat(100*e,"%"):e}var E=(0,r.Z)({prop:"width",transform:P}),O=function(e){if(void 0!==e.maxWidth&&null!==e.maxWidth){return(0,s.k9)(e,e.maxWidth,(function(t){var n,r,a;return{maxWidth:(null==(n=e.theme)||null==(r=n.breakpoints)||null==(a=r.values)?void 0:a[t])||s.VO[t]||P(t)}}))}return null};O.filterProps=["maxWidth"];var N=(0,r.Z)({prop:"minWidth",transform:P}),I=(0,r.Z)({prop:"height",transform:P}),M=(0,r.Z)({prop:"maxHeight",transform:P}),z=(0,r.Z)({prop:"minHeight",transform:P}),D=((0,r.Z)({prop:"size",cssProperty:"width",transform:P}),(0,r.Z)({prop:"size",cssProperty:"height",transform:P}),o(E,O,N,I,M,z,(0,r.Z)({prop:"boxSizing"}))),L=(0,r.Z)({prop:"fontFamily",themeKey:"typography"}),Z=(0,r.Z)({prop:"fontSize",themeKey:"typography"}),j=(0,r.Z)({prop:"fontStyle",themeKey:"typography"}),B=(0,r.Z)({prop:"fontWeight",themeKey:"typography"}),W=(0,r.Z)({prop:"letterSpacing"}),J=(0,r.Z)({prop:"textTransform"}),U=(0,r.Z)({prop:"lineHeight"}),V=(0,r.Z)({prop:"textAlign"}),$=o((0,r.Z)({prop:"typography",cssProperty:!1,themeKey:"typography"}),L,Z,j,B,W,U,V,J),H={borders:_.filterProps,display:w.filterProps,flexbox:S.filterProps,grid:A.filterProps,positions:x.filterProps,palette:F.filterProps,shadows:R.filterProps,sizing:D.filterProps,spacing:i.ZP.filterProps,typography:$.filterProps},G={borders:_,display:w,flexbox:S,grid:A,positions:x,palette:F,shadows:R,sizing:D,spacing:i.ZP,typography:$},q=Object.keys(H).reduce((function(e,t){return H[t].forEach((function(n){e[n]=G[t]})),e}),{})},8247:function(e,t,n){"use strict";var r=n(2466);t.Z=function(e,t){return t?(0,r.Z)(e,t,{clone:!1}):e}},5682:function(e,t,n){"use strict";n.d(t,{hB:function(){return h},eI:function(){return m},ZP:function(){return S},NA:function(){return v}});var r=n(885),a=n(1184),o=n(8529),i=n(8247);var s={m:"margin",p:"padding"},l={t:"Top",r:"Right",b:"Bottom",l:"Left",x:["Left","Right"],y:["Top","Bottom"]},u={marginX:"mx",marginY:"my",paddingX:"px",paddingY:"py"},c=function(e){var t={};return function(n){return void 0===t[n]&&(t[n]=e(n)),t[n]}}((function(e){if(e.length>2){if(!u[e])return[e];e=u[e]}var t=e.split(""),n=(0,r.Z)(t,2),a=n[0],o=n[1],i=s[a],c=l[o]||"";return Array.isArray(c)?c.map((function(e){return i+e})):[i+c]})),d=["m","mt","mr","mb","ml","mx","my","margin","marginTop","marginRight","marginBottom","marginLeft","marginX","marginY","marginInline","marginInlineStart","marginInlineEnd","marginBlock","marginBlockStart","marginBlockEnd"],p=["p","pt","pr","pb","pl","px","py","padding","paddingTop","paddingRight","paddingBottom","paddingLeft","paddingX","paddingY","paddingInline","paddingInlineStart","paddingInlineEnd","paddingBlock","paddingBlockStart","paddingBlockEnd"],f=[].concat(d,p);function m(e,t,n,r){var a,i=null!=(a=(0,o.D)(e,t,!1))?a:n;return"number"===typeof i?function(e){return"string"===typeof e?e:i*e}:Array.isArray(i)?function(e){return"string"===typeof e?e:i[e]}:"function"===typeof i?i:function(){}}function h(e){return m(e,"spacing",8)}function v(e,t){if("string"===typeof t||null==t)return t;var n=e(Math.abs(t));return t>=0?n:"number"===typeof n?-n:"-".concat(n)}function y(e,t,n,r){if(-1===t.indexOf(n))return null;var o=function(e,t){return function(n){return e.reduce((function(e,r){return e[r]=v(t,n),e}),{})}}(c(n),r),i=e[n];return(0,a.k9)(e,i,o)}function b(e,t){var n=h(e.theme);return Object.keys(e).map((function(r){return y(e,t,r,n)})).reduce(i.Z,{})}function g(e){return b(e,d)}function _(e){return b(e,p)}function w(e){return b(e,f)}g.propTypes={},g.filterProps=d,_.propTypes={},_.filterProps=p,w.propTypes={},w.filterProps=f;var S=w},8529:function(e,t,n){"use strict";n.d(t,{D:function(){return i}});var r=n(4942),a=n(7312),o=n(1184);function i(e,t){var n=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];if(!t||"string"!==typeof t)return null;if(e&&e.vars&&n){var r="vars.".concat(t).split(".").reduce((function(e,t){return e&&e[t]?e[t]:null}),e);if(null!=r)return r}return t.split(".").reduce((function(e,t){return e&&null!=e[t]?e[t]:null}),e)}function s(e,t,n){var r,a=arguments.length>3&&void 0!==arguments[3]?arguments[3]:n;return r="function"===typeof e?e(n):Array.isArray(e)?e[n]||a:i(e,n)||a,t&&(r=t(r)),r}t.Z=function(e){var t=e.prop,n=e.cssProperty,l=void 0===n?e.prop:n,u=e.themeKey,c=e.transform,d=function(e){if(null==e[t])return null;var n=e[t],d=i(e.theme,u)||{};return(0,o.k9)(e,n,(function(e){var n=s(d,c,e);return e===n&&"string"===typeof e&&(n=s(d,c,"".concat(t).concat("default"===e?"":(0,a.Z)(e)),e)),!1===l?n:(0,r.Z)({},l,n)}))};return d.propTypes={},d.filterProps=[t],d}},104:function(e,t,n){"use strict";var r=n(4942),a=n(8247),o=n(114),i=n(1184);function s(){for(var e=arguments.length,t=new Array(e),n=0;n<e;n++)t[n]=arguments[n];var r=t.reduce((function(e,t){return e.concat(Object.keys(t))}),[]),a=new Set(r);return t.every((function(e){return a.size===Object.keys(e).length}))}function l(e,t){return"function"===typeof e?e(t):e}var u=function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:o.G$,t=Object.keys(e).reduce((function(t,n){return e[n].filterProps.forEach((function(r){t[r]=e[n]})),t}),{});function n(e,n,a){var o,i=(o={},(0,r.Z)(o,e,n),(0,r.Z)(o,"theme",a),o),s=t[e];return s?s(i):(0,r.Z)({},e,n)}function u(e){var o=e||{},c=o.sx,d=o.theme,p=void 0===d?{}:d;if(!c)return null;function f(e){var o=e;if("function"===typeof e)o=e(p);else if("object"!==typeof e)return e;if(!o)return null;var c=(0,i.W8)(p.breakpoints),d=Object.keys(c),f=c;return Object.keys(o).forEach((function(e){var c=l(o[e],p);if(null!==c&&void 0!==c)if("object"===typeof c)if(t[e])f=(0,a.Z)(f,n(e,c,p));else{var d=(0,i.k9)({theme:p},c,(function(t){return(0,r.Z)({},e,t)}));s(d,c)?f[e]=u({sx:c,theme:p}):f=(0,a.Z)(f,d)}else f=(0,a.Z)(f,n(e,c,p))})),(0,i.L7)(d,f)}return Array.isArray(c)?c.map(f):f(c)}return u}();u.filterProps=["sx"],t.Z=u},886:function(e,t,n){"use strict";n.d(t,{Z:function(){return c}});var r=n(5080),a=n(2791);var o=a.createContext(null);function i(){return a.useContext(o)}function s(e){return 0===Object.keys(e).length}var l=function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:null,t=i();return!t||s(t)?e:t},u=(0,r.Z)();var c=function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:u;return l(e)}},8691:function(e,t,n){"use strict";n.d(t,{Z:function(){return i}});var r=n(7462);function a(e){var t=e.theme,n=e.name,a=e.props;return t&&t.components&&t.components[n]&&t.components[n].defaultProps?function(e,t){var n=(0,r.Z)({},t);return Object.keys(e).forEach((function(t){void 0===n[t]&&(n[t]=e[t])})),n}(t.components[n].defaultProps,a):a}var o=n(886);function i(e){var t=e.props,n=e.name,r=e.defaultTheme;return a({theme:(0,o.Z)(r),name:n,props:t})}},5902:function(e,t){"use strict";var n=function(e){return e},r=function(){var e=n;return{configure:function(t){e=t},generate:function(t){return e(t)},reset:function(){e=n}}}();t.Z=r},7312:function(e,t,n){"use strict";n.d(t,{Z:function(){return a}});var r=n(6189);function a(e){if("string"!==typeof e)throw new Error((0,r.Z)(7));return e.charAt(0).toUpperCase()+e.slice(1)}},4419:function(e,t,n){"use strict";function r(e,t,n){var r={};return Object.keys(e).forEach((function(a){r[a]=e[a].reduce((function(e,r){return r&&(e.push(t(r)),n&&n[r]&&e.push(n[r])),e}),[]).join(" ")})),r}n.d(t,{Z:function(){return r}})},2466:function(e,t,n){"use strict";n.d(t,{P:function(){return a},Z:function(){return o}});var r=n(7462);function a(e){return null!==e&&"object"===typeof e&&e.constructor===Object}function o(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:{clone:!0},i=n.clone?(0,r.Z)({},e):e;return a(e)&&a(t)&&Object.keys(t).forEach((function(r){"__proto__"!==r&&(a(t[r])&&r in e&&a(e[r])?i[r]=o(e[r],t[r],n):i[r]=t[r])})),i}},6189:function(e,t,n){"use strict";function r(e){for(var t="https://mui.com/production-error/?code="+e,n=1;n<arguments.length;n+=1)t+="&args[]="+encodeURIComponent(arguments[n]);return"Minified MUI error #"+e+"; visit "+t+" for the full message."}n.d(t,{Z:function(){return r}})},1217:function(e,t,n){"use strict";n.d(t,{Z:function(){return o}});var r=n(5902),a={active:"active",checked:"checked",completed:"completed",disabled:"disabled",error:"error",expanded:"expanded",focused:"focused",focusVisible:"focusVisible",required:"required",selected:"selected"};function o(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:"Mui",o=a[t];return o?"".concat(n,"-").concat(o):"".concat(r.Z.generate(e),"-").concat(t)}},5878:function(e,t,n){"use strict";n.d(t,{Z:function(){return a}});var r=n(1217);function a(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:"Mui",a={};return t.forEach((function(t){a[t]=(0,r.Z)(e,t,n)})),a}},2971:function(e,t,n){"use strict";function r(e,t){"function"===typeof e?e(t):e&&(e.current=t)}n.d(t,{Z:function(){return r}})},5721:function(e,t,n){"use strict";var r=n(2791),a="undefined"!==typeof window?r.useLayoutEffect:r.useEffect;t.Z=a},1694:function(e,t){var n;!function(){"use strict";var r={}.hasOwnProperty;function a(){for(var e=[],t=0;t<arguments.length;t++){var n=arguments[t];if(n){var o=typeof n;if("string"===o||"number"===o)e.push(n);else if(Array.isArray(n)){if(n.length){var i=a.apply(null,n);i&&e.push(i)}}else if("object"===o){if(n.toString!==Object.prototype.toString&&!n.toString.toString().includes("[native code]")){e.push(n.toString());continue}for(var s in n)r.call(n,s)&&n[s]&&e.push(s)}}}return e.join(" ")}e.exports?(a.default=a,e.exports=a):void 0===(n=function(){return a}.apply(t,[]))||(e.exports=n)}()},8182:function(e,t,n){"use strict";function r(e){var t,n,a="";if("string"==typeof e||"number"==typeof e)a+=e;else if("object"==typeof e)if(Array.isArray(e))for(t=0;t<e.length;t++)e[t]&&(n=r(e[t]))&&(a&&(a+=" "),a+=n);else for(t in e)e[t]&&(a&&(a+=" "),a+=t);return a}t.Z=function(){for(var e,t,n=0,a="";n<arguments.length;)(e=arguments[n++])&&(t=r(e))&&(a&&(a+=" "),a+=t);return a}},4173:function(e,t){!function(e){"use strict";function t(){}function n(e,t,n,r,a){for(var o=0,i=t.length,s=0,l=0;o<i;o++){var u=t[o];if(u.removed){if(u.value=e.join(r.slice(l,l+u.count)),l+=u.count,o&&t[o-1].added){var c=t[o-1];t[o-1]=t[o],t[o]=c}}else{if(!u.added&&a){var d=n.slice(s,s+u.count);d=d.map((function(e,t){var n=r[l+t];return n.length>e.length?n:e})),u.value=e.join(d)}else u.value=e.join(n.slice(s,s+u.count));s+=u.count,u.added||(l+=u.count)}}var p=t[i-1];return i>1&&"string"===typeof p.value&&(p.added||p.removed)&&e.equals("",p.value)&&(t[i-2].value+=p.value,t.pop()),t}function r(e){return{newPos:e.newPos,components:e.components.slice(0)}}t.prototype={diff:function(e,t){var a=arguments.length>2&&void 0!==arguments[2]?arguments[2]:{},o=a.callback;"function"===typeof a&&(o=a,a={}),this.options=a;var i=this;function s(e){return o?(setTimeout((function(){o(void 0,e)}),0),!0):e}e=this.castInput(e),t=this.castInput(t),e=this.removeEmpty(this.tokenize(e));var l=(t=this.removeEmpty(this.tokenize(t))).length,u=e.length,c=1,d=l+u,p=[{newPos:-1,components:[]}],f=this.extractCommon(p[0],t,e,0);if(p[0].newPos+1>=l&&f+1>=u)return s([{value:this.join(t),count:t.length}]);function m(){for(var a=-1*c;a<=c;a+=2){var o=void 0,d=p[a-1],f=p[a+1],m=(f?f.newPos:0)-a;d&&(p[a-1]=void 0);var h=d&&d.newPos+1<l,v=f&&0<=m&&m<u;if(h||v){if(!h||v&&d.newPos<f.newPos?(o=r(f),i.pushComponent(o.components,void 0,!0)):((o=d).newPos++,i.pushComponent(o.components,!0,void 0)),m=i.extractCommon(o,t,e,a),o.newPos+1>=l&&m+1>=u)return s(n(i,o.components,t,e,i.useLongestToken));p[a]=o}else p[a]=void 0}c++}if(o)!function e(){setTimeout((function(){if(c>d)return o();m()||e()}),0)}();else for(;c<=d;){var h=m();if(h)return h}},pushComponent:function(e,t,n){var r=e[e.length-1];r&&r.added===t&&r.removed===n?e[e.length-1]={count:r.count+1,added:t,removed:n}:e.push({count:1,added:t,removed:n})},extractCommon:function(e,t,n,r){for(var a=t.length,o=n.length,i=e.newPos,s=i-r,l=0;i+1<a&&s+1<o&&this.equals(t[i+1],n[s+1]);)i++,s++,l++;return l&&e.components.push({count:l}),e.newPos=i,s},equals:function(e,t){return this.options.comparator?this.options.comparator(e,t):e===t||this.options.ignoreCase&&e.toLowerCase()===t.toLowerCase()},removeEmpty:function(e){for(var t=[],n=0;n<e.length;n++)e[n]&&t.push(e[n]);return t},castInput:function(e){return e},tokenize:function(e){return e.split("")},join:function(e){return e.join("")}};var a=new t;function o(e,t,n){return a.diff(e,t,n)}function i(e,t){if("function"===typeof e)t.callback=e;else if(e)for(var n in e)e.hasOwnProperty(n)&&(t[n]=e[n]);return t}var s=/^[A-Za-z\xC0-\u02C6\u02C8-\u02D7\u02DE-\u02FF\u1E00-\u1EFF]+$/,l=/\S/,u=new t;function c(e,t,n){return n=i(n,{ignoreWhitespace:!0}),u.diff(e,t,n)}function d(e,t,n){return u.diff(e,t,n)}u.equals=function(e,t){return this.options.ignoreCase&&(e=e.toLowerCase(),t=t.toLowerCase()),e===t||this.options.ignoreWhitespace&&!l.test(e)&&!l.test(t)},u.tokenize=function(e){for(var t=e.split(/(\s+|[()[\]{}'"]|\b)/),n=0;n<t.length-1;n++)!t[n+1]&&t[n+2]&&s.test(t[n])&&s.test(t[n+2])&&(t[n]+=t[n+2],t.splice(n+1,2),n--);return t};var p=new t;function f(e,t,n){return p.diff(e,t,n)}function m(e,t,n){var r=i(n,{ignoreWhitespace:!0});return p.diff(e,t,r)}p.tokenize=function(e){var t=[],n=e.split(/(\n|\r\n)/);n[n.length-1]||n.pop();for(var r=0;r<n.length;r++){var a=n[r];r%2&&!this.options.newlineIsToken?t[t.length-1]+=a:(this.options.ignoreWhitespace&&(a=a.trim()),t.push(a))}return t};var h=new t;function v(e,t,n){return h.diff(e,t,n)}h.tokenize=function(e){return e.split(/(\S.+?[.!?])(?=\s+|$)/)};var y=new t;function b(e,t,n){return y.diff(e,t,n)}function g(e){return g="function"===typeof Symbol&&"symbol"===typeof Symbol.iterator?function(e){return typeof e}:function(e){return e&&"function"===typeof Symbol&&e.constructor===Symbol&&e!==Symbol.prototype?"symbol":typeof e},g(e)}function _(e){return w(e)||S(e)||T()}function w(e){if(Array.isArray(e)){for(var t=0,n=new Array(e.length);t<e.length;t++)n[t]=e[t];return n}}function S(e){if(Symbol.iterator in Object(e)||"[object Arguments]"===Object.prototype.toString.call(e))return Array.from(e)}function T(){throw new TypeError("Invalid attempt to spread non-iterable instance")}y.tokenize=function(e){return e.split(/([{}:;,]|\s+)/)};var C=Object.prototype.toString,k=new t;function A(e,t,n){return k.diff(e,t,n)}function x(e,t,n,r,a){var o,i;for(t=t||[],n=n||[],r&&(e=r(a,e)),o=0;o<t.length;o+=1)if(t[o]===e)return n[o];if("[object Array]"===C.call(e)){for(t.push(e),i=new Array(e.length),n.push(i),o=0;o<e.length;o+=1)i[o]=x(e[o],t,n,r,a);return t.pop(),n.pop(),i}if(e&&e.toJSON&&(e=e.toJSON()),"object"===g(e)&&null!==e){t.push(e),i={},n.push(i);var s,l=[];for(s in e)e.hasOwnProperty(s)&&l.push(s);for(l.sort(),o=0;o<l.length;o+=1)i[s=l[o]]=x(e[s],t,n,r,s);t.pop(),n.pop()}else i=e;return i}k.useLongestToken=!0,k.tokenize=p.tokenize,k.castInput=function(e){var t=this.options,n=t.undefinedReplacement,r=t.stringifyReplacer,a=void 0===r?function(e,t){return"undefined"===typeof t?n:t}:r;return"string"===typeof e?e:JSON.stringify(x(e,null,null,a),a,"  ")},k.equals=function(e,n){return t.prototype.equals.call(k,e.replace(/,([\r\n])/g,"$1"),n.replace(/,([\r\n])/g,"$1"))};var F=new t;function R(e,t,n){return F.diff(e,t,n)}function P(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},n=e.split(/\r\n|[\n\v\f\r\x85]/),r=e.match(/\r\n|[\n\v\f\r\x85]/g)||[],a=[],o=0;function i(){var e={};for(a.push(e);o<n.length;){var r=n[o];if(/^(\-\-\-|\+\+\+|@@)\s/.test(r))break;var i=/^(?:Index:|diff(?: -r \w+)+)\s+(.+?)\s*$/.exec(r);i&&(e.index=i[1]),o++}for(s(e),s(e),e.hunks=[];o<n.length;){var u=n[o];if(/^(Index:|diff|\-\-\-|\+\+\+)\s/.test(u))break;if(/^@@/.test(u))e.hunks.push(l());else{if(u&&t.strict)throw new Error("Unknown line "+(o+1)+" "+JSON.stringify(u));o++}}}function s(e){var t=/^(---|\+\+\+)\s+(.*)$/.exec(n[o]);if(t){var r="---"===t[1]?"old":"new",a=t[2].split("\t",2),i=a[0].replace(/\\\\/g,"\\");/^".*"$/.test(i)&&(i=i.substr(1,i.length-2)),e[r+"FileName"]=i,e[r+"Header"]=(a[1]||"").trim(),o++}}function l(){for(var e=o,a=n[o++].split(/@@ -(\d+)(?:,(\d+))? \+(\d+)(?:,(\d+))? @@/),i={oldStart:+a[1],oldLines:+a[2]||1,newStart:+a[3],newLines:+a[4]||1,lines:[],linedelimiters:[]},s=0,l=0;o<n.length&&!(0===n[o].indexOf("--- ")&&o+2<n.length&&0===n[o+1].indexOf("+++ ")&&0===n[o+2].indexOf("@@"));o++){var u=0==n[o].length&&o!=n.length-1?" ":n[o][0];if("+"!==u&&"-"!==u&&" "!==u&&"\\"!==u)break;i.lines.push(n[o]),i.linedelimiters.push(r[o]||"\n"),"+"===u?s++:"-"===u?l++:" "===u&&(s++,l++)}if(s||1!==i.newLines||(i.newLines=0),l||1!==i.oldLines||(i.oldLines=0),t.strict){if(s!==i.newLines)throw new Error("Added line count did not match for hunk at line "+(e+1));if(l!==i.oldLines)throw new Error("Removed line count did not match for hunk at line "+(e+1))}return i}for(;o<n.length;)i();return a}function E(e,t,n){var r=!0,a=!1,o=!1,i=1;return function s(){if(r&&!o){if(a?i++:r=!1,e+i<=n)return i;o=!0}if(!a)return o||(r=!0),t<=e-i?-i++:(a=!0,s())}}function O(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:{};if("string"===typeof t&&(t=P(t)),Array.isArray(t)){if(t.length>1)throw new Error("applyPatch only works with a single input.");t=t[0]}var r,a,o=e.split(/\r\n|[\n\v\f\r\x85]/),i=e.match(/\r\n|[\n\v\f\r\x85]/g)||[],s=t.hunks,l=n.compareLine||function(e,t,n,r){return t===r},u=0,c=n.fuzzFactor||0,d=0,p=0;function f(e,t){for(var n=0;n<e.lines.length;n++){var r=e.lines[n],a=r.length>0?r[0]:" ",i=r.length>0?r.substr(1):r;if(" "===a||"-"===a){if(!l(t+1,o[t],a,i)&&++u>c)return!1;t++}}return!0}for(var m=0;m<s.length;m++){for(var h=s[m],v=o.length-h.oldLines,y=0,b=p+h.oldStart-1,g=E(b,d,v);void 0!==y;y=g())if(f(h,b+y)){h.offset=p+=y;break}if(void 0===y)return!1;d=h.offset+h.oldStart+h.oldLines}for(var _=0,w=0;w<s.length;w++){var S=s[w],T=S.oldStart+S.offset+_-1;_+=S.newLines-S.oldLines,T<0&&(T=0);for(var C=0;C<S.lines.length;C++){var k=S.lines[C],A=k.length>0?k[0]:" ",x=k.length>0?k.substr(1):k,F=S.linedelimiters[C];if(" "===A)T++;else if("-"===A)o.splice(T,1),i.splice(T,1);else if("+"===A)o.splice(T,0,x),i.splice(T,0,F),T++;else if("\\"===A){var R=S.lines[C-1]?S.lines[C-1][0]:null;"+"===R?r=!0:"-"===R&&(a=!0)}}}if(r)for(;!o[o.length-1];)o.pop(),i.pop();else a&&(o.push(""),i.push("\n"));for(var O=0;O<o.length-1;O++)o[O]=o[O]+i[O];return o.join("")}function N(e,t){"string"===typeof e&&(e=P(e));var n=0;function r(){var a=e[n++];if(!a)return t.complete();t.loadFile(a,(function(e,n){if(e)return t.complete(e);var o=O(n,a,t);t.patched(a,o,(function(e){if(e)return t.complete(e);r()}))}))}r()}function I(e,t,n,r,a,o,i){i||(i={}),"undefined"===typeof i.context&&(i.context=4);var s=f(n,r,i);function l(e){return e.map((function(e){return" "+e}))}s.push({value:"",lines:[]});for(var u=[],c=0,d=0,p=[],m=1,h=1,v=function(e){var t=s[e],a=t.lines||t.value.replace(/\n$/,"").split("\n");if(t.lines=a,t.added||t.removed){var o;if(!c){var f=s[e-1];c=m,d=h,f&&(p=i.context>0?l(f.lines.slice(-i.context)):[],c-=p.length,d-=p.length)}(o=p).push.apply(o,_(a.map((function(e){return(t.added?"+":"-")+e})))),t.added?h+=a.length:m+=a.length}else{if(c)if(a.length<=2*i.context&&e<s.length-2){var v;(v=p).push.apply(v,_(l(a)))}else{var y,b=Math.min(a.length,i.context);(y=p).push.apply(y,_(l(a.slice(0,b))));var g={oldStart:c,oldLines:m-c+b,newStart:d,newLines:h-d+b,lines:p};if(e>=s.length-2&&a.length<=i.context){var w=/\n$/.test(n),S=/\n$/.test(r),T=0==a.length&&p.length>g.oldLines;!w&&T&&p.splice(g.oldLines,0,"\\ No newline at end of file"),(w||T)&&S||p.push("\\ No newline at end of file")}u.push(g),c=0,d=0,p=[]}m+=a.length,h+=a.length}},y=0;y<s.length;y++)v(y);return{oldFileName:e,newFileName:t,oldHeader:a,newHeader:o,hunks:u}}function M(e,t,n,r,a,o,i){var s=I(e,t,n,r,a,o,i),l=[];e==t&&l.push("Index: "+e),l.push("==================================================================="),l.push("--- "+s.oldFileName+("undefined"===typeof s.oldHeader?"":"\t"+s.oldHeader)),l.push("+++ "+s.newFileName+("undefined"===typeof s.newHeader?"":"\t"+s.newHeader));for(var u=0;u<s.hunks.length;u++){var c=s.hunks[u];l.push("@@ -"+c.oldStart+","+c.oldLines+" +"+c.newStart+","+c.newLines+" @@"),l.push.apply(l,c.lines)}return l.join("\n")+"\n"}function z(e,t,n,r,a,o){return M(e,e,t,n,r,a,o)}function D(e,t){return e.length===t.length&&L(e,t)}function L(e,t){if(t.length>e.length)return!1;for(var n=0;n<t.length;n++)if(t[n]!==e[n])return!1;return!0}function Z(e){var t=ne(e.lines),n=t.oldLines,r=t.newLines;void 0!==n?e.oldLines=n:delete e.oldLines,void 0!==r?e.newLines=r:delete e.newLines}function j(e,t,n){e=B(e,n),t=B(t,n);var r={};(e.index||t.index)&&(r.index=e.index||t.index),(e.newFileName||t.newFileName)&&(W(e)?W(t)?(r.oldFileName=J(r,e.oldFileName,t.oldFileName),r.newFileName=J(r,e.newFileName,t.newFileName),r.oldHeader=J(r,e.oldHeader,t.oldHeader),r.newHeader=J(r,e.newHeader,t.newHeader)):(r.oldFileName=e.oldFileName,r.newFileName=e.newFileName,r.oldHeader=e.oldHeader,r.newHeader=e.newHeader):(r.oldFileName=t.oldFileName||e.oldFileName,r.newFileName=t.newFileName||e.newFileName,r.oldHeader=t.oldHeader||e.oldHeader,r.newHeader=t.newHeader||e.newHeader)),r.hunks=[];for(var a=0,o=0,i=0,s=0;a<e.hunks.length||o<t.hunks.length;){var l=e.hunks[a]||{oldStart:1/0},u=t.hunks[o]||{oldStart:1/0};if(U(l,u))r.hunks.push(V(l,i)),a++,s+=l.newLines-l.oldLines;else if(U(u,l))r.hunks.push(V(u,s)),o++,i+=u.newLines-u.oldLines;else{var c={oldStart:Math.min(l.oldStart,u.oldStart),oldLines:0,newStart:Math.min(l.newStart+i,u.oldStart+s),newLines:0,lines:[]};$(c,l.oldStart,l.lines,u.oldStart,u.lines),o++,a++,r.hunks.push(c)}}return r}function B(e,t){if("string"===typeof e){if(/^@@/m.test(e)||/^Index:/m.test(e))return P(e)[0];if(!t)throw new Error("Must provide a base reference or pass in a patch");return I(void 0,void 0,t,e)}return e}function W(e){return e.newFileName&&e.newFileName!==e.oldFileName}function J(e,t,n){return t===n?t:(e.conflict=!0,{mine:t,theirs:n})}function U(e,t){return e.oldStart<t.oldStart&&e.oldStart+e.oldLines<t.oldStart}function V(e,t){return{oldStart:e.oldStart,oldLines:e.oldLines,newStart:e.newStart+t,newLines:e.newLines,lines:e.lines}}function $(e,t,n,r,a){var o={offset:t,lines:n,index:0},i={offset:r,lines:a,index:0};for(K(e,o,i),K(e,i,o);o.index<o.lines.length&&i.index<i.lines.length;){var s=o.lines[o.index],l=i.lines[i.index];if("-"!==s[0]&&"+"!==s[0]||"-"!==l[0]&&"+"!==l[0])if("+"===s[0]&&" "===l[0]){var u;(u=e.lines).push.apply(u,_(X(o)))}else if("+"===l[0]&&" "===s[0]){var c;(c=e.lines).push.apply(c,_(X(i)))}else"-"===s[0]&&" "===l[0]?G(e,o,i):"-"===l[0]&&" "===s[0]?G(e,i,o,!0):s===l?(e.lines.push(s),o.index++,i.index++):q(e,X(o),X(i));else H(e,o,i)}Q(e,o),Q(e,i),Z(e)}function H(e,t,n){var r=X(t),a=X(n);if(ee(r)&&ee(a)){var o,i;if(L(r,a)&&te(n,r,r.length-a.length))return void(o=e.lines).push.apply(o,_(r));if(L(a,r)&&te(t,a,a.length-r.length))return void(i=e.lines).push.apply(i,_(a))}else if(D(r,a)){var s;return void(s=e.lines).push.apply(s,_(r))}q(e,r,a)}function G(e,t,n,r){var a,o=X(t),i=Y(n,o);i.merged?(a=e.lines).push.apply(a,_(i.merged)):q(e,r?i:o,r?o:i)}function q(e,t,n){e.conflict=!0,e.lines.push({conflict:!0,mine:t,theirs:n})}function K(e,t,n){for(;t.offset<n.offset&&t.index<t.lines.length;){var r=t.lines[t.index++];e.lines.push(r),t.offset++}}function Q(e,t){for(;t.index<t.lines.length;){var n=t.lines[t.index++];e.lines.push(n)}}function X(e){for(var t=[],n=e.lines[e.index][0];e.index<e.lines.length;){var r=e.lines[e.index];if("-"===n&&"+"===r[0]&&(n="+"),n!==r[0])break;t.push(r),e.index++}return t}function Y(e,t){for(var n=[],r=[],a=0,o=!1,i=!1;a<t.length&&e.index<e.lines.length;){var s=e.lines[e.index],l=t[a];if("+"===l[0])break;if(o=o||" "!==s[0],r.push(l),a++,"+"===s[0])for(i=!0;"+"===s[0];)n.push(s),s=e.lines[++e.index];l.substr(1)===s.substr(1)?(n.push(s),e.index++):i=!0}if("+"===(t[a]||"")[0]&&o&&(i=!0),i)return n;for(;a<t.length;)r.push(t[a++]);return{merged:r,changes:n}}function ee(e){return e.reduce((function(e,t){return e&&"-"===t[0]}),!0)}function te(e,t,n){for(var r=0;r<n;r++){var a=t[t.length-n+r].substr(1);if(e.lines[e.index+r]!==" "+a)return!1}return e.index+=n,!0}function ne(e){var t=0,n=0;return e.forEach((function(e){if("string"!==typeof e){var r=ne(e.mine),a=ne(e.theirs);void 0!==t&&(r.oldLines===a.oldLines?t+=r.oldLines:t=void 0),void 0!==n&&(r.newLines===a.newLines?n+=r.newLines:n=void 0)}else void 0===n||"+"!==e[0]&&" "!==e[0]||n++,void 0===t||"-"!==e[0]&&" "!==e[0]||t++})),{oldLines:t,newLines:n}}function re(e){for(var t,n,r=[],a=0;a<e.length;a++)n=(t=e[a]).added?1:t.removed?-1:0,r.push([n,t.value]);return r}function ae(e){for(var t=[],n=0;n<e.length;n++){var r=e[n];r.added?t.push("<ins>"):r.removed&&t.push("<del>"),t.push(oe(r.value)),r.added?t.push("</ins>"):r.removed&&t.push("</del>")}return t.join("")}function oe(e){var t=e;return t=(t=(t=(t=t.replace(/&/g,"&amp;")).replace(/</g,"&lt;")).replace(/>/g,"&gt;")).replace(/"/g,"&quot;")}F.tokenize=function(e){return e.slice()},F.join=F.removeEmpty=function(e){return e},e.Diff=t,e.diffChars=o,e.diffWords=c,e.diffWordsWithSpace=d,e.diffLines=f,e.diffTrimmedLines=m,e.diffSentences=v,e.diffCss=b,e.diffJson=A,e.diffArrays=R,e.structuredPatch=I,e.createTwoFilesPatch=M,e.createPatch=z,e.applyPatch=O,e.applyPatches=N,e.parsePatch=P,e.merge=j,e.convertChangesToDMP=re,e.convertChangesToXML=ae,e.canonicalize=x,Object.defineProperty(e,"__esModule",{value:!0})}(t)},6025:function(e,t,n){"use strict";n.r(t),n.d(t,{cache:function(){return Z},css:function(){return D},cx:function(){return O},flush:function(){return P},getRegisteredStyles:function(){return I},hydrate:function(){return E},injectGlobal:function(){return M},keyframes:function(){return z},merge:function(){return N},sheet:function(){return L}});var r=function(){function e(e){this.isSpeedy=void 0===e.speedy||e.speedy,this.tags=[],this.ctr=0,this.nonce=e.nonce,this.key=e.key,this.container=e.container,this.before=null}var t=e.prototype;return t.insert=function(e){if(this.ctr%(this.isSpeedy?65e3:1)===0){var t,n=function(e){var t=document.createElement("style");return t.setAttribute("data-emotion",e.key),void 0!==e.nonce&&t.setAttribute("nonce",e.nonce),t.appendChild(document.createTextNode("")),t}(this);t=0===this.tags.length?this.before:this.tags[this.tags.length-1].nextSibling,this.container.insertBefore(n,t),this.tags.push(n)}var r=this.tags[this.tags.length-1];if(this.isSpeedy){var a=function(e){if(e.sheet)return e.sheet;for(var t=0;t<document.styleSheets.length;t++)if(document.styleSheets[t].ownerNode===e)return document.styleSheets[t]}(r);try{var o=105===e.charCodeAt(1)&&64===e.charCodeAt(0);a.insertRule(e,o?0:a.cssRules.length)}catch(i){0}}else r.appendChild(document.createTextNode(e));this.ctr++},t.flush=function(){this.tags.forEach((function(e){return e.parentNode.removeChild(e)})),this.tags=[],this.ctr=0},e}();var a=function(e){function t(e,r,l,u,p){for(var f,m,h,v,_,S=0,T=0,C=0,k=0,A=0,O=0,I=h=f=0,z=0,D=0,L=0,Z=0,j=l.length,B=j-1,W="",J="",U="",V="";z<j;){if(m=l.charCodeAt(z),z===B&&0!==T+k+C+S&&(0!==T&&(m=47===T?10:47),k=C=S=0,j++,B++),0===T+k+C+S){if(z===B&&(0<D&&(W=W.replace(d,"")),0<W.trim().length)){switch(m){case 32:case 9:case 59:case 13:case 10:break;default:W+=l.charAt(z)}m=59}switch(m){case 123:for(f=(W=W.trim()).charCodeAt(0),h=1,Z=++z;z<j;){switch(m=l.charCodeAt(z)){case 123:h++;break;case 125:h--;break;case 47:switch(m=l.charCodeAt(z+1)){case 42:case 47:e:{for(I=z+1;I<B;++I)switch(l.charCodeAt(I)){case 47:if(42===m&&42===l.charCodeAt(I-1)&&z+2!==I){z=I+1;break e}break;case 10:if(47===m){z=I+1;break e}}z=I}}break;case 91:m++;case 40:m++;case 34:case 39:for(;z++<B&&l.charCodeAt(z)!==m;);}if(0===h)break;z++}if(h=l.substring(Z,z),0===f&&(f=(W=W.replace(c,"").trim()).charCodeAt(0)),64===f){switch(0<D&&(W=W.replace(d,"")),m=W.charCodeAt(1)){case 100:case 109:case 115:case 45:D=r;break;default:D=E}if(Z=(h=t(r,D,h,m,p+1)).length,0<N&&(_=s(3,h,D=n(E,W,L),r,F,x,Z,m,p,u),W=D.join(""),void 0!==_&&0===(Z=(h=_.trim()).length)&&(m=0,h="")),0<Z)switch(m){case 115:W=W.replace(w,i);case 100:case 109:case 45:h=W+"{"+h+"}";break;case 107:h=(W=W.replace(y,"$1 $2"))+"{"+h+"}",h=1===P||2===P&&o("@"+h,3)?"@-webkit-"+h+"@"+h:"@"+h;break;default:h=W+h,112===u&&(J+=h,h="")}else h=""}else h=t(r,n(r,W,L),h,u,p+1);U+=h,h=L=D=I=f=0,W="",m=l.charCodeAt(++z);break;case 125:case 59:if(1<(Z=(W=(0<D?W.replace(d,""):W).trim()).length))switch(0===I&&(f=W.charCodeAt(0),45===f||96<f&&123>f)&&(Z=(W=W.replace(" ",":")).length),0<N&&void 0!==(_=s(1,W,r,e,F,x,J.length,u,p,u))&&0===(Z=(W=_.trim()).length)&&(W="\0\0"),f=W.charCodeAt(0),m=W.charCodeAt(1),f){case 0:break;case 64:if(105===m||99===m){V+=W+l.charAt(z);break}default:58!==W.charCodeAt(Z-1)&&(J+=a(W,f,m,W.charCodeAt(2)))}L=D=I=f=0,W="",m=l.charCodeAt(++z)}}switch(m){case 13:case 10:47===T?T=0:0===1+f&&107!==u&&0<W.length&&(D=1,W+="\0"),0<N*M&&s(0,W,r,e,F,x,J.length,u,p,u),x=1,F++;break;case 59:case 125:if(0===T+k+C+S){x++;break}default:switch(x++,v=l.charAt(z),m){case 9:case 32:if(0===k+S+T)switch(A){case 44:case 58:case 9:case 32:v="";break;default:32!==m&&(v=" ")}break;case 0:v="\\0";break;case 12:v="\\f";break;case 11:v="\\v";break;case 38:0===k+T+S&&(D=L=1,v="\f"+v);break;case 108:if(0===k+T+S+R&&0<I)switch(z-I){case 2:112===A&&58===l.charCodeAt(z-3)&&(R=A);case 8:111===O&&(R=O)}break;case 58:0===k+T+S&&(I=z);break;case 44:0===T+C+k+S&&(D=1,v+="\r");break;case 34:case 39:0===T&&(k=k===m?0:0===k?m:k);break;case 91:0===k+T+C&&S++;break;case 93:0===k+T+C&&S--;break;case 41:0===k+T+S&&C--;break;case 40:if(0===k+T+S){if(0===f)if(2*A+3*O===533);else f=1;C++}break;case 64:0===T+C+k+S+I+h&&(h=1);break;case 42:case 47:if(!(0<k+S+C))switch(T){case 0:switch(2*m+3*l.charCodeAt(z+1)){case 235:T=47;break;case 220:Z=z,T=42}break;case 42:47===m&&42===A&&Z+2!==z&&(33===l.charCodeAt(Z+2)&&(J+=l.substring(Z,z+1)),v="",T=0)}}0===T&&(W+=v)}O=A,A=m,z++}if(0<(Z=J.length)){if(D=r,0<N&&(void 0!==(_=s(2,J,D,e,F,x,Z,u,p,u))&&0===(J=_).length))return V+J+U;if(J=D.join(",")+"{"+J+"}",0!==P*R){switch(2!==P||o(J,2)||(R=0),R){case 111:J=J.replace(g,":-moz-$1")+J;break;case 112:J=J.replace(b,"::-webkit-input-$1")+J.replace(b,"::-moz-$1")+J.replace(b,":-ms-input-$1")+J}R=0}}return V+J+U}function n(e,t,n){var a=t.trim().split(h);t=a;var o=a.length,i=e.length;switch(i){case 0:case 1:var s=0;for(e=0===i?"":e[0]+" ";s<o;++s)t[s]=r(e,t[s],n).trim();break;default:var l=s=0;for(t=[];s<o;++s)for(var u=0;u<i;++u)t[l++]=r(e[u]+" ",a[s],n).trim()}return t}function r(e,t,n){var r=t.charCodeAt(0);switch(33>r&&(r=(t=t.trim()).charCodeAt(0)),r){case 38:return t.replace(v,"$1"+e.trim());case 58:return e.trim()+t.replace(v,"$1"+e.trim());default:if(0<1*n&&0<t.indexOf("\f"))return t.replace(v,(58===e.charCodeAt(0)?"":"$1")+e.trim())}return e+t}function a(e,t,n,r){var i=e+";",s=2*t+3*n+4*r;if(944===s){e=i.indexOf(":",9)+1;var l=i.substring(e,i.length-1).trim();return l=i.substring(0,e).trim()+l+";",1===P||2===P&&o(l,1)?"-webkit-"+l+l:l}if(0===P||2===P&&!o(i,1))return i;switch(s){case 1015:return 97===i.charCodeAt(10)?"-webkit-"+i+i:i;case 951:return 116===i.charCodeAt(3)?"-webkit-"+i+i:i;case 963:return 110===i.charCodeAt(5)?"-webkit-"+i+i:i;case 1009:if(100!==i.charCodeAt(4))break;case 969:case 942:return"-webkit-"+i+i;case 978:return"-webkit-"+i+"-moz-"+i+i;case 1019:case 983:return"-webkit-"+i+"-moz-"+i+"-ms-"+i+i;case 883:if(45===i.charCodeAt(8))return"-webkit-"+i+i;if(0<i.indexOf("image-set(",11))return i.replace(A,"$1-webkit-$2")+i;break;case 932:if(45===i.charCodeAt(4))switch(i.charCodeAt(5)){case 103:return"-webkit-box-"+i.replace("-grow","")+"-webkit-"+i+"-ms-"+i.replace("grow","positive")+i;case 115:return"-webkit-"+i+"-ms-"+i.replace("shrink","negative")+i;case 98:return"-webkit-"+i+"-ms-"+i.replace("basis","preferred-size")+i}return"-webkit-"+i+"-ms-"+i+i;case 964:return"-webkit-"+i+"-ms-flex-"+i+i;case 1023:if(99!==i.charCodeAt(8))break;return"-webkit-box-pack"+(l=i.substring(i.indexOf(":",15)).replace("flex-","").replace("space-between","justify"))+"-webkit-"+i+"-ms-flex-pack"+l+i;case 1005:return f.test(i)?i.replace(p,":-webkit-")+i.replace(p,":-moz-")+i:i;case 1e3:switch(t=(l=i.substring(13).trim()).indexOf("-")+1,l.charCodeAt(0)+l.charCodeAt(t)){case 226:l=i.replace(_,"tb");break;case 232:l=i.replace(_,"tb-rl");break;case 220:l=i.replace(_,"lr");break;default:return i}return"-webkit-"+i+"-ms-"+l+i;case 1017:if(-1===i.indexOf("sticky",9))break;case 975:switch(t=(i=e).length-10,s=(l=(33===i.charCodeAt(t)?i.substring(0,t):i).substring(e.indexOf(":",7)+1).trim()).charCodeAt(0)+(0|l.charCodeAt(7))){case 203:if(111>l.charCodeAt(8))break;case 115:i=i.replace(l,"-webkit-"+l)+";"+i;break;case 207:case 102:i=i.replace(l,"-webkit-"+(102<s?"inline-":"")+"box")+";"+i.replace(l,"-webkit-"+l)+";"+i.replace(l,"-ms-"+l+"box")+";"+i}return i+";";case 938:if(45===i.charCodeAt(5))switch(i.charCodeAt(6)){case 105:return l=i.replace("-items",""),"-webkit-"+i+"-webkit-box-"+l+"-ms-flex-"+l+i;case 115:return"-webkit-"+i+"-ms-flex-item-"+i.replace(T,"")+i;default:return"-webkit-"+i+"-ms-flex-line-pack"+i.replace("align-content","").replace(T,"")+i}break;case 973:case 989:if(45!==i.charCodeAt(3)||122===i.charCodeAt(4))break;case 931:case 953:if(!0===k.test(e))return 115===(l=e.substring(e.indexOf(":")+1)).charCodeAt(0)?a(e.replace("stretch","fill-available"),t,n,r).replace(":fill-available",":stretch"):i.replace(l,"-webkit-"+l)+i.replace(l,"-moz-"+l.replace("fill-",""))+i;break;case 962:if(i="-webkit-"+i+(102===i.charCodeAt(5)?"-ms-"+i:"")+i,211===n+r&&105===i.charCodeAt(13)&&0<i.indexOf("transform",10))return i.substring(0,i.indexOf(";",27)+1).replace(m,"$1-webkit-$2")+i}return i}function o(e,t){var n=e.indexOf(1===t?":":"{"),r=e.substring(0,3!==t?n:10);return n=e.substring(n+1,e.length-1),I(2!==t?r:r.replace(C,"$1"),n,t)}function i(e,t){var n=a(t,t.charCodeAt(0),t.charCodeAt(1),t.charCodeAt(2));return n!==t+";"?n.replace(S," or ($1)").substring(4):"("+t+")"}function s(e,t,n,r,a,o,i,s,l,c){for(var d,p=0,f=t;p<N;++p)switch(d=O[p].call(u,e,f,n,r,a,o,i,s,l,c)){case void 0:case!1:case!0:case null:break;default:f=d}if(f!==t)return f}function l(e){return void 0!==(e=e.prefix)&&(I=null,e?"function"!==typeof e?P=1:(P=2,I=e):P=0),l}function u(e,n){var r=e;if(33>r.charCodeAt(0)&&(r=r.trim()),r=[r],0<N){var a=s(-1,n,r,r,F,x,0,0,0,0);void 0!==a&&"string"===typeof a&&(n=a)}var o=t(E,r,n,0,0);return 0<N&&(void 0!==(a=s(-2,o,r,r,F,x,o.length,0,0,0))&&(o=a)),"",R=0,x=F=1,o}var c=/^\0+/g,d=/[\0\r\f]/g,p=/: */g,f=/zoo|gra/,m=/([,: ])(transform)/g,h=/,\r+?/g,v=/([\t\r\n ])*\f?&/g,y=/@(k\w+)\s*(\S*)\s*/,b=/::(place)/g,g=/:(read-only)/g,_=/[svh]\w+-[tblr]{2}/,w=/\(\s*(.*)\s*\)/g,S=/([\s\S]*?);/g,T=/-self|flex-/g,C=/[^]*?(:[rp][el]a[\w-]+)[^]*/,k=/stretch|:\s*\w+\-(?:conte|avail)/,A=/([^-])(image-set\()/,x=1,F=1,R=0,P=1,E=[],O=[],N=0,I=null,M=0;return u.use=function e(t){switch(t){case void 0:case null:N=O.length=0;break;default:if("function"===typeof t)O[N++]=t;else if("object"===typeof t)for(var n=0,r=t.length;n<r;++n)e(t[n]);else M=0|!!t}return e},u.set=l,void 0!==e&&l(e),u},o="/*|*/";function i(e){e&&s.current.insert(e+"}")}var s={current:null},l=function(e,t,n,r,a,l,u,c,d,p){switch(e){case 1:switch(t.charCodeAt(0)){case 64:return s.current.insert(t+";"),"";case 108:if(98===t.charCodeAt(2))return""}break;case 2:if(0===c)return t+o;break;case 3:switch(c){case 102:case 112:return s.current.insert(n[0]+t),"";default:return t+(0===p?o:"")}case-2:t.split("/*|*/}").forEach(i)}},u=function(e){void 0===e&&(e={});var t,n=e.key||"css";void 0!==e.prefix&&(t={prefix:e.prefix});var o=new a(t);var i,u={};i=e.container||document.head;var c,d=document.querySelectorAll("style[data-emotion-"+n+"]");Array.prototype.forEach.call(d,(function(e){e.getAttribute("data-emotion-"+n).split(" ").forEach((function(e){u[e]=!0})),e.parentNode!==i&&i.appendChild(e)})),o.use(e.stylisPlugins)(l),c=function(e,t,n,r){var a=t.name;s.current=n,o(e,t.styles),r&&(p.inserted[a]=!0)};var p={key:n,sheet:new r({key:n,container:i,nonce:e.nonce,speedy:e.speedy}),nonce:e.nonce,inserted:u,registered:{},insert:c};return p};var c=function(e){for(var t,n=0,r=0,a=e.length;a>=4;++r,a-=4)t=1540483477*(65535&(t=255&e.charCodeAt(r)|(255&e.charCodeAt(++r))<<8|(255&e.charCodeAt(++r))<<16|(255&e.charCodeAt(++r))<<24))+(59797*(t>>>16)<<16),n=1540483477*(65535&(t^=t>>>24))+(59797*(t>>>16)<<16)^1540483477*(65535&n)+(59797*(n>>>16)<<16);switch(a){case 3:n^=(255&e.charCodeAt(r+2))<<16;case 2:n^=(255&e.charCodeAt(r+1))<<8;case 1:n=1540483477*(65535&(n^=255&e.charCodeAt(r)))+(59797*(n>>>16)<<16)}return(((n=1540483477*(65535&(n^=n>>>13))+(59797*(n>>>16)<<16))^n>>>15)>>>0).toString(36)},d={animationIterationCount:1,borderImageOutset:1,borderImageSlice:1,borderImageWidth:1,boxFlex:1,boxFlexGroup:1,boxOrdinalGroup:1,columnCount:1,columns:1,flex:1,flexGrow:1,flexPositive:1,flexShrink:1,flexNegative:1,flexOrder:1,gridRow:1,gridRowEnd:1,gridRowSpan:1,gridRowStart:1,gridColumn:1,gridColumnEnd:1,gridColumnSpan:1,gridColumnStart:1,msGridRow:1,msGridRowSpan:1,msGridColumn:1,msGridColumnSpan:1,fontWeight:1,lineHeight:1,opacity:1,order:1,orphans:1,tabSize:1,widows:1,zIndex:1,zoom:1,WebkitLineClamp:1,fillOpacity:1,floodOpacity:1,stopOpacity:1,strokeDasharray:1,strokeDashoffset:1,strokeMiterlimit:1,strokeOpacity:1,strokeWidth:1};var p=function(e){var t={};return function(n){return void 0===t[n]&&(t[n]=e(n)),t[n]}},f=/[A-Z]|^ms/g,m=/_EMO_([^_]+?)_([^]*?)_EMO_/g,h=function(e){return 45===e.charCodeAt(1)},v=function(e){return null!=e&&"boolean"!==typeof e},y=p((function(e){return h(e)?e:e.replace(f,"-$&").toLowerCase()})),b=function(e,t){switch(e){case"animation":case"animationName":if("string"===typeof t)return t.replace(m,(function(e,t,n){return _={name:t,styles:n,next:_},t}))}return 1===d[e]||h(e)||"number"!==typeof t||0===t?t:t+"px"};function g(e,t,n,r){if(null==n)return"";if(void 0!==n.__emotion_styles)return n;switch(typeof n){case"boolean":return"";case"object":if(1===n.anim)return _={name:n.name,styles:n.styles,next:_},n.name;if(void 0!==n.styles){var a=n.next;if(void 0!==a)for(;void 0!==a;)_={name:a.name,styles:a.styles,next:_},a=a.next;return n.styles+";"}return function(e,t,n){var r="";if(Array.isArray(n))for(var a=0;a<n.length;a++)r+=g(e,t,n[a],!1);else for(var o in n){var i=n[o];if("object"!==typeof i)null!=t&&void 0!==t[i]?r+=o+"{"+t[i]+"}":v(i)&&(r+=y(o)+":"+b(o,i)+";");else if(!Array.isArray(i)||"string"!==typeof i[0]||null!=t&&void 0!==t[i[0]]){var s=g(e,t,i,!1);switch(o){case"animation":case"animationName":r+=y(o)+":"+s+";";break;default:r+=o+"{"+s+"}"}}else for(var l=0;l<i.length;l++)v(i[l])&&(r+=y(o)+":"+b(o,i[l])+";")}return r}(e,t,n);case"function":if(void 0!==e){var o=_,i=n(e);return _=o,g(e,t,i,r)}}if(null==t)return n;var s=t[n];return void 0===s||r?n:s}var _,w=/label:\s*([^\s;\n{]+)\s*;/g;var S=function(e,t,n){if(1===e.length&&"object"===typeof e[0]&&null!==e[0]&&void 0!==e[0].styles)return e[0];var r=!0,a="";_=void 0;var o=e[0];null==o||void 0===o.raw?(r=!1,a+=g(n,t,o,!1)):a+=o[0];for(var i=1;i<e.length;i++)a+=g(n,t,e[i],46===a.charCodeAt(a.length-1)),r&&(a+=o[i]);w.lastIndex=0;for(var s,l="";null!==(s=w.exec(a));)l+="-"+s[1];return{name:c(a)+l,styles:a,next:_}};function T(e,t,n){var r="";return n.split(" ").forEach((function(n){void 0!==e[n]?t.push(e[n]):r+=n+" "})),r}var C=function(e,t,n){var r=e.key+"-"+t.name;if(!1===n&&void 0===e.registered[r]&&(e.registered[r]=t.styles),void 0===e.inserted[t.name]){var a=t;do{e.insert("."+r,a,e.sheet,!0);a=a.next}while(void 0!==a)}};function k(e,t){if(void 0===e.inserted[t.name])return e.insert("",t,e.sheet,!0)}function A(e,t,n){var r=[],a=T(e,r,n);return r.length<2?n:a+t(r)}var x=function e(t){for(var n="",r=0;r<t.length;r++){var a=t[r];if(null!=a){var o=void 0;switch(typeof a){case"boolean":break;case"object":if(Array.isArray(a))o=e(a);else for(var i in o="",a)a[i]&&i&&(o&&(o+=" "),o+=i);break;default:o=a}o&&(n&&(n+=" "),n+=o)}}return n},F=function(e){var t=u(e);t.sheet.speedy=function(e){this.isSpeedy=e},t.compat=!0;var n=function(){for(var e=arguments.length,n=new Array(e),r=0;r<e;r++)n[r]=arguments[r];var a=S(n,t.registered,void 0);return C(t,a,!1),t.key+"-"+a.name};return{css:n,cx:function(){for(var e=arguments.length,r=new Array(e),a=0;a<e;a++)r[a]=arguments[a];return A(t.registered,n,x(r))},injectGlobal:function(){for(var e=arguments.length,n=new Array(e),r=0;r<e;r++)n[r]=arguments[r];var a=S(n,t.registered);k(t,a)},keyframes:function(){for(var e=arguments.length,n=new Array(e),r=0;r<e;r++)n[r]=arguments[r];var a=S(n,t.registered),o="animation-"+a.name;return k(t,{name:a.name,styles:"@keyframes "+o+"{"+a.styles+"}"}),o},hydrate:function(e){e.forEach((function(e){t.inserted[e]=!0}))},flush:function(){t.registered={},t.inserted={},t.sheet.flush()},sheet:t.sheet,cache:t,getRegisteredStyles:T.bind(null,t.registered),merge:A.bind(null,t.registered,n)}},R=F(),P=R.flush,E=R.hydrate,O=R.cx,N=R.merge,I=R.getRegisteredStyles,M=R.injectGlobal,z=R.keyframes,D=R.css,L=R.sheet,Z=R.cache},2110:function(e,t,n){"use strict";var r=n(8309),a={childContextTypes:!0,contextType:!0,contextTypes:!0,defaultProps:!0,displayName:!0,getDefaultProps:!0,getDerivedStateFromError:!0,getDerivedStateFromProps:!0,mixins:!0,propTypes:!0,type:!0},o={name:!0,length:!0,prototype:!0,caller:!0,callee:!0,arguments:!0,arity:!0},i={$$typeof:!0,compare:!0,defaultProps:!0,displayName:!0,propTypes:!0,type:!0},s={};function l(e){return r.isMemo(e)?i:s[e.$$typeof]||a}s[r.ForwardRef]={$$typeof:!0,render:!0,defaultProps:!0,displayName:!0,propTypes:!0},s[r.Memo]=i;var u=Object.defineProperty,c=Object.getOwnPropertyNames,d=Object.getOwnPropertySymbols,p=Object.getOwnPropertyDescriptor,f=Object.getPrototypeOf,m=Object.prototype;e.exports=function e(t,n,r){if("string"!==typeof n){if(m){var a=f(n);a&&a!==m&&e(t,a,r)}var i=c(n);d&&(i=i.concat(d(n)));for(var s=l(t),h=l(n),v=0;v<i.length;++v){var y=i[v];if(!o[y]&&(!r||!r[y])&&(!h||!h[y])&&(!s||!s[y])){var b=p(n,y);try{u(t,y,b)}catch(g){}}}}return t}},746:function(e,t){"use strict";var n="function"===typeof Symbol&&Symbol.for,r=n?Symbol.for("react.element"):60103,a=n?Symbol.for("react.portal"):60106,o=n?Symbol.for("react.fragment"):60107,i=n?Symbol.for("react.strict_mode"):60108,s=n?Symbol.for("react.profiler"):60114,l=n?Symbol.for("react.provider"):60109,u=n?Symbol.for("react.context"):60110,c=n?Symbol.for("react.async_mode"):60111,d=n?Symbol.for("react.concurrent_mode"):60111,p=n?Symbol.for("react.forward_ref"):60112,f=n?Symbol.for("react.suspense"):60113,m=n?Symbol.for("react.suspense_list"):60120,h=n?Symbol.for("react.memo"):60115,v=n?Symbol.for("react.lazy"):60116,y=n?Symbol.for("react.block"):60121,b=n?Symbol.for("react.fundamental"):60117,g=n?Symbol.for("react.responder"):60118,_=n?Symbol.for("react.scope"):60119;function w(e){if("object"===typeof e&&null!==e){var t=e.$$typeof;switch(t){case r:switch(e=e.type){case c:case d:case o:case s:case i:case f:return e;default:switch(e=e&&e.$$typeof){case u:case p:case v:case h:case l:return e;default:return t}}case a:return t}}}function S(e){return w(e)===d}t.AsyncMode=c,t.ConcurrentMode=d,t.ContextConsumer=u,t.ContextProvider=l,t.Element=r,t.ForwardRef=p,t.Fragment=o,t.Lazy=v,t.Memo=h,t.Portal=a,t.Profiler=s,t.StrictMode=i,t.Suspense=f,t.isAsyncMode=function(e){return S(e)||w(e)===c},t.isConcurrentMode=S,t.isContextConsumer=function(e){return w(e)===u},t.isContextProvider=function(e){return w(e)===l},t.isElement=function(e){return"object"===typeof e&&null!==e&&e.$$typeof===r},t.isForwardRef=function(e){return w(e)===p},t.isFragment=function(e){return w(e)===o},t.isLazy=function(e){return w(e)===v},t.isMemo=function(e){return w(e)===h},t.isPortal=function(e){return w(e)===a},t.isProfiler=function(e){return w(e)===s},t.isStrictMode=function(e){return w(e)===i},t.isSuspense=function(e){return w(e)===f},t.isValidElementType=function(e){return"string"===typeof e||"function"===typeof e||e===o||e===d||e===s||e===i||e===f||e===m||"object"===typeof e&&null!==e&&(e.$$typeof===v||e.$$typeof===h||e.$$typeof===l||e.$$typeof===u||e.$$typeof===p||e.$$typeof===b||e.$$typeof===g||e.$$typeof===_||e.$$typeof===y)},t.typeOf=w},8309:function(e,t,n){"use strict";e.exports=n(746)},5781:function(e,t,n){"use strict";n.r(t);var r=Number.isNaN||function(e){return"number"===typeof e&&e!==e};function a(e,t){if(e.length!==t.length)return!1;for(var n=0;n<e.length;n++)if(a=e[n],o=t[n],!(a===o||r(a)&&r(o)))return!1;var a,o;return!0}t.default=function(e,t){var n;void 0===t&&(t=a);var r,o=[],i=!1;return function(){for(var a=[],s=0;s<arguments.length;s++)a[s]=arguments[s];return i&&n===this&&t(a,o)||(r=e.apply(this,a),i=!0,n=this,o=a),r}}},888:function(e,t,n){"use strict";var r=n(9047);function a(){}function o(){}o.resetWarningCache=a,e.exports=function(){function e(e,t,n,a,o,i){if(i!==r){var s=new Error("Calling PropTypes validators directly is not supported by the `prop-types` package. Use PropTypes.checkPropTypes() to call them. Read more at http://fb.me/use-check-prop-types");throw s.name="Invariant Violation",s}}function t(){return e}e.isRequired=e;var n={array:e,bigint:e,bool:e,func:e,number:e,object:e,string:e,symbol:e,any:e,arrayOf:t,element:e,elementType:e,instanceOf:t,node:e,objectOf:t,oneOf:t,oneOfType:t,shape:t,exact:t,checkPropTypes:o,resetWarningCache:a};return n.PropTypes=n,n}},2007:function(e,t,n){e.exports=n(888)()},9047:function(e){"use strict";e.exports="SECRET_DO_NOT_PASS_THIS_OR_YOU_WILL_BE_FIRED"},8472:function(e,t,n){n(3561)},8015:function(e,t,n){"use strict";Object.defineProperty(t,"__esModule",{value:!0});var r,a=function(){function e(e,t){for(var n=0;n<t.length;n++){var r=t[n];r.enumerable=r.enumerable||!1,r.configurable=!0,"value"in r&&(r.writable=!0),Object.defineProperty(e,r.key,r)}}return function(t,n,r){return n&&e(t.prototype,n),r&&e(t,r),t}}(),o=n(2791),i=(r=o)&&r.__esModule?r:{default:r},s=n(1509),l=n(8333);var u=function(e){function t(e){!function(e,t){if(!(e instanceof t))throw new TypeError("Cannot call a class as a function")}(this,t);var n=function(e,t){if(!e)throw new ReferenceError("this hasn't been initialised - super() hasn't been called");return!t||"object"!==typeof t&&"function"!==typeof t?e:t}(this,(t.__proto__||Object.getPrototypeOf(t)).call(this,e));return n.state={},n}return function(e,t){if("function"!==typeof t&&null!==t)throw new TypeError("Super expression must either be null or a function, not "+typeof t);e.prototype=Object.create(t&&t.prototype,{constructor:{value:e,enumerable:!1,writable:!0,configurable:!0}}),t&&(Object.setPrototypeOf?Object.setPrototypeOf(e,t):e.__proto__=t)}(t,e),a(t,[{key:"buildURI",value:function(){return s.buildURI.apply(void 0,arguments)}},{key:"componentDidMount",value:function(){var e=this.props,t=e.data,n=e.headers,r=e.separator,a=e.enclosingCharacter,o=e.uFEFF,i=e.target,s=e.specs,l=e.replace;this.state.page=window.open(this.buildURI(t,o,n,r,a),i,s,l)}},{key:"getWindow",value:function(){return this.state.page}},{key:"render",value:function(){return null}}]),t}(i.default.Component);u.defaultProps=Object.assign(l.defaultProps,{target:"_blank"}),u.propTypes=l.propTypes,t.default=u},9088:function(e,t,n){"use strict";Object.defineProperty(t,"__esModule",{value:!0});var r,a=Object.assign||function(e){for(var t=1;t<arguments.length;t++){var n=arguments[t];for(var r in n)Object.prototype.hasOwnProperty.call(n,r)&&(e[r]=n[r])}return e},o=function(){function e(e,t){for(var n=0;n<t.length;n++){var r=t[n];r.enumerable=r.enumerable||!1,r.configurable=!0,"value"in r&&(r.writable=!0),Object.defineProperty(e,r.key,r)}}return function(t,n,r){return n&&e(t.prototype,n),r&&e(t,r),t}}(),i=n(2791),s=(r=i)&&r.__esModule?r:{default:r},l=n(1509),u=n(8333);var c=function(e){function t(e){!function(e,t){if(!(e instanceof t))throw new TypeError("Cannot call a class as a function")}(this,t);var n=function(e,t){if(!e)throw new ReferenceError("this hasn't been initialised - super() hasn't been called");return!t||"object"!==typeof t&&"function"!==typeof t?e:t}(this,(t.__proto__||Object.getPrototypeOf(t)).call(this,e));return n.buildURI=n.buildURI.bind(n),n}return function(e,t){if("function"!==typeof t&&null!==t)throw new TypeError("Super expression must either be null or a function, not "+typeof t);e.prototype=Object.create(t&&t.prototype,{constructor:{value:e,enumerable:!1,writable:!0,configurable:!0}}),t&&(Object.setPrototypeOf?Object.setPrototypeOf(e,t):e.__proto__=t)}(t,e),o(t,[{key:"buildURI",value:function(){return l.buildURI.apply(void 0,arguments)}},{key:"handleLegacy",value:function(e){var t=arguments.length>1&&void 0!==arguments[1]&&arguments[1];if(window.navigator.msSaveOrOpenBlob){e.preventDefault();var n=this.props,r=n.data,a=n.headers,o=n.separator,i=n.filename,s=n.enclosingCharacter,u=n.uFEFF,c=t&&"function"===typeof r?r():r,d=new Blob([u?"\ufeff":"",(0,l.toCSV)(c,a,o,s)]);return window.navigator.msSaveBlob(d,i),!1}}},{key:"handleAsyncClick",value:function(e){var t=this;this.props.onClick(e,(function(n){!1!==n?t.handleLegacy(e,!0):e.preventDefault()}))}},{key:"handleSyncClick",value:function(e){!1===this.props.onClick(e)?e.preventDefault():this.handleLegacy(e)}},{key:"handleClick",value:function(){var e=this;return function(t){if("function"===typeof e.props.onClick)return e.props.asyncOnClick?e.handleAsyncClick(t):e.handleSyncClick(t);e.handleLegacy(t)}}},{key:"render",value:function(){var e=this,t=this.props,n=t.data,r=t.headers,o=t.separator,i=t.filename,l=t.uFEFF,u=t.children,c=(t.onClick,t.asyncOnClick,t.enclosingCharacter),d=function(e,t){var n={};for(var r in e)t.indexOf(r)>=0||Object.prototype.hasOwnProperty.call(e,r)&&(n[r]=e[r]);return n}(t,["data","headers","separator","filename","uFEFF","children","onClick","asyncOnClick","enclosingCharacter"]),p="undefined"===typeof window?"":this.buildURI(n,l,r,o,c);return s.default.createElement("a",a({download:i},d,{ref:function(t){return e.link=t},target:"_self",href:p,onClick:this.handleClick()}),u)}}]),t}(s.default.Component);c.defaultProps=u.defaultProps,c.propTypes=u.propTypes,t.default=c},1509:function(e,t){"use strict";Object.defineProperty(t,"__esModule",{value:!0});var n="function"===typeof Symbol&&"symbol"===typeof Symbol.iterator?function(e){return typeof e}:function(e){return e&&"function"===typeof Symbol&&e.constructor===Symbol&&e!==Symbol.prototype?"symbol":typeof e};function r(e){if(Array.isArray(e)){for(var t=0,n=Array(e.length);t<e.length;t++)n[t]=e[t];return n}return Array.from(e)}var a=t.isSafari=function(){return/^((?!chrome|android).)*safari/i.test(navigator.userAgent)},o=t.isJsons=function(e){return Array.isArray(e)&&e.every((function(e){return"object"===("undefined"===typeof e?"undefined":n(e))&&!(e instanceof Array)}))},i=t.isArrays=function(e){return Array.isArray(e)&&e.every((function(e){return Array.isArray(e)}))},s=t.jsonsHeaders=function(e){return Array.from(e.map((function(e){return Object.keys(e)})).reduce((function(e,t){return new Set([].concat(r(e),r(t)))}),[]))},l=t.jsons2arrays=function(e,t){var n=t=t||s(e),a=t;o(t)&&(n=t.map((function(e){return e.label})),a=t.map((function(e){return e.key})));var i=e.map((function(e){return a.map((function(t){return u(t,e)}))}));return[n].concat(r(i))},u=t.getHeaderValue=function(e,t){var n=e.replace(/\[([^\]]+)]/g,".$1").split(".").reduce((function(e,t,n,r){var a=e[t];if(void 0!==a&&null!==a)return a;r.splice(1)}),t);return void 0===n?e in t?t[e]:"":n},c=t.elementOrEmpty=function(e){return"undefined"===typeof e||null===e?"":e},d=t.joiner=function(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:",",n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:'"';return e.filter((function(e){return e})).map((function(e){return e.map((function(e){return c(e)})).map((function(e){return""+n+e+n})).join(t)})).join("\n")},p=t.arrays2csv=function(e,t,n,a){return d(t?[t].concat(r(e)):e,n,a)},f=t.jsons2csv=function(e,t,n,r){return d(l(e,t),n,r)},m=t.string2csv=function(e,t,n,r){return t?t.join(n)+"\n"+e:e.replace(/"/g,'""')},h=t.toCSV=function(e,t,n,r){if(o(e))return f(e,t,n,r);if(i(e))return p(e,t,n,r);if("string"===typeof e)return m(e,t,n);throw new TypeError('Data should be a "String", "Array of arrays" OR "Array of objects" ')};t.buildURI=function(e,t,n,r,o){var i=h(e,n,r,o),s=a()?"application/csv":"text/csv",l=new Blob([t?"\ufeff":"",i],{type:s}),u="data:"+s+";charset=utf-8,"+(t?"\ufeff":"")+i,c=window.URL||window.webkitURL;return"undefined"===typeof c.createObjectURL?u:c.createObjectURL(l)}},3561:function(e,t,n){"use strict";var r=o(n(8015)),a=o(n(9088));function o(e){return e&&e.__esModule?e:{default:e}}r.default,a.default},8333:function(e,t,n){"use strict";Object.defineProperty(t,"__esModule",{value:!0}),t.PropsNotForwarded=t.defaultProps=t.propTypes=void 0;var r,a=n(2791),o=((r=a)&&r.__esModule,n(2007));t.propTypes={data:(0,o.oneOfType)([o.string,o.array,o.func]).isRequired,headers:o.array,target:o.string,separator:o.string,filename:o.string,uFEFF:o.bool,onClick:o.func,asyncOnClick:o.bool,enclosingCharacter:o.string},t.defaultProps={separator:",",filename:"generatedBy_react-csv.csv",uFEFF:!0,asyncOnClick:!1,enclosingCharacter:'"'},t.PropsNotForwarded=["data","headers"]},7786:function(e,t,n){"use strict";var r=this&&this.__read||function(e,t){var n="function"===typeof Symbol&&e[Symbol.iterator];if(!n)return e;var r,a,o=n.call(e),i=[];try{for(;(void 0===t||t-- >0)&&!(r=o.next()).done;)i.push(r.value)}catch(s){a={error:s}}finally{try{r&&!r.done&&(n=o.return)&&n.call(o)}finally{if(a)throw a.error}}return i},a=this&&this.__spread||function(){for(var e=[],t=0;t<arguments.length;t++)e=e.concat(r(arguments[t]));return e};Object.defineProperty(t,"__esModule",{value:!0});var o,i,s=n(4173),l=s;!function(e){e[e.DEFAULT=0]="DEFAULT",e[e.ADDED=1]="ADDED",e[e.REMOVED=2]="REMOVED"}(o=t.DiffType||(t.DiffType={})),function(e){e.CHARS="diffChars",e.WORDS="diffWords",e.WORDS_WITH_SPACE="diffWordsWithSpace",e.LINES="diffLines",e.TRIMMED_LINES="diffTrimmedLines",e.SENTENCES="diffSentences",e.CSS="diffCss"}(i=t.DiffMethod||(t.DiffMethod={}));var u=function(e){var t=e.split("\n");if(t.every((function(e){return!e})))return 2===t.length?[]:(t.pop(),t);var n=t[t.length-1],r=t[0];return n||t.pop(),r||t.shift(),t};t.computeLineInformation=function(e,t,n,r,c){void 0===n&&(n=!1),void 0===r&&(r=i.CHARS),void 0===c&&(c=0);var d=s.diffLines(e.trimRight(),t.trimRight(),{newlineIsToken:!0,ignoreWhitespace:!1,ignoreCase:!1}),p=c,f=c,m=[],h=0,v=[],y=[],b=function e(t,a,s,c,m){return u(t).map((function(t,b){var g={},_={};if(!(y.includes(a+"-"+b)||m&&0!==b)){if(s||c)if(v.includes(h)||v.push(h),c){f+=1,g.lineNumber=f,g.type=o.REMOVED,g.value=t||" ";var w=d[a+1];if(w&&w.added)if(u(w.value)[b]){var S=e(w.value,a,!0,!1,!0)[0].right,T=S.value,C=S.lineNumber,k=S.type;if(y.push(a+1+"-"+b),_.lineNumber=C,_.type=k,n)_.value=T;else{var A=function(e,t,n){void 0===n&&(n=i.CHARS);var r=l[n](e,t),a={left:[],right:[]};return r.forEach((function(e){var t=e.added,n=e.removed,r=e.value,i={};return t&&(i.type=o.ADDED,i.value=r,a.right.push(i)),n&&(i.type=o.REMOVED,i.value=r,a.left.push(i)),n||t||(i.type=o.DEFAULT,i.value=r,a.right.push(i),a.left.push(i)),i})),a}(t,T,r);_.value=A.right,g.value=A.left}}}else p+=1,_.lineNumber=p,_.type=o.ADDED,_.value=t;else f+=1,p+=1,g.lineNumber=f,g.type=o.DEFAULT,g.value=t,_.lineNumber=p,_.type=o.DEFAULT,_.value=t;return h+=1,{right:_,left:g}}})).filter(Boolean)};return d.forEach((function(e,t){var n=e.added,r=e.removed,o=e.value;m=a(m,b(o,t,n,r))})),{lineInformation:m,diffLines:v}}},1774:function(e,t,n){"use strict";var r=this&&this.__extends||function(){var e=function(t,n){return e=Object.setPrototypeOf||{__proto__:[]}instanceof Array&&function(e,t){e.__proto__=t}||function(e,t){for(var n in t)t.hasOwnProperty(n)&&(e[n]=t[n])},e(t,n)};return function(t,n){function r(){this.constructor=t}e(t,n),t.prototype=null===n?Object.create(n):(r.prototype=n.prototype,new r)}}();Object.defineProperty(t,"__esModule",{value:!0});var a=n(2791),o=n(2007),i=n(1694),s=n(7786);t.DiffMethod=s.DiffMethod;var l,u=n(2813),c=n(5781),d=c.default||c;!function(e){e.LEFT="L",e.RIGHT="R"}(l=t.LineNumberPrefix||(t.LineNumberPrefix={}));var p=function(e){function t(t){var n=e.call(this,t)||this;return n.resetCodeBlocks=function(){return n.state.expandedBlocks.length>0&&(n.setState({expandedBlocks:[]}),!0)},n.onBlockExpand=function(e){var t=n.state.expandedBlocks.slice();t.push(e),n.setState({expandedBlocks:t})},n.computeStyles=d(u.default),n.onLineNumberClickProxy=function(e){return n.props.onLineNumberClick?function(t){return n.props.onLineNumberClick(e,t)}:function(){}},n.renderWordDiff=function(e,t){return e.map((function(e,r){var o;return a.createElement("span",{key:r,className:i.default(n.styles.wordDiff,(o={},o[n.styles.wordAdded]=e.type===s.DiffType.ADDED,o[n.styles.wordRemoved]=e.type===s.DiffType.REMOVED,o))},t?t(e.value):e.value)}))},n.renderLine=function(e,t,r,o,l,u){var c,d,p,f,m,h=r+"-"+e,v=u+"-"+l,y=n.props.highlightLines.includes(h)||n.props.highlightLines.includes(v),b=t===s.DiffType.ADDED,g=t===s.DiffType.REMOVED;return m=Array.isArray(o)?n.renderWordDiff(o,n.props.renderContent):n.props.renderContent?n.props.renderContent(o):o,a.createElement(a.Fragment,null,!n.props.hideLineNumbers&&a.createElement("td",{onClick:e&&n.onLineNumberClickProxy(h),className:i.default(n.styles.gutter,(c={},c[n.styles.emptyGutter]=!e,c[n.styles.diffAdded]=b,c[n.styles.diffRemoved]=g,c[n.styles.highlightedGutter]=y,c))},a.createElement("pre",{className:n.styles.lineNumber},e)),!n.props.splitView&&!n.props.hideLineNumbers&&a.createElement("td",{onClick:l&&n.onLineNumberClickProxy(v),className:i.default(n.styles.gutter,(d={},d[n.styles.emptyGutter]=!l,d[n.styles.diffAdded]=b,d[n.styles.diffRemoved]=g,d[n.styles.highlightedGutter]=y,d))},a.createElement("pre",{className:n.styles.lineNumber},l)),a.createElement("td",{className:i.default(n.styles.marker,(p={},p[n.styles.emptyLine]=!m,p[n.styles.diffAdded]=b,p[n.styles.diffRemoved]=g,p[n.styles.highlightedLine]=y,p))},a.createElement("pre",null,b&&"+",g&&"-")),a.createElement("td",{className:i.default(n.styles.content,(f={},f[n.styles.emptyLine]=!m,f[n.styles.diffAdded]=b,f[n.styles.diffRemoved]=g,f[n.styles.highlightedLine]=y,f))},a.createElement("pre",{className:n.styles.contentText},m)))},n.renderSplitView=function(e,t){var r=e.left,o=e.right;return a.createElement("tr",{key:t,className:n.styles.line},n.renderLine(r.lineNumber,r.type,l.LEFT,r.value),n.renderLine(o.lineNumber,o.type,l.RIGHT,o.value))},n.renderInlineView=function(e,t){var r,o=e.left,i=e.right;return o.type===s.DiffType.REMOVED&&i.type===s.DiffType.ADDED?a.createElement(a.Fragment,{key:t},a.createElement("tr",{className:n.styles.line},n.renderLine(o.lineNumber,o.type,l.LEFT,o.value,null)),a.createElement("tr",{className:n.styles.line},n.renderLine(null,i.type,l.RIGHT,i.value,i.lineNumber))):(o.type===s.DiffType.REMOVED&&(r=n.renderLine(o.lineNumber,o.type,l.LEFT,o.value,null)),o.type===s.DiffType.DEFAULT&&(r=n.renderLine(o.lineNumber,o.type,l.LEFT,o.value,i.lineNumber,l.RIGHT)),i.type===s.DiffType.ADDED&&(r=n.renderLine(null,i.type,l.RIGHT,i.value,i.lineNumber)),a.createElement("tr",{key:t,className:n.styles.line},r))},n.onBlockClickProxy=function(e){return function(){return n.onBlockExpand(e)}},n.renderSkippedLineIndicator=function(e,t,r,o){var s,l=n.props,u=l.hideLineNumbers,c=l.splitView,d=n.props.codeFoldMessageRenderer?n.props.codeFoldMessageRenderer(e,r,o):a.createElement("pre",{className:n.styles.codeFoldContent},"Expand ",e," lines ..."),p=a.createElement("td",null,a.createElement("a",{onClick:n.onBlockClickProxy(t),tabIndex:0},d)),f=!c&&!u;return a.createElement("tr",{key:r+"-"+o,className:n.styles.codeFold},!u&&a.createElement("td",{className:n.styles.codeFoldGutter}),a.createElement("td",{className:i.default((s={},s[n.styles.codeFoldGutter]=f,s))}),f?a.createElement(a.Fragment,null,a.createElement("td",null),p):a.createElement(a.Fragment,null,p,a.createElement("td",null)),a.createElement("td",null),a.createElement("td",null))},n.renderDiff=function(){var e=n.props,t=e.oldValue,r=e.newValue,o=e.splitView,i=e.disableWordDiff,l=e.compareMethod,u=e.linesOffset,c=s.computeLineInformation(t,r,i,l,u),d=c.lineInformation,p=c.diffLines,f=n.props.extraLinesSurroundingDiff<0?0:n.props.extraLinesSurroundingDiff,m=[];return d.map((function(e,t){var r=p[0],i=r-t;if(n.props.showDiffOnly&&(i===-f&&(m=[],p.shift()),e.left.type===s.DiffType.DEFAULT&&(i>f||"undefined"===typeof r)&&!n.state.expandedBlocks.includes(r)))return m.push(t+1),t===d.length-1&&m.length>1?n.renderSkippedLineIndicator(m.length,r,e.left.lineNumber,e.right.lineNumber):null;var l=o?n.renderSplitView(e,t):n.renderInlineView(e,t);if(i===f&&m.length>0){var u=m.length;return m=[],a.createElement(a.Fragment,{key:t},n.renderSkippedLineIndicator(u,r,e.left.lineNumber,e.right.lineNumber),l)}return l}))},n.render=function(){var e,t=n.props,r=t.oldValue,o=t.newValue,s=t.useDarkTheme,l=t.leftTitle,u=t.rightTitle,c=t.splitView,d=t.hideLineNumbers;if("string"!==typeof r||"string"!==typeof o)throw Error('"oldValue" and "newValue" should be strings');n.styles=n.computeStyles(n.props.styles,s);var p=n.renderDiff(),f=d?2:3,m=d?2:4,h=(l||u)&&a.createElement("tr",null,a.createElement("td",{colSpan:c?f:m,className:n.styles.titleBlock},a.createElement("pre",{className:n.styles.contentText},l)),c&&a.createElement("td",{colSpan:f,className:n.styles.titleBlock},a.createElement("pre",{className:n.styles.contentText},u)));return a.createElement("table",{className:i.default(n.styles.diffContainer,(e={},e[n.styles.splitView]=c,e))},a.createElement("tbody",null,h,p))},n.state={expandedBlocks:[]},n}return r(t,e),t.defaultProps={oldValue:"",newValue:"",splitView:!0,highlightLines:[],disableWordDiff:!1,compareMethod:s.DiffMethod.CHARS,styles:{},hideLineNumbers:!1,extraLinesSurroundingDiff:3,showDiffOnly:!0,useDarkTheme:!1,linesOffset:0},t.propTypes={oldValue:o.string.isRequired,newValue:o.string.isRequired,splitView:o.bool,disableWordDiff:o.bool,compareMethod:o.oneOf(Object.values(s.DiffMethod)),renderContent:o.func,onLineNumberClick:o.func,extraLinesSurroundingDiff:o.number,styles:o.object,hideLineNumbers:o.bool,showDiffOnly:o.bool,highlightLines:o.arrayOf(o.string),leftTitle:o.oneOfType([o.string,o.element]),rightTitle:o.oneOfType([o.string,o.element]),linesOffset:o.number},t}(a.Component);t.default=p},2813:function(e,t,n){"use strict";var r=this&&this.__assign||function(){return r=Object.assign||function(e){for(var t,n=1,r=arguments.length;n<r;n++)for(var a in t=arguments[n])Object.prototype.hasOwnProperty.call(t,a)&&(e[a]=t[a]);return e},r.apply(this,arguments)},a=this&&this.__rest||function(e,t){var n={};for(var r in e)Object.prototype.hasOwnProperty.call(e,r)&&t.indexOf(r)<0&&(n[r]=e[r]);if(null!=e&&"function"===typeof Object.getOwnPropertySymbols){var a=0;for(r=Object.getOwnPropertySymbols(e);a<r.length;a++)t.indexOf(r[a])<0&&Object.prototype.propertyIsEnumerable.call(e,r[a])&&(n[r[a]]=e[r[a]])}return n};Object.defineProperty(t,"__esModule",{value:!0});var o=n(6025);t.default=function(e,t){var n,i,s,l,u,c,d;void 0===t&&(t=!1);var p=e.variables,f=void 0===p?{}:p,m=a(e,["variables"]),h={light:r({diffViewerBackground:"#fff",diffViewerColor:"212529",addedBackground:"#e6ffed",addedColor:"#24292e",removedBackground:"#ffeef0",removedColor:"#24292e",wordAddedBackground:"#acf2bd",wordRemovedBackground:"#fdb8c0",addedGutterBackground:"#cdffd8",removedGutterBackground:"#ffdce0",gutterBackground:"#f7f7f7",gutterBackgroundDark:"#f3f1f1",highlightBackground:"#fffbdd",highlightGutterBackground:"#fff5b1",codeFoldGutterBackground:"#dbedff",codeFoldBackground:"#f1f8ff",emptyLineBackground:"#fafbfc",gutterColor:"#212529",addedGutterColor:"#212529",removedGutterColor:"#212529",codeFoldContentColor:"#212529",diffViewerTitleBackground:"#fafbfc",diffViewerTitleColor:"#212529",diffViewerTitleBorderColor:"#eee"},f.light||{}),dark:r({diffViewerBackground:"#2e303c",diffViewerColor:"#FFF",addedBackground:"#044B53",addedColor:"white",removedBackground:"#632F34",removedColor:"white",wordAddedBackground:"#055d67",wordRemovedBackground:"#7d383f",addedGutterBackground:"#034148",removedGutterBackground:"#632b30",gutterBackground:"#2c2f3a",gutterBackgroundDark:"#262933",highlightBackground:"#2a3967",highlightGutterBackground:"#2d4077",codeFoldGutterBackground:"#21232b",codeFoldBackground:"#262831",emptyLineBackground:"#363946",gutterColor:"#464c67",addedGutterColor:"#8c8c8c",removedGutterColor:"#8c8c8c",codeFoldContentColor:"#555a7b",diffViewerTitleBackground:"#2f323e",diffViewerTitleColor:"#555a7b",diffViewerTitleBorderColor:"#353846"},f.dark||{})},v=t?h.dark:h.light,y=o.css({width:"100%",label:"content"}),b=o.css(((n={})["."+y]={width:"50%"},n.label="split-view",n)),g=o.css({width:"100%",background:v.diffViewerBackground,pre:{margin:0,whiteSpace:"pre-wrap",lineHeight:"25px"},label:"diff-container",borderCollapse:"collapse"}),_=o.css({color:v.codeFoldContentColor,label:"code-fold-content"}),w=o.css({color:v.diffViewerColor,label:"content-text"}),S=o.css(((i={background:v.diffViewerTitleBackground,padding:10,borderBottom:"1px solid "+v.diffViewerTitleBorderColor,label:"title-block",":last-child":{borderLeft:"1px solid "+v.diffViewerTitleBorderColor}})["."+w]={color:v.diffViewerTitleColor},i)),T=o.css({color:v.gutterColor,label:"line-number"}),C=o.css(((s={background:v.removedBackground,color:v.removedColor,pre:{color:v.removedColor}})["."+T]={color:v.removedGutterColor},s.label="diff-removed",s)),k=o.css(((l={background:v.addedBackground,color:v.addedColor,pre:{color:v.addedColor}})["."+T]={color:v.addedGutterColor},l.label="diff-added",l)),A=o.css({padding:2,display:"inline-flex",borderRadius:1,label:"word-diff"}),x=o.css({background:v.wordAddedBackground,label:"word-added"}),F=o.css({background:v.wordRemovedBackground,label:"word-removed"}),R=o.css({backgroundColor:v.codeFoldGutterBackground,label:"code-fold-gutter"}),P=o.css({backgroundColor:v.codeFoldBackground,height:40,fontSize:14,fontWeight:700,label:"code-fold",a:{textDecoration:"underline !important",cursor:"pointer",pre:{display:"inline"}}}),E=o.css({backgroundColor:v.emptyLineBackground,label:"empty-line"}),O=o.css(((u={width:25,paddingLeft:10,paddingRight:10,userSelect:"none",label:"marker"})["&."+k]={pre:{color:v.addedColor}},u["&."+C]={pre:{color:v.removedColor}},u)),N=o.css(((c={background:v.highlightBackground,label:"highlighted-line"})["."+x+", ."+F]={backgroundColor:"initial"},c)),I=o.css({label:"highlighted-gutter"}),M=o.css(((d={userSelect:"none",minWidth:50,padding:"0 10px",label:"gutter",textAlign:"right",background:v.gutterBackground,"&:hover":{cursor:"pointer",background:v.gutterBackgroundDark,pre:{opacity:1}},pre:{opacity:.5}})["&."+k]={background:v.addedGutterBackground},d["&."+C]={background:v.removedGutterBackground},d["&."+I]={background:v.highlightGutterBackground,"&:hover":{background:v.highlightGutterBackground}},d)),z=o.css({"&:hover":{background:v.gutterBackground,cursor:"initial"},label:"empty-gutter"}),D={diffContainer:g,diffRemoved:C,diffAdded:k,splitView:b,marker:O,highlightedGutter:I,highlightedLine:N,gutter:M,line:o.css({verticalAlign:"baseline",label:"line"}),wordDiff:A,wordAdded:x,wordRemoved:F,codeFoldGutter:R,codeFold:P,emptyGutter:z,emptyLine:E,lineNumber:T,contentText:w,content:y,codeFoldContent:_,titleBlock:S},L=Object.keys(m).reduce((function(e,t){var n;return r({},e,((n={})[t]=o.css(m[t]),n))}),{});return Object.keys(D).reduce((function(e,t){var n;return r({},e,((n={})[t]=L[t]?o.cx(D[t],L[t]):D[t],n))}),{})}},4463:function(e,t,n){"use strict";var r=n(2791),a=n(5296);function o(e){for(var t="https://reactjs.org/docs/error-decoder.html?invariant="+e,n=1;n<arguments.length;n++)t+="&args[]="+encodeURIComponent(arguments[n]);return"Minified React error #"+e+"; visit "+t+" for the full message or use the non-minified dev environment for full errors and additional helpful warnings."}var i=new Set,s={};function l(e,t){u(e,t),u(e+"Capture",t)}function u(e,t){for(s[e]=t,e=0;e<t.length;e++)i.add(t[e])}var c=!("undefined"===typeof window||"undefined"===typeof window.document||"undefined"===typeof window.document.createElement),d=Object.prototype.hasOwnProperty,p=/^[:A-Z_a-z\u00C0-\u00D6\u00D8-\u00F6\u00F8-\u02FF\u0370-\u037D\u037F-\u1FFF\u200C-\u200D\u2070-\u218F\u2C00-\u2FEF\u3001-\uD7FF\uF900-\uFDCF\uFDF0-\uFFFD][:A-Z_a-z\u00C0-\u00D6\u00D8-\u00F6\u00F8-\u02FF\u0370-\u037D\u037F-\u1FFF\u200C-\u200D\u2070-\u218F\u2C00-\u2FEF\u3001-\uD7FF\uF900-\uFDCF\uFDF0-\uFFFD\-.0-9\u00B7\u0300-\u036F\u203F-\u2040]*$/,f={},m={};function h(e,t,n,r,a,o,i){this.acceptsBooleans=2===t||3===t||4===t,this.attributeName=r,this.attributeNamespace=a,this.mustUseProperty=n,this.propertyName=e,this.type=t,this.sanitizeURL=o,this.removeEmptyString=i}var v={};"children dangerouslySetInnerHTML defaultValue defaultChecked innerHTML suppressContentEditableWarning suppressHydrationWarning style".split(" ").forEach((function(e){v[e]=new h(e,0,!1,e,null,!1,!1)})),[["acceptCharset","accept-charset"],["className","class"],["htmlFor","for"],["httpEquiv","http-equiv"]].forEach((function(e){var t=e[0];v[t]=new h(t,1,!1,e[1],null,!1,!1)})),["contentEditable","draggable","spellCheck","value"].forEach((function(e){v[e]=new h(e,2,!1,e.toLowerCase(),null,!1,!1)})),["autoReverse","externalResourcesRequired","focusable","preserveAlpha"].forEach((function(e){v[e]=new h(e,2,!1,e,null,!1,!1)})),"allowFullScreen async autoFocus autoPlay controls default defer disabled disablePictureInPicture disableRemotePlayback formNoValidate hidden loop noModule noValidate open playsInline readOnly required reversed scoped seamless itemScope".split(" ").forEach((function(e){v[e]=new h(e,3,!1,e.toLowerCase(),null,!1,!1)})),["checked","multiple","muted","selected"].forEach((function(e){v[e]=new h(e,3,!0,e,null,!1,!1)})),["capture","download"].forEach((function(e){v[e]=new h(e,4,!1,e,null,!1,!1)})),["cols","rows","size","span"].forEach((function(e){v[e]=new h(e,6,!1,e,null,!1,!1)})),["rowSpan","start"].forEach((function(e){v[e]=new h(e,5,!1,e.toLowerCase(),null,!1,!1)}));var y=/[\-:]([a-z])/g;function b(e){return e[1].toUpperCase()}function g(e,t,n,r){var a=v.hasOwnProperty(t)?v[t]:null;(null!==a?0!==a.type:r||!(2<t.length)||"o"!==t[0]&&"O"!==t[0]||"n"!==t[1]&&"N"!==t[1])&&(function(e,t,n,r){if(null===t||"undefined"===typeof t||function(e,t,n,r){if(null!==n&&0===n.type)return!1;switch(typeof t){case"function":case"symbol":return!0;case"boolean":return!r&&(null!==n?!n.acceptsBooleans:"data-"!==(e=e.toLowerCase().slice(0,5))&&"aria-"!==e);default:return!1}}(e,t,n,r))return!0;if(r)return!1;if(null!==n)switch(n.type){case 3:return!t;case 4:return!1===t;case 5:return isNaN(t);case 6:return isNaN(t)||1>t}return!1}(t,n,a,r)&&(n=null),r||null===a?function(e){return!!d.call(m,e)||!d.call(f,e)&&(p.test(e)?m[e]=!0:(f[e]=!0,!1))}(t)&&(null===n?e.removeAttribute(t):e.setAttribute(t,""+n)):a.mustUseProperty?e[a.propertyName]=null===n?3!==a.type&&"":n:(t=a.attributeName,r=a.attributeNamespace,null===n?e.removeAttribute(t):(n=3===(a=a.type)||4===a&&!0===n?"":""+n,r?e.setAttributeNS(r,t,n):e.setAttribute(t,n))))}"accent-height alignment-baseline arabic-form baseline-shift cap-height clip-path clip-rule color-interpolation color-interpolation-filters color-profile color-rendering dominant-baseline enable-background fill-opacity fill-rule flood-color flood-opacity font-family font-size font-size-adjust font-stretch font-style font-variant font-weight glyph-name glyph-orientation-horizontal glyph-orientation-vertical horiz-adv-x horiz-origin-x image-rendering letter-spacing lighting-color marker-end marker-mid marker-start overline-position overline-thickness paint-order panose-1 pointer-events rendering-intent shape-rendering stop-color stop-opacity strikethrough-position strikethrough-thickness stroke-dasharray stroke-dashoffset stroke-linecap stroke-linejoin stroke-miterlimit stroke-opacity stroke-width text-anchor text-decoration text-rendering underline-position underline-thickness unicode-bidi unicode-range units-per-em v-alphabetic v-hanging v-ideographic v-mathematical vector-effect vert-adv-y vert-origin-x vert-origin-y word-spacing writing-mode xmlns:xlink x-height".split(" ").forEach((function(e){var t=e.replace(y,b);v[t]=new h(t,1,!1,e,null,!1,!1)})),"xlink:actuate xlink:arcrole xlink:role xlink:show xlink:title xlink:type".split(" ").forEach((function(e){var t=e.replace(y,b);v[t]=new h(t,1,!1,e,"http://www.w3.org/1999/xlink",!1,!1)})),["xml:base","xml:lang","xml:space"].forEach((function(e){var t=e.replace(y,b);v[t]=new h(t,1,!1,e,"http://www.w3.org/XML/1998/namespace",!1,!1)})),["tabIndex","crossOrigin"].forEach((function(e){v[e]=new h(e,1,!1,e.toLowerCase(),null,!1,!1)})),v.xlinkHref=new h("xlinkHref",1,!1,"xlink:href","http://www.w3.org/1999/xlink",!0,!1),["src","href","action","formAction"].forEach((function(e){v[e]=new h(e,1,!1,e.toLowerCase(),null,!0,!0)}));var _=r.__SECRET_INTERNALS_DO_NOT_USE_OR_YOU_WILL_BE_FIRED,w=Symbol.for("react.element"),S=Symbol.for("react.portal"),T=Symbol.for("react.fragment"),C=Symbol.for("react.strict_mode"),k=Symbol.for("react.profiler"),A=Symbol.for("react.provider"),x=Symbol.for("react.context"),F=Symbol.for("react.forward_ref"),R=Symbol.for("react.suspense"),P=Symbol.for("react.suspense_list"),E=Symbol.for("react.memo"),O=Symbol.for("react.lazy");Symbol.for("react.scope"),Symbol.for("react.debug_trace_mode");var N=Symbol.for("react.offscreen");Symbol.for("react.legacy_hidden"),Symbol.for("react.cache"),Symbol.for("react.tracing_marker");var I=Symbol.iterator;function M(e){return null===e||"object"!==typeof e?null:"function"===typeof(e=I&&e[I]||e["@@iterator"])?e:null}var z,D=Object.assign;function L(e){if(void 0===z)try{throw Error()}catch(n){var t=n.stack.trim().match(/\n( *(at )?)/);z=t&&t[1]||""}return"\n"+z+e}var Z=!1;function j(e,t){if(!e||Z)return"";Z=!0;var n=Error.prepareStackTrace;Error.prepareStackTrace=void 0;try{if(t)if(t=function(){throw Error()},Object.defineProperty(t.prototype,"props",{set:function(){throw Error()}}),"object"===typeof Reflect&&Reflect.construct){try{Reflect.construct(t,[])}catch(u){var r=u}Reflect.construct(e,[],t)}else{try{t.call()}catch(u){r=u}e.call(t.prototype)}else{try{throw Error()}catch(u){r=u}e()}}catch(u){if(u&&r&&"string"===typeof u.stack){for(var a=u.stack.split("\n"),o=r.stack.split("\n"),i=a.length-1,s=o.length-1;1<=i&&0<=s&&a[i]!==o[s];)s--;for(;1<=i&&0<=s;i--,s--)if(a[i]!==o[s]){if(1!==i||1!==s)do{if(i--,0>--s||a[i]!==o[s]){var l="\n"+a[i].replace(" at new "," at ");return e.displayName&&l.includes("<anonymous>")&&(l=l.replace("<anonymous>",e.displayName)),l}}while(1<=i&&0<=s);break}}}finally{Z=!1,Error.prepareStackTrace=n}return(e=e?e.displayName||e.name:"")?L(e):""}function B(e){switch(e.tag){case 5:return L(e.type);case 16:return L("Lazy");case 13:return L("Suspense");case 19:return L("SuspenseList");case 0:case 2:case 15:return e=j(e.type,!1);case 11:return e=j(e.type.render,!1);case 1:return e=j(e.type,!0);default:return""}}function W(e){if(null==e)return null;if("function"===typeof e)return e.displayName||e.name||null;if("string"===typeof e)return e;switch(e){case T:return"Fragment";case S:return"Portal";case k:return"Profiler";case C:return"StrictMode";case R:return"Suspense";case P:return"SuspenseList"}if("object"===typeof e)switch(e.$$typeof){case x:return(e.displayName||"Context")+".Consumer";case A:return(e._context.displayName||"Context")+".Provider";case F:var t=e.render;return(e=e.displayName)||(e=""!==(e=t.displayName||t.name||"")?"ForwardRef("+e+")":"ForwardRef"),e;case E:return null!==(t=e.displayName||null)?t:W(e.type)||"Memo";case O:t=e._payload,e=e._init;try{return W(e(t))}catch(n){}}return null}function J(e){var t=e.type;switch(e.tag){case 24:return"Cache";case 9:return(t.displayName||"Context")+".Consumer";case 10:return(t._context.displayName||"Context")+".Provider";case 18:return"DehydratedFragment";case 11:return e=(e=t.render).displayName||e.name||"",t.displayName||(""!==e?"ForwardRef("+e+")":"ForwardRef");case 7:return"Fragment";case 5:return t;case 4:return"Portal";case 3:return"Root";case 6:return"Text";case 16:return W(t);case 8:return t===C?"StrictMode":"Mode";case 22:return"Offscreen";case 12:return"Profiler";case 21:return"Scope";case 13:return"Suspense";case 19:return"SuspenseList";case 25:return"TracingMarker";case 1:case 0:case 17:case 2:case 14:case 15:if("function"===typeof t)return t.displayName||t.name||null;if("string"===typeof t)return t}return null}function U(e){switch(typeof e){case"boolean":case"number":case"string":case"undefined":case"object":return e;default:return""}}function V(e){var t=e.type;return(e=e.nodeName)&&"input"===e.toLowerCase()&&("checkbox"===t||"radio"===t)}function $(e){e._valueTracker||(e._valueTracker=function(e){var t=V(e)?"checked":"value",n=Object.getOwnPropertyDescriptor(e.constructor.prototype,t),r=""+e[t];if(!e.hasOwnProperty(t)&&"undefined"!==typeof n&&"function"===typeof n.get&&"function"===typeof n.set){var a=n.get,o=n.set;return Object.defineProperty(e,t,{configurable:!0,get:function(){return a.call(this)},set:function(e){r=""+e,o.call(this,e)}}),Object.defineProperty(e,t,{enumerable:n.enumerable}),{getValue:function(){return r},setValue:function(e){r=""+e},stopTracking:function(){e._valueTracker=null,delete e[t]}}}}(e))}function H(e){if(!e)return!1;var t=e._valueTracker;if(!t)return!0;var n=t.getValue(),r="";return e&&(r=V(e)?e.checked?"true":"false":e.value),(e=r)!==n&&(t.setValue(e),!0)}function G(e){if("undefined"===typeof(e=e||("undefined"!==typeof document?document:void 0)))return null;try{return e.activeElement||e.body}catch(t){return e.body}}function q(e,t){var n=t.checked;return D({},t,{defaultChecked:void 0,defaultValue:void 0,value:void 0,checked:null!=n?n:e._wrapperState.initialChecked})}function K(e,t){var n=null==t.defaultValue?"":t.defaultValue,r=null!=t.checked?t.checked:t.defaultChecked;n=U(null!=t.value?t.value:n),e._wrapperState={initialChecked:r,initialValue:n,controlled:"checkbox"===t.type||"radio"===t.type?null!=t.checked:null!=t.value}}function Q(e,t){null!=(t=t.checked)&&g(e,"checked",t,!1)}function X(e,t){Q(e,t);var n=U(t.value),r=t.type;if(null!=n)"number"===r?(0===n&&""===e.value||e.value!=n)&&(e.value=""+n):e.value!==""+n&&(e.value=""+n);else if("submit"===r||"reset"===r)return void e.removeAttribute("value");t.hasOwnProperty("value")?ee(e,t.type,n):t.hasOwnProperty("defaultValue")&&ee(e,t.type,U(t.defaultValue)),null==t.checked&&null!=t.defaultChecked&&(e.defaultChecked=!!t.defaultChecked)}function Y(e,t,n){if(t.hasOwnProperty("value")||t.hasOwnProperty("defaultValue")){var r=t.type;if(!("submit"!==r&&"reset"!==r||void 0!==t.value&&null!==t.value))return;t=""+e._wrapperState.initialValue,n||t===e.value||(e.value=t),e.defaultValue=t}""!==(n=e.name)&&(e.name=""),e.defaultChecked=!!e._wrapperState.initialChecked,""!==n&&(e.name=n)}function ee(e,t,n){"number"===t&&G(e.ownerDocument)===e||(null==n?e.defaultValue=""+e._wrapperState.initialValue:e.defaultValue!==""+n&&(e.defaultValue=""+n))}var te=Array.isArray;function ne(e,t,n,r){if(e=e.options,t){t={};for(var a=0;a<n.length;a++)t["$"+n[a]]=!0;for(n=0;n<e.length;n++)a=t.hasOwnProperty("$"+e[n].value),e[n].selected!==a&&(e[n].selected=a),a&&r&&(e[n].defaultSelected=!0)}else{for(n=""+U(n),t=null,a=0;a<e.length;a++){if(e[a].value===n)return e[a].selected=!0,void(r&&(e[a].defaultSelected=!0));null!==t||e[a].disabled||(t=e[a])}null!==t&&(t.selected=!0)}}function re(e,t){if(null!=t.dangerouslySetInnerHTML)throw Error(o(91));return D({},t,{value:void 0,defaultValue:void 0,children:""+e._wrapperState.initialValue})}function ae(e,t){var n=t.value;if(null==n){if(n=t.children,t=t.defaultValue,null!=n){if(null!=t)throw Error(o(92));if(te(n)){if(1<n.length)throw Error(o(93));n=n[0]}t=n}null==t&&(t=""),n=t}e._wrapperState={initialValue:U(n)}}function oe(e,t){var n=U(t.value),r=U(t.defaultValue);null!=n&&((n=""+n)!==e.value&&(e.value=n),null==t.defaultValue&&e.defaultValue!==n&&(e.defaultValue=n)),null!=r&&(e.defaultValue=""+r)}function ie(e){var t=e.textContent;t===e._wrapperState.initialValue&&""!==t&&null!==t&&(e.value=t)}function se(e){switch(e){case"svg":return"http://www.w3.org/2000/svg";case"math":return"http://www.w3.org/1998/Math/MathML";default:return"http://www.w3.org/1999/xhtml"}}function le(e,t){return null==e||"http://www.w3.org/1999/xhtml"===e?se(t):"http://www.w3.org/2000/svg"===e&&"foreignObject"===t?"http://www.w3.org/1999/xhtml":e}var ue,ce,de=(ce=function(e,t){if("http://www.w3.org/2000/svg"!==e.namespaceURI||"innerHTML"in e)e.innerHTML=t;else{for((ue=ue||document.createElement("div")).innerHTML="<svg>"+t.valueOf().toString()+"</svg>",t=ue.firstChild;e.firstChild;)e.removeChild(e.firstChild);for(;t.firstChild;)e.appendChild(t.firstChild)}},"undefined"!==typeof MSApp&&MSApp.execUnsafeLocalFunction?function(e,t,n,r){MSApp.execUnsafeLocalFunction((function(){return ce(e,t)}))}:ce);function pe(e,t){if(t){var n=e.firstChild;if(n&&n===e.lastChild&&3===n.nodeType)return void(n.nodeValue=t)}e.textContent=t}var fe={animationIterationCount:!0,aspectRatio:!0,borderImageOutset:!0,borderImageSlice:!0,borderImageWidth:!0,boxFlex:!0,boxFlexGroup:!0,boxOrdinalGroup:!0,columnCount:!0,columns:!0,flex:!0,flexGrow:!0,flexPositive:!0,flexShrink:!0,flexNegative:!0,flexOrder:!0,gridArea:!0,gridRow:!0,gridRowEnd:!0,gridRowSpan:!0,gridRowStart:!0,gridColumn:!0,gridColumnEnd:!0,gridColumnSpan:!0,gridColumnStart:!0,fontWeight:!0,lineClamp:!0,lineHeight:!0,opacity:!0,order:!0,orphans:!0,tabSize:!0,widows:!0,zIndex:!0,zoom:!0,fillOpacity:!0,floodOpacity:!0,stopOpacity:!0,strokeDasharray:!0,strokeDashoffset:!0,strokeMiterlimit:!0,strokeOpacity:!0,strokeWidth:!0},me=["Webkit","ms","Moz","O"];function he(e,t,n){return null==t||"boolean"===typeof t||""===t?"":n||"number"!==typeof t||0===t||fe.hasOwnProperty(e)&&fe[e]?(""+t).trim():t+"px"}function ve(e,t){for(var n in e=e.style,t)if(t.hasOwnProperty(n)){var r=0===n.indexOf("--"),a=he(n,t[n],r);"float"===n&&(n="cssFloat"),r?e.setProperty(n,a):e[n]=a}}Object.keys(fe).forEach((function(e){me.forEach((function(t){t=t+e.charAt(0).toUpperCase()+e.substring(1),fe[t]=fe[e]}))}));var ye=D({menuitem:!0},{area:!0,base:!0,br:!0,col:!0,embed:!0,hr:!0,img:!0,input:!0,keygen:!0,link:!0,meta:!0,param:!0,source:!0,track:!0,wbr:!0});function be(e,t){if(t){if(ye[e]&&(null!=t.children||null!=t.dangerouslySetInnerHTML))throw Error(o(137,e));if(null!=t.dangerouslySetInnerHTML){if(null!=t.children)throw Error(o(60));if("object"!==typeof t.dangerouslySetInnerHTML||!("__html"in t.dangerouslySetInnerHTML))throw Error(o(61))}if(null!=t.style&&"object"!==typeof t.style)throw Error(o(62))}}function ge(e,t){if(-1===e.indexOf("-"))return"string"===typeof t.is;switch(e){case"annotation-xml":case"color-profile":case"font-face":case"font-face-src":case"font-face-uri":case"font-face-format":case"font-face-name":case"missing-glyph":return!1;default:return!0}}var _e=null;function we(e){return(e=e.target||e.srcElement||window).correspondingUseElement&&(e=e.correspondingUseElement),3===e.nodeType?e.parentNode:e}var Se=null,Te=null,Ce=null;function ke(e){if(e=ga(e)){if("function"!==typeof Se)throw Error(o(280));var t=e.stateNode;t&&(t=wa(t),Se(e.stateNode,e.type,t))}}function Ae(e){Te?Ce?Ce.push(e):Ce=[e]:Te=e}function xe(){if(Te){var e=Te,t=Ce;if(Ce=Te=null,ke(e),t)for(e=0;e<t.length;e++)ke(t[e])}}function Fe(e,t){return e(t)}function Re(){}var Pe=!1;function Ee(e,t,n){if(Pe)return e(t,n);Pe=!0;try{return Fe(e,t,n)}finally{Pe=!1,(null!==Te||null!==Ce)&&(Re(),xe())}}function Oe(e,t){var n=e.stateNode;if(null===n)return null;var r=wa(n);if(null===r)return null;n=r[t];e:switch(t){case"onClick":case"onClickCapture":case"onDoubleClick":case"onDoubleClickCapture":case"onMouseDown":case"onMouseDownCapture":case"onMouseMove":case"onMouseMoveCapture":case"onMouseUp":case"onMouseUpCapture":case"onMouseEnter":(r=!r.disabled)||(r=!("button"===(e=e.type)||"input"===e||"select"===e||"textarea"===e)),e=!r;break e;default:e=!1}if(e)return null;if(n&&"function"!==typeof n)throw Error(o(231,t,typeof n));return n}var Ne=!1;if(c)try{var Ie={};Object.defineProperty(Ie,"passive",{get:function(){Ne=!0}}),window.addEventListener("test",Ie,Ie),window.removeEventListener("test",Ie,Ie)}catch(ce){Ne=!1}function Me(e,t,n,r,a,o,i,s,l){var u=Array.prototype.slice.call(arguments,3);try{t.apply(n,u)}catch(c){this.onError(c)}}var ze=!1,De=null,Le=!1,Ze=null,je={onError:function(e){ze=!0,De=e}};function Be(e,t,n,r,a,o,i,s,l){ze=!1,De=null,Me.apply(je,arguments)}function We(e){var t=e,n=e;if(e.alternate)for(;t.return;)t=t.return;else{e=t;do{0!==(4098&(t=e).flags)&&(n=t.return),e=t.return}while(e)}return 3===t.tag?n:null}function Je(e){if(13===e.tag){var t=e.memoizedState;if(null===t&&(null!==(e=e.alternate)&&(t=e.memoizedState)),null!==t)return t.dehydrated}return null}function Ue(e){if(We(e)!==e)throw Error(o(188))}function Ve(e){return null!==(e=function(e){var t=e.alternate;if(!t){if(null===(t=We(e)))throw Error(o(188));return t!==e?null:e}for(var n=e,r=t;;){var a=n.return;if(null===a)break;var i=a.alternate;if(null===i){if(null!==(r=a.return)){n=r;continue}break}if(a.child===i.child){for(i=a.child;i;){if(i===n)return Ue(a),e;if(i===r)return Ue(a),t;i=i.sibling}throw Error(o(188))}if(n.return!==r.return)n=a,r=i;else{for(var s=!1,l=a.child;l;){if(l===n){s=!0,n=a,r=i;break}if(l===r){s=!0,r=a,n=i;break}l=l.sibling}if(!s){for(l=i.child;l;){if(l===n){s=!0,n=i,r=a;break}if(l===r){s=!0,r=i,n=a;break}l=l.sibling}if(!s)throw Error(o(189))}}if(n.alternate!==r)throw Error(o(190))}if(3!==n.tag)throw Error(o(188));return n.stateNode.current===n?e:t}(e))?$e(e):null}function $e(e){if(5===e.tag||6===e.tag)return e;for(e=e.child;null!==e;){var t=$e(e);if(null!==t)return t;e=e.sibling}return null}var He=a.unstable_scheduleCallback,Ge=a.unstable_cancelCallback,qe=a.unstable_shouldYield,Ke=a.unstable_requestPaint,Qe=a.unstable_now,Xe=a.unstable_getCurrentPriorityLevel,Ye=a.unstable_ImmediatePriority,et=a.unstable_UserBlockingPriority,tt=a.unstable_NormalPriority,nt=a.unstable_LowPriority,rt=a.unstable_IdlePriority,at=null,ot=null;var it=Math.clz32?Math.clz32:function(e){return 0===(e>>>=0)?32:31-(st(e)/lt|0)|0},st=Math.log,lt=Math.LN2;var ut=64,ct=4194304;function dt(e){switch(e&-e){case 1:return 1;case 2:return 2;case 4:return 4;case 8:return 8;case 16:return 16;case 32:return 32;case 64:case 128:case 256:case 512:case 1024:case 2048:case 4096:case 8192:case 16384:case 32768:case 65536:case 131072:case 262144:case 524288:case 1048576:case 2097152:return 4194240&e;case 4194304:case 8388608:case 16777216:case 33554432:case 67108864:return 130023424&e;case 134217728:return 134217728;case 268435456:return 268435456;case 536870912:return 536870912;case 1073741824:return 1073741824;default:return e}}function pt(e,t){var n=e.pendingLanes;if(0===n)return 0;var r=0,a=e.suspendedLanes,o=e.pingedLanes,i=268435455&n;if(0!==i){var s=i&~a;0!==s?r=dt(s):0!==(o&=i)&&(r=dt(o))}else 0!==(i=n&~a)?r=dt(i):0!==o&&(r=dt(o));if(0===r)return 0;if(0!==t&&t!==r&&0===(t&a)&&((a=r&-r)>=(o=t&-t)||16===a&&0!==(4194240&o)))return t;if(0!==(4&r)&&(r|=16&n),0!==(t=e.entangledLanes))for(e=e.entanglements,t&=r;0<t;)a=1<<(n=31-it(t)),r|=e[n],t&=~a;return r}function ft(e,t){switch(e){case 1:case 2:case 4:return t+250;case 8:case 16:case 32:case 64:case 128:case 256:case 512:case 1024:case 2048:case 4096:case 8192:case 16384:case 32768:case 65536:case 131072:case 262144:case 524288:case 1048576:case 2097152:return t+5e3;default:return-1}}function mt(e){return 0!==(e=-1073741825&e.pendingLanes)?e:1073741824&e?1073741824:0}function ht(){var e=ut;return 0===(4194240&(ut<<=1))&&(ut=64),e}function vt(e){for(var t=[],n=0;31>n;n++)t.push(e);return t}function yt(e,t,n){e.pendingLanes|=t,536870912!==t&&(e.suspendedLanes=0,e.pingedLanes=0),(e=e.eventTimes)[t=31-it(t)]=n}function bt(e,t){var n=e.entangledLanes|=t;for(e=e.entanglements;n;){var r=31-it(n),a=1<<r;a&t|e[r]&t&&(e[r]|=t),n&=~a}}var gt=0;function _t(e){return 1<(e&=-e)?4<e?0!==(268435455&e)?16:536870912:4:1}var wt,St,Tt,Ct,kt,At=!1,xt=[],Ft=null,Rt=null,Pt=null,Et=new Map,Ot=new Map,Nt=[],It="mousedown mouseup touchcancel touchend touchstart auxclick dblclick pointercancel pointerdown pointerup dragend dragstart drop compositionend compositionstart keydown keypress keyup input textInput copy cut paste click change contextmenu reset submit".split(" ");function Mt(e,t){switch(e){case"focusin":case"focusout":Ft=null;break;case"dragenter":case"dragleave":Rt=null;break;case"mouseover":case"mouseout":Pt=null;break;case"pointerover":case"pointerout":Et.delete(t.pointerId);break;case"gotpointercapture":case"lostpointercapture":Ot.delete(t.pointerId)}}function zt(e,t,n,r,a,o){return null===e||e.nativeEvent!==o?(e={blockedOn:t,domEventName:n,eventSystemFlags:r,nativeEvent:o,targetContainers:[a]},null!==t&&(null!==(t=ga(t))&&St(t)),e):(e.eventSystemFlags|=r,t=e.targetContainers,null!==a&&-1===t.indexOf(a)&&t.push(a),e)}function Dt(e){var t=ba(e.target);if(null!==t){var n=We(t);if(null!==n)if(13===(t=n.tag)){if(null!==(t=Je(n)))return e.blockedOn=t,void kt(e.priority,(function(){Tt(n)}))}else if(3===t&&n.stateNode.current.memoizedState.isDehydrated)return void(e.blockedOn=3===n.tag?n.stateNode.containerInfo:null)}e.blockedOn=null}function Lt(e){if(null!==e.blockedOn)return!1;for(var t=e.targetContainers;0<t.length;){var n=qt(e.domEventName,e.eventSystemFlags,t[0],e.nativeEvent);if(null!==n)return null!==(t=ga(n))&&St(t),e.blockedOn=n,!1;var r=new(n=e.nativeEvent).constructor(n.type,n);_e=r,n.target.dispatchEvent(r),_e=null,t.shift()}return!0}function Zt(e,t,n){Lt(e)&&n.delete(t)}function jt(){At=!1,null!==Ft&&Lt(Ft)&&(Ft=null),null!==Rt&&Lt(Rt)&&(Rt=null),null!==Pt&&Lt(Pt)&&(Pt=null),Et.forEach(Zt),Ot.forEach(Zt)}function Bt(e,t){e.blockedOn===t&&(e.blockedOn=null,At||(At=!0,a.unstable_scheduleCallback(a.unstable_NormalPriority,jt)))}function Wt(e){function t(t){return Bt(t,e)}if(0<xt.length){Bt(xt[0],e);for(var n=1;n<xt.length;n++){var r=xt[n];r.blockedOn===e&&(r.blockedOn=null)}}for(null!==Ft&&Bt(Ft,e),null!==Rt&&Bt(Rt,e),null!==Pt&&Bt(Pt,e),Et.forEach(t),Ot.forEach(t),n=0;n<Nt.length;n++)(r=Nt[n]).blockedOn===e&&(r.blockedOn=null);for(;0<Nt.length&&null===(n=Nt[0]).blockedOn;)Dt(n),null===n.blockedOn&&Nt.shift()}var Jt=_.ReactCurrentBatchConfig,Ut=!0;function Vt(e,t,n,r){var a=gt,o=Jt.transition;Jt.transition=null;try{gt=1,Ht(e,t,n,r)}finally{gt=a,Jt.transition=o}}function $t(e,t,n,r){var a=gt,o=Jt.transition;Jt.transition=null;try{gt=4,Ht(e,t,n,r)}finally{gt=a,Jt.transition=o}}function Ht(e,t,n,r){if(Ut){var a=qt(e,t,n,r);if(null===a)Ur(e,t,r,Gt,n),Mt(e,r);else if(function(e,t,n,r,a){switch(t){case"focusin":return Ft=zt(Ft,e,t,n,r,a),!0;case"dragenter":return Rt=zt(Rt,e,t,n,r,a),!0;case"mouseover":return Pt=zt(Pt,e,t,n,r,a),!0;case"pointerover":var o=a.pointerId;return Et.set(o,zt(Et.get(o)||null,e,t,n,r,a)),!0;case"gotpointercapture":return o=a.pointerId,Ot.set(o,zt(Ot.get(o)||null,e,t,n,r,a)),!0}return!1}(a,e,t,n,r))r.stopPropagation();else if(Mt(e,r),4&t&&-1<It.indexOf(e)){for(;null!==a;){var o=ga(a);if(null!==o&&wt(o),null===(o=qt(e,t,n,r))&&Ur(e,t,r,Gt,n),o===a)break;a=o}null!==a&&r.stopPropagation()}else Ur(e,t,r,null,n)}}var Gt=null;function qt(e,t,n,r){if(Gt=null,null!==(e=ba(e=we(r))))if(null===(t=We(e)))e=null;else if(13===(n=t.tag)){if(null!==(e=Je(t)))return e;e=null}else if(3===n){if(t.stateNode.current.memoizedState.isDehydrated)return 3===t.tag?t.stateNode.containerInfo:null;e=null}else t!==e&&(e=null);return Gt=e,null}function Kt(e){switch(e){case"cancel":case"click":case"close":case"contextmenu":case"copy":case"cut":case"auxclick":case"dblclick":case"dragend":case"dragstart":case"drop":case"focusin":case"focusout":case"input":case"invalid":case"keydown":case"keypress":case"keyup":case"mousedown":case"mouseup":case"paste":case"pause":case"play":case"pointercancel":case"pointerdown":case"pointerup":case"ratechange":case"reset":case"resize":case"seeked":case"submit":case"touchcancel":case"touchend":case"touchstart":case"volumechange":case"change":case"selectionchange":case"textInput":case"compositionstart":case"compositionend":case"compositionupdate":case"beforeblur":case"afterblur":case"beforeinput":case"blur":case"fullscreenchange":case"focus":case"hashchange":case"popstate":case"select":case"selectstart":return 1;case"drag":case"dragenter":case"dragexit":case"dragleave":case"dragover":case"mousemove":case"mouseout":case"mouseover":case"pointermove":case"pointerout":case"pointerover":case"scroll":case"toggle":case"touchmove":case"wheel":case"mouseenter":case"mouseleave":case"pointerenter":case"pointerleave":return 4;case"message":switch(Xe()){case Ye:return 1;case et:return 4;case tt:case nt:return 16;case rt:return 536870912;default:return 16}default:return 16}}var Qt=null,Xt=null,Yt=null;function en(){if(Yt)return Yt;var e,t,n=Xt,r=n.length,a="value"in Qt?Qt.value:Qt.textContent,o=a.length;for(e=0;e<r&&n[e]===a[e];e++);var i=r-e;for(t=1;t<=i&&n[r-t]===a[o-t];t++);return Yt=a.slice(e,1<t?1-t:void 0)}function tn(e){var t=e.keyCode;return"charCode"in e?0===(e=e.charCode)&&13===t&&(e=13):e=t,10===e&&(e=13),32<=e||13===e?e:0}function nn(){return!0}function rn(){return!1}function an(e){function t(t,n,r,a,o){for(var i in this._reactName=t,this._targetInst=r,this.type=n,this.nativeEvent=a,this.target=o,this.currentTarget=null,e)e.hasOwnProperty(i)&&(t=e[i],this[i]=t?t(a):a[i]);return this.isDefaultPrevented=(null!=a.defaultPrevented?a.defaultPrevented:!1===a.returnValue)?nn:rn,this.isPropagationStopped=rn,this}return D(t.prototype,{preventDefault:function(){this.defaultPrevented=!0;var e=this.nativeEvent;e&&(e.preventDefault?e.preventDefault():"unknown"!==typeof e.returnValue&&(e.returnValue=!1),this.isDefaultPrevented=nn)},stopPropagation:function(){var e=this.nativeEvent;e&&(e.stopPropagation?e.stopPropagation():"unknown"!==typeof e.cancelBubble&&(e.cancelBubble=!0),this.isPropagationStopped=nn)},persist:function(){},isPersistent:nn}),t}var on,sn,ln,un={eventPhase:0,bubbles:0,cancelable:0,timeStamp:function(e){return e.timeStamp||Date.now()},defaultPrevented:0,isTrusted:0},cn=an(un),dn=D({},un,{view:0,detail:0}),pn=an(dn),fn=D({},dn,{screenX:0,screenY:0,clientX:0,clientY:0,pageX:0,pageY:0,ctrlKey:0,shiftKey:0,altKey:0,metaKey:0,getModifierState:kn,button:0,buttons:0,relatedTarget:function(e){return void 0===e.relatedTarget?e.fromElement===e.srcElement?e.toElement:e.fromElement:e.relatedTarget},movementX:function(e){return"movementX"in e?e.movementX:(e!==ln&&(ln&&"mousemove"===e.type?(on=e.screenX-ln.screenX,sn=e.screenY-ln.screenY):sn=on=0,ln=e),on)},movementY:function(e){return"movementY"in e?e.movementY:sn}}),mn=an(fn),hn=an(D({},fn,{dataTransfer:0})),vn=an(D({},dn,{relatedTarget:0})),yn=an(D({},un,{animationName:0,elapsedTime:0,pseudoElement:0})),bn=D({},un,{clipboardData:function(e){return"clipboardData"in e?e.clipboardData:window.clipboardData}}),gn=an(bn),_n=an(D({},un,{data:0})),wn={Esc:"Escape",Spacebar:" ",Left:"ArrowLeft",Up:"ArrowUp",Right:"ArrowRight",Down:"ArrowDown",Del:"Delete",Win:"OS",Menu:"ContextMenu",Apps:"ContextMenu",Scroll:"ScrollLock",MozPrintableKey:"Unidentified"},Sn={8:"Backspace",9:"Tab",12:"Clear",13:"Enter",16:"Shift",17:"Control",18:"Alt",19:"Pause",20:"CapsLock",27:"Escape",32:" ",33:"PageUp",34:"PageDown",35:"End",36:"Home",37:"ArrowLeft",38:"ArrowUp",39:"ArrowRight",40:"ArrowDown",45:"Insert",46:"Delete",112:"F1",113:"F2",114:"F3",115:"F4",116:"F5",117:"F6",118:"F7",119:"F8",120:"F9",121:"F10",122:"F11",123:"F12",144:"NumLock",145:"ScrollLock",224:"Meta"},Tn={Alt:"altKey",Control:"ctrlKey",Meta:"metaKey",Shift:"shiftKey"};function Cn(e){var t=this.nativeEvent;return t.getModifierState?t.getModifierState(e):!!(e=Tn[e])&&!!t[e]}function kn(){return Cn}var An=D({},dn,{key:function(e){if(e.key){var t=wn[e.key]||e.key;if("Unidentified"!==t)return t}return"keypress"===e.type?13===(e=tn(e))?"Enter":String.fromCharCode(e):"keydown"===e.type||"keyup"===e.type?Sn[e.keyCode]||"Unidentified":""},code:0,location:0,ctrlKey:0,shiftKey:0,altKey:0,metaKey:0,repeat:0,locale:0,getModifierState:kn,charCode:function(e){return"keypress"===e.type?tn(e):0},keyCode:function(e){return"keydown"===e.type||"keyup"===e.type?e.keyCode:0},which:function(e){return"keypress"===e.type?tn(e):"keydown"===e.type||"keyup"===e.type?e.keyCode:0}}),xn=an(An),Fn=an(D({},fn,{pointerId:0,width:0,height:0,pressure:0,tangentialPressure:0,tiltX:0,tiltY:0,twist:0,pointerType:0,isPrimary:0})),Rn=an(D({},dn,{touches:0,targetTouches:0,changedTouches:0,altKey:0,metaKey:0,ctrlKey:0,shiftKey:0,getModifierState:kn})),Pn=an(D({},un,{propertyName:0,elapsedTime:0,pseudoElement:0})),En=D({},fn,{deltaX:function(e){return"deltaX"in e?e.deltaX:"wheelDeltaX"in e?-e.wheelDeltaX:0},deltaY:function(e){return"deltaY"in e?e.deltaY:"wheelDeltaY"in e?-e.wheelDeltaY:"wheelDelta"in e?-e.wheelDelta:0},deltaZ:0,deltaMode:0}),On=an(En),Nn=[9,13,27,32],In=c&&"CompositionEvent"in window,Mn=null;c&&"documentMode"in document&&(Mn=document.documentMode);var zn=c&&"TextEvent"in window&&!Mn,Dn=c&&(!In||Mn&&8<Mn&&11>=Mn),Ln=String.fromCharCode(32),Zn=!1;function jn(e,t){switch(e){case"keyup":return-1!==Nn.indexOf(t.keyCode);case"keydown":return 229!==t.keyCode;case"keypress":case"mousedown":case"focusout":return!0;default:return!1}}function Bn(e){return"object"===typeof(e=e.detail)&&"data"in e?e.data:null}var Wn=!1;var Jn={color:!0,date:!0,datetime:!0,"datetime-local":!0,email:!0,month:!0,number:!0,password:!0,range:!0,search:!0,tel:!0,text:!0,time:!0,url:!0,week:!0};function Un(e){var t=e&&e.nodeName&&e.nodeName.toLowerCase();return"input"===t?!!Jn[e.type]:"textarea"===t}function Vn(e,t,n,r){Ae(r),0<(t=$r(t,"onChange")).length&&(n=new cn("onChange","change",null,n,r),e.push({event:n,listeners:t}))}var $n=null,Hn=null;function Gn(e){Lr(e,0)}function qn(e){if(H(_a(e)))return e}function Kn(e,t){if("change"===e)return t}var Qn=!1;if(c){var Xn;if(c){var Yn="oninput"in document;if(!Yn){var er=document.createElement("div");er.setAttribute("oninput","return;"),Yn="function"===typeof er.oninput}Xn=Yn}else Xn=!1;Qn=Xn&&(!document.documentMode||9<document.documentMode)}function tr(){$n&&($n.detachEvent("onpropertychange",nr),Hn=$n=null)}function nr(e){if("value"===e.propertyName&&qn(Hn)){var t=[];Vn(t,Hn,e,we(e)),Ee(Gn,t)}}function rr(e,t,n){"focusin"===e?(tr(),Hn=n,($n=t).attachEvent("onpropertychange",nr)):"focusout"===e&&tr()}function ar(e){if("selectionchange"===e||"keyup"===e||"keydown"===e)return qn(Hn)}function or(e,t){if("click"===e)return qn(t)}function ir(e,t){if("input"===e||"change"===e)return qn(t)}var sr="function"===typeof Object.is?Object.is:function(e,t){return e===t&&(0!==e||1/e===1/t)||e!==e&&t!==t};function lr(e,t){if(sr(e,t))return!0;if("object"!==typeof e||null===e||"object"!==typeof t||null===t)return!1;var n=Object.keys(e),r=Object.keys(t);if(n.length!==r.length)return!1;for(r=0;r<n.length;r++){var a=n[r];if(!d.call(t,a)||!sr(e[a],t[a]))return!1}return!0}function ur(e){for(;e&&e.firstChild;)e=e.firstChild;return e}function cr(e,t){var n,r=ur(e);for(e=0;r;){if(3===r.nodeType){if(n=e+r.textContent.length,e<=t&&n>=t)return{node:r,offset:t-e};e=n}e:{for(;r;){if(r.nextSibling){r=r.nextSibling;break e}r=r.parentNode}r=void 0}r=ur(r)}}function dr(e,t){return!(!e||!t)&&(e===t||(!e||3!==e.nodeType)&&(t&&3===t.nodeType?dr(e,t.parentNode):"contains"in e?e.contains(t):!!e.compareDocumentPosition&&!!(16&e.compareDocumentPosition(t))))}function pr(){for(var e=window,t=G();t instanceof e.HTMLIFrameElement;){try{var n="string"===typeof t.contentWindow.location.href}catch(r){n=!1}if(!n)break;t=G((e=t.contentWindow).document)}return t}function fr(e){var t=e&&e.nodeName&&e.nodeName.toLowerCase();return t&&("input"===t&&("text"===e.type||"search"===e.type||"tel"===e.type||"url"===e.type||"password"===e.type)||"textarea"===t||"true"===e.contentEditable)}function mr(e){var t=pr(),n=e.focusedElem,r=e.selectionRange;if(t!==n&&n&&n.ownerDocument&&dr(n.ownerDocument.documentElement,n)){if(null!==r&&fr(n))if(t=r.start,void 0===(e=r.end)&&(e=t),"selectionStart"in n)n.selectionStart=t,n.selectionEnd=Math.min(e,n.value.length);else if((e=(t=n.ownerDocument||document)&&t.defaultView||window).getSelection){e=e.getSelection();var a=n.textContent.length,o=Math.min(r.start,a);r=void 0===r.end?o:Math.min(r.end,a),!e.extend&&o>r&&(a=r,r=o,o=a),a=cr(n,o);var i=cr(n,r);a&&i&&(1!==e.rangeCount||e.anchorNode!==a.node||e.anchorOffset!==a.offset||e.focusNode!==i.node||e.focusOffset!==i.offset)&&((t=t.createRange()).setStart(a.node,a.offset),e.removeAllRanges(),o>r?(e.addRange(t),e.extend(i.node,i.offset)):(t.setEnd(i.node,i.offset),e.addRange(t)))}for(t=[],e=n;e=e.parentNode;)1===e.nodeType&&t.push({element:e,left:e.scrollLeft,top:e.scrollTop});for("function"===typeof n.focus&&n.focus(),n=0;n<t.length;n++)(e=t[n]).element.scrollLeft=e.left,e.element.scrollTop=e.top}}var hr=c&&"documentMode"in document&&11>=document.documentMode,vr=null,yr=null,br=null,gr=!1;function _r(e,t,n){var r=n.window===n?n.document:9===n.nodeType?n:n.ownerDocument;gr||null==vr||vr!==G(r)||("selectionStart"in(r=vr)&&fr(r)?r={start:r.selectionStart,end:r.selectionEnd}:r={anchorNode:(r=(r.ownerDocument&&r.ownerDocument.defaultView||window).getSelection()).anchorNode,anchorOffset:r.anchorOffset,focusNode:r.focusNode,focusOffset:r.focusOffset},br&&lr(br,r)||(br=r,0<(r=$r(yr,"onSelect")).length&&(t=new cn("onSelect","select",null,t,n),e.push({event:t,listeners:r}),t.target=vr)))}function wr(e,t){var n={};return n[e.toLowerCase()]=t.toLowerCase(),n["Webkit"+e]="webkit"+t,n["Moz"+e]="moz"+t,n}var Sr={animationend:wr("Animation","AnimationEnd"),animationiteration:wr("Animation","AnimationIteration"),animationstart:wr("Animation","AnimationStart"),transitionend:wr("Transition","TransitionEnd")},Tr={},Cr={};function kr(e){if(Tr[e])return Tr[e];if(!Sr[e])return e;var t,n=Sr[e];for(t in n)if(n.hasOwnProperty(t)&&t in Cr)return Tr[e]=n[t];return e}c&&(Cr=document.createElement("div").style,"AnimationEvent"in window||(delete Sr.animationend.animation,delete Sr.animationiteration.animation,delete Sr.animationstart.animation),"TransitionEvent"in window||delete Sr.transitionend.transition);var Ar=kr("animationend"),xr=kr("animationiteration"),Fr=kr("animationstart"),Rr=kr("transitionend"),Pr=new Map,Er="abort auxClick cancel canPlay canPlayThrough click close contextMenu copy cut drag dragEnd dragEnter dragExit dragLeave dragOver dragStart drop durationChange emptied encrypted ended error gotPointerCapture input invalid keyDown keyPress keyUp load loadedData loadedMetadata loadStart lostPointerCapture mouseDown mouseMove mouseOut mouseOver mouseUp paste pause play playing pointerCancel pointerDown pointerMove pointerOut pointerOver pointerUp progress rateChange reset resize seeked seeking stalled submit suspend timeUpdate touchCancel touchEnd touchStart volumeChange scroll toggle touchMove waiting wheel".split(" ");function Or(e,t){Pr.set(e,t),l(t,[e])}for(var Nr=0;Nr<Er.length;Nr++){var Ir=Er[Nr];Or(Ir.toLowerCase(),"on"+(Ir[0].toUpperCase()+Ir.slice(1)))}Or(Ar,"onAnimationEnd"),Or(xr,"onAnimationIteration"),Or(Fr,"onAnimationStart"),Or("dblclick","onDoubleClick"),Or("focusin","onFocus"),Or("focusout","onBlur"),Or(Rr,"onTransitionEnd"),u("onMouseEnter",["mouseout","mouseover"]),u("onMouseLeave",["mouseout","mouseover"]),u("onPointerEnter",["pointerout","pointerover"]),u("onPointerLeave",["pointerout","pointerover"]),l("onChange","change click focusin focusout input keydown keyup selectionchange".split(" ")),l("onSelect","focusout contextmenu dragend focusin keydown keyup mousedown mouseup selectionchange".split(" ")),l("onBeforeInput",["compositionend","keypress","textInput","paste"]),l("onCompositionEnd","compositionend focusout keydown keypress keyup mousedown".split(" ")),l("onCompositionStart","compositionstart focusout keydown keypress keyup mousedown".split(" ")),l("onCompositionUpdate","compositionupdate focusout keydown keypress keyup mousedown".split(" "));var Mr="abort canplay canplaythrough durationchange emptied encrypted ended error loadeddata loadedmetadata loadstart pause play playing progress ratechange resize seeked seeking stalled suspend timeupdate volumechange waiting".split(" "),zr=new Set("cancel close invalid load scroll toggle".split(" ").concat(Mr));function Dr(e,t,n){var r=e.type||"unknown-event";e.currentTarget=n,function(e,t,n,r,a,i,s,l,u){if(Be.apply(this,arguments),ze){if(!ze)throw Error(o(198));var c=De;ze=!1,De=null,Le||(Le=!0,Ze=c)}}(r,t,void 0,e),e.currentTarget=null}function Lr(e,t){t=0!==(4&t);for(var n=0;n<e.length;n++){var r=e[n],a=r.event;r=r.listeners;e:{var o=void 0;if(t)for(var i=r.length-1;0<=i;i--){var s=r[i],l=s.instance,u=s.currentTarget;if(s=s.listener,l!==o&&a.isPropagationStopped())break e;Dr(a,s,u),o=l}else for(i=0;i<r.length;i++){if(l=(s=r[i]).instance,u=s.currentTarget,s=s.listener,l!==o&&a.isPropagationStopped())break e;Dr(a,s,u),o=l}}}if(Le)throw e=Ze,Le=!1,Ze=null,e}function Zr(e,t){var n=t[ha];void 0===n&&(n=t[ha]=new Set);var r=e+"__bubble";n.has(r)||(Jr(t,e,2,!1),n.add(r))}function jr(e,t,n){var r=0;t&&(r|=4),Jr(n,e,r,t)}var Br="_reactListening"+Math.random().toString(36).slice(2);function Wr(e){if(!e[Br]){e[Br]=!0,i.forEach((function(t){"selectionchange"!==t&&(zr.has(t)||jr(t,!1,e),jr(t,!0,e))}));var t=9===e.nodeType?e:e.ownerDocument;null===t||t[Br]||(t[Br]=!0,jr("selectionchange",!1,t))}}function Jr(e,t,n,r){switch(Kt(t)){case 1:var a=Vt;break;case 4:a=$t;break;default:a=Ht}n=a.bind(null,t,n,e),a=void 0,!Ne||"touchstart"!==t&&"touchmove"!==t&&"wheel"!==t||(a=!0),r?void 0!==a?e.addEventListener(t,n,{capture:!0,passive:a}):e.addEventListener(t,n,!0):void 0!==a?e.addEventListener(t,n,{passive:a}):e.addEventListener(t,n,!1)}function Ur(e,t,n,r,a){var o=r;if(0===(1&t)&&0===(2&t)&&null!==r)e:for(;;){if(null===r)return;var i=r.tag;if(3===i||4===i){var s=r.stateNode.containerInfo;if(s===a||8===s.nodeType&&s.parentNode===a)break;if(4===i)for(i=r.return;null!==i;){var l=i.tag;if((3===l||4===l)&&((l=i.stateNode.containerInfo)===a||8===l.nodeType&&l.parentNode===a))return;i=i.return}for(;null!==s;){if(null===(i=ba(s)))return;if(5===(l=i.tag)||6===l){r=o=i;continue e}s=s.parentNode}}r=r.return}Ee((function(){var r=o,a=we(n),i=[];e:{var s=Pr.get(e);if(void 0!==s){var l=cn,u=e;switch(e){case"keypress":if(0===tn(n))break e;case"keydown":case"keyup":l=xn;break;case"focusin":u="focus",l=vn;break;case"focusout":u="blur",l=vn;break;case"beforeblur":case"afterblur":l=vn;break;case"click":if(2===n.button)break e;case"auxclick":case"dblclick":case"mousedown":case"mousemove":case"mouseup":case"mouseout":case"mouseover":case"contextmenu":l=mn;break;case"drag":case"dragend":case"dragenter":case"dragexit":case"dragleave":case"dragover":case"dragstart":case"drop":l=hn;break;case"touchcancel":case"touchend":case"touchmove":case"touchstart":l=Rn;break;case Ar:case xr:case Fr:l=yn;break;case Rr:l=Pn;break;case"scroll":l=pn;break;case"wheel":l=On;break;case"copy":case"cut":case"paste":l=gn;break;case"gotpointercapture":case"lostpointercapture":case"pointercancel":case"pointerdown":case"pointermove":case"pointerout":case"pointerover":case"pointerup":l=Fn}var c=0!==(4&t),d=!c&&"scroll"===e,p=c?null!==s?s+"Capture":null:s;c=[];for(var f,m=r;null!==m;){var h=(f=m).stateNode;if(5===f.tag&&null!==h&&(f=h,null!==p&&(null!=(h=Oe(m,p))&&c.push(Vr(m,h,f)))),d)break;m=m.return}0<c.length&&(s=new l(s,u,null,n,a),i.push({event:s,listeners:c}))}}if(0===(7&t)){if(l="mouseout"===e||"pointerout"===e,(!(s="mouseover"===e||"pointerover"===e)||n===_e||!(u=n.relatedTarget||n.fromElement)||!ba(u)&&!u[ma])&&(l||s)&&(s=a.window===a?a:(s=a.ownerDocument)?s.defaultView||s.parentWindow:window,l?(l=r,null!==(u=(u=n.relatedTarget||n.toElement)?ba(u):null)&&(u!==(d=We(u))||5!==u.tag&&6!==u.tag)&&(u=null)):(l=null,u=r),l!==u)){if(c=mn,h="onMouseLeave",p="onMouseEnter",m="mouse","pointerout"!==e&&"pointerover"!==e||(c=Fn,h="onPointerLeave",p="onPointerEnter",m="pointer"),d=null==l?s:_a(l),f=null==u?s:_a(u),(s=new c(h,m+"leave",l,n,a)).target=d,s.relatedTarget=f,h=null,ba(a)===r&&((c=new c(p,m+"enter",u,n,a)).target=f,c.relatedTarget=d,h=c),d=h,l&&u)e:{for(p=u,m=0,f=c=l;f;f=Hr(f))m++;for(f=0,h=p;h;h=Hr(h))f++;for(;0<m-f;)c=Hr(c),m--;for(;0<f-m;)p=Hr(p),f--;for(;m--;){if(c===p||null!==p&&c===p.alternate)break e;c=Hr(c),p=Hr(p)}c=null}else c=null;null!==l&&Gr(i,s,l,c,!1),null!==u&&null!==d&&Gr(i,d,u,c,!0)}if("select"===(l=(s=r?_a(r):window).nodeName&&s.nodeName.toLowerCase())||"input"===l&&"file"===s.type)var v=Kn;else if(Un(s))if(Qn)v=ir;else{v=ar;var y=rr}else(l=s.nodeName)&&"input"===l.toLowerCase()&&("checkbox"===s.type||"radio"===s.type)&&(v=or);switch(v&&(v=v(e,r))?Vn(i,v,n,a):(y&&y(e,s,r),"focusout"===e&&(y=s._wrapperState)&&y.controlled&&"number"===s.type&&ee(s,"number",s.value)),y=r?_a(r):window,e){case"focusin":(Un(y)||"true"===y.contentEditable)&&(vr=y,yr=r,br=null);break;case"focusout":br=yr=vr=null;break;case"mousedown":gr=!0;break;case"contextmenu":case"mouseup":case"dragend":gr=!1,_r(i,n,a);break;case"selectionchange":if(hr)break;case"keydown":case"keyup":_r(i,n,a)}var b;if(In)e:{switch(e){case"compositionstart":var g="onCompositionStart";break e;case"compositionend":g="onCompositionEnd";break e;case"compositionupdate":g="onCompositionUpdate";break e}g=void 0}else Wn?jn(e,n)&&(g="onCompositionEnd"):"keydown"===e&&229===n.keyCode&&(g="onCompositionStart");g&&(Dn&&"ko"!==n.locale&&(Wn||"onCompositionStart"!==g?"onCompositionEnd"===g&&Wn&&(b=en()):(Xt="value"in(Qt=a)?Qt.value:Qt.textContent,Wn=!0)),0<(y=$r(r,g)).length&&(g=new _n(g,e,null,n,a),i.push({event:g,listeners:y}),b?g.data=b:null!==(b=Bn(n))&&(g.data=b))),(b=zn?function(e,t){switch(e){case"compositionend":return Bn(t);case"keypress":return 32!==t.which?null:(Zn=!0,Ln);case"textInput":return(e=t.data)===Ln&&Zn?null:e;default:return null}}(e,n):function(e,t){if(Wn)return"compositionend"===e||!In&&jn(e,t)?(e=en(),Yt=Xt=Qt=null,Wn=!1,e):null;switch(e){case"paste":default:return null;case"keypress":if(!(t.ctrlKey||t.altKey||t.metaKey)||t.ctrlKey&&t.altKey){if(t.char&&1<t.char.length)return t.char;if(t.which)return String.fromCharCode(t.which)}return null;case"compositionend":return Dn&&"ko"!==t.locale?null:t.data}}(e,n))&&(0<(r=$r(r,"onBeforeInput")).length&&(a=new _n("onBeforeInput","beforeinput",null,n,a),i.push({event:a,listeners:r}),a.data=b))}Lr(i,t)}))}function Vr(e,t,n){return{instance:e,listener:t,currentTarget:n}}function $r(e,t){for(var n=t+"Capture",r=[];null!==e;){var a=e,o=a.stateNode;5===a.tag&&null!==o&&(a=o,null!=(o=Oe(e,n))&&r.unshift(Vr(e,o,a)),null!=(o=Oe(e,t))&&r.push(Vr(e,o,a))),e=e.return}return r}function Hr(e){if(null===e)return null;do{e=e.return}while(e&&5!==e.tag);return e||null}function Gr(e,t,n,r,a){for(var o=t._reactName,i=[];null!==n&&n!==r;){var s=n,l=s.alternate,u=s.stateNode;if(null!==l&&l===r)break;5===s.tag&&null!==u&&(s=u,a?null!=(l=Oe(n,o))&&i.unshift(Vr(n,l,s)):a||null!=(l=Oe(n,o))&&i.push(Vr(n,l,s))),n=n.return}0!==i.length&&e.push({event:t,listeners:i})}var qr=/\r\n?/g,Kr=/\u0000|\uFFFD/g;function Qr(e){return("string"===typeof e?e:""+e).replace(qr,"\n").replace(Kr,"")}function Xr(e,t,n){if(t=Qr(t),Qr(e)!==t&&n)throw Error(o(425))}function Yr(){}var ea=null,ta=null;function na(e,t){return"textarea"===e||"noscript"===e||"string"===typeof t.children||"number"===typeof t.children||"object"===typeof t.dangerouslySetInnerHTML&&null!==t.dangerouslySetInnerHTML&&null!=t.dangerouslySetInnerHTML.__html}var ra="function"===typeof setTimeout?setTimeout:void 0,aa="function"===typeof clearTimeout?clearTimeout:void 0,oa="function"===typeof Promise?Promise:void 0,ia="function"===typeof queueMicrotask?queueMicrotask:"undefined"!==typeof oa?function(e){return oa.resolve(null).then(e).catch(sa)}:ra;function sa(e){setTimeout((function(){throw e}))}function la(e,t){var n=t,r=0;do{var a=n.nextSibling;if(e.removeChild(n),a&&8===a.nodeType)if("/$"===(n=a.data)){if(0===r)return e.removeChild(a),void Wt(t);r--}else"$"!==n&&"$?"!==n&&"$!"!==n||r++;n=a}while(n);Wt(t)}function ua(e){for(;null!=e;e=e.nextSibling){var t=e.nodeType;if(1===t||3===t)break;if(8===t){if("$"===(t=e.data)||"$!"===t||"$?"===t)break;if("/$"===t)return null}}return e}function ca(e){e=e.previousSibling;for(var t=0;e;){if(8===e.nodeType){var n=e.data;if("$"===n||"$!"===n||"$?"===n){if(0===t)return e;t--}else"/$"===n&&t++}e=e.previousSibling}return null}var da=Math.random().toString(36).slice(2),pa="__reactFiber$"+da,fa="__reactProps$"+da,ma="__reactContainer$"+da,ha="__reactEvents$"+da,va="__reactListeners$"+da,ya="__reactHandles$"+da;function ba(e){var t=e[pa];if(t)return t;for(var n=e.parentNode;n;){if(t=n[ma]||n[pa]){if(n=t.alternate,null!==t.child||null!==n&&null!==n.child)for(e=ca(e);null!==e;){if(n=e[pa])return n;e=ca(e)}return t}n=(e=n).parentNode}return null}function ga(e){return!(e=e[pa]||e[ma])||5!==e.tag&&6!==e.tag&&13!==e.tag&&3!==e.tag?null:e}function _a(e){if(5===e.tag||6===e.tag)return e.stateNode;throw Error(o(33))}function wa(e){return e[fa]||null}var Sa=[],Ta=-1;function Ca(e){return{current:e}}function ka(e){0>Ta||(e.current=Sa[Ta],Sa[Ta]=null,Ta--)}function Aa(e,t){Ta++,Sa[Ta]=e.current,e.current=t}var xa={},Fa=Ca(xa),Ra=Ca(!1),Pa=xa;function Ea(e,t){var n=e.type.contextTypes;if(!n)return xa;var r=e.stateNode;if(r&&r.__reactInternalMemoizedUnmaskedChildContext===t)return r.__reactInternalMemoizedMaskedChildContext;var a,o={};for(a in n)o[a]=t[a];return r&&((e=e.stateNode).__reactInternalMemoizedUnmaskedChildContext=t,e.__reactInternalMemoizedMaskedChildContext=o),o}function Oa(e){return null!==(e=e.childContextTypes)&&void 0!==e}function Na(){ka(Ra),ka(Fa)}function Ia(e,t,n){if(Fa.current!==xa)throw Error(o(168));Aa(Fa,t),Aa(Ra,n)}function Ma(e,t,n){var r=e.stateNode;if(t=t.childContextTypes,"function"!==typeof r.getChildContext)return n;for(var a in r=r.getChildContext())if(!(a in t))throw Error(o(108,J(e)||"Unknown",a));return D({},n,r)}function za(e){return e=(e=e.stateNode)&&e.__reactInternalMemoizedMergedChildContext||xa,Pa=Fa.current,Aa(Fa,e),Aa(Ra,Ra.current),!0}function Da(e,t,n){var r=e.stateNode;if(!r)throw Error(o(169));n?(e=Ma(e,t,Pa),r.__reactInternalMemoizedMergedChildContext=e,ka(Ra),ka(Fa),Aa(Fa,e)):ka(Ra),Aa(Ra,n)}var La=null,Za=!1,ja=!1;function Ba(e){null===La?La=[e]:La.push(e)}function Wa(){if(!ja&&null!==La){ja=!0;var e=0,t=gt;try{var n=La;for(gt=1;e<n.length;e++){var r=n[e];do{r=r(!0)}while(null!==r)}La=null,Za=!1}catch(a){throw null!==La&&(La=La.slice(e+1)),He(Ye,Wa),a}finally{gt=t,ja=!1}}return null}var Ja=[],Ua=0,Va=null,$a=0,Ha=[],Ga=0,qa=null,Ka=1,Qa="";function Xa(e,t){Ja[Ua++]=$a,Ja[Ua++]=Va,Va=e,$a=t}function Ya(e,t,n){Ha[Ga++]=Ka,Ha[Ga++]=Qa,Ha[Ga++]=qa,qa=e;var r=Ka;e=Qa;var a=32-it(r)-1;r&=~(1<<a),n+=1;var o=32-it(t)+a;if(30<o){var i=a-a%5;o=(r&(1<<i)-1).toString(32),r>>=i,a-=i,Ka=1<<32-it(t)+a|n<<a|r,Qa=o+e}else Ka=1<<o|n<<a|r,Qa=e}function eo(e){null!==e.return&&(Xa(e,1),Ya(e,1,0))}function to(e){for(;e===Va;)Va=Ja[--Ua],Ja[Ua]=null,$a=Ja[--Ua],Ja[Ua]=null;for(;e===qa;)qa=Ha[--Ga],Ha[Ga]=null,Qa=Ha[--Ga],Ha[Ga]=null,Ka=Ha[--Ga],Ha[Ga]=null}var no=null,ro=null,ao=!1,oo=null;function io(e,t){var n=Eu(5,null,null,0);n.elementType="DELETED",n.stateNode=t,n.return=e,null===(t=e.deletions)?(e.deletions=[n],e.flags|=16):t.push(n)}function so(e,t){switch(e.tag){case 5:var n=e.type;return null!==(t=1!==t.nodeType||n.toLowerCase()!==t.nodeName.toLowerCase()?null:t)&&(e.stateNode=t,no=e,ro=ua(t.firstChild),!0);case 6:return null!==(t=""===e.pendingProps||3!==t.nodeType?null:t)&&(e.stateNode=t,no=e,ro=null,!0);case 13:return null!==(t=8!==t.nodeType?null:t)&&(n=null!==qa?{id:Ka,overflow:Qa}:null,e.memoizedState={dehydrated:t,treeContext:n,retryLane:1073741824},(n=Eu(18,null,null,0)).stateNode=t,n.return=e,e.child=n,no=e,ro=null,!0);default:return!1}}function lo(e){return 0!==(1&e.mode)&&0===(128&e.flags)}function uo(e){if(ao){var t=ro;if(t){var n=t;if(!so(e,t)){if(lo(e))throw Error(o(418));t=ua(n.nextSibling);var r=no;t&&so(e,t)?io(r,n):(e.flags=-4097&e.flags|2,ao=!1,no=e)}}else{if(lo(e))throw Error(o(418));e.flags=-4097&e.flags|2,ao=!1,no=e}}}function co(e){for(e=e.return;null!==e&&5!==e.tag&&3!==e.tag&&13!==e.tag;)e=e.return;no=e}function po(e){if(e!==no)return!1;if(!ao)return co(e),ao=!0,!1;var t;if((t=3!==e.tag)&&!(t=5!==e.tag)&&(t="head"!==(t=e.type)&&"body"!==t&&!na(e.type,e.memoizedProps)),t&&(t=ro)){if(lo(e))throw fo(),Error(o(418));for(;t;)io(e,t),t=ua(t.nextSibling)}if(co(e),13===e.tag){if(!(e=null!==(e=e.memoizedState)?e.dehydrated:null))throw Error(o(317));e:{for(e=e.nextSibling,t=0;e;){if(8===e.nodeType){var n=e.data;if("/$"===n){if(0===t){ro=ua(e.nextSibling);break e}t--}else"$"!==n&&"$!"!==n&&"$?"!==n||t++}e=e.nextSibling}ro=null}}else ro=no?ua(e.stateNode.nextSibling):null;return!0}function fo(){for(var e=ro;e;)e=ua(e.nextSibling)}function mo(){ro=no=null,ao=!1}function ho(e){null===oo?oo=[e]:oo.push(e)}var vo=_.ReactCurrentBatchConfig;function yo(e,t){if(e&&e.defaultProps){for(var n in t=D({},t),e=e.defaultProps)void 0===t[n]&&(t[n]=e[n]);return t}return t}var bo=Ca(null),go=null,_o=null,wo=null;function So(){wo=_o=go=null}function To(e){var t=bo.current;ka(bo),e._currentValue=t}function Co(e,t,n){for(;null!==e;){var r=e.alternate;if((e.childLanes&t)!==t?(e.childLanes|=t,null!==r&&(r.childLanes|=t)):null!==r&&(r.childLanes&t)!==t&&(r.childLanes|=t),e===n)break;e=e.return}}function ko(e,t){go=e,wo=_o=null,null!==(e=e.dependencies)&&null!==e.firstContext&&(0!==(e.lanes&t)&&(_s=!0),e.firstContext=null)}function Ao(e){var t=e._currentValue;if(wo!==e)if(e={context:e,memoizedValue:t,next:null},null===_o){if(null===go)throw Error(o(308));_o=e,go.dependencies={lanes:0,firstContext:e}}else _o=_o.next=e;return t}var xo=null;function Fo(e){null===xo?xo=[e]:xo.push(e)}function Ro(e,t,n,r){var a=t.interleaved;return null===a?(n.next=n,Fo(t)):(n.next=a.next,a.next=n),t.interleaved=n,Po(e,r)}function Po(e,t){e.lanes|=t;var n=e.alternate;for(null!==n&&(n.lanes|=t),n=e,e=e.return;null!==e;)e.childLanes|=t,null!==(n=e.alternate)&&(n.childLanes|=t),n=e,e=e.return;return 3===n.tag?n.stateNode:null}var Eo=!1;function Oo(e){e.updateQueue={baseState:e.memoizedState,firstBaseUpdate:null,lastBaseUpdate:null,shared:{pending:null,interleaved:null,lanes:0},effects:null}}function No(e,t){e=e.updateQueue,t.updateQueue===e&&(t.updateQueue={baseState:e.baseState,firstBaseUpdate:e.firstBaseUpdate,lastBaseUpdate:e.lastBaseUpdate,shared:e.shared,effects:e.effects})}function Io(e,t){return{eventTime:e,lane:t,tag:0,payload:null,callback:null,next:null}}function Mo(e,t,n){var r=e.updateQueue;if(null===r)return null;if(r=r.shared,0!==(2&Fl)){var a=r.pending;return null===a?t.next=t:(t.next=a.next,a.next=t),r.pending=t,Po(e,n)}return null===(a=r.interleaved)?(t.next=t,Fo(r)):(t.next=a.next,a.next=t),r.interleaved=t,Po(e,n)}function zo(e,t,n){if(null!==(t=t.updateQueue)&&(t=t.shared,0!==(4194240&n))){var r=t.lanes;n|=r&=e.pendingLanes,t.lanes=n,bt(e,n)}}function Do(e,t){var n=e.updateQueue,r=e.alternate;if(null!==r&&n===(r=r.updateQueue)){var a=null,o=null;if(null!==(n=n.firstBaseUpdate)){do{var i={eventTime:n.eventTime,lane:n.lane,tag:n.tag,payload:n.payload,callback:n.callback,next:null};null===o?a=o=i:o=o.next=i,n=n.next}while(null!==n);null===o?a=o=t:o=o.next=t}else a=o=t;return n={baseState:r.baseState,firstBaseUpdate:a,lastBaseUpdate:o,shared:r.shared,effects:r.effects},void(e.updateQueue=n)}null===(e=n.lastBaseUpdate)?n.firstBaseUpdate=t:e.next=t,n.lastBaseUpdate=t}function Lo(e,t,n,r){var a=e.updateQueue;Eo=!1;var o=a.firstBaseUpdate,i=a.lastBaseUpdate,s=a.shared.pending;if(null!==s){a.shared.pending=null;var l=s,u=l.next;l.next=null,null===i?o=u:i.next=u,i=l;var c=e.alternate;null!==c&&((s=(c=c.updateQueue).lastBaseUpdate)!==i&&(null===s?c.firstBaseUpdate=u:s.next=u,c.lastBaseUpdate=l))}if(null!==o){var d=a.baseState;for(i=0,c=u=l=null,s=o;;){var p=s.lane,f=s.eventTime;if((r&p)===p){null!==c&&(c=c.next={eventTime:f,lane:0,tag:s.tag,payload:s.payload,callback:s.callback,next:null});e:{var m=e,h=s;switch(p=t,f=n,h.tag){case 1:if("function"===typeof(m=h.payload)){d=m.call(f,d,p);break e}d=m;break e;case 3:m.flags=-65537&m.flags|128;case 0:if(null===(p="function"===typeof(m=h.payload)?m.call(f,d,p):m)||void 0===p)break e;d=D({},d,p);break e;case 2:Eo=!0}}null!==s.callback&&0!==s.lane&&(e.flags|=64,null===(p=a.effects)?a.effects=[s]:p.push(s))}else f={eventTime:f,lane:p,tag:s.tag,payload:s.payload,callback:s.callback,next:null},null===c?(u=c=f,l=d):c=c.next=f,i|=p;if(null===(s=s.next)){if(null===(s=a.shared.pending))break;s=(p=s).next,p.next=null,a.lastBaseUpdate=p,a.shared.pending=null}}if(null===c&&(l=d),a.baseState=l,a.firstBaseUpdate=u,a.lastBaseUpdate=c,null!==(t=a.shared.interleaved)){a=t;do{i|=a.lane,a=a.next}while(a!==t)}else null===o&&(a.shared.lanes=0);zl|=i,e.lanes=i,e.memoizedState=d}}function Zo(e,t,n){if(e=t.effects,t.effects=null,null!==e)for(t=0;t<e.length;t++){var r=e[t],a=r.callback;if(null!==a){if(r.callback=null,r=n,"function"!==typeof a)throw Error(o(191,a));a.call(r)}}}var jo=(new r.Component).refs;function Bo(e,t,n,r){n=null===(n=n(r,t=e.memoizedState))||void 0===n?t:D({},t,n),e.memoizedState=n,0===e.lanes&&(e.updateQueue.baseState=n)}var Wo={isMounted:function(e){return!!(e=e._reactInternals)&&We(e)===e},enqueueSetState:function(e,t,n){e=e._reactInternals;var r=eu(),a=tu(e),o=Io(r,a);o.payload=t,void 0!==n&&null!==n&&(o.callback=n),null!==(t=Mo(e,o,a))&&(nu(t,e,a,r),zo(t,e,a))},enqueueReplaceState:function(e,t,n){e=e._reactInternals;var r=eu(),a=tu(e),o=Io(r,a);o.tag=1,o.payload=t,void 0!==n&&null!==n&&(o.callback=n),null!==(t=Mo(e,o,a))&&(nu(t,e,a,r),zo(t,e,a))},enqueueForceUpdate:function(e,t){e=e._reactInternals;var n=eu(),r=tu(e),a=Io(n,r);a.tag=2,void 0!==t&&null!==t&&(a.callback=t),null!==(t=Mo(e,a,r))&&(nu(t,e,r,n),zo(t,e,r))}};function Jo(e,t,n,r,a,o,i){return"function"===typeof(e=e.stateNode).shouldComponentUpdate?e.shouldComponentUpdate(r,o,i):!t.prototype||!t.prototype.isPureReactComponent||(!lr(n,r)||!lr(a,o))}function Uo(e,t,n){var r=!1,a=xa,o=t.contextType;return"object"===typeof o&&null!==o?o=Ao(o):(a=Oa(t)?Pa:Fa.current,o=(r=null!==(r=t.contextTypes)&&void 0!==r)?Ea(e,a):xa),t=new t(n,o),e.memoizedState=null!==t.state&&void 0!==t.state?t.state:null,t.updater=Wo,e.stateNode=t,t._reactInternals=e,r&&((e=e.stateNode).__reactInternalMemoizedUnmaskedChildContext=a,e.__reactInternalMemoizedMaskedChildContext=o),t}function Vo(e,t,n,r){e=t.state,"function"===typeof t.componentWillReceiveProps&&t.componentWillReceiveProps(n,r),"function"===typeof t.UNSAFE_componentWillReceiveProps&&t.UNSAFE_componentWillReceiveProps(n,r),t.state!==e&&Wo.enqueueReplaceState(t,t.state,null)}function $o(e,t,n,r){var a=e.stateNode;a.props=n,a.state=e.memoizedState,a.refs=jo,Oo(e);var o=t.contextType;"object"===typeof o&&null!==o?a.context=Ao(o):(o=Oa(t)?Pa:Fa.current,a.context=Ea(e,o)),a.state=e.memoizedState,"function"===typeof(o=t.getDerivedStateFromProps)&&(Bo(e,t,o,n),a.state=e.memoizedState),"function"===typeof t.getDerivedStateFromProps||"function"===typeof a.getSnapshotBeforeUpdate||"function"!==typeof a.UNSAFE_componentWillMount&&"function"!==typeof a.componentWillMount||(t=a.state,"function"===typeof a.componentWillMount&&a.componentWillMount(),"function"===typeof a.UNSAFE_componentWillMount&&a.UNSAFE_componentWillMount(),t!==a.state&&Wo.enqueueReplaceState(a,a.state,null),Lo(e,n,a,r),a.state=e.memoizedState),"function"===typeof a.componentDidMount&&(e.flags|=4194308)}function Ho(e,t,n){if(null!==(e=n.ref)&&"function"!==typeof e&&"object"!==typeof e){if(n._owner){if(n=n._owner){if(1!==n.tag)throw Error(o(309));var r=n.stateNode}if(!r)throw Error(o(147,e));var a=r,i=""+e;return null!==t&&null!==t.ref&&"function"===typeof t.ref&&t.ref._stringRef===i?t.ref:(t=function(e){var t=a.refs;t===jo&&(t=a.refs={}),null===e?delete t[i]:t[i]=e},t._stringRef=i,t)}if("string"!==typeof e)throw Error(o(284));if(!n._owner)throw Error(o(290,e))}return e}function Go(e,t){throw e=Object.prototype.toString.call(t),Error(o(31,"[object Object]"===e?"object with keys {"+Object.keys(t).join(", ")+"}":e))}function qo(e){return(0,e._init)(e._payload)}function Ko(e){function t(t,n){if(e){var r=t.deletions;null===r?(t.deletions=[n],t.flags|=16):r.push(n)}}function n(n,r){if(!e)return null;for(;null!==r;)t(n,r),r=r.sibling;return null}function r(e,t){for(e=new Map;null!==t;)null!==t.key?e.set(t.key,t):e.set(t.index,t),t=t.sibling;return e}function a(e,t){return(e=Nu(e,t)).index=0,e.sibling=null,e}function i(t,n,r){return t.index=r,e?null!==(r=t.alternate)?(r=r.index)<n?(t.flags|=2,n):r:(t.flags|=2,n):(t.flags|=1048576,n)}function s(t){return e&&null===t.alternate&&(t.flags|=2),t}function l(e,t,n,r){return null===t||6!==t.tag?((t=Du(n,e.mode,r)).return=e,t):((t=a(t,n)).return=e,t)}function u(e,t,n,r){var o=n.type;return o===T?d(e,t,n.props.children,r,n.key):null!==t&&(t.elementType===o||"object"===typeof o&&null!==o&&o.$$typeof===O&&qo(o)===t.type)?((r=a(t,n.props)).ref=Ho(e,t,n),r.return=e,r):((r=Iu(n.type,n.key,n.props,null,e.mode,r)).ref=Ho(e,t,n),r.return=e,r)}function c(e,t,n,r){return null===t||4!==t.tag||t.stateNode.containerInfo!==n.containerInfo||t.stateNode.implementation!==n.implementation?((t=Lu(n,e.mode,r)).return=e,t):((t=a(t,n.children||[])).return=e,t)}function d(e,t,n,r,o){return null===t||7!==t.tag?((t=Mu(n,e.mode,r,o)).return=e,t):((t=a(t,n)).return=e,t)}function p(e,t,n){if("string"===typeof t&&""!==t||"number"===typeof t)return(t=Du(""+t,e.mode,n)).return=e,t;if("object"===typeof t&&null!==t){switch(t.$$typeof){case w:return(n=Iu(t.type,t.key,t.props,null,e.mode,n)).ref=Ho(e,null,t),n.return=e,n;case S:return(t=Lu(t,e.mode,n)).return=e,t;case O:return p(e,(0,t._init)(t._payload),n)}if(te(t)||M(t))return(t=Mu(t,e.mode,n,null)).return=e,t;Go(e,t)}return null}function f(e,t,n,r){var a=null!==t?t.key:null;if("string"===typeof n&&""!==n||"number"===typeof n)return null!==a?null:l(e,t,""+n,r);if("object"===typeof n&&null!==n){switch(n.$$typeof){case w:return n.key===a?u(e,t,n,r):null;case S:return n.key===a?c(e,t,n,r):null;case O:return f(e,t,(a=n._init)(n._payload),r)}if(te(n)||M(n))return null!==a?null:d(e,t,n,r,null);Go(e,n)}return null}function m(e,t,n,r,a){if("string"===typeof r&&""!==r||"number"===typeof r)return l(t,e=e.get(n)||null,""+r,a);if("object"===typeof r&&null!==r){switch(r.$$typeof){case w:return u(t,e=e.get(null===r.key?n:r.key)||null,r,a);case S:return c(t,e=e.get(null===r.key?n:r.key)||null,r,a);case O:return m(e,t,n,(0,r._init)(r._payload),a)}if(te(r)||M(r))return d(t,e=e.get(n)||null,r,a,null);Go(t,r)}return null}function h(a,o,s,l){for(var u=null,c=null,d=o,h=o=0,v=null;null!==d&&h<s.length;h++){d.index>h?(v=d,d=null):v=d.sibling;var y=f(a,d,s[h],l);if(null===y){null===d&&(d=v);break}e&&d&&null===y.alternate&&t(a,d),o=i(y,o,h),null===c?u=y:c.sibling=y,c=y,d=v}if(h===s.length)return n(a,d),ao&&Xa(a,h),u;if(null===d){for(;h<s.length;h++)null!==(d=p(a,s[h],l))&&(o=i(d,o,h),null===c?u=d:c.sibling=d,c=d);return ao&&Xa(a,h),u}for(d=r(a,d);h<s.length;h++)null!==(v=m(d,a,h,s[h],l))&&(e&&null!==v.alternate&&d.delete(null===v.key?h:v.key),o=i(v,o,h),null===c?u=v:c.sibling=v,c=v);return e&&d.forEach((function(e){return t(a,e)})),ao&&Xa(a,h),u}function v(a,s,l,u){var c=M(l);if("function"!==typeof c)throw Error(o(150));if(null==(l=c.call(l)))throw Error(o(151));for(var d=c=null,h=s,v=s=0,y=null,b=l.next();null!==h&&!b.done;v++,b=l.next()){h.index>v?(y=h,h=null):y=h.sibling;var g=f(a,h,b.value,u);if(null===g){null===h&&(h=y);break}e&&h&&null===g.alternate&&t(a,h),s=i(g,s,v),null===d?c=g:d.sibling=g,d=g,h=y}if(b.done)return n(a,h),ao&&Xa(a,v),c;if(null===h){for(;!b.done;v++,b=l.next())null!==(b=p(a,b.value,u))&&(s=i(b,s,v),null===d?c=b:d.sibling=b,d=b);return ao&&Xa(a,v),c}for(h=r(a,h);!b.done;v++,b=l.next())null!==(b=m(h,a,v,b.value,u))&&(e&&null!==b.alternate&&h.delete(null===b.key?v:b.key),s=i(b,s,v),null===d?c=b:d.sibling=b,d=b);return e&&h.forEach((function(e){return t(a,e)})),ao&&Xa(a,v),c}return function e(r,o,i,l){if("object"===typeof i&&null!==i&&i.type===T&&null===i.key&&(i=i.props.children),"object"===typeof i&&null!==i){switch(i.$$typeof){case w:e:{for(var u=i.key,c=o;null!==c;){if(c.key===u){if((u=i.type)===T){if(7===c.tag){n(r,c.sibling),(o=a(c,i.props.children)).return=r,r=o;break e}}else if(c.elementType===u||"object"===typeof u&&null!==u&&u.$$typeof===O&&qo(u)===c.type){n(r,c.sibling),(o=a(c,i.props)).ref=Ho(r,c,i),o.return=r,r=o;break e}n(r,c);break}t(r,c),c=c.sibling}i.type===T?((o=Mu(i.props.children,r.mode,l,i.key)).return=r,r=o):((l=Iu(i.type,i.key,i.props,null,r.mode,l)).ref=Ho(r,o,i),l.return=r,r=l)}return s(r);case S:e:{for(c=i.key;null!==o;){if(o.key===c){if(4===o.tag&&o.stateNode.containerInfo===i.containerInfo&&o.stateNode.implementation===i.implementation){n(r,o.sibling),(o=a(o,i.children||[])).return=r,r=o;break e}n(r,o);break}t(r,o),o=o.sibling}(o=Lu(i,r.mode,l)).return=r,r=o}return s(r);case O:return e(r,o,(c=i._init)(i._payload),l)}if(te(i))return h(r,o,i,l);if(M(i))return v(r,o,i,l);Go(r,i)}return"string"===typeof i&&""!==i||"number"===typeof i?(i=""+i,null!==o&&6===o.tag?(n(r,o.sibling),(o=a(o,i)).return=r,r=o):(n(r,o),(o=Du(i,r.mode,l)).return=r,r=o),s(r)):n(r,o)}}var Qo=Ko(!0),Xo=Ko(!1),Yo={},ei=Ca(Yo),ti=Ca(Yo),ni=Ca(Yo);function ri(e){if(e===Yo)throw Error(o(174));return e}function ai(e,t){switch(Aa(ni,t),Aa(ti,e),Aa(ei,Yo),e=t.nodeType){case 9:case 11:t=(t=t.documentElement)?t.namespaceURI:le(null,"");break;default:t=le(t=(e=8===e?t.parentNode:t).namespaceURI||null,e=e.tagName)}ka(ei),Aa(ei,t)}function oi(){ka(ei),ka(ti),ka(ni)}function ii(e){ri(ni.current);var t=ri(ei.current),n=le(t,e.type);t!==n&&(Aa(ti,e),Aa(ei,n))}function si(e){ti.current===e&&(ka(ei),ka(ti))}var li=Ca(0);function ui(e){for(var t=e;null!==t;){if(13===t.tag){var n=t.memoizedState;if(null!==n&&(null===(n=n.dehydrated)||"$?"===n.data||"$!"===n.data))return t}else if(19===t.tag&&void 0!==t.memoizedProps.revealOrder){if(0!==(128&t.flags))return t}else if(null!==t.child){t.child.return=t,t=t.child;continue}if(t===e)break;for(;null===t.sibling;){if(null===t.return||t.return===e)return null;t=t.return}t.sibling.return=t.return,t=t.sibling}return null}var ci=[];function di(){for(var e=0;e<ci.length;e++)ci[e]._workInProgressVersionPrimary=null;ci.length=0}var pi=_.ReactCurrentDispatcher,fi=_.ReactCurrentBatchConfig,mi=0,hi=null,vi=null,yi=null,bi=!1,gi=!1,_i=0,wi=0;function Si(){throw Error(o(321))}function Ti(e,t){if(null===t)return!1;for(var n=0;n<t.length&&n<e.length;n++)if(!sr(e[n],t[n]))return!1;return!0}function Ci(e,t,n,r,a,i){if(mi=i,hi=t,t.memoizedState=null,t.updateQueue=null,t.lanes=0,pi.current=null===e||null===e.memoizedState?ss:ls,e=n(r,a),gi){i=0;do{if(gi=!1,_i=0,25<=i)throw Error(o(301));i+=1,yi=vi=null,t.updateQueue=null,pi.current=us,e=n(r,a)}while(gi)}if(pi.current=is,t=null!==vi&&null!==vi.next,mi=0,yi=vi=hi=null,bi=!1,t)throw Error(o(300));return e}function ki(){var e=0!==_i;return _i=0,e}function Ai(){var e={memoizedState:null,baseState:null,baseQueue:null,queue:null,next:null};return null===yi?hi.memoizedState=yi=e:yi=yi.next=e,yi}function xi(){if(null===vi){var e=hi.alternate;e=null!==e?e.memoizedState:null}else e=vi.next;var t=null===yi?hi.memoizedState:yi.next;if(null!==t)yi=t,vi=e;else{if(null===e)throw Error(o(310));e={memoizedState:(vi=e).memoizedState,baseState:vi.baseState,baseQueue:vi.baseQueue,queue:vi.queue,next:null},null===yi?hi.memoizedState=yi=e:yi=yi.next=e}return yi}function Fi(e,t){return"function"===typeof t?t(e):t}function Ri(e){var t=xi(),n=t.queue;if(null===n)throw Error(o(311));n.lastRenderedReducer=e;var r=vi,a=r.baseQueue,i=n.pending;if(null!==i){if(null!==a){var s=a.next;a.next=i.next,i.next=s}r.baseQueue=a=i,n.pending=null}if(null!==a){i=a.next,r=r.baseState;var l=s=null,u=null,c=i;do{var d=c.lane;if((mi&d)===d)null!==u&&(u=u.next={lane:0,action:c.action,hasEagerState:c.hasEagerState,eagerState:c.eagerState,next:null}),r=c.hasEagerState?c.eagerState:e(r,c.action);else{var p={lane:d,action:c.action,hasEagerState:c.hasEagerState,eagerState:c.eagerState,next:null};null===u?(l=u=p,s=r):u=u.next=p,hi.lanes|=d,zl|=d}c=c.next}while(null!==c&&c!==i);null===u?s=r:u.next=l,sr(r,t.memoizedState)||(_s=!0),t.memoizedState=r,t.baseState=s,t.baseQueue=u,n.lastRenderedState=r}if(null!==(e=n.interleaved)){a=e;do{i=a.lane,hi.lanes|=i,zl|=i,a=a.next}while(a!==e)}else null===a&&(n.lanes=0);return[t.memoizedState,n.dispatch]}function Pi(e){var t=xi(),n=t.queue;if(null===n)throw Error(o(311));n.lastRenderedReducer=e;var r=n.dispatch,a=n.pending,i=t.memoizedState;if(null!==a){n.pending=null;var s=a=a.next;do{i=e(i,s.action),s=s.next}while(s!==a);sr(i,t.memoizedState)||(_s=!0),t.memoizedState=i,null===t.baseQueue&&(t.baseState=i),n.lastRenderedState=i}return[i,r]}function Ei(){}function Oi(e,t){var n=hi,r=xi(),a=t(),i=!sr(r.memoizedState,a);if(i&&(r.memoizedState=a,_s=!0),r=r.queue,Ui(Mi.bind(null,n,r,e),[e]),r.getSnapshot!==t||i||null!==yi&&1&yi.memoizedState.tag){if(n.flags|=2048,Zi(9,Ii.bind(null,n,r,a,t),void 0,null),null===Rl)throw Error(o(349));0!==(30&mi)||Ni(n,t,a)}return a}function Ni(e,t,n){e.flags|=16384,e={getSnapshot:t,value:n},null===(t=hi.updateQueue)?(t={lastEffect:null,stores:null},hi.updateQueue=t,t.stores=[e]):null===(n=t.stores)?t.stores=[e]:n.push(e)}function Ii(e,t,n,r){t.value=n,t.getSnapshot=r,zi(t)&&Di(e)}function Mi(e,t,n){return n((function(){zi(t)&&Di(e)}))}function zi(e){var t=e.getSnapshot;e=e.value;try{var n=t();return!sr(e,n)}catch(r){return!0}}function Di(e){var t=Po(e,1);null!==t&&nu(t,e,1,-1)}function Li(e){var t=Ai();return"function"===typeof e&&(e=e()),t.memoizedState=t.baseState=e,e={pending:null,interleaved:null,lanes:0,dispatch:null,lastRenderedReducer:Fi,lastRenderedState:e},t.queue=e,e=e.dispatch=ns.bind(null,hi,e),[t.memoizedState,e]}function Zi(e,t,n,r){return e={tag:e,create:t,destroy:n,deps:r,next:null},null===(t=hi.updateQueue)?(t={lastEffect:null,stores:null},hi.updateQueue=t,t.lastEffect=e.next=e):null===(n=t.lastEffect)?t.lastEffect=e.next=e:(r=n.next,n.next=e,e.next=r,t.lastEffect=e),e}function ji(){return xi().memoizedState}function Bi(e,t,n,r){var a=Ai();hi.flags|=e,a.memoizedState=Zi(1|t,n,void 0,void 0===r?null:r)}function Wi(e,t,n,r){var a=xi();r=void 0===r?null:r;var o=void 0;if(null!==vi){var i=vi.memoizedState;if(o=i.destroy,null!==r&&Ti(r,i.deps))return void(a.memoizedState=Zi(t,n,o,r))}hi.flags|=e,a.memoizedState=Zi(1|t,n,o,r)}function Ji(e,t){return Bi(8390656,8,e,t)}function Ui(e,t){return Wi(2048,8,e,t)}function Vi(e,t){return Wi(4,2,e,t)}function $i(e,t){return Wi(4,4,e,t)}function Hi(e,t){return"function"===typeof t?(e=e(),t(e),function(){t(null)}):null!==t&&void 0!==t?(e=e(),t.current=e,function(){t.current=null}):void 0}function Gi(e,t,n){return n=null!==n&&void 0!==n?n.concat([e]):null,Wi(4,4,Hi.bind(null,t,e),n)}function qi(){}function Ki(e,t){var n=xi();t=void 0===t?null:t;var r=n.memoizedState;return null!==r&&null!==t&&Ti(t,r[1])?r[0]:(n.memoizedState=[e,t],e)}function Qi(e,t){var n=xi();t=void 0===t?null:t;var r=n.memoizedState;return null!==r&&null!==t&&Ti(t,r[1])?r[0]:(e=e(),n.memoizedState=[e,t],e)}function Xi(e,t,n){return 0===(21&mi)?(e.baseState&&(e.baseState=!1,_s=!0),e.memoizedState=n):(sr(n,t)||(n=ht(),hi.lanes|=n,zl|=n,e.baseState=!0),t)}function Yi(e,t){var n=gt;gt=0!==n&&4>n?n:4,e(!0);var r=fi.transition;fi.transition={};try{e(!1),t()}finally{gt=n,fi.transition=r}}function es(){return xi().memoizedState}function ts(e,t,n){var r=tu(e);if(n={lane:r,action:n,hasEagerState:!1,eagerState:null,next:null},rs(e))as(t,n);else if(null!==(n=Ro(e,t,n,r))){nu(n,e,r,eu()),os(n,t,r)}}function ns(e,t,n){var r=tu(e),a={lane:r,action:n,hasEagerState:!1,eagerState:null,next:null};if(rs(e))as(t,a);else{var o=e.alternate;if(0===e.lanes&&(null===o||0===o.lanes)&&null!==(o=t.lastRenderedReducer))try{var i=t.lastRenderedState,s=o(i,n);if(a.hasEagerState=!0,a.eagerState=s,sr(s,i)){var l=t.interleaved;return null===l?(a.next=a,Fo(t)):(a.next=l.next,l.next=a),void(t.interleaved=a)}}catch(u){}null!==(n=Ro(e,t,a,r))&&(nu(n,e,r,a=eu()),os(n,t,r))}}function rs(e){var t=e.alternate;return e===hi||null!==t&&t===hi}function as(e,t){gi=bi=!0;var n=e.pending;null===n?t.next=t:(t.next=n.next,n.next=t),e.pending=t}function os(e,t,n){if(0!==(4194240&n)){var r=t.lanes;n|=r&=e.pendingLanes,t.lanes=n,bt(e,n)}}var is={readContext:Ao,useCallback:Si,useContext:Si,useEffect:Si,useImperativeHandle:Si,useInsertionEffect:Si,useLayoutEffect:Si,useMemo:Si,useReducer:Si,useRef:Si,useState:Si,useDebugValue:Si,useDeferredValue:Si,useTransition:Si,useMutableSource:Si,useSyncExternalStore:Si,useId:Si,unstable_isNewReconciler:!1},ss={readContext:Ao,useCallback:function(e,t){return Ai().memoizedState=[e,void 0===t?null:t],e},useContext:Ao,useEffect:Ji,useImperativeHandle:function(e,t,n){return n=null!==n&&void 0!==n?n.concat([e]):null,Bi(4194308,4,Hi.bind(null,t,e),n)},useLayoutEffect:function(e,t){return Bi(4194308,4,e,t)},useInsertionEffect:function(e,t){return Bi(4,2,e,t)},useMemo:function(e,t){var n=Ai();return t=void 0===t?null:t,e=e(),n.memoizedState=[e,t],e},useReducer:function(e,t,n){var r=Ai();return t=void 0!==n?n(t):t,r.memoizedState=r.baseState=t,e={pending:null,interleaved:null,lanes:0,dispatch:null,lastRenderedReducer:e,lastRenderedState:t},r.queue=e,e=e.dispatch=ts.bind(null,hi,e),[r.memoizedState,e]},useRef:function(e){return e={current:e},Ai().memoizedState=e},useState:Li,useDebugValue:qi,useDeferredValue:function(e){return Ai().memoizedState=e},useTransition:function(){var e=Li(!1),t=e[0];return e=Yi.bind(null,e[1]),Ai().memoizedState=e,[t,e]},useMutableSource:function(){},useSyncExternalStore:function(e,t,n){var r=hi,a=Ai();if(ao){if(void 0===n)throw Error(o(407));n=n()}else{if(n=t(),null===Rl)throw Error(o(349));0!==(30&mi)||Ni(r,t,n)}a.memoizedState=n;var i={value:n,getSnapshot:t};return a.queue=i,Ji(Mi.bind(null,r,i,e),[e]),r.flags|=2048,Zi(9,Ii.bind(null,r,i,n,t),void 0,null),n},useId:function(){var e=Ai(),t=Rl.identifierPrefix;if(ao){var n=Qa;t=":"+t+"R"+(n=(Ka&~(1<<32-it(Ka)-1)).toString(32)+n),0<(n=_i++)&&(t+="H"+n.toString(32)),t+=":"}else t=":"+t+"r"+(n=wi++).toString(32)+":";return e.memoizedState=t},unstable_isNewReconciler:!1},ls={readContext:Ao,useCallback:Ki,useContext:Ao,useEffect:Ui,useImperativeHandle:Gi,useInsertionEffect:Vi,useLayoutEffect:$i,useMemo:Qi,useReducer:Ri,useRef:ji,useState:function(){return Ri(Fi)},useDebugValue:qi,useDeferredValue:function(e){return Xi(xi(),vi.memoizedState,e)},useTransition:function(){return[Ri(Fi)[0],xi().memoizedState]},useMutableSource:Ei,useSyncExternalStore:Oi,useId:es,unstable_isNewReconciler:!1},us={readContext:Ao,useCallback:Ki,useContext:Ao,useEffect:Ui,useImperativeHandle:Gi,useInsertionEffect:Vi,useLayoutEffect:$i,useMemo:Qi,useReducer:Pi,useRef:ji,useState:function(){return Pi(Fi)},useDebugValue:qi,useDeferredValue:function(e){var t=xi();return null===vi?t.memoizedState=e:Xi(t,vi.memoizedState,e)},useTransition:function(){return[Pi(Fi)[0],xi().memoizedState]},useMutableSource:Ei,useSyncExternalStore:Oi,useId:es,unstable_isNewReconciler:!1};function cs(e,t){try{var n="",r=t;do{n+=B(r),r=r.return}while(r);var a=n}catch(o){a="\nError generating stack: "+o.message+"\n"+o.stack}return{value:e,source:t,stack:a,digest:null}}function ds(e,t,n){return{value:e,source:null,stack:null!=n?n:null,digest:null!=t?t:null}}function ps(e,t){try{console.error(t.value)}catch(n){setTimeout((function(){throw n}))}}var fs="function"===typeof WeakMap?WeakMap:Map;function ms(e,t,n){(n=Io(-1,n)).tag=3,n.payload={element:null};var r=t.value;return n.callback=function(){Ul||(Ul=!0,Vl=r),ps(0,t)},n}function hs(e,t,n){(n=Io(-1,n)).tag=3;var r=e.type.getDerivedStateFromError;if("function"===typeof r){var a=t.value;n.payload=function(){return r(a)},n.callback=function(){ps(0,t)}}var o=e.stateNode;return null!==o&&"function"===typeof o.componentDidCatch&&(n.callback=function(){ps(0,t),"function"!==typeof r&&(null===$l?$l=new Set([this]):$l.add(this));var e=t.stack;this.componentDidCatch(t.value,{componentStack:null!==e?e:""})}),n}function vs(e,t,n){var r=e.pingCache;if(null===r){r=e.pingCache=new fs;var a=new Set;r.set(t,a)}else void 0===(a=r.get(t))&&(a=new Set,r.set(t,a));a.has(n)||(a.add(n),e=ku.bind(null,e,t,n),t.then(e,e))}function ys(e){do{var t;if((t=13===e.tag)&&(t=null===(t=e.memoizedState)||null!==t.dehydrated),t)return e;e=e.return}while(null!==e);return null}function bs(e,t,n,r,a){return 0===(1&e.mode)?(e===t?e.flags|=65536:(e.flags|=128,n.flags|=131072,n.flags&=-52805,1===n.tag&&(null===n.alternate?n.tag=17:((t=Io(-1,1)).tag=2,Mo(n,t,1))),n.lanes|=1),e):(e.flags|=65536,e.lanes=a,e)}var gs=_.ReactCurrentOwner,_s=!1;function ws(e,t,n,r){t.child=null===e?Xo(t,null,n,r):Qo(t,e.child,n,r)}function Ss(e,t,n,r,a){n=n.render;var o=t.ref;return ko(t,a),r=Ci(e,t,n,r,o,a),n=ki(),null===e||_s?(ao&&n&&eo(t),t.flags|=1,ws(e,t,r,a),t.child):(t.updateQueue=e.updateQueue,t.flags&=-2053,e.lanes&=~a,Us(e,t,a))}function Ts(e,t,n,r,a){if(null===e){var o=n.type;return"function"!==typeof o||Ou(o)||void 0!==o.defaultProps||null!==n.compare||void 0!==n.defaultProps?((e=Iu(n.type,null,r,t,t.mode,a)).ref=t.ref,e.return=t,t.child=e):(t.tag=15,t.type=o,Cs(e,t,o,r,a))}if(o=e.child,0===(e.lanes&a)){var i=o.memoizedProps;if((n=null!==(n=n.compare)?n:lr)(i,r)&&e.ref===t.ref)return Us(e,t,a)}return t.flags|=1,(e=Nu(o,r)).ref=t.ref,e.return=t,t.child=e}function Cs(e,t,n,r,a){if(null!==e){var o=e.memoizedProps;if(lr(o,r)&&e.ref===t.ref){if(_s=!1,t.pendingProps=r=o,0===(e.lanes&a))return t.lanes=e.lanes,Us(e,t,a);0!==(131072&e.flags)&&(_s=!0)}}return xs(e,t,n,r,a)}function ks(e,t,n){var r=t.pendingProps,a=r.children,o=null!==e?e.memoizedState:null;if("hidden"===r.mode)if(0===(1&t.mode))t.memoizedState={baseLanes:0,cachePool:null,transitions:null},Aa(Nl,Ol),Ol|=n;else{if(0===(1073741824&n))return e=null!==o?o.baseLanes|n:n,t.lanes=t.childLanes=1073741824,t.memoizedState={baseLanes:e,cachePool:null,transitions:null},t.updateQueue=null,Aa(Nl,Ol),Ol|=e,null;t.memoizedState={baseLanes:0,cachePool:null,transitions:null},r=null!==o?o.baseLanes:n,Aa(Nl,Ol),Ol|=r}else null!==o?(r=o.baseLanes|n,t.memoizedState=null):r=n,Aa(Nl,Ol),Ol|=r;return ws(e,t,a,n),t.child}function As(e,t){var n=t.ref;(null===e&&null!==n||null!==e&&e.ref!==n)&&(t.flags|=512,t.flags|=2097152)}function xs(e,t,n,r,a){var o=Oa(n)?Pa:Fa.current;return o=Ea(t,o),ko(t,a),n=Ci(e,t,n,r,o,a),r=ki(),null===e||_s?(ao&&r&&eo(t),t.flags|=1,ws(e,t,n,a),t.child):(t.updateQueue=e.updateQueue,t.flags&=-2053,e.lanes&=~a,Us(e,t,a))}function Fs(e,t,n,r,a){if(Oa(n)){var o=!0;za(t)}else o=!1;if(ko(t,a),null===t.stateNode)Js(e,t),Uo(t,n,r),$o(t,n,r,a),r=!0;else if(null===e){var i=t.stateNode,s=t.memoizedProps;i.props=s;var l=i.context,u=n.contextType;"object"===typeof u&&null!==u?u=Ao(u):u=Ea(t,u=Oa(n)?Pa:Fa.current);var c=n.getDerivedStateFromProps,d="function"===typeof c||"function"===typeof i.getSnapshotBeforeUpdate;d||"function"!==typeof i.UNSAFE_componentWillReceiveProps&&"function"!==typeof i.componentWillReceiveProps||(s!==r||l!==u)&&Vo(t,i,r,u),Eo=!1;var p=t.memoizedState;i.state=p,Lo(t,r,i,a),l=t.memoizedState,s!==r||p!==l||Ra.current||Eo?("function"===typeof c&&(Bo(t,n,c,r),l=t.memoizedState),(s=Eo||Jo(t,n,s,r,p,l,u))?(d||"function"!==typeof i.UNSAFE_componentWillMount&&"function"!==typeof i.componentWillMount||("function"===typeof i.componentWillMount&&i.componentWillMount(),"function"===typeof i.UNSAFE_componentWillMount&&i.UNSAFE_componentWillMount()),"function"===typeof i.componentDidMount&&(t.flags|=4194308)):("function"===typeof i.componentDidMount&&(t.flags|=4194308),t.memoizedProps=r,t.memoizedState=l),i.props=r,i.state=l,i.context=u,r=s):("function"===typeof i.componentDidMount&&(t.flags|=4194308),r=!1)}else{i=t.stateNode,No(e,t),s=t.memoizedProps,u=t.type===t.elementType?s:yo(t.type,s),i.props=u,d=t.pendingProps,p=i.context,"object"===typeof(l=n.contextType)&&null!==l?l=Ao(l):l=Ea(t,l=Oa(n)?Pa:Fa.current);var f=n.getDerivedStateFromProps;(c="function"===typeof f||"function"===typeof i.getSnapshotBeforeUpdate)||"function"!==typeof i.UNSAFE_componentWillReceiveProps&&"function"!==typeof i.componentWillReceiveProps||(s!==d||p!==l)&&Vo(t,i,r,l),Eo=!1,p=t.memoizedState,i.state=p,Lo(t,r,i,a);var m=t.memoizedState;s!==d||p!==m||Ra.current||Eo?("function"===typeof f&&(Bo(t,n,f,r),m=t.memoizedState),(u=Eo||Jo(t,n,u,r,p,m,l)||!1)?(c||"function"!==typeof i.UNSAFE_componentWillUpdate&&"function"!==typeof i.componentWillUpdate||("function"===typeof i.componentWillUpdate&&i.componentWillUpdate(r,m,l),"function"===typeof i.UNSAFE_componentWillUpdate&&i.UNSAFE_componentWillUpdate(r,m,l)),"function"===typeof i.componentDidUpdate&&(t.flags|=4),"function"===typeof i.getSnapshotBeforeUpdate&&(t.flags|=1024)):("function"!==typeof i.componentDidUpdate||s===e.memoizedProps&&p===e.memoizedState||(t.flags|=4),"function"!==typeof i.getSnapshotBeforeUpdate||s===e.memoizedProps&&p===e.memoizedState||(t.flags|=1024),t.memoizedProps=r,t.memoizedState=m),i.props=r,i.state=m,i.context=l,r=u):("function"!==typeof i.componentDidUpdate||s===e.memoizedProps&&p===e.memoizedState||(t.flags|=4),"function"!==typeof i.getSnapshotBeforeUpdate||s===e.memoizedProps&&p===e.memoizedState||(t.flags|=1024),r=!1)}return Rs(e,t,n,r,o,a)}function Rs(e,t,n,r,a,o){As(e,t);var i=0!==(128&t.flags);if(!r&&!i)return a&&Da(t,n,!1),Us(e,t,o);r=t.stateNode,gs.current=t;var s=i&&"function"!==typeof n.getDerivedStateFromError?null:r.render();return t.flags|=1,null!==e&&i?(t.child=Qo(t,e.child,null,o),t.child=Qo(t,null,s,o)):ws(e,t,s,o),t.memoizedState=r.state,a&&Da(t,n,!0),t.child}function Ps(e){var t=e.stateNode;t.pendingContext?Ia(0,t.pendingContext,t.pendingContext!==t.context):t.context&&Ia(0,t.context,!1),ai(e,t.containerInfo)}function Es(e,t,n,r,a){return mo(),ho(a),t.flags|=256,ws(e,t,n,r),t.child}var Os,Ns,Is,Ms={dehydrated:null,treeContext:null,retryLane:0};function zs(e){return{baseLanes:e,cachePool:null,transitions:null}}function Ds(e,t,n){var r,a=t.pendingProps,i=li.current,s=!1,l=0!==(128&t.flags);if((r=l)||(r=(null===e||null!==e.memoizedState)&&0!==(2&i)),r?(s=!0,t.flags&=-129):null!==e&&null===e.memoizedState||(i|=1),Aa(li,1&i),null===e)return uo(t),null!==(e=t.memoizedState)&&null!==(e=e.dehydrated)?(0===(1&t.mode)?t.lanes=1:"$!"===e.data?t.lanes=8:t.lanes=1073741824,null):(l=a.children,e=a.fallback,s?(a=t.mode,s=t.child,l={mode:"hidden",children:l},0===(1&a)&&null!==s?(s.childLanes=0,s.pendingProps=l):s=zu(l,a,0,null),e=Mu(e,a,n,null),s.return=t,e.return=t,s.sibling=e,t.child=s,t.child.memoizedState=zs(n),t.memoizedState=Ms,e):Ls(t,l));if(null!==(i=e.memoizedState)&&null!==(r=i.dehydrated))return function(e,t,n,r,a,i,s){if(n)return 256&t.flags?(t.flags&=-257,Zs(e,t,s,r=ds(Error(o(422))))):null!==t.memoizedState?(t.child=e.child,t.flags|=128,null):(i=r.fallback,a=t.mode,r=zu({mode:"visible",children:r.children},a,0,null),(i=Mu(i,a,s,null)).flags|=2,r.return=t,i.return=t,r.sibling=i,t.child=r,0!==(1&t.mode)&&Qo(t,e.child,null,s),t.child.memoizedState=zs(s),t.memoizedState=Ms,i);if(0===(1&t.mode))return Zs(e,t,s,null);if("$!"===a.data){if(r=a.nextSibling&&a.nextSibling.dataset)var l=r.dgst;return r=l,Zs(e,t,s,r=ds(i=Error(o(419)),r,void 0))}if(l=0!==(s&e.childLanes),_s||l){if(null!==(r=Rl)){switch(s&-s){case 4:a=2;break;case 16:a=8;break;case 64:case 128:case 256:case 512:case 1024:case 2048:case 4096:case 8192:case 16384:case 32768:case 65536:case 131072:case 262144:case 524288:case 1048576:case 2097152:case 4194304:case 8388608:case 16777216:case 33554432:case 67108864:a=32;break;case 536870912:a=268435456;break;default:a=0}0!==(a=0!==(a&(r.suspendedLanes|s))?0:a)&&a!==i.retryLane&&(i.retryLane=a,Po(e,a),nu(r,e,a,-1))}return hu(),Zs(e,t,s,r=ds(Error(o(421))))}return"$?"===a.data?(t.flags|=128,t.child=e.child,t=xu.bind(null,e),a._reactRetry=t,null):(e=i.treeContext,ro=ua(a.nextSibling),no=t,ao=!0,oo=null,null!==e&&(Ha[Ga++]=Ka,Ha[Ga++]=Qa,Ha[Ga++]=qa,Ka=e.id,Qa=e.overflow,qa=t),(t=Ls(t,r.children)).flags|=4096,t)}(e,t,l,a,r,i,n);if(s){s=a.fallback,l=t.mode,r=(i=e.child).sibling;var u={mode:"hidden",children:a.children};return 0===(1&l)&&t.child!==i?((a=t.child).childLanes=0,a.pendingProps=u,t.deletions=null):(a=Nu(i,u)).subtreeFlags=14680064&i.subtreeFlags,null!==r?s=Nu(r,s):(s=Mu(s,l,n,null)).flags|=2,s.return=t,a.return=t,a.sibling=s,t.child=a,a=s,s=t.child,l=null===(l=e.child.memoizedState)?zs(n):{baseLanes:l.baseLanes|n,cachePool:null,transitions:l.transitions},s.memoizedState=l,s.childLanes=e.childLanes&~n,t.memoizedState=Ms,a}return e=(s=e.child).sibling,a=Nu(s,{mode:"visible",children:a.children}),0===(1&t.mode)&&(a.lanes=n),a.return=t,a.sibling=null,null!==e&&(null===(n=t.deletions)?(t.deletions=[e],t.flags|=16):n.push(e)),t.child=a,t.memoizedState=null,a}function Ls(e,t){return(t=zu({mode:"visible",children:t},e.mode,0,null)).return=e,e.child=t}function Zs(e,t,n,r){return null!==r&&ho(r),Qo(t,e.child,null,n),(e=Ls(t,t.pendingProps.children)).flags|=2,t.memoizedState=null,e}function js(e,t,n){e.lanes|=t;var r=e.alternate;null!==r&&(r.lanes|=t),Co(e.return,t,n)}function Bs(e,t,n,r,a){var o=e.memoizedState;null===o?e.memoizedState={isBackwards:t,rendering:null,renderingStartTime:0,last:r,tail:n,tailMode:a}:(o.isBackwards=t,o.rendering=null,o.renderingStartTime=0,o.last=r,o.tail=n,o.tailMode=a)}function Ws(e,t,n){var r=t.pendingProps,a=r.revealOrder,o=r.tail;if(ws(e,t,r.children,n),0!==(2&(r=li.current)))r=1&r|2,t.flags|=128;else{if(null!==e&&0!==(128&e.flags))e:for(e=t.child;null!==e;){if(13===e.tag)null!==e.memoizedState&&js(e,n,t);else if(19===e.tag)js(e,n,t);else if(null!==e.child){e.child.return=e,e=e.child;continue}if(e===t)break e;for(;null===e.sibling;){if(null===e.return||e.return===t)break e;e=e.return}e.sibling.return=e.return,e=e.sibling}r&=1}if(Aa(li,r),0===(1&t.mode))t.memoizedState=null;else switch(a){case"forwards":for(n=t.child,a=null;null!==n;)null!==(e=n.alternate)&&null===ui(e)&&(a=n),n=n.sibling;null===(n=a)?(a=t.child,t.child=null):(a=n.sibling,n.sibling=null),Bs(t,!1,a,n,o);break;case"backwards":for(n=null,a=t.child,t.child=null;null!==a;){if(null!==(e=a.alternate)&&null===ui(e)){t.child=a;break}e=a.sibling,a.sibling=n,n=a,a=e}Bs(t,!0,n,null,o);break;case"together":Bs(t,!1,null,null,void 0);break;default:t.memoizedState=null}return t.child}function Js(e,t){0===(1&t.mode)&&null!==e&&(e.alternate=null,t.alternate=null,t.flags|=2)}function Us(e,t,n){if(null!==e&&(t.dependencies=e.dependencies),zl|=t.lanes,0===(n&t.childLanes))return null;if(null!==e&&t.child!==e.child)throw Error(o(153));if(null!==t.child){for(n=Nu(e=t.child,e.pendingProps),t.child=n,n.return=t;null!==e.sibling;)e=e.sibling,(n=n.sibling=Nu(e,e.pendingProps)).return=t;n.sibling=null}return t.child}function Vs(e,t){if(!ao)switch(e.tailMode){case"hidden":t=e.tail;for(var n=null;null!==t;)null!==t.alternate&&(n=t),t=t.sibling;null===n?e.tail=null:n.sibling=null;break;case"collapsed":n=e.tail;for(var r=null;null!==n;)null!==n.alternate&&(r=n),n=n.sibling;null===r?t||null===e.tail?e.tail=null:e.tail.sibling=null:r.sibling=null}}function $s(e){var t=null!==e.alternate&&e.alternate.child===e.child,n=0,r=0;if(t)for(var a=e.child;null!==a;)n|=a.lanes|a.childLanes,r|=14680064&a.subtreeFlags,r|=14680064&a.flags,a.return=e,a=a.sibling;else for(a=e.child;null!==a;)n|=a.lanes|a.childLanes,r|=a.subtreeFlags,r|=a.flags,a.return=e,a=a.sibling;return e.subtreeFlags|=r,e.childLanes=n,t}function Hs(e,t,n){var r=t.pendingProps;switch(to(t),t.tag){case 2:case 16:case 15:case 0:case 11:case 7:case 8:case 12:case 9:case 14:return $s(t),null;case 1:case 17:return Oa(t.type)&&Na(),$s(t),null;case 3:return r=t.stateNode,oi(),ka(Ra),ka(Fa),di(),r.pendingContext&&(r.context=r.pendingContext,r.pendingContext=null),null!==e&&null!==e.child||(po(t)?t.flags|=4:null===e||e.memoizedState.isDehydrated&&0===(256&t.flags)||(t.flags|=1024,null!==oo&&(iu(oo),oo=null))),$s(t),null;case 5:si(t);var a=ri(ni.current);if(n=t.type,null!==e&&null!=t.stateNode)Ns(e,t,n,r),e.ref!==t.ref&&(t.flags|=512,t.flags|=2097152);else{if(!r){if(null===t.stateNode)throw Error(o(166));return $s(t),null}if(e=ri(ei.current),po(t)){r=t.stateNode,n=t.type;var i=t.memoizedProps;switch(r[pa]=t,r[fa]=i,e=0!==(1&t.mode),n){case"dialog":Zr("cancel",r),Zr("close",r);break;case"iframe":case"object":case"embed":Zr("load",r);break;case"video":case"audio":for(a=0;a<Mr.length;a++)Zr(Mr[a],r);break;case"source":Zr("error",r);break;case"img":case"image":case"link":Zr("error",r),Zr("load",r);break;case"details":Zr("toggle",r);break;case"input":K(r,i),Zr("invalid",r);break;case"select":r._wrapperState={wasMultiple:!!i.multiple},Zr("invalid",r);break;case"textarea":ae(r,i),Zr("invalid",r)}for(var l in be(n,i),a=null,i)if(i.hasOwnProperty(l)){var u=i[l];"children"===l?"string"===typeof u?r.textContent!==u&&(!0!==i.suppressHydrationWarning&&Xr(r.textContent,u,e),a=["children",u]):"number"===typeof u&&r.textContent!==""+u&&(!0!==i.suppressHydrationWarning&&Xr(r.textContent,u,e),a=["children",""+u]):s.hasOwnProperty(l)&&null!=u&&"onScroll"===l&&Zr("scroll",r)}switch(n){case"input":$(r),Y(r,i,!0);break;case"textarea":$(r),ie(r);break;case"select":case"option":break;default:"function"===typeof i.onClick&&(r.onclick=Yr)}r=a,t.updateQueue=r,null!==r&&(t.flags|=4)}else{l=9===a.nodeType?a:a.ownerDocument,"http://www.w3.org/1999/xhtml"===e&&(e=se(n)),"http://www.w3.org/1999/xhtml"===e?"script"===n?((e=l.createElement("div")).innerHTML="<script><\/script>",e=e.removeChild(e.firstChild)):"string"===typeof r.is?e=l.createElement(n,{is:r.is}):(e=l.createElement(n),"select"===n&&(l=e,r.multiple?l.multiple=!0:r.size&&(l.size=r.size))):e=l.createElementNS(e,n),e[pa]=t,e[fa]=r,Os(e,t),t.stateNode=e;e:{switch(l=ge(n,r),n){case"dialog":Zr("cancel",e),Zr("close",e),a=r;break;case"iframe":case"object":case"embed":Zr("load",e),a=r;break;case"video":case"audio":for(a=0;a<Mr.length;a++)Zr(Mr[a],e);a=r;break;case"source":Zr("error",e),a=r;break;case"img":case"image":case"link":Zr("error",e),Zr("load",e),a=r;break;case"details":Zr("toggle",e),a=r;break;case"input":K(e,r),a=q(e,r),Zr("invalid",e);break;case"option":default:a=r;break;case"select":e._wrapperState={wasMultiple:!!r.multiple},a=D({},r,{value:void 0}),Zr("invalid",e);break;case"textarea":ae(e,r),a=re(e,r),Zr("invalid",e)}for(i in be(n,a),u=a)if(u.hasOwnProperty(i)){var c=u[i];"style"===i?ve(e,c):"dangerouslySetInnerHTML"===i?null!=(c=c?c.__html:void 0)&&de(e,c):"children"===i?"string"===typeof c?("textarea"!==n||""!==c)&&pe(e,c):"number"===typeof c&&pe(e,""+c):"suppressContentEditableWarning"!==i&&"suppressHydrationWarning"!==i&&"autoFocus"!==i&&(s.hasOwnProperty(i)?null!=c&&"onScroll"===i&&Zr("scroll",e):null!=c&&g(e,i,c,l))}switch(n){case"input":$(e),Y(e,r,!1);break;case"textarea":$(e),ie(e);break;case"option":null!=r.value&&e.setAttribute("value",""+U(r.value));break;case"select":e.multiple=!!r.multiple,null!=(i=r.value)?ne(e,!!r.multiple,i,!1):null!=r.defaultValue&&ne(e,!!r.multiple,r.defaultValue,!0);break;default:"function"===typeof a.onClick&&(e.onclick=Yr)}switch(n){case"button":case"input":case"select":case"textarea":r=!!r.autoFocus;break e;case"img":r=!0;break e;default:r=!1}}r&&(t.flags|=4)}null!==t.ref&&(t.flags|=512,t.flags|=2097152)}return $s(t),null;case 6:if(e&&null!=t.stateNode)Is(0,t,e.memoizedProps,r);else{if("string"!==typeof r&&null===t.stateNode)throw Error(o(166));if(n=ri(ni.current),ri(ei.current),po(t)){if(r=t.stateNode,n=t.memoizedProps,r[pa]=t,(i=r.nodeValue!==n)&&null!==(e=no))switch(e.tag){case 3:Xr(r.nodeValue,n,0!==(1&e.mode));break;case 5:!0!==e.memoizedProps.suppressHydrationWarning&&Xr(r.nodeValue,n,0!==(1&e.mode))}i&&(t.flags|=4)}else(r=(9===n.nodeType?n:n.ownerDocument).createTextNode(r))[pa]=t,t.stateNode=r}return $s(t),null;case 13:if(ka(li),r=t.memoizedState,null===e||null!==e.memoizedState&&null!==e.memoizedState.dehydrated){if(ao&&null!==ro&&0!==(1&t.mode)&&0===(128&t.flags))fo(),mo(),t.flags|=98560,i=!1;else if(i=po(t),null!==r&&null!==r.dehydrated){if(null===e){if(!i)throw Error(o(318));if(!(i=null!==(i=t.memoizedState)?i.dehydrated:null))throw Error(o(317));i[pa]=t}else mo(),0===(128&t.flags)&&(t.memoizedState=null),t.flags|=4;$s(t),i=!1}else null!==oo&&(iu(oo),oo=null),i=!0;if(!i)return 65536&t.flags?t:null}return 0!==(128&t.flags)?(t.lanes=n,t):((r=null!==r)!==(null!==e&&null!==e.memoizedState)&&r&&(t.child.flags|=8192,0!==(1&t.mode)&&(null===e||0!==(1&li.current)?0===Il&&(Il=3):hu())),null!==t.updateQueue&&(t.flags|=4),$s(t),null);case 4:return oi(),null===e&&Wr(t.stateNode.containerInfo),$s(t),null;case 10:return To(t.type._context),$s(t),null;case 19:if(ka(li),null===(i=t.memoizedState))return $s(t),null;if(r=0!==(128&t.flags),null===(l=i.rendering))if(r)Vs(i,!1);else{if(0!==Il||null!==e&&0!==(128&e.flags))for(e=t.child;null!==e;){if(null!==(l=ui(e))){for(t.flags|=128,Vs(i,!1),null!==(r=l.updateQueue)&&(t.updateQueue=r,t.flags|=4),t.subtreeFlags=0,r=n,n=t.child;null!==n;)e=r,(i=n).flags&=14680066,null===(l=i.alternate)?(i.childLanes=0,i.lanes=e,i.child=null,i.subtreeFlags=0,i.memoizedProps=null,i.memoizedState=null,i.updateQueue=null,i.dependencies=null,i.stateNode=null):(i.childLanes=l.childLanes,i.lanes=l.lanes,i.child=l.child,i.subtreeFlags=0,i.deletions=null,i.memoizedProps=l.memoizedProps,i.memoizedState=l.memoizedState,i.updateQueue=l.updateQueue,i.type=l.type,e=l.dependencies,i.dependencies=null===e?null:{lanes:e.lanes,firstContext:e.firstContext}),n=n.sibling;return Aa(li,1&li.current|2),t.child}e=e.sibling}null!==i.tail&&Qe()>Wl&&(t.flags|=128,r=!0,Vs(i,!1),t.lanes=4194304)}else{if(!r)if(null!==(e=ui(l))){if(t.flags|=128,r=!0,null!==(n=e.updateQueue)&&(t.updateQueue=n,t.flags|=4),Vs(i,!0),null===i.tail&&"hidden"===i.tailMode&&!l.alternate&&!ao)return $s(t),null}else 2*Qe()-i.renderingStartTime>Wl&&1073741824!==n&&(t.flags|=128,r=!0,Vs(i,!1),t.lanes=4194304);i.isBackwards?(l.sibling=t.child,t.child=l):(null!==(n=i.last)?n.sibling=l:t.child=l,i.last=l)}return null!==i.tail?(t=i.tail,i.rendering=t,i.tail=t.sibling,i.renderingStartTime=Qe(),t.sibling=null,n=li.current,Aa(li,r?1&n|2:1&n),t):($s(t),null);case 22:case 23:return du(),r=null!==t.memoizedState,null!==e&&null!==e.memoizedState!==r&&(t.flags|=8192),r&&0!==(1&t.mode)?0!==(1073741824&Ol)&&($s(t),6&t.subtreeFlags&&(t.flags|=8192)):$s(t),null;case 24:case 25:return null}throw Error(o(156,t.tag))}function Gs(e,t){switch(to(t),t.tag){case 1:return Oa(t.type)&&Na(),65536&(e=t.flags)?(t.flags=-65537&e|128,t):null;case 3:return oi(),ka(Ra),ka(Fa),di(),0!==(65536&(e=t.flags))&&0===(128&e)?(t.flags=-65537&e|128,t):null;case 5:return si(t),null;case 13:if(ka(li),null!==(e=t.memoizedState)&&null!==e.dehydrated){if(null===t.alternate)throw Error(o(340));mo()}return 65536&(e=t.flags)?(t.flags=-65537&e|128,t):null;case 19:return ka(li),null;case 4:return oi(),null;case 10:return To(t.type._context),null;case 22:case 23:return du(),null;default:return null}}Os=function(e,t){for(var n=t.child;null!==n;){if(5===n.tag||6===n.tag)e.appendChild(n.stateNode);else if(4!==n.tag&&null!==n.child){n.child.return=n,n=n.child;continue}if(n===t)break;for(;null===n.sibling;){if(null===n.return||n.return===t)return;n=n.return}n.sibling.return=n.return,n=n.sibling}},Ns=function(e,t,n,r){var a=e.memoizedProps;if(a!==r){e=t.stateNode,ri(ei.current);var o,i=null;switch(n){case"input":a=q(e,a),r=q(e,r),i=[];break;case"select":a=D({},a,{value:void 0}),r=D({},r,{value:void 0}),i=[];break;case"textarea":a=re(e,a),r=re(e,r),i=[];break;default:"function"!==typeof a.onClick&&"function"===typeof r.onClick&&(e.onclick=Yr)}for(c in be(n,r),n=null,a)if(!r.hasOwnProperty(c)&&a.hasOwnProperty(c)&&null!=a[c])if("style"===c){var l=a[c];for(o in l)l.hasOwnProperty(o)&&(n||(n={}),n[o]="")}else"dangerouslySetInnerHTML"!==c&&"children"!==c&&"suppressContentEditableWarning"!==c&&"suppressHydrationWarning"!==c&&"autoFocus"!==c&&(s.hasOwnProperty(c)?i||(i=[]):(i=i||[]).push(c,null));for(c in r){var u=r[c];if(l=null!=a?a[c]:void 0,r.hasOwnProperty(c)&&u!==l&&(null!=u||null!=l))if("style"===c)if(l){for(o in l)!l.hasOwnProperty(o)||u&&u.hasOwnProperty(o)||(n||(n={}),n[o]="");for(o in u)u.hasOwnProperty(o)&&l[o]!==u[o]&&(n||(n={}),n[o]=u[o])}else n||(i||(i=[]),i.push(c,n)),n=u;else"dangerouslySetInnerHTML"===c?(u=u?u.__html:void 0,l=l?l.__html:void 0,null!=u&&l!==u&&(i=i||[]).push(c,u)):"children"===c?"string"!==typeof u&&"number"!==typeof u||(i=i||[]).push(c,""+u):"suppressContentEditableWarning"!==c&&"suppressHydrationWarning"!==c&&(s.hasOwnProperty(c)?(null!=u&&"onScroll"===c&&Zr("scroll",e),i||l===u||(i=[])):(i=i||[]).push(c,u))}n&&(i=i||[]).push("style",n);var c=i;(t.updateQueue=c)&&(t.flags|=4)}},Is=function(e,t,n,r){n!==r&&(t.flags|=4)};var qs=!1,Ks=!1,Qs="function"===typeof WeakSet?WeakSet:Set,Xs=null;function Ys(e,t){var n=e.ref;if(null!==n)if("function"===typeof n)try{n(null)}catch(r){Cu(e,t,r)}else n.current=null}function el(e,t,n){try{n()}catch(r){Cu(e,t,r)}}var tl=!1;function nl(e,t,n){var r=t.updateQueue;if(null!==(r=null!==r?r.lastEffect:null)){var a=r=r.next;do{if((a.tag&e)===e){var o=a.destroy;a.destroy=void 0,void 0!==o&&el(t,n,o)}a=a.next}while(a!==r)}}function rl(e,t){if(null!==(t=null!==(t=t.updateQueue)?t.lastEffect:null)){var n=t=t.next;do{if((n.tag&e)===e){var r=n.create;n.destroy=r()}n=n.next}while(n!==t)}}function al(e){var t=e.ref;if(null!==t){var n=e.stateNode;e.tag,e=n,"function"===typeof t?t(e):t.current=e}}function ol(e){var t=e.alternate;null!==t&&(e.alternate=null,ol(t)),e.child=null,e.deletions=null,e.sibling=null,5===e.tag&&(null!==(t=e.stateNode)&&(delete t[pa],delete t[fa],delete t[ha],delete t[va],delete t[ya])),e.stateNode=null,e.return=null,e.dependencies=null,e.memoizedProps=null,e.memoizedState=null,e.pendingProps=null,e.stateNode=null,e.updateQueue=null}function il(e){return 5===e.tag||3===e.tag||4===e.tag}function sl(e){e:for(;;){for(;null===e.sibling;){if(null===e.return||il(e.return))return null;e=e.return}for(e.sibling.return=e.return,e=e.sibling;5!==e.tag&&6!==e.tag&&18!==e.tag;){if(2&e.flags)continue e;if(null===e.child||4===e.tag)continue e;e.child.return=e,e=e.child}if(!(2&e.flags))return e.stateNode}}function ll(e,t,n){var r=e.tag;if(5===r||6===r)e=e.stateNode,t?8===n.nodeType?n.parentNode.insertBefore(e,t):n.insertBefore(e,t):(8===n.nodeType?(t=n.parentNode).insertBefore(e,n):(t=n).appendChild(e),null!==(n=n._reactRootContainer)&&void 0!==n||null!==t.onclick||(t.onclick=Yr));else if(4!==r&&null!==(e=e.child))for(ll(e,t,n),e=e.sibling;null!==e;)ll(e,t,n),e=e.sibling}function ul(e,t,n){var r=e.tag;if(5===r||6===r)e=e.stateNode,t?n.insertBefore(e,t):n.appendChild(e);else if(4!==r&&null!==(e=e.child))for(ul(e,t,n),e=e.sibling;null!==e;)ul(e,t,n),e=e.sibling}var cl=null,dl=!1;function pl(e,t,n){for(n=n.child;null!==n;)fl(e,t,n),n=n.sibling}function fl(e,t,n){if(ot&&"function"===typeof ot.onCommitFiberUnmount)try{ot.onCommitFiberUnmount(at,n)}catch(s){}switch(n.tag){case 5:Ks||Ys(n,t);case 6:var r=cl,a=dl;cl=null,pl(e,t,n),dl=a,null!==(cl=r)&&(dl?(e=cl,n=n.stateNode,8===e.nodeType?e.parentNode.removeChild(n):e.removeChild(n)):cl.removeChild(n.stateNode));break;case 18:null!==cl&&(dl?(e=cl,n=n.stateNode,8===e.nodeType?la(e.parentNode,n):1===e.nodeType&&la(e,n),Wt(e)):la(cl,n.stateNode));break;case 4:r=cl,a=dl,cl=n.stateNode.containerInfo,dl=!0,pl(e,t,n),cl=r,dl=a;break;case 0:case 11:case 14:case 15:if(!Ks&&(null!==(r=n.updateQueue)&&null!==(r=r.lastEffect))){a=r=r.next;do{var o=a,i=o.destroy;o=o.tag,void 0!==i&&(0!==(2&o)||0!==(4&o))&&el(n,t,i),a=a.next}while(a!==r)}pl(e,t,n);break;case 1:if(!Ks&&(Ys(n,t),"function"===typeof(r=n.stateNode).componentWillUnmount))try{r.props=n.memoizedProps,r.state=n.memoizedState,r.componentWillUnmount()}catch(s){Cu(n,t,s)}pl(e,t,n);break;case 21:pl(e,t,n);break;case 22:1&n.mode?(Ks=(r=Ks)||null!==n.memoizedState,pl(e,t,n),Ks=r):pl(e,t,n);break;default:pl(e,t,n)}}function ml(e){var t=e.updateQueue;if(null!==t){e.updateQueue=null;var n=e.stateNode;null===n&&(n=e.stateNode=new Qs),t.forEach((function(t){var r=Fu.bind(null,e,t);n.has(t)||(n.add(t),t.then(r,r))}))}}function hl(e,t){var n=t.deletions;if(null!==n)for(var r=0;r<n.length;r++){var a=n[r];try{var i=e,s=t,l=s;e:for(;null!==l;){switch(l.tag){case 5:cl=l.stateNode,dl=!1;break e;case 3:case 4:cl=l.stateNode.containerInfo,dl=!0;break e}l=l.return}if(null===cl)throw Error(o(160));fl(i,s,a),cl=null,dl=!1;var u=a.alternate;null!==u&&(u.return=null),a.return=null}catch(c){Cu(a,t,c)}}if(12854&t.subtreeFlags)for(t=t.child;null!==t;)vl(t,e),t=t.sibling}function vl(e,t){var n=e.alternate,r=e.flags;switch(e.tag){case 0:case 11:case 14:case 15:if(hl(t,e),yl(e),4&r){try{nl(3,e,e.return),rl(3,e)}catch(v){Cu(e,e.return,v)}try{nl(5,e,e.return)}catch(v){Cu(e,e.return,v)}}break;case 1:hl(t,e),yl(e),512&r&&null!==n&&Ys(n,n.return);break;case 5:if(hl(t,e),yl(e),512&r&&null!==n&&Ys(n,n.return),32&e.flags){var a=e.stateNode;try{pe(a,"")}catch(v){Cu(e,e.return,v)}}if(4&r&&null!=(a=e.stateNode)){var i=e.memoizedProps,s=null!==n?n.memoizedProps:i,l=e.type,u=e.updateQueue;if(e.updateQueue=null,null!==u)try{"input"===l&&"radio"===i.type&&null!=i.name&&Q(a,i),ge(l,s);var c=ge(l,i);for(s=0;s<u.length;s+=2){var d=u[s],p=u[s+1];"style"===d?ve(a,p):"dangerouslySetInnerHTML"===d?de(a,p):"children"===d?pe(a,p):g(a,d,p,c)}switch(l){case"input":X(a,i);break;case"textarea":oe(a,i);break;case"select":var f=a._wrapperState.wasMultiple;a._wrapperState.wasMultiple=!!i.multiple;var m=i.value;null!=m?ne(a,!!i.multiple,m,!1):f!==!!i.multiple&&(null!=i.defaultValue?ne(a,!!i.multiple,i.defaultValue,!0):ne(a,!!i.multiple,i.multiple?[]:"",!1))}a[fa]=i}catch(v){Cu(e,e.return,v)}}break;case 6:if(hl(t,e),yl(e),4&r){if(null===e.stateNode)throw Error(o(162));a=e.stateNode,i=e.memoizedProps;try{a.nodeValue=i}catch(v){Cu(e,e.return,v)}}break;case 3:if(hl(t,e),yl(e),4&r&&null!==n&&n.memoizedState.isDehydrated)try{Wt(t.containerInfo)}catch(v){Cu(e,e.return,v)}break;case 4:default:hl(t,e),yl(e);break;case 13:hl(t,e),yl(e),8192&(a=e.child).flags&&(i=null!==a.memoizedState,a.stateNode.isHidden=i,!i||null!==a.alternate&&null!==a.alternate.memoizedState||(Bl=Qe())),4&r&&ml(e);break;case 22:if(d=null!==n&&null!==n.memoizedState,1&e.mode?(Ks=(c=Ks)||d,hl(t,e),Ks=c):hl(t,e),yl(e),8192&r){if(c=null!==e.memoizedState,(e.stateNode.isHidden=c)&&!d&&0!==(1&e.mode))for(Xs=e,d=e.child;null!==d;){for(p=Xs=d;null!==Xs;){switch(m=(f=Xs).child,f.tag){case 0:case 11:case 14:case 15:nl(4,f,f.return);break;case 1:Ys(f,f.return);var h=f.stateNode;if("function"===typeof h.componentWillUnmount){r=f,n=f.return;try{t=r,h.props=t.memoizedProps,h.state=t.memoizedState,h.componentWillUnmount()}catch(v){Cu(r,n,v)}}break;case 5:Ys(f,f.return);break;case 22:if(null!==f.memoizedState){wl(p);continue}}null!==m?(m.return=f,Xs=m):wl(p)}d=d.sibling}e:for(d=null,p=e;;){if(5===p.tag){if(null===d){d=p;try{a=p.stateNode,c?"function"===typeof(i=a.style).setProperty?i.setProperty("display","none","important"):i.display="none":(l=p.stateNode,s=void 0!==(u=p.memoizedProps.style)&&null!==u&&u.hasOwnProperty("display")?u.display:null,l.style.display=he("display",s))}catch(v){Cu(e,e.return,v)}}}else if(6===p.tag){if(null===d)try{p.stateNode.nodeValue=c?"":p.memoizedProps}catch(v){Cu(e,e.return,v)}}else if((22!==p.tag&&23!==p.tag||null===p.memoizedState||p===e)&&null!==p.child){p.child.return=p,p=p.child;continue}if(p===e)break e;for(;null===p.sibling;){if(null===p.return||p.return===e)break e;d===p&&(d=null),p=p.return}d===p&&(d=null),p.sibling.return=p.return,p=p.sibling}}break;case 19:hl(t,e),yl(e),4&r&&ml(e);case 21:}}function yl(e){var t=e.flags;if(2&t){try{e:{for(var n=e.return;null!==n;){if(il(n)){var r=n;break e}n=n.return}throw Error(o(160))}switch(r.tag){case 5:var a=r.stateNode;32&r.flags&&(pe(a,""),r.flags&=-33),ul(e,sl(e),a);break;case 3:case 4:var i=r.stateNode.containerInfo;ll(e,sl(e),i);break;default:throw Error(o(161))}}catch(s){Cu(e,e.return,s)}e.flags&=-3}4096&t&&(e.flags&=-4097)}function bl(e,t,n){Xs=e,gl(e,t,n)}function gl(e,t,n){for(var r=0!==(1&e.mode);null!==Xs;){var a=Xs,o=a.child;if(22===a.tag&&r){var i=null!==a.memoizedState||qs;if(!i){var s=a.alternate,l=null!==s&&null!==s.memoizedState||Ks;s=qs;var u=Ks;if(qs=i,(Ks=l)&&!u)for(Xs=a;null!==Xs;)l=(i=Xs).child,22===i.tag&&null!==i.memoizedState?Sl(a):null!==l?(l.return=i,Xs=l):Sl(a);for(;null!==o;)Xs=o,gl(o,t,n),o=o.sibling;Xs=a,qs=s,Ks=u}_l(e)}else 0!==(8772&a.subtreeFlags)&&null!==o?(o.return=a,Xs=o):_l(e)}}function _l(e){for(;null!==Xs;){var t=Xs;if(0!==(8772&t.flags)){var n=t.alternate;try{if(0!==(8772&t.flags))switch(t.tag){case 0:case 11:case 15:Ks||rl(5,t);break;case 1:var r=t.stateNode;if(4&t.flags&&!Ks)if(null===n)r.componentDidMount();else{var a=t.elementType===t.type?n.memoizedProps:yo(t.type,n.memoizedProps);r.componentDidUpdate(a,n.memoizedState,r.__reactInternalSnapshotBeforeUpdate)}var i=t.updateQueue;null!==i&&Zo(t,i,r);break;case 3:var s=t.updateQueue;if(null!==s){if(n=null,null!==t.child)switch(t.child.tag){case 5:case 1:n=t.child.stateNode}Zo(t,s,n)}break;case 5:var l=t.stateNode;if(null===n&&4&t.flags){n=l;var u=t.memoizedProps;switch(t.type){case"button":case"input":case"select":case"textarea":u.autoFocus&&n.focus();break;case"img":u.src&&(n.src=u.src)}}break;case 6:case 4:case 12:case 19:case 17:case 21:case 22:case 23:case 25:break;case 13:if(null===t.memoizedState){var c=t.alternate;if(null!==c){var d=c.memoizedState;if(null!==d){var p=d.dehydrated;null!==p&&Wt(p)}}}break;default:throw Error(o(163))}Ks||512&t.flags&&al(t)}catch(f){Cu(t,t.return,f)}}if(t===e){Xs=null;break}if(null!==(n=t.sibling)){n.return=t.return,Xs=n;break}Xs=t.return}}function wl(e){for(;null!==Xs;){var t=Xs;if(t===e){Xs=null;break}var n=t.sibling;if(null!==n){n.return=t.return,Xs=n;break}Xs=t.return}}function Sl(e){for(;null!==Xs;){var t=Xs;try{switch(t.tag){case 0:case 11:case 15:var n=t.return;try{rl(4,t)}catch(l){Cu(t,n,l)}break;case 1:var r=t.stateNode;if("function"===typeof r.componentDidMount){var a=t.return;try{r.componentDidMount()}catch(l){Cu(t,a,l)}}var o=t.return;try{al(t)}catch(l){Cu(t,o,l)}break;case 5:var i=t.return;try{al(t)}catch(l){Cu(t,i,l)}}}catch(l){Cu(t,t.return,l)}if(t===e){Xs=null;break}var s=t.sibling;if(null!==s){s.return=t.return,Xs=s;break}Xs=t.return}}var Tl,Cl=Math.ceil,kl=_.ReactCurrentDispatcher,Al=_.ReactCurrentOwner,xl=_.ReactCurrentBatchConfig,Fl=0,Rl=null,Pl=null,El=0,Ol=0,Nl=Ca(0),Il=0,Ml=null,zl=0,Dl=0,Ll=0,Zl=null,jl=null,Bl=0,Wl=1/0,Jl=null,Ul=!1,Vl=null,$l=null,Hl=!1,Gl=null,ql=0,Kl=0,Ql=null,Xl=-1,Yl=0;function eu(){return 0!==(6&Fl)?Qe():-1!==Xl?Xl:Xl=Qe()}function tu(e){return 0===(1&e.mode)?1:0!==(2&Fl)&&0!==El?El&-El:null!==vo.transition?(0===Yl&&(Yl=ht()),Yl):0!==(e=gt)?e:e=void 0===(e=window.event)?16:Kt(e.type)}function nu(e,t,n,r){if(50<Kl)throw Kl=0,Ql=null,Error(o(185));yt(e,n,r),0!==(2&Fl)&&e===Rl||(e===Rl&&(0===(2&Fl)&&(Dl|=n),4===Il&&su(e,El)),ru(e,r),1===n&&0===Fl&&0===(1&t.mode)&&(Wl=Qe()+500,Za&&Wa()))}function ru(e,t){var n=e.callbackNode;!function(e,t){for(var n=e.suspendedLanes,r=e.pingedLanes,a=e.expirationTimes,o=e.pendingLanes;0<o;){var i=31-it(o),s=1<<i,l=a[i];-1===l?0!==(s&n)&&0===(s&r)||(a[i]=ft(s,t)):l<=t&&(e.expiredLanes|=s),o&=~s}}(e,t);var r=pt(e,e===Rl?El:0);if(0===r)null!==n&&Ge(n),e.callbackNode=null,e.callbackPriority=0;else if(t=r&-r,e.callbackPriority!==t){if(null!=n&&Ge(n),1===t)0===e.tag?function(e){Za=!0,Ba(e)}(lu.bind(null,e)):Ba(lu.bind(null,e)),ia((function(){0===(6&Fl)&&Wa()})),n=null;else{switch(_t(r)){case 1:n=Ye;break;case 4:n=et;break;case 16:default:n=tt;break;case 536870912:n=rt}n=Ru(n,au.bind(null,e))}e.callbackPriority=t,e.callbackNode=n}}function au(e,t){if(Xl=-1,Yl=0,0!==(6&Fl))throw Error(o(327));var n=e.callbackNode;if(Su()&&e.callbackNode!==n)return null;var r=pt(e,e===Rl?El:0);if(0===r)return null;if(0!==(30&r)||0!==(r&e.expiredLanes)||t)t=vu(e,r);else{t=r;var a=Fl;Fl|=2;var i=mu();for(Rl===e&&El===t||(Jl=null,Wl=Qe()+500,pu(e,t));;)try{bu();break}catch(l){fu(e,l)}So(),kl.current=i,Fl=a,null!==Pl?t=0:(Rl=null,El=0,t=Il)}if(0!==t){if(2===t&&(0!==(a=mt(e))&&(r=a,t=ou(e,a))),1===t)throw n=Ml,pu(e,0),su(e,r),ru(e,Qe()),n;if(6===t)su(e,r);else{if(a=e.current.alternate,0===(30&r)&&!function(e){for(var t=e;;){if(16384&t.flags){var n=t.updateQueue;if(null!==n&&null!==(n=n.stores))for(var r=0;r<n.length;r++){var a=n[r],o=a.getSnapshot;a=a.value;try{if(!sr(o(),a))return!1}catch(s){return!1}}}if(n=t.child,16384&t.subtreeFlags&&null!==n)n.return=t,t=n;else{if(t===e)break;for(;null===t.sibling;){if(null===t.return||t.return===e)return!0;t=t.return}t.sibling.return=t.return,t=t.sibling}}return!0}(a)&&(2===(t=vu(e,r))&&(0!==(i=mt(e))&&(r=i,t=ou(e,i))),1===t))throw n=Ml,pu(e,0),su(e,r),ru(e,Qe()),n;switch(e.finishedWork=a,e.finishedLanes=r,t){case 0:case 1:throw Error(o(345));case 2:case 5:wu(e,jl,Jl);break;case 3:if(su(e,r),(130023424&r)===r&&10<(t=Bl+500-Qe())){if(0!==pt(e,0))break;if(((a=e.suspendedLanes)&r)!==r){eu(),e.pingedLanes|=e.suspendedLanes&a;break}e.timeoutHandle=ra(wu.bind(null,e,jl,Jl),t);break}wu(e,jl,Jl);break;case 4:if(su(e,r),(4194240&r)===r)break;for(t=e.eventTimes,a=-1;0<r;){var s=31-it(r);i=1<<s,(s=t[s])>a&&(a=s),r&=~i}if(r=a,10<(r=(120>(r=Qe()-r)?120:480>r?480:1080>r?1080:1920>r?1920:3e3>r?3e3:4320>r?4320:1960*Cl(r/1960))-r)){e.timeoutHandle=ra(wu.bind(null,e,jl,Jl),r);break}wu(e,jl,Jl);break;default:throw Error(o(329))}}}return ru(e,Qe()),e.callbackNode===n?au.bind(null,e):null}function ou(e,t){var n=Zl;return e.current.memoizedState.isDehydrated&&(pu(e,t).flags|=256),2!==(e=vu(e,t))&&(t=jl,jl=n,null!==t&&iu(t)),e}function iu(e){null===jl?jl=e:jl.push.apply(jl,e)}function su(e,t){for(t&=~Ll,t&=~Dl,e.suspendedLanes|=t,e.pingedLanes&=~t,e=e.expirationTimes;0<t;){var n=31-it(t),r=1<<n;e[n]=-1,t&=~r}}function lu(e){if(0!==(6&Fl))throw Error(o(327));Su();var t=pt(e,0);if(0===(1&t))return ru(e,Qe()),null;var n=vu(e,t);if(0!==e.tag&&2===n){var r=mt(e);0!==r&&(t=r,n=ou(e,r))}if(1===n)throw n=Ml,pu(e,0),su(e,t),ru(e,Qe()),n;if(6===n)throw Error(o(345));return e.finishedWork=e.current.alternate,e.finishedLanes=t,wu(e,jl,Jl),ru(e,Qe()),null}function uu(e,t){var n=Fl;Fl|=1;try{return e(t)}finally{0===(Fl=n)&&(Wl=Qe()+500,Za&&Wa())}}function cu(e){null!==Gl&&0===Gl.tag&&0===(6&Fl)&&Su();var t=Fl;Fl|=1;var n=xl.transition,r=gt;try{if(xl.transition=null,gt=1,e)return e()}finally{gt=r,xl.transition=n,0===(6&(Fl=t))&&Wa()}}function du(){Ol=Nl.current,ka(Nl)}function pu(e,t){e.finishedWork=null,e.finishedLanes=0;var n=e.timeoutHandle;if(-1!==n&&(e.timeoutHandle=-1,aa(n)),null!==Pl)for(n=Pl.return;null!==n;){var r=n;switch(to(r),r.tag){case 1:null!==(r=r.type.childContextTypes)&&void 0!==r&&Na();break;case 3:oi(),ka(Ra),ka(Fa),di();break;case 5:si(r);break;case 4:oi();break;case 13:case 19:ka(li);break;case 10:To(r.type._context);break;case 22:case 23:du()}n=n.return}if(Rl=e,Pl=e=Nu(e.current,null),El=Ol=t,Il=0,Ml=null,Ll=Dl=zl=0,jl=Zl=null,null!==xo){for(t=0;t<xo.length;t++)if(null!==(r=(n=xo[t]).interleaved)){n.interleaved=null;var a=r.next,o=n.pending;if(null!==o){var i=o.next;o.next=a,r.next=i}n.pending=r}xo=null}return e}function fu(e,t){for(;;){var n=Pl;try{if(So(),pi.current=is,bi){for(var r=hi.memoizedState;null!==r;){var a=r.queue;null!==a&&(a.pending=null),r=r.next}bi=!1}if(mi=0,yi=vi=hi=null,gi=!1,_i=0,Al.current=null,null===n||null===n.return){Il=1,Ml=t,Pl=null;break}e:{var i=e,s=n.return,l=n,u=t;if(t=El,l.flags|=32768,null!==u&&"object"===typeof u&&"function"===typeof u.then){var c=u,d=l,p=d.tag;if(0===(1&d.mode)&&(0===p||11===p||15===p)){var f=d.alternate;f?(d.updateQueue=f.updateQueue,d.memoizedState=f.memoizedState,d.lanes=f.lanes):(d.updateQueue=null,d.memoizedState=null)}var m=ys(s);if(null!==m){m.flags&=-257,bs(m,s,l,0,t),1&m.mode&&vs(i,c,t),u=c;var h=(t=m).updateQueue;if(null===h){var v=new Set;v.add(u),t.updateQueue=v}else h.add(u);break e}if(0===(1&t)){vs(i,c,t),hu();break e}u=Error(o(426))}else if(ao&&1&l.mode){var y=ys(s);if(null!==y){0===(65536&y.flags)&&(y.flags|=256),bs(y,s,l,0,t),ho(cs(u,l));break e}}i=u=cs(u,l),4!==Il&&(Il=2),null===Zl?Zl=[i]:Zl.push(i),i=s;do{switch(i.tag){case 3:i.flags|=65536,t&=-t,i.lanes|=t,Do(i,ms(0,u,t));break e;case 1:l=u;var b=i.type,g=i.stateNode;if(0===(128&i.flags)&&("function"===typeof b.getDerivedStateFromError||null!==g&&"function"===typeof g.componentDidCatch&&(null===$l||!$l.has(g)))){i.flags|=65536,t&=-t,i.lanes|=t,Do(i,hs(i,l,t));break e}}i=i.return}while(null!==i)}_u(n)}catch(_){t=_,Pl===n&&null!==n&&(Pl=n=n.return);continue}break}}function mu(){var e=kl.current;return kl.current=is,null===e?is:e}function hu(){0!==Il&&3!==Il&&2!==Il||(Il=4),null===Rl||0===(268435455&zl)&&0===(268435455&Dl)||su(Rl,El)}function vu(e,t){var n=Fl;Fl|=2;var r=mu();for(Rl===e&&El===t||(Jl=null,pu(e,t));;)try{yu();break}catch(a){fu(e,a)}if(So(),Fl=n,kl.current=r,null!==Pl)throw Error(o(261));return Rl=null,El=0,Il}function yu(){for(;null!==Pl;)gu(Pl)}function bu(){for(;null!==Pl&&!qe();)gu(Pl)}function gu(e){var t=Tl(e.alternate,e,Ol);e.memoizedProps=e.pendingProps,null===t?_u(e):Pl=t,Al.current=null}function _u(e){var t=e;do{var n=t.alternate;if(e=t.return,0===(32768&t.flags)){if(null!==(n=Hs(n,t,Ol)))return void(Pl=n)}else{if(null!==(n=Gs(n,t)))return n.flags&=32767,void(Pl=n);if(null===e)return Il=6,void(Pl=null);e.flags|=32768,e.subtreeFlags=0,e.deletions=null}if(null!==(t=t.sibling))return void(Pl=t);Pl=t=e}while(null!==t);0===Il&&(Il=5)}function wu(e,t,n){var r=gt,a=xl.transition;try{xl.transition=null,gt=1,function(e,t,n,r){do{Su()}while(null!==Gl);if(0!==(6&Fl))throw Error(o(327));n=e.finishedWork;var a=e.finishedLanes;if(null===n)return null;if(e.finishedWork=null,e.finishedLanes=0,n===e.current)throw Error(o(177));e.callbackNode=null,e.callbackPriority=0;var i=n.lanes|n.childLanes;if(function(e,t){var n=e.pendingLanes&~t;e.pendingLanes=t,e.suspendedLanes=0,e.pingedLanes=0,e.expiredLanes&=t,e.mutableReadLanes&=t,e.entangledLanes&=t,t=e.entanglements;var r=e.eventTimes;for(e=e.expirationTimes;0<n;){var a=31-it(n),o=1<<a;t[a]=0,r[a]=-1,e[a]=-1,n&=~o}}(e,i),e===Rl&&(Pl=Rl=null,El=0),0===(2064&n.subtreeFlags)&&0===(2064&n.flags)||Hl||(Hl=!0,Ru(tt,(function(){return Su(),null}))),i=0!==(15990&n.flags),0!==(15990&n.subtreeFlags)||i){i=xl.transition,xl.transition=null;var s=gt;gt=1;var l=Fl;Fl|=4,Al.current=null,function(e,t){if(ea=Ut,fr(e=pr())){if("selectionStart"in e)var n={start:e.selectionStart,end:e.selectionEnd};else e:{var r=(n=(n=e.ownerDocument)&&n.defaultView||window).getSelection&&n.getSelection();if(r&&0!==r.rangeCount){n=r.anchorNode;var a=r.anchorOffset,i=r.focusNode;r=r.focusOffset;try{n.nodeType,i.nodeType}catch(w){n=null;break e}var s=0,l=-1,u=-1,c=0,d=0,p=e,f=null;t:for(;;){for(var m;p!==n||0!==a&&3!==p.nodeType||(l=s+a),p!==i||0!==r&&3!==p.nodeType||(u=s+r),3===p.nodeType&&(s+=p.nodeValue.length),null!==(m=p.firstChild);)f=p,p=m;for(;;){if(p===e)break t;if(f===n&&++c===a&&(l=s),f===i&&++d===r&&(u=s),null!==(m=p.nextSibling))break;f=(p=f).parentNode}p=m}n=-1===l||-1===u?null:{start:l,end:u}}else n=null}n=n||{start:0,end:0}}else n=null;for(ta={focusedElem:e,selectionRange:n},Ut=!1,Xs=t;null!==Xs;)if(e=(t=Xs).child,0!==(1028&t.subtreeFlags)&&null!==e)e.return=t,Xs=e;else for(;null!==Xs;){t=Xs;try{var h=t.alternate;if(0!==(1024&t.flags))switch(t.tag){case 0:case 11:case 15:case 5:case 6:case 4:case 17:break;case 1:if(null!==h){var v=h.memoizedProps,y=h.memoizedState,b=t.stateNode,g=b.getSnapshotBeforeUpdate(t.elementType===t.type?v:yo(t.type,v),y);b.__reactInternalSnapshotBeforeUpdate=g}break;case 3:var _=t.stateNode.containerInfo;1===_.nodeType?_.textContent="":9===_.nodeType&&_.documentElement&&_.removeChild(_.documentElement);break;default:throw Error(o(163))}}catch(w){Cu(t,t.return,w)}if(null!==(e=t.sibling)){e.return=t.return,Xs=e;break}Xs=t.return}h=tl,tl=!1}(e,n),vl(n,e),mr(ta),Ut=!!ea,ta=ea=null,e.current=n,bl(n,e,a),Ke(),Fl=l,gt=s,xl.transition=i}else e.current=n;if(Hl&&(Hl=!1,Gl=e,ql=a),0===(i=e.pendingLanes)&&($l=null),function(e){if(ot&&"function"===typeof ot.onCommitFiberRoot)try{ot.onCommitFiberRoot(at,e,void 0,128===(128&e.current.flags))}catch(t){}}(n.stateNode),ru(e,Qe()),null!==t)for(r=e.onRecoverableError,n=0;n<t.length;n++)r((a=t[n]).value,{componentStack:a.stack,digest:a.digest});if(Ul)throw Ul=!1,e=Vl,Vl=null,e;0!==(1&ql)&&0!==e.tag&&Su(),0!==(1&(i=e.pendingLanes))?e===Ql?Kl++:(Kl=0,Ql=e):Kl=0,Wa()}(e,t,n,r)}finally{xl.transition=a,gt=r}return null}function Su(){if(null!==Gl){var e=_t(ql),t=xl.transition,n=gt;try{if(xl.transition=null,gt=16>e?16:e,null===Gl)var r=!1;else{if(e=Gl,Gl=null,ql=0,0!==(6&Fl))throw Error(o(331));var a=Fl;for(Fl|=4,Xs=e.current;null!==Xs;){var i=Xs,s=i.child;if(0!==(16&Xs.flags)){var l=i.deletions;if(null!==l){for(var u=0;u<l.length;u++){var c=l[u];for(Xs=c;null!==Xs;){var d=Xs;switch(d.tag){case 0:case 11:case 15:nl(8,d,i)}var p=d.child;if(null!==p)p.return=d,Xs=p;else for(;null!==Xs;){var f=(d=Xs).sibling,m=d.return;if(ol(d),d===c){Xs=null;break}if(null!==f){f.return=m,Xs=f;break}Xs=m}}}var h=i.alternate;if(null!==h){var v=h.child;if(null!==v){h.child=null;do{var y=v.sibling;v.sibling=null,v=y}while(null!==v)}}Xs=i}}if(0!==(2064&i.subtreeFlags)&&null!==s)s.return=i,Xs=s;else e:for(;null!==Xs;){if(0!==(2048&(i=Xs).flags))switch(i.tag){case 0:case 11:case 15:nl(9,i,i.return)}var b=i.sibling;if(null!==b){b.return=i.return,Xs=b;break e}Xs=i.return}}var g=e.current;for(Xs=g;null!==Xs;){var _=(s=Xs).child;if(0!==(2064&s.subtreeFlags)&&null!==_)_.return=s,Xs=_;else e:for(s=g;null!==Xs;){if(0!==(2048&(l=Xs).flags))try{switch(l.tag){case 0:case 11:case 15:rl(9,l)}}catch(S){Cu(l,l.return,S)}if(l===s){Xs=null;break e}var w=l.sibling;if(null!==w){w.return=l.return,Xs=w;break e}Xs=l.return}}if(Fl=a,Wa(),ot&&"function"===typeof ot.onPostCommitFiberRoot)try{ot.onPostCommitFiberRoot(at,e)}catch(S){}r=!0}return r}finally{gt=n,xl.transition=t}}return!1}function Tu(e,t,n){e=Mo(e,t=ms(0,t=cs(n,t),1),1),t=eu(),null!==e&&(yt(e,1,t),ru(e,t))}function Cu(e,t,n){if(3===e.tag)Tu(e,e,n);else for(;null!==t;){if(3===t.tag){Tu(t,e,n);break}if(1===t.tag){var r=t.stateNode;if("function"===typeof t.type.getDerivedStateFromError||"function"===typeof r.componentDidCatch&&(null===$l||!$l.has(r))){t=Mo(t,e=hs(t,e=cs(n,e),1),1),e=eu(),null!==t&&(yt(t,1,e),ru(t,e));break}}t=t.return}}function ku(e,t,n){var r=e.pingCache;null!==r&&r.delete(t),t=eu(),e.pingedLanes|=e.suspendedLanes&n,Rl===e&&(El&n)===n&&(4===Il||3===Il&&(130023424&El)===El&&500>Qe()-Bl?pu(e,0):Ll|=n),ru(e,t)}function Au(e,t){0===t&&(0===(1&e.mode)?t=1:(t=ct,0===(130023424&(ct<<=1))&&(ct=4194304)));var n=eu();null!==(e=Po(e,t))&&(yt(e,t,n),ru(e,n))}function xu(e){var t=e.memoizedState,n=0;null!==t&&(n=t.retryLane),Au(e,n)}function Fu(e,t){var n=0;switch(e.tag){case 13:var r=e.stateNode,a=e.memoizedState;null!==a&&(n=a.retryLane);break;case 19:r=e.stateNode;break;default:throw Error(o(314))}null!==r&&r.delete(t),Au(e,n)}function Ru(e,t){return He(e,t)}function Pu(e,t,n,r){this.tag=e,this.key=n,this.sibling=this.child=this.return=this.stateNode=this.type=this.elementType=null,this.index=0,this.ref=null,this.pendingProps=t,this.dependencies=this.memoizedState=this.updateQueue=this.memoizedProps=null,this.mode=r,this.subtreeFlags=this.flags=0,this.deletions=null,this.childLanes=this.lanes=0,this.alternate=null}function Eu(e,t,n,r){return new Pu(e,t,n,r)}function Ou(e){return!(!(e=e.prototype)||!e.isReactComponent)}function Nu(e,t){var n=e.alternate;return null===n?((n=Eu(e.tag,t,e.key,e.mode)).elementType=e.elementType,n.type=e.type,n.stateNode=e.stateNode,n.alternate=e,e.alternate=n):(n.pendingProps=t,n.type=e.type,n.flags=0,n.subtreeFlags=0,n.deletions=null),n.flags=14680064&e.flags,n.childLanes=e.childLanes,n.lanes=e.lanes,n.child=e.child,n.memoizedProps=e.memoizedProps,n.memoizedState=e.memoizedState,n.updateQueue=e.updateQueue,t=e.dependencies,n.dependencies=null===t?null:{lanes:t.lanes,firstContext:t.firstContext},n.sibling=e.sibling,n.index=e.index,n.ref=e.ref,n}function Iu(e,t,n,r,a,i){var s=2;if(r=e,"function"===typeof e)Ou(e)&&(s=1);else if("string"===typeof e)s=5;else e:switch(e){case T:return Mu(n.children,a,i,t);case C:s=8,a|=8;break;case k:return(e=Eu(12,n,t,2|a)).elementType=k,e.lanes=i,e;case R:return(e=Eu(13,n,t,a)).elementType=R,e.lanes=i,e;case P:return(e=Eu(19,n,t,a)).elementType=P,e.lanes=i,e;case N:return zu(n,a,i,t);default:if("object"===typeof e&&null!==e)switch(e.$$typeof){case A:s=10;break e;case x:s=9;break e;case F:s=11;break e;case E:s=14;break e;case O:s=16,r=null;break e}throw Error(o(130,null==e?e:typeof e,""))}return(t=Eu(s,n,t,a)).elementType=e,t.type=r,t.lanes=i,t}function Mu(e,t,n,r){return(e=Eu(7,e,r,t)).lanes=n,e}function zu(e,t,n,r){return(e=Eu(22,e,r,t)).elementType=N,e.lanes=n,e.stateNode={isHidden:!1},e}function Du(e,t,n){return(e=Eu(6,e,null,t)).lanes=n,e}function Lu(e,t,n){return(t=Eu(4,null!==e.children?e.children:[],e.key,t)).lanes=n,t.stateNode={containerInfo:e.containerInfo,pendingChildren:null,implementation:e.implementation},t}function Zu(e,t,n,r,a){this.tag=t,this.containerInfo=e,this.finishedWork=this.pingCache=this.current=this.pendingChildren=null,this.timeoutHandle=-1,this.callbackNode=this.pendingContext=this.context=null,this.callbackPriority=0,this.eventTimes=vt(0),this.expirationTimes=vt(-1),this.entangledLanes=this.finishedLanes=this.mutableReadLanes=this.expiredLanes=this.pingedLanes=this.suspendedLanes=this.pendingLanes=0,this.entanglements=vt(0),this.identifierPrefix=r,this.onRecoverableError=a,this.mutableSourceEagerHydrationData=null}function ju(e,t,n,r,a,o,i,s,l){return e=new Zu(e,t,n,s,l),1===t?(t=1,!0===o&&(t|=8)):t=0,o=Eu(3,null,null,t),e.current=o,o.stateNode=e,o.memoizedState={element:r,isDehydrated:n,cache:null,transitions:null,pendingSuspenseBoundaries:null},Oo(o),e}function Bu(e,t,n){var r=3<arguments.length&&void 0!==arguments[3]?arguments[3]:null;return{$$typeof:S,key:null==r?null:""+r,children:e,containerInfo:t,implementation:n}}function Wu(e){if(!e)return xa;e:{if(We(e=e._reactInternals)!==e||1!==e.tag)throw Error(o(170));var t=e;do{switch(t.tag){case 3:t=t.stateNode.context;break e;case 1:if(Oa(t.type)){t=t.stateNode.__reactInternalMemoizedMergedChildContext;break e}}t=t.return}while(null!==t);throw Error(o(171))}if(1===e.tag){var n=e.type;if(Oa(n))return Ma(e,n,t)}return t}function Ju(e,t,n,r,a,o,i,s,l){return(e=ju(n,r,!0,e,0,o,0,s,l)).context=Wu(null),n=e.current,(o=Io(r=eu(),a=tu(n))).callback=void 0!==t&&null!==t?t:null,Mo(n,o,a),e.current.lanes=a,yt(e,a,r),ru(e,r),e}function Uu(e,t,n,r){var a=t.current,o=eu(),i=tu(a);return n=Wu(n),null===t.context?t.context=n:t.pendingContext=n,(t=Io(o,i)).payload={element:e},null!==(r=void 0===r?null:r)&&(t.callback=r),null!==(e=Mo(a,t,i))&&(nu(e,a,i,o),zo(e,a,i)),i}function Vu(e){return(e=e.current).child?(e.child.tag,e.child.stateNode):null}function $u(e,t){if(null!==(e=e.memoizedState)&&null!==e.dehydrated){var n=e.retryLane;e.retryLane=0!==n&&n<t?n:t}}function Hu(e,t){$u(e,t),(e=e.alternate)&&$u(e,t)}Tl=function(e,t,n){if(null!==e)if(e.memoizedProps!==t.pendingProps||Ra.current)_s=!0;else{if(0===(e.lanes&n)&&0===(128&t.flags))return _s=!1,function(e,t,n){switch(t.tag){case 3:Ps(t),mo();break;case 5:ii(t);break;case 1:Oa(t.type)&&za(t);break;case 4:ai(t,t.stateNode.containerInfo);break;case 10:var r=t.type._context,a=t.memoizedProps.value;Aa(bo,r._currentValue),r._currentValue=a;break;case 13:if(null!==(r=t.memoizedState))return null!==r.dehydrated?(Aa(li,1&li.current),t.flags|=128,null):0!==(n&t.child.childLanes)?Ds(e,t,n):(Aa(li,1&li.current),null!==(e=Us(e,t,n))?e.sibling:null);Aa(li,1&li.current);break;case 19:if(r=0!==(n&t.childLanes),0!==(128&e.flags)){if(r)return Ws(e,t,n);t.flags|=128}if(null!==(a=t.memoizedState)&&(a.rendering=null,a.tail=null,a.lastEffect=null),Aa(li,li.current),r)break;return null;case 22:case 23:return t.lanes=0,ks(e,t,n)}return Us(e,t,n)}(e,t,n);_s=0!==(131072&e.flags)}else _s=!1,ao&&0!==(1048576&t.flags)&&Ya(t,$a,t.index);switch(t.lanes=0,t.tag){case 2:var r=t.type;Js(e,t),e=t.pendingProps;var a=Ea(t,Fa.current);ko(t,n),a=Ci(null,t,r,e,a,n);var i=ki();return t.flags|=1,"object"===typeof a&&null!==a&&"function"===typeof a.render&&void 0===a.$$typeof?(t.tag=1,t.memoizedState=null,t.updateQueue=null,Oa(r)?(i=!0,za(t)):i=!1,t.memoizedState=null!==a.state&&void 0!==a.state?a.state:null,Oo(t),a.updater=Wo,t.stateNode=a,a._reactInternals=t,$o(t,r,e,n),t=Rs(null,t,r,!0,i,n)):(t.tag=0,ao&&i&&eo(t),ws(null,t,a,n),t=t.child),t;case 16:r=t.elementType;e:{switch(Js(e,t),e=t.pendingProps,r=(a=r._init)(r._payload),t.type=r,a=t.tag=function(e){if("function"===typeof e)return Ou(e)?1:0;if(void 0!==e&&null!==e){if((e=e.$$typeof)===F)return 11;if(e===E)return 14}return 2}(r),e=yo(r,e),a){case 0:t=xs(null,t,r,e,n);break e;case 1:t=Fs(null,t,r,e,n);break e;case 11:t=Ss(null,t,r,e,n);break e;case 14:t=Ts(null,t,r,yo(r.type,e),n);break e}throw Error(o(306,r,""))}return t;case 0:return r=t.type,a=t.pendingProps,xs(e,t,r,a=t.elementType===r?a:yo(r,a),n);case 1:return r=t.type,a=t.pendingProps,Fs(e,t,r,a=t.elementType===r?a:yo(r,a),n);case 3:e:{if(Ps(t),null===e)throw Error(o(387));r=t.pendingProps,a=(i=t.memoizedState).element,No(e,t),Lo(t,r,null,n);var s=t.memoizedState;if(r=s.element,i.isDehydrated){if(i={element:r,isDehydrated:!1,cache:s.cache,pendingSuspenseBoundaries:s.pendingSuspenseBoundaries,transitions:s.transitions},t.updateQueue.baseState=i,t.memoizedState=i,256&t.flags){t=Es(e,t,r,n,a=cs(Error(o(423)),t));break e}if(r!==a){t=Es(e,t,r,n,a=cs(Error(o(424)),t));break e}for(ro=ua(t.stateNode.containerInfo.firstChild),no=t,ao=!0,oo=null,n=Xo(t,null,r,n),t.child=n;n;)n.flags=-3&n.flags|4096,n=n.sibling}else{if(mo(),r===a){t=Us(e,t,n);break e}ws(e,t,r,n)}t=t.child}return t;case 5:return ii(t),null===e&&uo(t),r=t.type,a=t.pendingProps,i=null!==e?e.memoizedProps:null,s=a.children,na(r,a)?s=null:null!==i&&na(r,i)&&(t.flags|=32),As(e,t),ws(e,t,s,n),t.child;case 6:return null===e&&uo(t),null;case 13:return Ds(e,t,n);case 4:return ai(t,t.stateNode.containerInfo),r=t.pendingProps,null===e?t.child=Qo(t,null,r,n):ws(e,t,r,n),t.child;case 11:return r=t.type,a=t.pendingProps,Ss(e,t,r,a=t.elementType===r?a:yo(r,a),n);case 7:return ws(e,t,t.pendingProps,n),t.child;case 8:case 12:return ws(e,t,t.pendingProps.children,n),t.child;case 10:e:{if(r=t.type._context,a=t.pendingProps,i=t.memoizedProps,s=a.value,Aa(bo,r._currentValue),r._currentValue=s,null!==i)if(sr(i.value,s)){if(i.children===a.children&&!Ra.current){t=Us(e,t,n);break e}}else for(null!==(i=t.child)&&(i.return=t);null!==i;){var l=i.dependencies;if(null!==l){s=i.child;for(var u=l.firstContext;null!==u;){if(u.context===r){if(1===i.tag){(u=Io(-1,n&-n)).tag=2;var c=i.updateQueue;if(null!==c){var d=(c=c.shared).pending;null===d?u.next=u:(u.next=d.next,d.next=u),c.pending=u}}i.lanes|=n,null!==(u=i.alternate)&&(u.lanes|=n),Co(i.return,n,t),l.lanes|=n;break}u=u.next}}else if(10===i.tag)s=i.type===t.type?null:i.child;else if(18===i.tag){if(null===(s=i.return))throw Error(o(341));s.lanes|=n,null!==(l=s.alternate)&&(l.lanes|=n),Co(s,n,t),s=i.sibling}else s=i.child;if(null!==s)s.return=i;else for(s=i;null!==s;){if(s===t){s=null;break}if(null!==(i=s.sibling)){i.return=s.return,s=i;break}s=s.return}i=s}ws(e,t,a.children,n),t=t.child}return t;case 9:return a=t.type,r=t.pendingProps.children,ko(t,n),r=r(a=Ao(a)),t.flags|=1,ws(e,t,r,n),t.child;case 14:return a=yo(r=t.type,t.pendingProps),Ts(e,t,r,a=yo(r.type,a),n);case 15:return Cs(e,t,t.type,t.pendingProps,n);case 17:return r=t.type,a=t.pendingProps,a=t.elementType===r?a:yo(r,a),Js(e,t),t.tag=1,Oa(r)?(e=!0,za(t)):e=!1,ko(t,n),Uo(t,r,a),$o(t,r,a,n),Rs(null,t,r,!0,e,n);case 19:return Ws(e,t,n);case 22:return ks(e,t,n)}throw Error(o(156,t.tag))};var Gu="function"===typeof reportError?reportError:function(e){console.error(e)};function qu(e){this._internalRoot=e}function Ku(e){this._internalRoot=e}function Qu(e){return!(!e||1!==e.nodeType&&9!==e.nodeType&&11!==e.nodeType)}function Xu(e){return!(!e||1!==e.nodeType&&9!==e.nodeType&&11!==e.nodeType&&(8!==e.nodeType||" react-mount-point-unstable "!==e.nodeValue))}function Yu(){}function ec(e,t,n,r,a){var o=n._reactRootContainer;if(o){var i=o;if("function"===typeof a){var s=a;a=function(){var e=Vu(i);s.call(e)}}Uu(t,i,e,a)}else i=function(e,t,n,r,a){if(a){if("function"===typeof r){var o=r;r=function(){var e=Vu(i);o.call(e)}}var i=Ju(t,r,e,0,null,!1,0,"",Yu);return e._reactRootContainer=i,e[ma]=i.current,Wr(8===e.nodeType?e.parentNode:e),cu(),i}for(;a=e.lastChild;)e.removeChild(a);if("function"===typeof r){var s=r;r=function(){var e=Vu(l);s.call(e)}}var l=ju(e,0,!1,null,0,!1,0,"",Yu);return e._reactRootContainer=l,e[ma]=l.current,Wr(8===e.nodeType?e.parentNode:e),cu((function(){Uu(t,l,n,r)})),l}(n,t,e,a,r);return Vu(i)}Ku.prototype.render=qu.prototype.render=function(e){var t=this._internalRoot;if(null===t)throw Error(o(409));Uu(e,t,null,null)},Ku.prototype.unmount=qu.prototype.unmount=function(){var e=this._internalRoot;if(null!==e){this._internalRoot=null;var t=e.containerInfo;cu((function(){Uu(null,e,null,null)})),t[ma]=null}},Ku.prototype.unstable_scheduleHydration=function(e){if(e){var t=Ct();e={blockedOn:null,target:e,priority:t};for(var n=0;n<Nt.length&&0!==t&&t<Nt[n].priority;n++);Nt.splice(n,0,e),0===n&&Dt(e)}},wt=function(e){switch(e.tag){case 3:var t=e.stateNode;if(t.current.memoizedState.isDehydrated){var n=dt(t.pendingLanes);0!==n&&(bt(t,1|n),ru(t,Qe()),0===(6&Fl)&&(Wl=Qe()+500,Wa()))}break;case 13:cu((function(){var t=Po(e,1);if(null!==t){var n=eu();nu(t,e,1,n)}})),Hu(e,1)}},St=function(e){if(13===e.tag){var t=Po(e,134217728);if(null!==t)nu(t,e,134217728,eu());Hu(e,134217728)}},Tt=function(e){if(13===e.tag){var t=tu(e),n=Po(e,t);if(null!==n)nu(n,e,t,eu());Hu(e,t)}},Ct=function(){return gt},kt=function(e,t){var n=gt;try{return gt=e,t()}finally{gt=n}},Se=function(e,t,n){switch(t){case"input":if(X(e,n),t=n.name,"radio"===n.type&&null!=t){for(n=e;n.parentNode;)n=n.parentNode;for(n=n.querySelectorAll("input[name="+JSON.stringify(""+t)+'][type="radio"]'),t=0;t<n.length;t++){var r=n[t];if(r!==e&&r.form===e.form){var a=wa(r);if(!a)throw Error(o(90));H(r),X(r,a)}}}break;case"textarea":oe(e,n);break;case"select":null!=(t=n.value)&&ne(e,!!n.multiple,t,!1)}},Fe=uu,Re=cu;var tc={usingClientEntryPoint:!1,Events:[ga,_a,wa,Ae,xe,uu]},nc={findFiberByHostInstance:ba,bundleType:0,version:"18.2.0",rendererPackageName:"react-dom"},rc={bundleType:nc.bundleType,version:nc.version,rendererPackageName:nc.rendererPackageName,rendererConfig:nc.rendererConfig,overrideHookState:null,overrideHookStateDeletePath:null,overrideHookStateRenamePath:null,overrideProps:null,overridePropsDeletePath:null,overridePropsRenamePath:null,setErrorHandler:null,setSuspenseHandler:null,scheduleUpdate:null,currentDispatcherRef:_.ReactCurrentDispatcher,findHostInstanceByFiber:function(e){return null===(e=Ve(e))?null:e.stateNode},findFiberByHostInstance:nc.findFiberByHostInstance||function(){return null},findHostInstancesForRefresh:null,scheduleRefresh:null,scheduleRoot:null,setRefreshHandler:null,getCurrentFiber:null,reconcilerVersion:"18.2.0-next-9e3b772b8-20220608"};if("undefined"!==typeof __REACT_DEVTOOLS_GLOBAL_HOOK__){var ac=__REACT_DEVTOOLS_GLOBAL_HOOK__;if(!ac.isDisabled&&ac.supportsFiber)try{at=ac.inject(rc),ot=ac}catch(ce){}}t.__SECRET_INTERNALS_DO_NOT_USE_OR_YOU_WILL_BE_FIRED=tc,t.createPortal=function(e,t){var n=2<arguments.length&&void 0!==arguments[2]?arguments[2]:null;if(!Qu(t))throw Error(o(200));return Bu(e,t,null,n)},t.createRoot=function(e,t){if(!Qu(e))throw Error(o(299));var n=!1,r="",a=Gu;return null!==t&&void 0!==t&&(!0===t.unstable_strictMode&&(n=!0),void 0!==t.identifierPrefix&&(r=t.identifierPrefix),void 0!==t.onRecoverableError&&(a=t.onRecoverableError)),t=ju(e,1,!1,null,0,n,0,r,a),e[ma]=t.current,Wr(8===e.nodeType?e.parentNode:e),new qu(t)},t.findDOMNode=function(e){if(null==e)return null;if(1===e.nodeType)return e;var t=e._reactInternals;if(void 0===t){if("function"===typeof e.render)throw Error(o(188));throw e=Object.keys(e).join(","),Error(o(268,e))}return e=null===(e=Ve(t))?null:e.stateNode},t.flushSync=function(e){return cu(e)},t.hydrate=function(e,t,n){if(!Xu(t))throw Error(o(200));return ec(null,e,t,!0,n)},t.hydrateRoot=function(e,t,n){if(!Qu(e))throw Error(o(405));var r=null!=n&&n.hydratedSources||null,a=!1,i="",s=Gu;if(null!==n&&void 0!==n&&(!0===n.unstable_strictMode&&(a=!0),void 0!==n.identifierPrefix&&(i=n.identifierPrefix),void 0!==n.onRecoverableError&&(s=n.onRecoverableError)),t=Ju(t,null,e,1,null!=n?n:null,a,0,i,s),e[ma]=t.current,Wr(e),r)for(e=0;e<r.length;e++)a=(a=(n=r[e])._getVersion)(n._source),null==t.mutableSourceEagerHydrationData?t.mutableSourceEagerHydrationData=[n,a]:t.mutableSourceEagerHydrationData.push(n,a);return new Ku(t)},t.render=function(e,t,n){if(!Xu(t))throw Error(o(200));return ec(null,e,t,!1,n)},t.unmountComponentAtNode=function(e){if(!Xu(e))throw Error(o(40));return!!e._reactRootContainer&&(cu((function(){ec(null,null,e,!1,(function(){e._reactRootContainer=null,e[ma]=null}))})),!0)},t.unstable_batchedUpdates=uu,t.unstable_renderSubtreeIntoContainer=function(e,t,n,r){if(!Xu(n))throw Error(o(200));if(null==e||void 0===e._reactInternals)throw Error(o(38));return ec(e,t,n,!1,r)},t.version="18.2.0-next-9e3b772b8-20220608"},1250:function(e,t,n){"use strict";var r=n(4164);t.createRoot=r.createRoot,t.hydrateRoot=r.hydrateRoot},4164:function(e,t,n){"use strict";!function e(){if("undefined"!==typeof __REACT_DEVTOOLS_GLOBAL_HOOK__&&"function"===typeof __REACT_DEVTOOLS_GLOBAL_HOOK__.checkDCE)try{__REACT_DEVTOOLS_GLOBAL_HOOK__.checkDCE(e)}catch(t){console.error(t)}}(),e.exports=n(4463)},6374:function(e,t,n){"use strict";var r=n(2791),a=Symbol.for("react.element"),o=Symbol.for("react.fragment"),i=Object.prototype.hasOwnProperty,s=r.__SECRET_INTERNALS_DO_NOT_USE_OR_YOU_WILL_BE_FIRED.ReactCurrentOwner,l={key:!0,ref:!0,__self:!0,__source:!0};function u(e,t,n){var r,o={},u=null,c=null;for(r in void 0!==n&&(u=""+n),void 0!==t.key&&(u=""+t.key),void 0!==t.ref&&(c=t.ref),t)i.call(t,r)&&!l.hasOwnProperty(r)&&(o[r]=t[r]);if(e&&e.defaultProps)for(r in t=e.defaultProps)void 0===o[r]&&(o[r]=t[r]);return{$$typeof:a,type:e,key:u,ref:c,props:o,_owner:s.current}}t.Fragment=o,t.jsx=u,t.jsxs=u},9117:function(e,t){"use strict";var n=Symbol.for("react.element"),r=Symbol.for("react.portal"),a=Symbol.for("react.fragment"),o=Symbol.for("react.strict_mode"),i=Symbol.for("react.profiler"),s=Symbol.for("react.provider"),l=Symbol.for("react.context"),u=Symbol.for("react.forward_ref"),c=Symbol.for("react.suspense"),d=Symbol.for("react.memo"),p=Symbol.for("react.lazy"),f=Symbol.iterator;var m={isMounted:function(){return!1},enqueueForceUpdate:function(){},enqueueReplaceState:function(){},enqueueSetState:function(){}},h=Object.assign,v={};function y(e,t,n){this.props=e,this.context=t,this.refs=v,this.updater=n||m}function b(){}function g(e,t,n){this.props=e,this.context=t,this.refs=v,this.updater=n||m}y.prototype.isReactComponent={},y.prototype.setState=function(e,t){if("object"!==typeof e&&"function"!==typeof e&&null!=e)throw Error("setState(...): takes an object of state variables to update or a function which returns an object of state variables.");this.updater.enqueueSetState(this,e,t,"setState")},y.prototype.forceUpdate=function(e){this.updater.enqueueForceUpdate(this,e,"forceUpdate")},b.prototype=y.prototype;var _=g.prototype=new b;_.constructor=g,h(_,y.prototype),_.isPureReactComponent=!0;var w=Array.isArray,S=Object.prototype.hasOwnProperty,T={current:null},C={key:!0,ref:!0,__self:!0,__source:!0};function k(e,t,r){var a,o={},i=null,s=null;if(null!=t)for(a in void 0!==t.ref&&(s=t.ref),void 0!==t.key&&(i=""+t.key),t)S.call(t,a)&&!C.hasOwnProperty(a)&&(o[a]=t[a]);var l=arguments.length-2;if(1===l)o.children=r;else if(1<l){for(var u=Array(l),c=0;c<l;c++)u[c]=arguments[c+2];o.children=u}if(e&&e.defaultProps)for(a in l=e.defaultProps)void 0===o[a]&&(o[a]=l[a]);return{$$typeof:n,type:e,key:i,ref:s,props:o,_owner:T.current}}function A(e){return"object"===typeof e&&null!==e&&e.$$typeof===n}var x=/\/+/g;function F(e,t){return"object"===typeof e&&null!==e&&null!=e.key?function(e){var t={"=":"=0",":":"=2"};return"$"+e.replace(/[=:]/g,(function(e){return t[e]}))}(""+e.key):t.toString(36)}function R(e,t,a,o,i){var s=typeof e;"undefined"!==s&&"boolean"!==s||(e=null);var l=!1;if(null===e)l=!0;else switch(s){case"string":case"number":l=!0;break;case"object":switch(e.$$typeof){case n:case r:l=!0}}if(l)return i=i(l=e),e=""===o?"."+F(l,0):o,w(i)?(a="",null!=e&&(a=e.replace(x,"$&/")+"/"),R(i,t,a,"",(function(e){return e}))):null!=i&&(A(i)&&(i=function(e,t){return{$$typeof:n,type:e.type,key:t,ref:e.ref,props:e.props,_owner:e._owner}}(i,a+(!i.key||l&&l.key===i.key?"":(""+i.key).replace(x,"$&/")+"/")+e)),t.push(i)),1;if(l=0,o=""===o?".":o+":",w(e))for(var u=0;u<e.length;u++){var c=o+F(s=e[u],u);l+=R(s,t,a,c,i)}else if(c=function(e){return null===e||"object"!==typeof e?null:"function"===typeof(e=f&&e[f]||e["@@iterator"])?e:null}(e),"function"===typeof c)for(e=c.call(e),u=0;!(s=e.next()).done;)l+=R(s=s.value,t,a,c=o+F(s,u++),i);else if("object"===s)throw t=String(e),Error("Objects are not valid as a React child (found: "+("[object Object]"===t?"object with keys {"+Object.keys(e).join(", ")+"}":t)+"). If you meant to render a collection of children, use an array instead.");return l}function P(e,t,n){if(null==e)return e;var r=[],a=0;return R(e,r,"","",(function(e){return t.call(n,e,a++)})),r}function E(e){if(-1===e._status){var t=e._result;(t=t()).then((function(t){0!==e._status&&-1!==e._status||(e._status=1,e._result=t)}),(function(t){0!==e._status&&-1!==e._status||(e._status=2,e._result=t)})),-1===e._status&&(e._status=0,e._result=t)}if(1===e._status)return e._result.default;throw e._result}var O={current:null},N={transition:null},I={ReactCurrentDispatcher:O,ReactCurrentBatchConfig:N,ReactCurrentOwner:T};t.Children={map:P,forEach:function(e,t,n){P(e,(function(){t.apply(this,arguments)}),n)},count:function(e){var t=0;return P(e,(function(){t++})),t},toArray:function(e){return P(e,(function(e){return e}))||[]},only:function(e){if(!A(e))throw Error("React.Children.only expected to receive a single React element child.");return e}},t.Component=y,t.Fragment=a,t.Profiler=i,t.PureComponent=g,t.StrictMode=o,t.Suspense=c,t.__SECRET_INTERNALS_DO_NOT_USE_OR_YOU_WILL_BE_FIRED=I,t.cloneElement=function(e,t,r){if(null===e||void 0===e)throw Error("React.cloneElement(...): The argument must be a React element, but you passed "+e+".");var a=h({},e.props),o=e.key,i=e.ref,s=e._owner;if(null!=t){if(void 0!==t.ref&&(i=t.ref,s=T.current),void 0!==t.key&&(o=""+t.key),e.type&&e.type.defaultProps)var l=e.type.defaultProps;for(u in t)S.call(t,u)&&!C.hasOwnProperty(u)&&(a[u]=void 0===t[u]&&void 0!==l?l[u]:t[u])}var u=arguments.length-2;if(1===u)a.children=r;else if(1<u){l=Array(u);for(var c=0;c<u;c++)l[c]=arguments[c+2];a.children=l}return{$$typeof:n,type:e.type,key:o,ref:i,props:a,_owner:s}},t.createContext=function(e){return(e={$$typeof:l,_currentValue:e,_currentValue2:e,_threadCount:0,Provider:null,Consumer:null,_defaultValue:null,_globalName:null}).Provider={$$typeof:s,_context:e},e.Consumer=e},t.createElement=k,t.createFactory=function(e){var t=k.bind(null,e);return t.type=e,t},t.createRef=function(){return{current:null}},t.forwardRef=function(e){return{$$typeof:u,render:e}},t.isValidElement=A,t.lazy=function(e){return{$$typeof:p,_payload:{_status:-1,_result:e},_init:E}},t.memo=function(e,t){return{$$typeof:d,type:e,compare:void 0===t?null:t}},t.startTransition=function(e){var t=N.transition;N.transition={};try{e()}finally{N.transition=t}},t.unstable_act=function(){throw Error("act(...) is not supported in production builds of React.")},t.useCallback=function(e,t){return O.current.useCallback(e,t)},t.useContext=function(e){return O.current.useContext(e)},t.useDebugValue=function(){},t.useDeferredValue=function(e){return O.current.useDeferredValue(e)},t.useEffect=function(e,t){return O.current.useEffect(e,t)},t.useId=function(){return O.current.useId()},t.useImperativeHandle=function(e,t,n){return O.current.useImperativeHandle(e,t,n)},t.useInsertionEffect=function(e,t){return O.current.useInsertionEffect(e,t)},t.useLayoutEffect=function(e,t){return O.current.useLayoutEffect(e,t)},t.useMemo=function(e,t){return O.current.useMemo(e,t)},t.useReducer=function(e,t,n){return O.current.useReducer(e,t,n)},t.useRef=function(e){return O.current.useRef(e)},t.useState=function(e){return O.current.useState(e)},t.useSyncExternalStore=function(e,t,n){return O.current.useSyncExternalStore(e,t,n)},t.useTransition=function(){return O.current.useTransition()},t.version="18.2.0"},2791:function(e,t,n){"use strict";e.exports=n(9117)},184:function(e,t,n){"use strict";e.exports=n(6374)},6813:function(e,t){"use strict";function n(e,t){var n=e.length;e.push(t);e:for(;0<n;){var r=n-1>>>1,a=e[r];if(!(0<o(a,t)))break e;e[r]=t,e[n]=a,n=r}}function r(e){return 0===e.length?null:e[0]}function a(e){if(0===e.length)return null;var t=e[0],n=e.pop();if(n!==t){e[0]=n;e:for(var r=0,a=e.length,i=a>>>1;r<i;){var s=2*(r+1)-1,l=e[s],u=s+1,c=e[u];if(0>o(l,n))u<a&&0>o(c,l)?(e[r]=c,e[u]=n,r=u):(e[r]=l,e[s]=n,r=s);else{if(!(u<a&&0>o(c,n)))break e;e[r]=c,e[u]=n,r=u}}}return t}function o(e,t){var n=e.sortIndex-t.sortIndex;return 0!==n?n:e.id-t.id}if("object"===typeof performance&&"function"===typeof performance.now){var i=performance;t.unstable_now=function(){return i.now()}}else{var s=Date,l=s.now();t.unstable_now=function(){return s.now()-l}}var u=[],c=[],d=1,p=null,f=3,m=!1,h=!1,v=!1,y="function"===typeof setTimeout?setTimeout:null,b="function"===typeof clearTimeout?clearTimeout:null,g="undefined"!==typeof setImmediate?setImmediate:null;function _(e){for(var t=r(c);null!==t;){if(null===t.callback)a(c);else{if(!(t.startTime<=e))break;a(c),t.sortIndex=t.expirationTime,n(u,t)}t=r(c)}}function w(e){if(v=!1,_(e),!h)if(null!==r(u))h=!0,N(S);else{var t=r(c);null!==t&&I(w,t.startTime-e)}}function S(e,n){h=!1,v&&(v=!1,b(A),A=-1),m=!0;var o=f;try{for(_(n),p=r(u);null!==p&&(!(p.expirationTime>n)||e&&!R());){var i=p.callback;if("function"===typeof i){p.callback=null,f=p.priorityLevel;var s=i(p.expirationTime<=n);n=t.unstable_now(),"function"===typeof s?p.callback=s:p===r(u)&&a(u),_(n)}else a(u);p=r(u)}if(null!==p)var l=!0;else{var d=r(c);null!==d&&I(w,d.startTime-n),l=!1}return l}finally{p=null,f=o,m=!1}}"undefined"!==typeof navigator&&void 0!==navigator.scheduling&&void 0!==navigator.scheduling.isInputPending&&navigator.scheduling.isInputPending.bind(navigator.scheduling);var T,C=!1,k=null,A=-1,x=5,F=-1;function R(){return!(t.unstable_now()-F<x)}function P(){if(null!==k){var e=t.unstable_now();F=e;var n=!0;try{n=k(!0,e)}finally{n?T():(C=!1,k=null)}}else C=!1}if("function"===typeof g)T=function(){g(P)};else if("undefined"!==typeof MessageChannel){var E=new MessageChannel,O=E.port2;E.port1.onmessage=P,T=function(){O.postMessage(null)}}else T=function(){y(P,0)};function N(e){k=e,C||(C=!0,T())}function I(e,n){A=y((function(){e(t.unstable_now())}),n)}t.unstable_IdlePriority=5,t.unstable_ImmediatePriority=1,t.unstable_LowPriority=4,t.unstable_NormalPriority=3,t.unstable_Profiling=null,t.unstable_UserBlockingPriority=2,t.unstable_cancelCallback=function(e){e.callback=null},t.unstable_continueExecution=function(){h||m||(h=!0,N(S))},t.unstable_forceFrameRate=function(e){0>e||125<e?console.error("forceFrameRate takes a positive int between 0 and 125, forcing frame rates higher than 125 fps is not supported"):x=0<e?Math.floor(1e3/e):5},t.unstable_getCurrentPriorityLevel=function(){return f},t.unstable_getFirstCallbackNode=function(){return r(u)},t.unstable_next=function(e){switch(f){case 1:case 2:case 3:var t=3;break;default:t=f}var n=f;f=t;try{return e()}finally{f=n}},t.unstable_pauseExecution=function(){},t.unstable_requestPaint=function(){},t.unstable_runWithPriority=function(e,t){switch(e){case 1:case 2:case 3:case 4:case 5:break;default:e=3}var n=f;f=e;try{return t()}finally{f=n}},t.unstable_scheduleCallback=function(e,a,o){var i=t.unstable_now();switch("object"===typeof o&&null!==o?o="number"===typeof(o=o.delay)&&0<o?i+o:i:o=i,e){case 1:var s=-1;break;case 2:s=250;break;case 5:s=1073741823;break;case 4:s=1e4;break;default:s=5e3}return e={id:d++,callback:a,priorityLevel:e,startTime:o,expirationTime:s=o+s,sortIndex:-1},o>i?(e.sortIndex=o,n(c,e),null===r(u)&&e===r(c)&&(v?(b(A),A=-1):v=!0,I(w,o-i))):(e.sortIndex=s,n(u,e),h||m||(h=!0,N(S))),e},t.unstable_shouldYield=R,t.unstable_wrapCallback=function(e){var t=f;return function(){var n=f;f=t;try{return e.apply(this,arguments)}finally{f=n}}}},5296:function(e,t,n){"use strict";e.exports=n(6813)},4836:function(e){e.exports=function(e){return e&&e.__esModule?e:{default:e}},e.exports.__esModule=!0,e.exports.default=e.exports},907:function(e,t,n){"use strict";function r(e,t){(null==t||t>e.length)&&(t=e.length);for(var n=0,r=new Array(t);n<t;n++)r[n]=e[n];return r}n.d(t,{Z:function(){return r}})},4942:function(e,t,n){"use strict";function r(e,t,n){return t in e?Object.defineProperty(e,t,{value:n,enumerable:!0,configurable:!0,writable:!0}):e[t]=n,e}n.d(t,{Z:function(){return r}})},7462:function(e,t,n){"use strict";function r(){return r=Object.assign?Object.assign.bind():function(e){for(var t=1;t<arguments.length;t++){var n=arguments[t];for(var r in n)Object.prototype.hasOwnProperty.call(n,r)&&(e[r]=n[r])}return e},r.apply(this,arguments)}n.d(t,{Z:function(){return r}})},3366:function(e,t,n){"use strict";function r(e,t){if(null==e)return{};var n,r,a={},o=Object.keys(e);for(r=0;r<o.length;r++)n=o[r],t.indexOf(n)>=0||(a[n]=e[n]);return a}n.d(t,{Z:function(){return r}})},885:function(e,t,n){"use strict";n.d(t,{Z:function(){return a}});var r=n(181);function a(e,t){return function(e){if(Array.isArray(e))return e}(e)||function(e,t){var n=null==e?null:"undefined"!==typeof Symbol&&e[Symbol.iterator]||e["@@iterator"];if(null!=n){var r,a,o=[],i=!0,s=!1;try{for(n=n.call(e);!(i=(r=n.next()).done)&&(o.push(r.value),!t||o.length!==t);i=!0);}catch(l){s=!0,a=l}finally{try{i||null==n.return||n.return()}finally{if(s)throw a}}return o}}(e,t)||(0,r.Z)(e,t)||function(){throw new TypeError("Invalid attempt to destructure non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}()}},2982:function(e,t,n){"use strict";n.d(t,{Z:function(){return o}});var r=n(907);var a=n(181);function o(e){return function(e){if(Array.isArray(e))return(0,r.Z)(e)}(e)||function(e){if("undefined"!==typeof Symbol&&null!=e[Symbol.iterator]||null!=e["@@iterator"])return Array.from(e)}(e)||(0,a.Z)(e)||function(){throw new TypeError("Invalid attempt to spread non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}()}},181:function(e,t,n){"use strict";n.d(t,{Z:function(){return a}});var r=n(907);function a(e,t){if(e){if("string"===typeof e)return(0,r.Z)(e,t);var n=Object.prototype.toString.call(e).slice(8,-1);return"Object"===n&&e.constructor&&(n=e.constructor.name),"Map"===n||"Set"===n?Array.from(e):"Arguments"===n||/^(?:Ui|I)nt(?:8|16|32)(?:Clamped)?Array$/.test(n)?(0,r.Z)(e,t):void 0}}}},t={};function n(r){var a=t[r];if(void 0!==a)return a.exports;var o=t[r]={exports:{}};return e[r].call(o.exports,o,o.exports,n),o.exports}n.n=function(e){var t=e&&e.__esModule?function(){return e.default}:function(){return e};return n.d(t,{a:t}),t},function(){var e,t=Object.getPrototypeOf?function(e){return Object.getPrototypeOf(e)}:function(e){return e.__proto__};n.t=function(r,a){if(1&a&&(r=this(r)),8&a)return r;if("object"===typeof r&&r){if(4&a&&r.__esModule)return r;if(16&a&&"function"===typeof r.then)return r}var o=Object.create(null);n.r(o);var i={};e=e||[null,t({}),t([]),t(t)];for(var s=2&a&&r;"object"==typeof s&&!~e.indexOf(s);s=t(s))Object.getOwnPropertyNames(s).forEach((function(e){i[e]=function(){return r[e]}}));return i.default=function(){return r},n.d(o,i),o}}(),n.d=function(e,t){for(var r in t)n.o(t,r)&&!n.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},n.o=function(e,t){return Object.prototype.hasOwnProperty.call(e,t)},n.r=function(e){"undefined"!==typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},function(){"use strict";var e=n(2791),t=n(1250),r=n(7462),a=n(5513),o=(n(76),n(9886)),i=(n(2110),n(5438)),s=n(9140),l=n(2561),u=(0,o.w)((function(t,n){var r=t.styles,a=(0,s.O)([r],void 0,(0,e.useContext)(o.T)),u=(0,e.useRef)();return(0,l.j)((function(){var e=n.key+"-global",t=new n.sheet.constructor({key:e,nonce:n.sheet.nonce,container:n.sheet.container,speedy:n.sheet.isSpeedy}),r=!1,o=document.querySelector('style[data-emotion="'+e+" "+a.name+'"]');return n.sheet.tags.length&&(t.before=n.sheet.tags[0]),null!==o&&(r=!0,o.setAttribute("data-emotion",e),t.hydrate([o])),u.current=[t,r],function(){t.flush()}}),[n]),(0,l.j)((function(){var e=u.current,t=e[0];if(e[1])e[1]=!1;else{if(void 0!==a.next&&(0,i.My)(n,a.next,!0),t.tags.length){var r=t.tags[t.tags.length-1].nextElementSibling;t.before=r,t.flush()}n.insert("",a,t,!1)}}),[n,a.name]),null}));function c(){for(var e=arguments.length,t=new Array(e),n=0;n<e;n++)t[n]=arguments[n];return(0,s.O)(t)}var d=function(){var e=c.apply(void 0,arguments),t="animation-"+e.name;return{name:t,styles:"@keyframes "+t+"{"+e.styles+"}",anim:1,toString:function(){return"_EMO_"+this.name+"_"+this.styles+"_EMO_"}}};var p=n(184);function f(e){var t=e.styles,n=e.defaultTheme,r=void 0===n?{}:n,a="function"===typeof t?function(e){return t(void 0===(n=e)||null===n||0===Object.keys(n).length?r:e);var n}:t;return(0,p.jsx)(u,{styles:a})}var m=n(4205);var h=function(e){return(0,p.jsx)(f,(0,r.Z)({},e,{defaultTheme:m.Z}))},v=function(e,t){return(0,r.Z)({WebkitFontSmoothing:"antialiased",MozOsxFontSmoothing:"grayscale",boxSizing:"border-box",WebkitTextSizeAdjust:"100%"},t&&{colorScheme:e.palette.mode})},y=function(e){return(0,r.Z)({color:(e.vars||e).palette.text.primary},e.typography.body1,{backgroundColor:(e.vars||e).palette.background.default,"@media print":{backgroundColor:(e.vars||e).palette.common.white}})};var b=function(t){var n=(0,a.Z)({props:t,name:"MuiCssBaseline"}),o=n.children,i=n.enableColorScheme,s=void 0!==i&&i;return(0,p.jsxs)(e.Fragment,{children:[(0,p.jsx)(h,{styles:function(e){return function(e){var t,n,a={html:v(e,arguments.length>1&&void 0!==arguments[1]&&arguments[1]),"*, *::before, *::after":{boxSizing:"inherit"},"strong, b":{fontWeight:e.typography.fontWeightBold},body:(0,r.Z)({margin:0},y(e),{"&::backdrop":{backgroundColor:(e.vars||e).palette.background.default}})},o=null==(t=e.components)||null==(n=t.MuiCssBaseline)?void 0:n.styleOverrides;return o&&(a=[a,o]),a}(e,s)}}),o]})},g=n(885),_=n(4942),w=n(3366),S=n(8182),T=n(7312),C=n(1217),k=n(4419),A=n(8691),x=(0,n(4046).ZP)(),F=n(5080),R=["className","component","disableGutters","fixed","maxWidth","classes"],P=(0,F.Z)(),E=x("div",{name:"MuiContainer",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,t["maxWidth".concat((0,T.Z)(String(n.maxWidth)))],n.fixed&&t.fixed,n.disableGutters&&t.disableGutters]}}),O=function(e){return(0,A.Z)({props:e,name:"MuiContainer",defaultTheme:P})},N=function(e,t){var n=e.classes,r=e.fixed,a=e.disableGutters,o=e.maxWidth,i={root:["root",o&&"maxWidth".concat((0,T.Z)(String(o))),r&&"fixed",a&&"disableGutters"]};return(0,k.Z)(i,(function(e){return(0,C.Z)(t,e)}),n)};var I=n(9853),M=n(277),z=function(){var t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},n=t.createStyledComponent,a=void 0===n?E:n,o=t.useThemeProps,i=void 0===o?O:o,s=t.componentName,l=void 0===s?"MuiContainer":s,u=a((function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({width:"100%",marginLeft:"auto",boxSizing:"border-box",marginRight:"auto",display:"block"},!n.disableGutters&&(0,_.Z)({paddingLeft:t.spacing(2),paddingRight:t.spacing(2)},t.breakpoints.up("sm"),{paddingLeft:t.spacing(3),paddingRight:t.spacing(3)}))}),(function(e){var t=e.theme;return e.ownerState.fixed&&Object.keys(t.breakpoints.values).reduce((function(e,n){var r=n,a=t.breakpoints.values[r];return 0!==a&&(e[t.breakpoints.up(r)]={maxWidth:"".concat(a).concat(t.breakpoints.unit)}),e}),{})}),(function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({},"xs"===n.maxWidth&&(0,_.Z)({},t.breakpoints.up("xs"),{maxWidth:Math.max(t.breakpoints.values.xs,444)}),n.maxWidth&&"xs"!==n.maxWidth&&(0,_.Z)({},t.breakpoints.up(n.maxWidth),{maxWidth:"".concat(t.breakpoints.values[n.maxWidth]).concat(t.breakpoints.unit)}))})),c=e.forwardRef((function(e,t){var n=i(e),a=n.className,o=n.component,s=void 0===o?"div":o,c=n.disableGutters,d=void 0!==c&&c,f=n.fixed,m=void 0!==f&&f,h=n.maxWidth,v=void 0===h?"lg":h,y=(0,w.Z)(n,R),b=(0,r.Z)({},n,{component:s,disableGutters:d,fixed:m,maxWidth:v}),g=N(b,l);return(0,p.jsx)(u,(0,r.Z)({as:s,ownerState:b,className:(0,S.Z)(g.root,a),ref:t},y))}));return c}({createStyledComponent:(0,M.ZP)("div",{name:"MuiContainer",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,t["maxWidth".concat((0,I.Z)(String(n.maxWidth)))],n.fixed&&t.fixed,n.disableGutters&&t.disableGutters]}}),useThemeProps:function(e){return(0,a.Z)({props:e,name:"MuiContainer"})}}),D=z,L=n(2421),Z=n(104),j=n(2982),B=n(2466),W=n(114),J=["sx"];function U(e){var t,n=e.sx,a=function(e){var t={systemProps:{},otherProps:{}};return Object.keys(e).forEach((function(n){W.Gc[n]?t.systemProps[n]=e[n]:t.otherProps[n]=e[n]})),t}((0,w.Z)(e,J)),o=a.systemProps,i=a.otherProps;return t=Array.isArray(n)?[o].concat((0,j.Z)(n)):"function"===typeof n?function(){var e=n.apply(void 0,arguments);return(0,B.P)(e)?(0,r.Z)({},o,e):o}:(0,r.Z)({},o,n),(0,r.Z)({},i,{sx:t})}var V=n(886),$=["className","component"];var H=n(5902),G=n(4360),q=function(){var t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},n=t.defaultTheme,a=t.defaultClassName,o=void 0===a?"MuiBox-root":a,i=t.generateClassName,s=t.styleFunctionSx,l=void 0===s?Z.Z:s,u=(0,L.ZP)("div",{shouldForwardProp:function(e){return"theme"!==e&&"sx"!==e&&"as"!==e}})(l),c=e.forwardRef((function(e,t){var a=(0,V.Z)(n),s=U(e),l=s.className,c=s.component,d=void 0===c?"div":c,f=(0,w.Z)(s,$);return(0,p.jsx)(u,(0,r.Z)({as:d,ref:t,className:(0,S.Z)(l,i?i(o):o),theme:a},f))}));return c}({defaultTheme:(0,G.Z)(),defaultClassName:"MuiBox-root",generateClassName:H.Z.generate}),K=q,Q=JSON.parse('{"e":0,"C":[{"nctid":"NCT03575351","version_a":11,"version_b":12,"version_a_date":"2019-01-24","version_b_date":"2019-02-28","pom_a":[{"label":"1.","content":"Event-free survival (EFS)[ Time Frame: Approximately 3 years ]Time from randomization to death from any cause, progressive disease (PD), as assessed by the independent review committee (IRC) or start of new antineoplastic therapy, whichever occurs first"}],"pom_b":[{"label":"1.","content":"Event-free survival (EFS)[ Time Frame: Approximately 3 years ]Time from randomization to death from any cause, progressive disease (PD), failure to achieve complete response (CR) or partial response (PR), or start of new antineoplastic therapy due to efficacy concerns, whichever occurs first"}],"start_date":"October 23, 2018","primary_completion_date":"December 8, 2023","completion_date":"December 8, 2023","first_posted":"July 2, 2018","last_update_posted":"September 2, 2022"},{"nctid":"NCT01337089","version_a":20,"version_b":21,"version_a_date":"2016-04-13","version_b_date":"2018-03-23","pom_a":[{"label":"1.","content":"Incidence of adverse events (AEs)[ Time Frame: 6 months ]Incidence of adverse events (AEs) coded according to the MedDRA dictionary. Descriptive presentations of treatment emergent AEs will be given by preferred term and system organ class. The number of patients reporting at least one AE will be provided."}],"pom_b":[{"label":"1.","content":"Percent Of Participants With Treatment-emergent Adverse Events[ Time Frame: Baseline, Day 183 ]Treatment-emergent Adverse Events (TEAEs) were coded according to the Medical Dictionary for Regulatory Activities (MedDRA) dictionary version 17.0. A TEAE is defined as an adverse event with an onset after the start of study drug treatment. The percent of participants who experienced one or more TEAEs is reported."}],"start_date":"January 19, 2011","primary_completion_date":"January 27, 2016","completion_date":"January 27, 2016","first_posted":"April 18, 2011","results_first_posted":"April 23, 2018","last_update_posted":"April 23, 2018"},{"nctid":"NCT01773187","version_a":15,"version_b":16,"version_a_date":"2016-12-15","version_b_date":"2018-10-18","pom_a":[{"label":"1.","content":"Efficacy[ Time Frame: Baseline to Week 24 ]To compare the efficacy of pacritinib with that of best available therapy (BAT) in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF); the efficacy measure for this analysis is the proportion of patients achieving a \u2265 35% reduction in spleen volume from baseline to week 24 by magnetic resonance imaging (MRI) or computed tomography (CT)"}],"pom_b":[{"label":"1.","content":"To compare the efficacy of pacritinib with that of best available therapy (BAT)[ Time Frame: Baseline to Week 24 ]To compare the efficacy of pacritinib with that of best available therapy (BAT) in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF); the efficacy measure for this analysis is the proportion of patients achieving a \u2265 35% reduction in spleen volume from baseline to week 24 by magnetic resonance imaging (MRI) or computed tomography (CT)"}],"start_date":"January 2013","primary_completion_date":"January 2015","completion_date":"April 2016","first_posted":"January 23, 2013","results_first_posted":"September 29, 2020","last_update_posted":"September 29, 2020"},{"nctid":"NCT01773187","version_a":16,"version_b":17,"version_a_date":"2018-10-18","version_b_date":"2020-09-25","pom_a":[{"label":"1.","content":"To compare the efficacy of pacritinib with that of best available therapy (BAT)[ Time Frame: Baseline to Week 24 ]To compare the efficacy of pacritinib with that of best available therapy (BAT) in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF); the efficacy measure for this analysis is the proportion of patients achieving a \u2265 35% reduction in spleen volume from baseline to week 24 by magnetic resonance imaging (MRI) or computed tomography (CT)"}],"pom_b":[{"label":"1.","content":"Spleen Volume Reduction[ Time Frame: Baseline to Week 24 ]Number of patients achieving a \u2265 35% reduction in spleen volume from baseline to week 24 as measured by magnetic resonance imaging (MRI) or computed tomography (CT)"}],"start_date":"January 2013","primary_completion_date":"January 2015","completion_date":"April 2016","first_posted":"January 23, 2013","results_first_posted":"September 29, 2020","last_update_posted":"September 29, 2020"},{"nctid":"NCT00004259","version_a":40,"version_b":41,"version_a_date":"2006-12-06","version_b_date":"2006-12-11","pom_a":[],"pom_b":[{"label":"1.","content":"Overall survival (OS)"},{"label":"2.","content":"Time to tumor progression (TTP)"},{"label":"3.","content":"Toxicity"},{"label":"4.","content":"Correlation of molecular analyses with OS and TTP"}],"start_date":"June 2000","primary_completion_date":"February 1, 2015","completion_date":"May 14, 2018","first_posted":"January 27, 2003","results_first_posted":"November 13, 2017","last_update_posted":"September 12, 2019"},{"nctid":"NCT00004259","version_a":62,"version_b":63,"version_a_date":"2012-08-03","version_b_date":"2013-12-10","pom_a":[{"label":"1.","content":"Overall survival (OS)"},{"label":"2.","content":"Time to tumor progression (TTP)"},{"label":"3.","content":"Toxicity"},{"label":"4.","content":"Correlation of molecular analyses with OS and TTP"}],"pom_b":[{"label":"1.","content":"Overall survival (OS)[ Time Frame: From randomization to date of death or last follow-up. Analysis occurs after 155 deaths have been reported. ]"}],"start_date":"June 2000","primary_completion_date":"February 1, 2015","completion_date":"May 14, 2018","first_posted":"January 27, 2003","results_first_posted":"November 13, 2017","last_update_posted":"September 12, 2019"},{"nctid":"NCT00004259","version_a":65,"version_b":66,"version_a_date":"2016-09-28","version_b_date":"2017-10-11","pom_a":[{"label":"1.","content":"Overall survival (OS)[ Time Frame: From randomization to date of death or last follow-up. Analysis occurs after 155 deaths have been reported. ]"}],"pom_b":[{"label":"1.","content":"(Phase III) Overall Survival (OS)[ Time Frame: From randomization to date of death. Patients are followed until death. Analysis occurs after 155 deaths have been reported, estimated at 5.5 years from the study opening. ]Survival time is defined as time from randomization to date of death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. Per the protocol, the pilot arms were not included in the Phase III analyses."},{"label":"2.","content":"(Phase I) Number of Subjects With Dose Limiting Toxicities (DLT) on the Two Pilot Arms[ Time Frame: From start of treatment to 3 months ]Adverse events were graded using CTCAE v2.0. Grade refers to the severity of the adverse event (AE). The CTCAE v2.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE. Dose limiting toxicity (DLT) was defined as grade 3+ pulmonary toxicity, grade 4+ thrombocytopenia (< 25,000 for 5 days), neutropenia (< 500/microl for 7 days), or neutropenia of any duration with fever requiring hospital admission after one dose reduction of 50% in BCNU. A 20% rate of grade 3+ pulmonary toxicities or a 40% rate of grade 4+ thrombocytopenia and neutropenia was considered unacceptable for a treatment arm combining RT, TMZ, and BCNU."}],"start_date":"June 2000","primary_completion_date":"February 1, 2015","completion_date":"May 14, 2018","first_posted":"January 27, 2003","results_first_posted":"November 13, 2017","last_update_posted":"September 12, 2019"},{"nctid":"NCT02760433","version_a":7,"version_b":8,"version_a_date":"2016-12-16","version_b_date":"2017-03-01","pom_a":[{"label":"1.","content":"ACR20 response[ Time Frame: at Week 14 ]A responder is defined as any subject satisfying ACR20 criteria and remaining on randomized treatment and in the study at Week 14. This endpoint will serve to demonstrate that the efficacy of OKZ is superior to placebo."}],"pom_b":[{"label":"1.","content":"ACR20 response[ Time Frame: at Week 12 ]A responder is defined as any subject satisfying ACR20 criteria and remaining on randomized treatment and in the study at Week 12. This endpoint will serve to demonstrate that the efficacy of OKZ is superior to placebo."}],"start_date":"January 9, 2017","primary_completion_date":"September 12, 2019","completion_date":"October 1, 2019","first_posted":"May 3, 2016","results_first_posted":"July 21, 2021","last_update_posted":"July 21, 2021"},{"nctid":"NCT02760433","version_a":16,"version_b":17,"version_a_date":"2020-09-15","version_b_date":"2021-06-30","pom_a":[{"label":"1.","content":"ACR20 response[ Time Frame: at Week 12 ]A responder is defined as any subject satisfying ACR20 criteria and remaining on randomized treatment and in the study at Week 12. This endpoint will serve to demonstrate that the efficacy of OKZ is superior to placebo."}],"pom_b":[{"label":"1.","content":"ACR20 Response[ Time Frame: at Week 12 ]The difference between OKZ and placebo in the percentage of subjects achieving an ACR20 response and remaining on randomized treatment and in the study at Week 12. A responder is defined as any subject satisfying ACR20 criteria and remaining on randomized treatment and in the study at Week 12.American College of Rheumatology 20 % response is a composite defined as a \u2265 20% improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a \u226520% improvement from baseline in at least 3 of the 5 remaining core set measures:Patient Global Assessment of Disease Activity (VAS)Patient Assessment of Pain (VAS)HAQ-DIPhysician Global Assessment (VAS)Level of acute phase reactant (CRP)"}],"start_date":"January 9, 2017","primary_completion_date":"September 12, 2019","completion_date":"October 1, 2019","first_posted":"May 3, 2016","results_first_posted":"July 21, 2021","last_update_posted":"July 21, 2021"},{"nctid":"NCT00002920","version_a":14,"version_b":15,"version_a_date":"2011-07-21","version_b_date":"2012-10-30","pom_a":[],"pom_b":[{"label":"1.","content":"Endometrial pathologic diagnosis[ Time Frame: 2 years after registration ]Endometrial pathologic diagnosis at 2 years after registration"}],"start_date":"March 1997","primary_completion_date":"December 2006","completion_date":"December 2009","first_posted":"January 27, 2003","last_update_posted":"October 31, 2012"},{"nctid":"NCT02569996","version_a":1,"version_b":2,"version_a_date":"2015-10-05","version_b_date":"2015-11-05","pom_a":[{"label":"1.","content":"Event-free survival[ Time Frame: Up to approximately 5 years ]"}],"pom_b":[{"label":"1.","content":"Event-free Survival[ Time Frame: From randomization to the time to progression, relapse, death from any cause, or institution of a new treatment, whichever occurs first, assessed up to 5 years ]Event-free survival (EFS) was defined as the time from baseline (Week 0) to the time to progression, relapse, death from any cause, or institution of a new treatment, whichever occurs first. Mean EFS was estimated by the Kaplan-Meier estimation and provided with their 95% confidence interval. ITT population (patients who received at least one maintenance MabThera infusion) was used for this analysis."}],"start_date":"July 2005","primary_completion_date":"August 2013","completion_date":"August 2013","first_posted":"October 7, 2015","results_first_posted":"December 10, 2015","last_update_posted":"December 10, 2015"},{"nctid":"NCT02426125","version_a":48,"version_b":49,"version_a_date":"2017-07-26","version_b_date":"2017-08-15","pom_a":[{"label":"1.","content":"Progression Free Survival[ Time Frame: Randomization to Radiological Disease Progression or Death from Any Cause (Approximately 19 Months) ]"}],"pom_b":[{"label":"1.","content":"Progression Free Survival[ Time Frame: Randomization to Radiological Disease Progression or Death from Any Cause (Approximately 19 Months) ]Progression Free Survival"}],"start_date":"July 13, 2015","primary_completion_date":"April 21, 2017","completion_date":"July 26, 2022","first_posted":"April 24, 2015","results_first_posted":"March 8, 2019","last_update_posted":"August 2, 2022"},{"nctid":"NCT02426125","version_a":55,"version_b":56,"version_a_date":"2018-11-19","version_b_date":"2019-03-06","pom_a":[{"label":"1.","content":"Progression Free Survival[ Time Frame: Randomization to Radiological Disease Progression or Death from Any Cause (Approximately 19 Months) ]Progression Free Survival"}],"pom_b":[{"label":"1.","content":"Progression Free Survival (PFS)[ Time Frame: Randomization to Radiological Disease Progression or Death from Any Cause (Up to 18 Months) ]PFS defined as time from first day of therapy to first evidence of disease progression defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1) or death from any cause. Progressive Disease (PD) is at least 20% increase in sum of diameters of target lesions, with reference being the smallest sum on study and plus absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If participant does not have complete baseline disease assessment, then PFS time was censored at date of first dose, regardless of whether or not objectively determined disease progression or death has been observed for participant. If participant is not known to have died or have objective progression as of data inclusion cutoff date for analysis, PFS time was censored at last adequate tumor assessment date."}],"start_date":"July 13, 2015","primary_completion_date":"April 21, 2017","completion_date":"July 26, 2022","first_posted":"April 24, 2015","results_first_posted":"March 8, 2019","last_update_posted":"August 2, 2022"},{"nctid":"NCT02970318","version_a":3,"version_b":4,"version_a_date":"2016-11-22","version_b_date":"2017-05-23","pom_a":[{"label":"1.","content":"Progression-free survival (PFS) in Arm A compared to Arm B[ Time Frame: 48 months ]"}],"pom_b":[{"label":"1.","content":"IRC-assessed progression-free survival (PFS) in Arm A compared to Arm B[ Time Frame: 48 months ]"}],"start_date":"February 2, 2017","primary_completion_date":"September 3, 2021","completion_date":"September 3, 2026","first_posted":"November 22, 2016","last_update_posted":"June 3, 2022"},{"nctid":"NCT02970318","version_a":6,"version_b":7,"version_a_date":"2019-08-14","version_b_date":"2020-02-28","pom_a":[{"label":"1.","content":"IRC-assessed progression-free survival (PFS) in Arm A compared to Arm B[ Time Frame: 48 months ]"}],"pom_b":[{"label":"1.","content":"IRC-assessed Progression-free Survival (PFS)[ Time Frame: The primary analysis was conducted after approximately 79 IRC-assessed PFS events occurred. At the time of interim analysis, the median follow-up time was 16.10 months in the acalabrutinib arm and 15.74 months in the IR/BR arm. ]The primary efficacy endpoint is progression-free survival (PFS), defined as the time from date of randomization to the date of first IRC-assessed disease progression or death due to any cause, whichever comes first. IRC assessment of PFS was conducted per IWCLL 2008 criteria (Hallek et al. 2008) with incorporation of the clarification for treatment-related lymphocytosis (Cheson et al. 2012)."}],"start_date":"February 2, 2017","primary_completion_date":"September 3, 2021","completion_date":"September 3, 2026","first_posted":"November 22, 2016","last_update_posted":"June 3, 2022"},{"nctid":"NCT02970318","version_a":7,"version_b":8,"version_a_date":"2020-02-28","version_b_date":"2021-04-29","pom_a":[{"label":"1.","content":"IRC-assessed Progression-free Survival (PFS)[ Time Frame: The primary analysis was conducted after approximately 79 IRC-assessed PFS events occurred. At the time of interim analysis, the median follow-up time was 16.10 months in the acalabrutinib arm and 15.74 months in the IR/BR arm. ]The primary efficacy endpoint is progression-free survival (PFS), defined as the time from date of randomization to the date of first IRC-assessed disease progression or death due to any cause, whichever comes first. IRC assessment of PFS was conducted per IWCLL 2008 criteria (Hallek et al. 2008) with incorporation of the clarification for treatment-related lymphocytosis (Cheson et al. 2012)."}],"pom_b":[{"label":"1.","content":"IRC-assessed progression-free survival (PFS) in Arm A compared to Arm B[ Time Frame: 48 months ]PFS, defined as the time from date of randomization to date of IRC-assessed disease progression or death due to any cause, whichever comes first. Response is per International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 20008 criteria (Hallek, et al), with clarification for treatment-related lymphocytosis (Cheson et al) 2012."}],"start_date":"February 2, 2017","primary_completion_date":"September 3, 2021","completion_date":"September 3, 2026","first_posted":"November 22, 2016","last_update_posted":"June 3, 2022"},{"nctid":"NCT00113607","version_a":5,"version_b":6,"version_a_date":"2006-06-14","version_b_date":"2006-06-23","pom_a":[],"pom_b":[{"label":"1.","content":"The primary objective of the study is to demonstrate that the combination of YONDELIS\u2122 (trabectedin) for intravenous infusion + DOXIL\xae/CAELYX\xae improves overall survival over DOXIL alone in the management of ovarian cancer in second line therapy."}],"start_date":"April 2005","primary_completion_date":"November 2010","completion_date":"November 2010","first_posted":"June 10, 2005","results_first_posted":"August 23, 2013","last_update_posted":"June 27, 2014"},{"nctid":"NCT00113607","version_a":9,"version_b":10,"version_a_date":"2007-06-06","version_b_date":"2007-12-27","pom_a":[{"label":"1.","content":"The primary objective of the study is to demonstrate that the combination of YONDELIS\u2122 (trabectedin) for intravenous infusion + DOXIL\xae/CAELYX\xae improves overall survival over DOXIL alone in the management of ovarian cancer in second line therapy."}],"pom_b":[{"label":"1.","content":"The primary objective of the study is to demonstrate that the combination of YONDELIS\u2122 (trabectedin) for intravenous infusion + DOXIL\xae/CAELYX\xae improves overall survival over DOXIL alone in the management of ovarian cancer in second line therapy.[ Time Frame: 6 months after last patient enrolled ]"}],"start_date":"April 2005","primary_completion_date":"November 2010","completion_date":"November 2010","first_posted":"June 10, 2005","results_first_posted":"August 23, 2013","last_update_posted":"June 27, 2014"},{"nctid":"NCT00113607","version_a":10,"version_b":11,"version_a_date":"2007-12-27","version_b_date":"2009-08-06","pom_a":[{"label":"1.","content":"The primary objective of the study is to demonstrate that the combination of YONDELIS\u2122 (trabectedin) for intravenous infusion + DOXIL\xae/CAELYX\xae improves overall survival over DOXIL alone in the management of ovarian cancer in second line therapy.[ Time Frame: 6 months after last patient enrolled ]"}],"pom_b":[{"label":"1.","content":"progression-free survival as assessed by independent radiology review[ Time Frame: every 8 weeks after randomization ]"}],"start_date":"April 2005","primary_completion_date":"November 2010","completion_date":"November 2010","first_posted":"June 10, 2005","results_first_posted":"August 23, 2013","last_update_posted":"June 27, 2014"},{"nctid":"NCT00113607","version_a":16,"version_b":17,"version_a_date":"2012-04-10","version_b_date":"2012-04-27","pom_a":[{"label":"1.","content":"progression-free survival as assessed by independent radiology review[ Time Frame: every 8 weeks after randomization ]"}],"pom_b":[{"label":"1.","content":"Progression-free survival as assessed by independent radiology review[ Time Frame: Every 8 weeks after randomization ]"}],"start_date":"April 2005","primary_completion_date":"November 2010","completion_date":"November 2010","first_posted":"June 10, 2005","results_first_posted":"August 23, 2013","last_update_posted":"June 27, 2014"},{"nctid":"NCT00113607","version_a":17,"version_b":18,"version_a_date":"2012-04-27","version_b_date":"2012-07-23","pom_a":[{"label":"1.","content":"Progression-free survival as assessed by independent radiology review[ Time Frame: Every 8 weeks after randomization ]"}],"pom_b":[{"label":"1.","content":"Comparing the Progression-free survival (PFS) of patients in the combination arm of trabectedin + DOXIL with DOXIL monotherapy arm[ Time Frame: Until disease progression or death ]"}],"start_date":"April 2005","primary_completion_date":"November 2010","completion_date":"November 2010","first_posted":"June 10, 2005","results_first_posted":"August 23, 2013","last_update_posted":"June 27, 2014"},{"nctid":"NCT00113607","version_a":22,"version_b":23,"version_a_date":"2013-01-30","version_b_date":"2013-06-18","pom_a":[{"label":"1.","content":"Comparing the Progression-free survival (PFS) of patients in the combination arm of trabectedin + DOXIL with DOXIL monotherapy arm[ Time Frame: Until disease progression or death ]"}],"pom_b":[{"label":"1.","content":"Progression-Free Survival (PFS): Independent Radiologist Review[ Time Frame: From the date of randomization until the date of disease progression or death, as assessed for approximately 3 years ]PFS is defined as the time between randomization and disease progression or death."}],"start_date":"April 2005","primary_completion_date":"November 2010","completion_date":"November 2010","first_posted":"June 10, 2005","results_first_posted":"August 23, 2013","last_update_posted":"June 27, 2014"},{"nctid":"NCT03480022","version_a":10,"version_b":11,"version_a_date":"2020-12-03","version_b_date":"2021-06-03","pom_a":[{"label":"1.","content":"Body weight (BW)[ Time Frame: Baseline to week 30 ]Treatment impact on percent change in BW and participants reaching >5% reduction"},{"label":"2.","content":"Free androgen index (FAI =total testosterone (T)/sex hormone binding globulin (SHBG) levels] )[ Time Frame: Baseline to week 30 ]Treatment impact on reduction of FAI"}],"pom_b":[{"label":"1.","content":"Absolute Body Weight (BW)[ Time Frame: 32 weeks of treatment ]Treatment impact on change in body weight after 32 weeks of treatment."},{"label":"2.","content":"Free Androgen Index (FAI)[ Time Frame: 32 weeks of treatment ]Drug treatment effect on free androgen levels as calculated as FAI= total testosterone (T) concentrations divided by sex hormone binding globulin (SHBG) levels. A higher score indicates a worse outcome (more androgenic)."}],"start_date":"September 26, 2018","primary_completion_date":"February 22, 2021","completion_date":"May 19, 2021","first_posted":"March 27, 2018","results_first_posted":"June 7, 2021","last_update_posted":"June 7, 2021"},{"nctid":"NCT00416208","version_a":33,"version_b":34,"version_a_date":"2009-04-30","version_b_date":"2009-05-21","pom_a":[{"label":"1.","content":"The difference in event-free survival time will be compared between both arms"}],"pom_b":[{"label":"1.","content":"The difference in event-free survival time will be compared between both arms[ Time Frame: Every 35 days during treatment phase, after 4, 8, 12, 18, 24 months during follow-up ]"}],"start_date":"October 2006","primary_completion_date":"May 2013","completion_date":"May 2013","first_posted":"December 27, 2006","last_update_posted":"March 5, 2015"},{"nctid":"NCT03673943","version_a":2,"version_b":3,"version_a_date":"2019-07-19","version_b_date":"2021-04-22","pom_a":[{"label":"1.","content":"Determine sensitivity and specificity on a per-subject basis of 64Cu-DOTATATE PET-CT imaging for detection of tumor location[ Time Frame: 12 months ]The detection of tumor location using Cu64-DOTATATE will be done in subjects with known or suspected NETs, when comparing individual reader results of PET/CT scans to a standard of truth (SOT) for each subject."}],"pom_b":[{"label":"1.","content":"Determine Sensitivity and Specificity on a Per-subject Basis of 64Cu-DOTATATE PET-CT Imaging for Detection of Tumor Location[ Time Frame: 12 months ]The co-primary effectiveness endpoints of the study were the sensitivity and specificity of 64Cu-DOTATATE PET-CT imaging when each imaging reader\'s subject-level result was compared to a SOT (standard of therapy) for the subject, with primary endpoint success defined as the same two out of three readers having sensitivity and specificity results exceeding the specified thresholds."},{"label":"Quality Control Review Comment provided by the National Library of Medicine:","content":"More than one baseline or outcome measure appears to be described, and it is unclear which measure the reported data represent."}],"start_date":"August 23, 2018","primary_completion_date":"March 23, 2019","completion_date":"March 23, 2019","first_posted":"September 17, 2018","last_update_posted":"July 23, 2019"},{"nctid":"NCT03673943","version_a":3,"version_b":4,"version_a_date":"2021-04-22","version_b_date":"2021-10-04","pom_a":[{"label":"1.","content":"Determine Sensitivity and Specificity on a Per-subject Basis of 64Cu-DOTATATE PET-CT Imaging for Detection of Tumor Location[ Time Frame: 12 months ]The co-primary effectiveness endpoints of the study were the sensitivity and specificity of 64Cu-DOTATATE PET-CT imaging when each imaging reader\'s subject-level result was compared to a SOT (standard of therapy) for the subject, with primary endpoint success defined as the same two out of three readers having sensitivity and specificity results exceeding the specified thresholds."},{"label":"Quality Control Review Comment provided by the National Library of Medicine:","content":"More than one baseline or outcome measure appears to be described, and it is unclear which measure the reported data represent."}],"pom_b":[{"label":"1.","content":"Specificity on a Per-subject Basis of 64Cu-DOTATATE PET-CT Imaging for Detection of Tumor Location[ Time Frame: 12 months ]The co-primary effectiveness endpoints of the study were the sensitivity and specificity of 64Cu-DOTATATE PET-CT imaging when each imaging reader\'s subject-level result was compared to a SOT (standard of therapy) for the subject, with primary endpoint success defined as the same two out of three readers having sensitivity and specificity results exceeding the specified thresholds."}],"start_date":"August 23, 2018","primary_completion_date":"March 23, 2019","completion_date":"March 23, 2019","first_posted":"September 17, 2018","last_update_posted":"July 23, 2019"},{"nctid":"NCT03673943","version_a":4,"version_b":5,"version_a_date":"2021-10-04","version_b_date":"2022-02-06","pom_a":[{"label":"1.","content":"Specificity on a Per-subject Basis of 64Cu-DOTATATE PET-CT Imaging for Detection of Tumor Location[ Time Frame: 12 months ]The co-primary effectiveness endpoints of the study were the sensitivity and specificity of 64Cu-DOTATATE PET-CT imaging when each imaging reader\'s subject-level result was compared to a SOT (standard of therapy) for the subject, with primary endpoint success defined as the same two out of three readers having sensitivity and specificity results exceeding the specified thresholds."}],"pom_b":[{"label":"1.","content":"Sensitivity on a Per-subject Basis of 64Cu-DOTATATE PET-CT Imaging for Detection of Tumor Location[ Time Frame: 12 months ]Three blinded readers evaluated the sensitivity of 64Cu-DOTATATE PET/CT in the detection of lesions compared with a SOT (standard of therapy) in 63 evaluable subjects with known or suspected NETs"},{"label":"2.","content":"Specificity of 64Cu- DOTATATE PET/CT for Detection of Neuroendocrine Tumor on a Per-patient Basis.[ Time Frame: 12 months ]Three blinded readers evaluated the specificity of 64Cu-DOTATATE PET/CT in the detection of lesions compared with a SOT (standard of therapy) in 63 evaluable subjects with known or suspected NETs"}],"start_date":"August 23, 2018","primary_completion_date":"March 23, 2019","completion_date":"March 23, 2019","first_posted":"September 17, 2018","last_update_posted":"July 23, 2019"},{"nctid":"NCT03673943","version_a":6,"version_b":7,"version_a_date":"2022-03-25","version_b_date":"2022-08-01","pom_a":[{"label":"1.","content":"Sensitivity on a Per-subject Basis of 64Cu-DOTATATE PET-CT Imaging for Detection of Tumor Location[ Time Frame: 12 months ]Three blinded readers evaluated the sensitivity of 64Cu-DOTATATE PET/CT in the detection of lesions compared with a SOT (standard of therapy) in 63 evaluable subjects with known or suspected NETs"},{"label":"2.","content":"Specificity of 64Cu- DOTATATE PET/CT for Detection of Neuroendocrine Tumor on a Per-patient Basis.[ Time Frame: 12 months ]Three blinded readers evaluated the specificity of 64Cu-DOTATATE PET/CT in the detection of lesions compared with a SOT (standard of therapy) in 63 evaluable subjects with known or suspected NETs"}],"pom_b":[{"label":"1.","content":"Sensitivity on a Per-subject Basis of 64Cu-DOTATATE PET-CT Imaging for Detection of Tumor Location[ Time Frame: 12 months ]Number of patients with NETs disease confirmed by SSTR(+) imaging using 64Cu-DOTATATE PET/CT and standard of care compared to the total of 63 subjects enrolled in the studies, (were 42 patients with known or suspected NET based on histology, conventional imaging, or clinical evaluations and 21 healthy volunteers)."},{"label":"2.","content":"Specificity of 64Cu- DOTATATE PET/CT for Detection of Neuroendocrine Tumor on a Per-patient Basis.[ Time Frame: 12 months ]The number of subjects who have no SSTR (+) NETs as determined by 64Cu-DOTATATE PET/CT as well as standard of care methods."}],"start_date":"August 23, 2018","primary_completion_date":"March 23, 2019","completion_date":"March 23, 2019","first_posted":"September 17, 2018","last_update_posted":"July 23, 2019"},{"nctid":"NCT02246127","version_a":3,"version_b":4,"version_a_date":"2015-06-23","version_b_date":"2015-11-03","pom_a":[{"label":"1.","content":"Second Progression Free Survival (second PFS)[ Time Frame: Up to 84 weeks ]PFS of Course 1 (PFS1) + interval between treatments + PFS of Course 2 (PFS2), where PFS1 represents progression free survival of Course 1 and PFS2 represents progression free survival of Course 2"}],"pom_b":[{"label":"1.","content":"Second Progression Free Survival (second PFS)[ Time Frame: Up to 140 +/- 8 weeks ]PFS of Course 1 (PFS1) + interval between treatments + PFS of Course 2 (PFS2), where PFS1 represents progression free survival of Course 1 and PFS2 represents progression free survival of Course 2"}],"start_date":"October 27, 2014","primary_completion_date":"December 2019","completion_date":"July 2021","first_posted":"September 22, 2014","last_update_posted":"March 5, 2020"},{"nctid":"NCT02246127","version_a":6,"version_b":7,"version_a_date":"2019-04-16","version_b_date":"2020-03-03","pom_a":[{"label":"1.","content":"Second Progression Free Survival (second PFS)[ Time Frame: Up to 140 +/- 8 weeks ]PFS of Course 1 (PFS1) + interval between treatments + PFS of Course 2 (PFS2), where PFS1 represents progression free survival of Course 1 and PFS2 represents progression free survival of Course 2"}],"pom_b":[{"label":"1.","content":"First Progression free survival[ Time Frame: At 12 months ]Proportion of patients who are alive without progression to Course 1 from the date of randomization in STZ based CT vs Everolimus arms"}],"start_date":"October 27, 2014","primary_completion_date":"December 2019","completion_date":"July 2021","first_posted":"September 22, 2014","last_update_posted":"March 5, 2020"},{"nctid":"NCT00357734","version_a":9,"version_b":10,"version_a_date":"2010-12-03","version_b_date":"2011-12-06","pom_a":[{"label":"1.","content":"To assess the long-term safety profile and the secondary objective to estimate clinical benefit of ZD1839."}],"pom_b":[{"label":"1.","content":"To assess the long-term safety profile and the secondary objective to estimate clinical benefit of ZD1839.[ Time Frame: Until 30 days after the last dose of trial drug ]Any AEs and SAEs occurring during treatment and any SAEs occurring within 30 days after stopping the trial drug must be followed to resolution unless, in the investigator\'s opinion, the condition is unlikely to resolve because of the patient\'s underlying disease"}],"start_date":"January 2005","primary_completion_date":"May 2015","completion_date":"May 2015","first_posted":"July 27, 2006","results_first_posted":"June 23, 2016","last_update_posted":"August 30, 2016"},{"nctid":"NCT00357734","version_a":23,"version_b":24,"version_a_date":"2015-02-12","version_b_date":"2015-05-13","pom_a":[{"label":"1.","content":"To assess the long-term safety profile and the secondary objective to estimate clinical benefit of ZD1839.[ Time Frame: Until 30 days after the last dose of trial drug ]Any AEs and SAEs occurring during treatment and any SAEs occurring within 30 days after stopping the trial drug must be followed to resolution unless, in the investigator\'s opinion, the condition is unlikely to resolve because of the patient\'s underlying disease"}],"pom_b":[],"start_date":"January 2005","primary_completion_date":"May 2015","completion_date":"May 2015","first_posted":"July 27, 2006","results_first_posted":"June 23, 2016","last_update_posted":"August 30, 2016"},{"nctid":"NCT00357734","version_a":24,"version_b":25,"version_a_date":"2015-05-13","version_b_date":"2015-06-03","pom_a":[],"pom_b":[{"label":"1.","content":"To assess the long-term safety profile and the secondary objective to estimate clinical benefit of ZD1839.[ Time Frame: Until 30 days after the last dose of trial drug ]Any AEs and SAEs occurring during treatment and any SAEs occurring within 30 days after stopping the trial drug must be followed to resolution unless, in the investigator\'s opinion, the condition is unlikely to resolve because of the patient\'s underlying disease"}],"start_date":"January 2005","primary_completion_date":"May 2015","completion_date":"May 2015","first_posted":"July 27, 2006","results_first_posted":"June 23, 2016","last_update_posted":"August 30, 2016"},{"nctid":"NCT00357734","version_a":25,"version_b":26,"version_a_date":"2015-06-03","version_b_date":"2016-05-17","pom_a":[{"label":"1.","content":"To assess the long-term safety profile and the secondary objective to estimate clinical benefit of ZD1839.[ Time Frame: Until 30 days after the last dose of trial drug ]Any AEs and SAEs occurring during treatment and any SAEs occurring within 30 days after stopping the trial drug must be followed to resolution unless, in the investigator\'s opinion, the condition is unlikely to resolve because of the patient\'s underlying disease"}],"pom_b":[{"label":"1.","content":"To Assess the Long-term Safety Profile of ZD1839 Therapy by Assessing the Incidence of Adverse Events[ Time Frame: Until 30 days after the last dose of trial drug ]Any adverse events (AEs) and serious adverse events (SAEs) occurring during treatment and any SAEs occurring within 30 days after stopping the trial drug must be followed to resolution unless, in the investigator\'s opinion, the condition is unlikely to resolve because of the patient\'s underlying disease"}],"start_date":"January 2005","primary_completion_date":"May 2015","completion_date":"May 2015","first_posted":"July 27, 2006","results_first_posted":"June 23, 2016","last_update_posted":"August 30, 2016"},{"nctid":"NCT00357734","version_a":26,"version_b":27,"version_a_date":"2016-05-17","version_b_date":"2016-07-21","pom_a":[{"label":"1.","content":"To Assess the Long-term Safety Profile of ZD1839 Therapy by Assessing the Incidence of Adverse Events[ Time Frame: Until 30 days after the last dose of trial drug ]Any adverse events (AEs) and serious adverse events (SAEs) occurring during treatment and any SAEs occurring within 30 days after stopping the trial drug must be followed to resolution unless, in the investigator\'s opinion, the condition is unlikely to resolve because of the patient\'s underlying disease"}],"pom_b":[{"label":"1.","content":"Number of Serious Adverse Events (SAEs)[ Time Frame: Serious adverse events (SAEs) and non-serious AEs were collected from the start of study treatment until 30 days after the last dose of study treatment or 30 days after last visit (up to approximately 120 months) ]Assessment of the long-term safety profile of ZD1839 therapy by assessing the incidence of adverse events. Any adverse events (AEs) and serious adverse events (SAEs) occurring during treatment and any SAEs occurring within 30 days after stopping the trial drug must be followed to resolution unless, in the investigator\'s opinion, the condition is unlikely to resolve because of the patient\'s underlying disease"},{"label":"2.","content":"Number of Seroius Adverse Events (SAEs) Related to ZD1839[ Time Frame: Serious adverse events (SAEs) and non-serious AEs were collected from the start of study treatment until 30 days after the last dose of study treatment or 30 days after last visit (up to approximately 120 months) ]Assessment of the long-term safety profile of ZD1839 therapy by assessing the incidence of adverse events. Any adverse events (AEs) and serious adverse events (SAEs) occurring during treatment and any SAEs occurring within 30 days after stopping the trial drug must be followed to resolution unless, in the investigator\'s opinion, the condition is unlikely to resolve because of the patient\'s underlying disease."},{"label":"3.","content":"Number of Other Adverse Events (AEs)[ Time Frame: Serious adverse events (SAEs) and non-serious AEs were collected from the start of study treatment until 30 days after the last dose of study treatment or 30 days after last visit (up to approximately 120 months) ]Assessment of the long-term safety profile of ZD1839 therapy by assessing the incidence of adverse events. Any adverse events (AEs) and serious adverse events (SAEs) occurring during treatment and any SAEs occurring within 30 days after stopping the trial drug must be followed to resolution unless, in the investigator\'s opinion, the condition is unlikely to resolve because of the patient\'s underlying disease."},{"label":"4.","content":"Number of Other Adverse Events (AEs) Related to ZD1839[ Time Frame: Serious adverse events (SAEs) and non-serious AEs were collected from the start of study treatment until 30 days after the last dose of study treatment or 30 days after last visit (up to approximately 120 months) ]Assessment of the long-term safety profile of ZD1839 therapy by assessing the incidence of adverse events. Any adverse events (AEs) and serious adverse events (SAEs) occurring during treatment and any SAEs occurring within 30 days after stopping the trial drug must be followed to resolution unless, in the investigator\'s opinion, the condition is unlikely to resolve because of the patient\'s underlying disease."}],"start_date":"January 2005","primary_completion_date":"May 2015","completion_date":"May 2015","first_posted":"July 27, 2006","results_first_posted":"June 23, 2016","last_update_posted":"August 30, 2016"},{"nctid":"NCT00357734","version_a":27,"version_b":28,"version_a_date":"2016-07-21","version_b_date":"2016-08-29","pom_a":[{"label":"1.","content":"Number of Serious Adverse Events (SAEs)[ Time Frame: Serious adverse events (SAEs) and non-serious AEs were collected from the start of study treatment until 30 days after the last dose of study treatment or 30 days after last visit (up to approximately 120 months) ]Assessment of the long-term safety profile of ZD1839 therapy by assessing the incidence of adverse events. Any adverse events (AEs) and serious adverse events (SAEs) occurring during treatment and any SAEs occurring within 30 days after stopping the trial drug must be followed to resolution unless, in the investigator\'s opinion, the condition is unlikely to resolve because of the patient\'s underlying disease"},{"label":"2.","content":"Number of Seroius Adverse Events (SAEs) Related to ZD1839[ Time Frame: Serious adverse events (SAEs) and non-serious AEs were collected from the start of study treatment until 30 days after the last dose of study treatment or 30 days after last visit (up to approximately 120 months) ]Assessment of the long-term safety profile of ZD1839 therapy by assessing the incidence of adverse events. Any adverse events (AEs) and serious adverse events (SAEs) occurring during treatment and any SAEs occurring within 30 days after stopping the trial drug must be followed to resolution unless, in the investigator\'s opinion, the condition is unlikely to resolve because of the patient\'s underlying disease."},{"label":"3.","content":"Number of Other Adverse Events (AEs)[ Time Frame: Serious adverse events (SAEs) and non-serious AEs were collected from the start of study treatment until 30 days after the last dose of study treatment or 30 days after last visit (up to approximately 120 months) ]Assessment of the long-term safety profile of ZD1839 therapy by assessing the incidence of adverse events. Any adverse events (AEs) and serious adverse events (SAEs) occurring during treatment and any SAEs occurring within 30 days after stopping the trial drug must be followed to resolution unless, in the investigator\'s opinion, the condition is unlikely to resolve because of the patient\'s underlying disease."},{"label":"4.","content":"Number of Other Adverse Events (AEs) Related to ZD1839[ Time Frame: Serious adverse events (SAEs) and non-serious AEs were collected from the start of study treatment until 30 days after the last dose of study treatment or 30 days after last visit (up to approximately 120 months) ]Assessment of the long-term safety profile of ZD1839 therapy by assessing the incidence of adverse events. Any adverse events (AEs) and serious adverse events (SAEs) occurring during treatment and any SAEs occurring within 30 days after stopping the trial drug must be followed to resolution unless, in the investigator\'s opinion, the condition is unlikely to resolve because of the patient\'s underlying disease."}],"pom_b":[{"label":"1.","content":"Number of Serious Adverse Events (SAEs)[ Time Frame: Serious adverse events (SAEs) and non-serious AEs were collected from the start of study treatment until 30 days after the last dose of study treatment or 30 days after last visit (up to approximately 120 months) ]Assessment of the long-term safety profile of ZD1839 therapy by assessing the incidence of adverse events. Any adverse events (AEs) and serious adverse events (SAEs) occurring during treatment and any SAEs occurring within 30 days after stopping the trial drug must be followed to resolution unless, in the investigator\'s opinion, the condition is unlikely to resolve because of the patient\'s underlying disease"},{"label":"2.","content":"Number of Serious Adverse Events (SAEs) Related to ZD1839[ Time Frame: Serious adverse events (SAEs) and non-serious AEs were collected from the start of study treatment until 30 days after the last dose of study treatment or 30 days after last visit (up to approximately 120 months) ]Assessment of the long-term safety profile of ZD1839 therapy by assessing the incidence of adverse events. Any adverse events (AEs) and serious adverse events (SAEs) occurring during treatment and any SAEs occurring within 30 days after stopping the trial drug must be followed to resolution unless, in the investigator\'s opinion, the condition is unlikely to resolve because of the patient\'s underlying disease."},{"label":"3.","content":"Number of Other Adverse Events (AEs)[ Time Frame: Serious adverse events (SAEs) and non-serious AEs were collected from the start of study treatment until 30 days after the last dose of study treatment or 30 days after last visit (up to approximately 120 months) ]Assessment of the long-term safety profile of ZD1839 therapy by assessing the incidence of adverse events. Any adverse events (AEs) and serious adverse events (SAEs) occurring during treatment and any SAEs occurring within 30 days after stopping the trial drug must be followed to resolution unless, in the investigator\'s opinion, the condition is unlikely to resolve because of the patient\'s underlying disease."},{"label":"4.","content":"Number of Other Adverse Events (AEs) Related to ZD1839[ Time Frame: Serious adverse events (SAEs) and non-serious AEs were collected from the start of study treatment until 30 days after the last dose of study treatment or 30 days after last visit (up to approximately 120 months) ]Assessment of the long-term safety profile of ZD1839 therapy by assessing the incidence of adverse events. Any adverse events (AEs) and serious adverse events (SAEs) occurring during treatment and any SAEs occurring within 30 days after stopping the trial drug must be followed to resolution unless, in the investigator\'s opinion, the condition is unlikely to resolve because of the patient\'s underlying disease."}],"start_date":"January 2005","primary_completion_date":"May 2015","completion_date":"May 2015","first_posted":"July 27, 2006","results_first_posted":"June 23, 2016","last_update_posted":"August 30, 2016"},{"nctid":"NCT03512197","version_a":87,"version_b":88,"version_a_date":"2022-01-24","version_b_date":"2022-02-11","pom_a":[{"label":"1.","content":"Event Free Survival (EFS)[ Time Frame: From date of Randomization up to 5 years of follow-up ]EFS is defined as the time from randomization to failure to obtain a Complete Remission (CR) or Morphologic Complete Remission without hematopoietic recovery (CRi) with adequate blood count recovery(adequate for treatment continuation) in induction, relapse after CR or CRi with adequate blood count recovery or death due to any cause, whichever occurs first as assessed by the investigator"}],"pom_b":[{"label":"1.","content":"Event Free Survival (EFS)[ Time Frame: From date of Randomization up to approx. 30 months ]EFS was defined as the time from randomization to failure to obtain a complete remission (CR) or Complete remission with incomplete hematologic recovery (CRi) with adequate blood count recovery in induction, relapse after CR or CRi with adequate blood countrecovery or death due to any cause, whichever occurred first as assessed by the investigator."}],"start_date":"July 20, 2018","primary_completion_date":"February 12, 2021","completion_date":"February 12, 2021","first_posted":"April 30, 2018","last_update_posted":"February 7, 2022"},{"nctid":"NCT03512197","version_a":88,"version_b":89,"version_a_date":"2022-02-11","version_b_date":"2022-04-02","pom_a":[{"label":"1.","content":"Event Free Survival (EFS)[ Time Frame: From date of Randomization up to approx. 30 months ]EFS was defined as the time from randomization to failure to obtain a complete remission (CR) or Complete remission with incomplete hematologic recovery (CRi) with adequate blood count recovery in induction, relapse after CR or CRi with adequate blood countrecovery or death due to any cause, whichever occurred first as assessed by the investigator."}],"pom_b":[{"label":"1.","content":"Event Free Survival (EFS)[ Time Frame: From date of Randomization up to approx. 30 months ]EFS was defined as the time from randomization to failure to obtain a complete remission (CR) or Complete remission with incomplete hematologic recovery (CRi) with adequate blood count recovery in induction, relapse after CR or CRi with adequate blood count recovery or death due to any cause, whichever occurred first as assessed by the investigator."}],"start_date":"July 20, 2018","primary_completion_date":"February 12, 2021","completion_date":"February 12, 2021","first_posted":"April 30, 2018","last_update_posted":"February 7, 2022"},{"nctid":"NCT04729608","version_a":8,"version_b":9,"version_a_date":"2021-09-22","version_b_date":"2021-11-17","pom_a":[{"label":"1.","content":"Anti-tumor activity of AVB-S6-500 in combination with Pac measured by progression free survival (PFS) in patients receiving AVB-S6-500+ Pac versus patients receiving Placebo+Pac[ Time Frame: 4 months ]PFS is the time interval between randomization and radiologically documented disease progression or death, whichever comes first."}],"pom_b":[{"label":"1.","content":"Anti-tumor activity of AVB-S6-500 in combination with Pac measured by progression free survival (PFS) in patients receiving AVB-S6-500 + Pac versus patients receiving Placebo+Pac[ Time Frame: 4 months ]PFS is the time interval between randomization and radiologically documented disease progression or death, whichever comes first."}],"start_date":"April 22, 2021","primary_completion_date":"July 2023","completion_date":"July 2024","first_posted":"January 28, 2021","last_update_posted":"July 1, 2022"},{"nctid":"NCT04729608","version_a":14,"version_b":15,"version_a_date":"2022-05-06","version_b_date":"2022-06-27","pom_a":[{"label":"1.","content":"Anti-tumor activity of AVB-S6-500 in combination with Pac measured by progression free survival (PFS) in patients receiving AVB-S6-500 + Pac versus patients receiving Placebo+Pac[ Time Frame: 4 months ]PFS is the time interval between randomization and radiologically documented disease progression or death, whichever comes first."}],"pom_b":[{"label":"1.","content":"Anti-tumor activity of batiraxcept in combination with PAC measured by progression free survival (PFS) in patients receiving batiraxcept + PAC versus patients receiving Placebo+PAC[ Time Frame: 4 months ]PFS is the time interval between randomization and radiologically documented disease progression or death, whichever comes first."}],"start_date":"April 22, 2021","primary_completion_date":"July 2023","completion_date":"July 2024","first_posted":"January 28, 2021","last_update_posted":"July 1, 2022"},{"nctid":"NCT01602211","version_a":1,"version_b":2,"version_a_date":"2012-05-16","version_b_date":"2012-09-24","pom_a":[{"label":"1.","content":"PHQ-8 depression score as reported on the PCA, using binary outcomes[ Time Frame: Baseline ]"},{"label":"2.","content":"PHQ-8 depression score as reported on the PCA, using binary outcomes[ Time Frame: 3 months ]"},{"label":"3.","content":"PHQ-8 depression score as reported on the PCA, using binary outcomes[ Time Frame: 12 months ]"},{"label":"4.","content":"Cancer and treatment distress (CTXD) score as reported on the PCA using binary outcomes[ Time Frame: Baseline ]"},{"label":"5.","content":"CTXD distress score as reported on the PCA using binary outcomes[ Time Frame: 3 months ]"},{"label":"6.","content":"CTXD distress score as reported on the PCA using binary outcomes[ Time Frame: 12 months ]"},{"label":"7.","content":"Proportion of survivorship and barriers to PCA using binary outcomes[ Time Frame: Baseline ]"},{"label":"8.","content":"Proportion of survivorship and barriers to PCA using binary outcomes[ Time Frame: 12 months ]"}],"pom_b":[{"label":"1.","content":"PHQ-8 depression score as reported on the PCA, using binary outcomes[ Time Frame: Up to 12 months ]"},{"label":"2.","content":"Cancer and treatment distress (CTXD) score as reported on the PCA using binary outcomes[ Time Frame: Up to 12 months ]"},{"label":"3.","content":"Proportion of adherence to recommended survivorship preventive care and barriers to PCA[ Time Frame: Up to 12 months ]"}],"start_date":"May 14, 2013","primary_completion_date":"November 28, 2016","completion_date":"November 28, 2016","first_posted":"May 18, 2012","last_update_posted":"July 31, 2020"},{"nctid":"NCT01602211","version_a":13,"version_b":14,"version_a_date":"2015-06-01","version_b_date":"2015-06-29","pom_a":[{"label":"1.","content":"PHQ-8 depression score as reported on the PCA, using binary outcomes[ Time Frame: Up to 12 months ]"},{"label":"2.","content":"Cancer and treatment distress (CTXD) score as reported on the PCA using binary outcomes[ Time Frame: Up to 12 months ]"},{"label":"3.","content":"Proportion of adherence to recommended survivorship preventive care and barriers to PCA[ Time Frame: Up to 12 months ]"}],"pom_b":[{"label":"1.","content":"Cancer and treatment distress (CTXD) score as reported on the PCA using binary outcomes[ Time Frame: Up to 12 months ]"},{"label":"2.","content":"PHQ-8 depression score as reported on the PCA, using binary outcomes[ Time Frame: Up to 12 months ]"},{"label":"3.","content":"Proportion of adherence to recommended survivorship preventive care and barriers to PCA[ Time Frame: Up to 12 months ]"}],"start_date":"May 14, 2013","primary_completion_date":"November 28, 2016","completion_date":"November 28, 2016","first_posted":"May 18, 2012","last_update_posted":"July 31, 2020"},{"nctid":"NCT02663908","version_a":12,"version_b":13,"version_a_date":"2017-04-11","version_b_date":"2017-06-13","pom_a":[{"label":"1.","content":"Time from randomization to the first confirmed (adjudicated) occurrence of the composite Major Adverse Cardiovascular Event (MACE) endpoint[ Time Frame: Up to 336 days ]Composite MACE endpoint defined as: death due to any cause, non-fatal myocardial infarction, non-fatal stroke, or non-fatal unstable angina requiring hospitalization"}],"pom_b":[{"label":"1.","content":"Time from randomization to the first confirmed (adjudicated) occurrence of the composite Major Adverse Cardiovascular Event (MACE) endpoint[ Time Frame: Up to 336 days ]Composite MACE endpoint defined as: death due to any cause, non-fatal myocardial infarction or non-fatal stroke"}],"start_date":"April 19, 2016","primary_completion_date":"March 29, 2021","completion_date":"March 29, 2021","first_posted":"January 26, 2016","results_first_posted":"June 29, 2022","last_update_posted":"June 29, 2022"},{"nctid":"NCT02663908","version_a":34,"version_b":35,"version_a_date":"2021-04-29","version_b_date":"2021-10-14","pom_a":[{"label":"1.","content":"Time from randomization to the first confirmed (adjudicated) occurrence of the composite Major Adverse Cardiovascular Event (MACE) endpoint[ Time Frame: Up to 336 days ]Composite MACE endpoint defined as: death due to any cause, non-fatal myocardial infarction or non-fatal stroke"}],"pom_b":[{"label":"1.","content":"Time from randomization to the first confirmed (adjudicated) occurrence of the composite Major Adverse Cardiovascular Event (MACE) endpoint[ Time Frame: Up to 336 days ]Time from randomization (in days) to the first confirmed (adjudicated) occurrence of the composite MACE endpoint are presented.Composite MACE endpoint was defined as: death due to any cause, non-fatal myocardial infarction or non-fatal stroke."}],"start_date":"April 19, 2016","primary_completion_date":"March 29, 2021","completion_date":"March 29, 2021","first_posted":"January 26, 2016","results_first_posted":"June 29, 2022","last_update_posted":"June 29, 2022"},{"nctid":"NCT02663908","version_a":35,"version_b":36,"version_a_date":"2021-10-14","version_b_date":"2022-06-28","pom_a":[{"label":"1.","content":"Time from randomization to the first confirmed (adjudicated) occurrence of the composite Major Adverse Cardiovascular Event (MACE) endpoint[ Time Frame: Up to 336 days ]Time from randomization (in days) to the first confirmed (adjudicated) occurrence of the composite MACE endpoint are presented.Composite MACE endpoint was defined as: death due to any cause, non-fatal myocardial infarction or non-fatal stroke."}],"pom_b":[{"label":"1.","content":"Time From Randomization to the First Confirmed (Adjudicated) Occurrence of the Composite Major Adverse Cardiovascular Event (MACE) Endpoint; Percentage of Observed Subjects With Outcome Measure Events During the Trial[ Time Frame: Randomization to Day 336 (end-of-trial) ]Composite MACE endpoint was defined as: death due to any cause, non-fatal myocardial infarction or non-fatal stroke.Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict first confirmed (adjudicated) occurrence of composite MACE over time. Percentage of observed subjects with outcome measure events during the trial are reported.Subjects were censored at the time a subject discontinued the trial, was lost to follow-up, discontinued treatment with IMP, initiated treatment with prohibited medication (including hormonal combination therapy), or at Day 336, whichever occurred first."}],"start_date":"April 19, 2016","primary_completion_date":"March 29, 2021","completion_date":"March 29, 2021","first_posted":"January 26, 2016","results_first_posted":"June 29, 2022","last_update_posted":"June 29, 2022"},{"nctid":"NCT04246177","version_a":2,"version_b":3,"version_a_date":"2020-01-31","version_b_date":"2020-04-13","pom_a":[{"label":"1.","content":"Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)[ Time Frame: Up to ~5 years ]PFS is defined as the time from randomization to the first documented progressive disease or death due to any cause, whichever occurs first. Responses are according to RECIST 1.1 as assessed by blinded independent central review (BICR). RECIST 1.1 has been modified for this study to define new intrahepatic lesions as meeting Liver Imaging Reporting and Data System version 5 (LI-RADS 5) criteria, and to include a maximum of 10 target lesions and a maximum of 5 target lesions per organ."},{"label":"2.","content":"Overall Survival (OS)[ Time Frame: Up to ~5 years ]OS is defined as the time from randomization to death due to any cause."}],"pom_b":[{"label":"1.","content":"Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)[ Time Frame: Up to ~5 years ]PFS is defined as the time from randomization to the first documented progressive disease or death due to any cause, whichever occurs first. Responses are according to RECIST 1.1 as assessed by blinded independent central review (BICR)."},{"label":"2.","content":"Overall Survival (OS)[ Time Frame: Up to ~5 years ]OS is defined as the time from randomization to death due to any cause."}],"start_date":"May 22, 2020","primary_completion_date":"April 25, 2025","completion_date":"December 31, 2029","first_posted":"January 29, 2020","last_update_posted":"September 16, 2022"},{"nctid":"NCT01301963","version_a":11,"version_b":12,"version_a_date":"2013-10-21","version_b_date":"2014-07-07","pom_a":[{"label":"1.","content":"Ability to reach target collection of 5 x 10^6 CD34+ cells/kg[ Time Frame: In =< 2 days of leukaphereses ]"}],"pom_b":[{"label":"1.","content":"Ability to Reach Target Collection of 5 x 10^6 CD34+ Cells/kg[ Time Frame: In =< 2 days of leukaphereses ]"}],"start_date":"July 2011","primary_completion_date":"June 2013","first_posted":"February 23, 2011","results_first_posted":"August 6, 2014","last_update_posted":"August 6, 2014"},{"nctid":"NCT03452137","version_a":16,"version_b":17,"version_a_date":"2019-01-07","version_b_date":"2019-01-18","pom_a":[{"label":"1.","content":"Independent Review Facility assessed Event Free Survival (IRF assessed EFS)[ Time Frame: Randomization to the first documented disease recurrence, or disease progression (per Response Evaluation Criteria In Solid Tumors (RECIST v1.1)), or death from any cause, whichever occurs first, through the end of study (approximately 64 months) ]"},{"label":"2.","content":"Overall Survival (OS) after Randomization[ Time Frame: Randomization to death from any cause, through the end of study (approximately 64 months) ]"}],"pom_b":[{"label":"1.","content":"Independent Review Facility assessed Event Free Survival (IRF assessed EFS)[ Time Frame: Randomization to the first documented disease recurrence, or disease progression (per Response Evaluation Criteria In Solid Tumors (RECIST v1.1)), or death from any cause, whichever occurs first, through the end of study (approximately 65 months) ]"},{"label":"2.","content":"Overall Survival (OS) after Randomization[ Time Frame: Randomization to death from any cause, through the end of study (approximately 65 months) ]"}],"start_date":"April 3, 2018","primary_completion_date":"September 3, 2023","completion_date":"February 1, 2025","first_posted":"March 2, 2018","last_update_posted":"August 19, 2022"},{"nctid":"NCT03452137","version_a":47,"version_b":48,"version_a_date":"2021-01-08","version_b_date":"2021-02-04","pom_a":[{"label":"1.","content":"Independent Review Facility assessed Event Free Survival (IRF assessed EFS)[ Time Frame: Randomization to the first documented disease recurrence, or disease progression (per Response Evaluation Criteria In Solid Tumors (RECIST v1.1)), or death from any cause, whichever occurs first, through the end of study (approximately 65 months) ]"},{"label":"2.","content":"Overall Survival (OS) after Randomization[ Time Frame: Randomization to death from any cause, through the end of study (approximately 65 months) ]"}],"pom_b":[{"label":"1.","content":"Investigator-assessed Event Free Survival (EFS)[ Time Frame: Randomization to the first documented disease recurrence, or disease progression (per Response Evaluation Criteria In Solid Tumors (RECIST v1.1)), or death from any cause, whichever occurs first, through the end of study (approximately 54 months) ]"},{"label":"2.","content":"Overall Survival (OS) after Randomization[ Time Frame: Randomization to death from any cause, through the end of study (approximately 54 months) ]"}],"start_date":"April 3, 2018","primary_completion_date":"September 3, 2023","completion_date":"February 1, 2025","first_posted":"March 2, 2018","last_update_posted":"August 19, 2022"},{"nctid":"NCT03452137","version_a":58,"version_b":59,"version_a_date":"2021-11-03","version_b_date":"2021-11-15","pom_a":[{"label":"1.","content":"Investigator-assessed Event Free Survival (EFS)[ Time Frame: Randomization to the first documented disease recurrence, or disease progression (per Response Evaluation Criteria In Solid Tumors (RECIST v1.1)), or death from any cause, whichever occurs first, through the end of study (approximately 54 months) ]"},{"label":"2.","content":"Overall Survival (OS) after Randomization[ Time Frame: Randomization to death from any cause, through the end of study (approximately 54 months) ]"}],"pom_b":[{"label":"1.","content":"Investigator-assessed Event Free Survival (EFS)[ Time Frame: Randomization to the first documented disease recurrence, or disease progression (per Response Evaluation Criteria In Solid Tumors (RECIST v1.1)), or death from any cause, whichever occurs first, through the end of study (approximately 65 months) ]"}],"start_date":"April 3, 2018","primary_completion_date":"September 3, 2023","completion_date":"February 1, 2025","first_posted":"March 2, 2018","last_update_posted":"August 19, 2022"},{"nctid":"NCT00281918","version_a":8,"version_b":9,"version_a_date":"2006-12-04","version_b_date":"2006-12-27","pom_a":[],"pom_b":[{"label":"1.","content":"Progression-free survival"}],"start_date":"July 2003","primary_completion_date":"July 2007","completion_date":"October 2011","first_posted":"January 25, 2006","results_first_posted":"March 29, 2011","last_update_posted":"September 19, 2013"},{"nctid":"NCT00281918","version_a":22,"version_b":23,"version_a_date":"2009-02-06","version_b_date":"2011-03-03","pom_a":[{"label":"1.","content":"Progression-free survival"}],"pom_b":[{"label":"1.","content":"Progression-free Survival (PFS)[ Time Frame: Median observation time at time of analysis was approximately 21 months ]Progression-free survival (PFS) was defined as the time between randomization and the date of first documented disease progression, relapse or death by any cause, whichever came first."}],"start_date":"July 2003","primary_completion_date":"July 2007","completion_date":"October 2011","first_posted":"January 25, 2006","results_first_posted":"March 29, 2011","last_update_posted":"September 19, 2013"},{"nctid":"NCT00281918","version_a":24,"version_b":25,"version_a_date":"2012-11-20","version_b_date":"2013-06-19","pom_a":[{"label":"1.","content":"Progression-free Survival (PFS)[ Time Frame: Median observation time at time of analysis was approximately 21 months ]Progression-free survival (PFS) was defined as the time between randomization and the date of first documented disease progression, relapse or death by any cause, whichever came first."}],"pom_b":[{"label":"1.","content":"Progression-free Survival (PFS)[ Time Frame: Median observation time at time of analysis was approximately 21 months ]Progression-free survival (PFS) was defined as the time between randomization and the date of first documented disease progression, relapse or death by any cause, whichever came first."},{"label":"2.","content":"Final Analysis: Time to Progression-free Survival Event[ Time Frame: Median observation time was approximately 66.4 months ]Progression-free survival was defined as the time between randomization and the date of first documented disease progression, relapse or death by any cause, whichever came first."}],"start_date":"July 2003","primary_completion_date":"July 2007","completion_date":"October 2011","first_posted":"January 25, 2006","results_first_posted":"March 29, 2011","last_update_posted":"September 19, 2013"},{"nctid":"NCT00981058","version_a":1,"version_b":2,"version_a_date":"2009-09-21","version_b_date":"2009-09-29","pom_a":[{"label":"1.","content":"Overall survival[ Time Frame: every 3 months ]"}],"pom_b":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: 31 months ]"}],"start_date":"January 7, 2010","primary_completion_date":"June 17, 2013","completion_date":"July 31, 2023","first_posted":"September 22, 2009","results_first_posted":"June 27, 2016","last_update_posted":"February 11, 2022"},{"nctid":"NCT00981058","version_a":15,"version_b":16,"version_a_date":"2010-07-08","version_b_date":"2010-09-07","pom_a":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: 31 months ]"}],"pom_b":[{"label":"1.","content":"Overall Survival time (OS)[ Time Frame: 31 months (placeholder actual timeframe driven by events) ]Overall survival time is measured as randomization to date of death from any cause. Participants who are alive when the study achieves 723 deaths or is lost to follow-up will have their overall survival time censored on the last date the participant is known to be alive."}],"start_date":"January 7, 2010","primary_completion_date":"June 17, 2013","completion_date":"July 31, 2023","first_posted":"September 22, 2009","results_first_posted":"June 27, 2016","last_update_posted":"February 11, 2022"},{"nctid":"NCT00981058","version_a":16,"version_b":17,"version_a_date":"2010-09-07","version_b_date":"2010-09-14","pom_a":[{"label":"1.","content":"Overall Survival time (OS)[ Time Frame: 31 months (placeholder actual timeframe driven by events) ]Overall survival time is measured as randomization to date of death from any cause. Participants who are alive when the study achieves 723 deaths or is lost to follow-up will have their overall survival time censored on the last date the participant is known to be alive."}],"pom_b":[{"label":"1.","content":"Overall Survival time (OS)[ Time Frame: Approximately 31 months ]Overall survival time is measured as randomization to date of death from any cause. Participants who are alive when the study achieves 723 deaths or is lost to follow-up will have their overall survival time censored on the last date the participant is known to be alive."}],"start_date":"January 7, 2010","primary_completion_date":"June 17, 2013","completion_date":"July 31, 2023","first_posted":"September 22, 2009","results_first_posted":"June 27, 2016","last_update_posted":"February 11, 2022"},{"nctid":"NCT00981058","version_a":22,"version_b":23,"version_a_date":"2010-12-09","version_b_date":"2011-02-01","pom_a":[{"label":"1.","content":"Overall Survival time (OS)[ Time Frame: Approximately 31 months ]Overall survival time is measured as randomization to date of death from any cause. Participants who are alive when the study achieves 723 deaths or is lost to follow-up will have their overall survival time censored on the last date the participant is known to be alive."}],"pom_b":[{"label":"1.","content":"Kaplan-Meier Estimate for Overall survival time (OS)[ Time Frame: Approximately 31 months ]Overall survival time is measured as randomization to date of death from any cause. Participants who are alive when the study achieves 723 deaths or is lost to follow-up will have their overall survival time censored on the last date the participant is known to be alive."}],"start_date":"January 7, 2010","primary_completion_date":"June 17, 2013","completion_date":"July 31, 2023","first_posted":"September 22, 2009","results_first_posted":"June 27, 2016","last_update_posted":"February 11, 2022"},{"nctid":"NCT00981058","version_a":35,"version_b":36,"version_a_date":"2011-12-27","version_b_date":"2012-02-29","pom_a":[{"label":"1.","content":"Kaplan-Meier Estimate for Overall survival time (OS)[ Time Frame: Approximately 31 months ]Overall survival time is measured as randomization to date of death from any cause. Participants who are alive when the study achieves 723 deaths or is lost to follow-up will have their overall survival time censored on the last date the participant is known to be alive."}],"pom_b":[{"label":"1.","content":"Kaplan-Meier Estimate for Overall survival time (OS)[ Time Frame: Approximately 31 months ]Overall survival time is measured as randomization to date of death from any cause. Participants who are alive when the study achieves 844 deaths or is lost to follow-up will have their overall survival time censored on the last date the participant is known to be alive."}],"start_date":"January 7, 2010","primary_completion_date":"June 17, 2013","completion_date":"July 31, 2023","first_posted":"September 22, 2009","results_first_posted":"June 27, 2016","last_update_posted":"February 11, 2022"},{"nctid":"NCT00981058","version_a":45,"version_b":46,"version_a_date":"2013-11-16","version_b_date":"2014-05-20","pom_a":[{"label":"1.","content":"Kaplan-Meier Estimate for Overall survival time (OS)[ Time Frame: Approximately 31 months ]Overall survival time is measured as randomization to date of death from any cause. Participants who are alive when the study achieves 844 deaths or is lost to follow-up will have their overall survival time censored on the last date the participant is known to be alive."}],"pom_b":[{"label":"1.","content":"Overall survival time (OS)[ Time Frame: Approximately 31 months ]Overall survival time is measured as randomization to date of death from any cause. Participants who are alive when the study achieves 844 deaths or is lost to follow-up will have their overall survival time censored on the last date the participant is known to be alive."}],"start_date":"January 7, 2010","primary_completion_date":"June 17, 2013","completion_date":"July 31, 2023","first_posted":"September 22, 2009","results_first_posted":"June 27, 2016","last_update_posted":"February 11, 2022"},{"nctid":"NCT00981058","version_a":47,"version_b":48,"version_a_date":"2014-11-11","version_b_date":"2016-05-20","pom_a":[{"label":"1.","content":"Overall survival time (OS)[ Time Frame: Approximately 31 months ]Overall survival time is measured as randomization to date of death from any cause. Participants who are alive when the study achieves 844 deaths or is lost to follow-up will have their overall survival time censored on the last date the participant is known to be alive."}],"pom_b":[{"label":"1.","content":"Overall Survival Time (OS)[ Time Frame: Randomization to Death from Any Cause (Up to 31 Months) ]Overall survival is defined as the time from randomization to death from any cause. Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive. OS was estimated by the Kaplan-Meier method."}],"start_date":"January 7, 2010","primary_completion_date":"June 17, 2013","completion_date":"July 31, 2023","first_posted":"September 22, 2009","results_first_posted":"June 27, 2016","last_update_posted":"February 11, 2022"},{"nctid":"NCT02116803","version_a":7,"version_b":8,"version_a_date":"2017-03-07","version_b_date":"2018-01-05","pom_a":[{"label":"1.","content":"Incidence and severity of adverse events[ Time Frame: Until the last patient discontinues dovitinib; anticipated 2 years ]Incidence and severity of adverse events according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03, unless otherwise specified; clinical laboratory tests, physical examinations, vital signs, ECGs, and cardiac imaging."}],"pom_b":[{"label":"1.","content":"Number of Participants With Adverse Events of Grades 3 and 4 Severity[ Time Frame: Until the last patient discontinued dovitinib up to 30 months ]Participants with grades 3 and 4 severity adverse events were assessed according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03, unless otherwise specified. AEs are provided by System Organ Class (SOC). A patient with multiple adverse events within a primary system organ class was counted only once in the total row."}],"start_date":"May 28, 2014","primary_completion_date":"November 28, 2016","completion_date":"November 28, 2016","first_posted":"April 17, 2014","results_first_posted":"February 1, 2018","last_update_posted":"March 1, 2018"},{"nctid":"NCT03197935","version_a":17,"version_b":18,"version_a_date":"2018-12-04","version_b_date":"2018-12-17","pom_a":[{"label":"1.","content":"Percentage of Participants with Pathologic Complete Response (pCR) Using American Joint Committee on Cancer (AJCC) Staging System[ Time Frame: Week 21 ]"}],"pom_b":[{"label":"1.","content":"Percentage of Participants with Pathologic Complete Response (pCR) Using American Joint Committee on Cancer (AJCC) Staging System[ Time Frame: Week 21 ]"},{"label":"2.","content":"Percentage of Participants with pCR in Subpopulation with PD-L1-Positive Tumor Status (tumor-infiltrating immune cell [IC] 1/2/3) Using AJCC Staging System[ Time Frame: Week 21 ]"}],"start_date":"July 24, 2017","primary_completion_date":"April 3, 2020","completion_date":"September 26, 2022","first_posted":"June 23, 2017","results_first_posted":"June 2, 2021","last_update_posted":"September 16, 2022"},{"nctid":"NCT03197935","version_a":37,"version_b":38,"version_a_date":"2021-01-13","version_b_date":"2021-03-29","pom_a":[{"label":"1.","content":"Percentage of Participants with Pathologic Complete Response (pCR) Using American Joint Committee on Cancer (AJCC) Staging System[ Time Frame: Week 21 ]"},{"label":"2.","content":"Percentage of Participants with pCR in Subpopulation with PD-L1-Positive Tumor Status (tumor-infiltrating immune cell [IC] 1/2/3) Using AJCC Staging System[ Time Frame: Week 21 ]"}],"pom_b":[{"label":"1.","content":"Number of Participants With Pathologic Complete Response (pCR) Using American Joint Committee on Cancer (AJCC) Staging System in ITT Population[ Time Frame: Up to data cut-off on 3 April 2020 ]Number of participants with Pathologic Complete Response (pCR) Using American Joint Committee on Cancer (AJCC) Staging System in ITT Population. pCR is defined as eradication of invasive tumor from both breast and lymph nodes (ypT0/is ypN0). Participants whose pCR assessment was missing will be counted as not achieving a pCR."},{"label":"Quality Control Review Comment provided by the National Library of Medicine:","content":"The Time Frame does not appear specific or in the correct format."},{"label":"2.","content":"Number of Participants With pCR in Subpopulation With PD-L1-Positive Tumor Status (Tumor-infiltrating Immune Cell [IC] 1/2/3) Using AJCC Staging System[ Time Frame: Up to data cut-off on 3 April 2020 ]Number of participants with Pathologic Complete Response (pCR) Using American Joint Committee on Cancer (AJCC) Staging System in the subpopulation with programmed death-ligand1 (PD-L1)-positive tumor status(tumor-infiltrating immune cell [IC] IC1/2/3) . pCR is defined as eradication of invasive tumor from both breast and lymph nodes (ypT0/is ypN0). Participants whose pCR assessment was missing will be counted as not achieving a pCR."},{"label":"Quality Control Review Comment provided by the National Library of Medicine:","content":"The Time Frame does not appear specific or in the correct format."}],"start_date":"July 24, 2017","primary_completion_date":"April 3, 2020","completion_date":"September 26, 2022","first_posted":"June 23, 2017","results_first_posted":"June 2, 2021","last_update_posted":"September 16, 2022"},{"nctid":"NCT03197935","version_a":38,"version_b":39,"version_a_date":"2021-03-29","version_b_date":"2021-05-07","pom_a":[{"label":"1.","content":"Number of Participants With Pathologic Complete Response (pCR) Using American Joint Committee on Cancer (AJCC) Staging System in ITT Population[ Time Frame: Up to data cut-off on 3 April 2020 ]Number of participants with Pathologic Complete Response (pCR) Using American Joint Committee on Cancer (AJCC) Staging System in ITT Population. pCR is defined as eradication of invasive tumor from both breast and lymph nodes (ypT0/is ypN0). Participants whose pCR assessment was missing will be counted as not achieving a pCR."},{"label":"Quality Control Review Comment provided by the National Library of Medicine:","content":"The Time Frame does not appear specific or in the correct format."},{"label":"2.","content":"Number of Participants With pCR in Subpopulation With PD-L1-Positive Tumor Status (Tumor-infiltrating Immune Cell [IC] 1/2/3) Using AJCC Staging System[ Time Frame: Up to data cut-off on 3 April 2020 ]Number of participants with Pathologic Complete Response (pCR) Using American Joint Committee on Cancer (AJCC) Staging System in the subpopulation with programmed death-ligand1 (PD-L1)-positive tumor status(tumor-infiltrating immune cell [IC] IC1/2/3) . pCR is defined as eradication of invasive tumor from both breast and lymph nodes (ypT0/is ypN0). Participants whose pCR assessment was missing will be counted as not achieving a pCR."},{"label":"Quality Control Review Comment provided by the National Library of Medicine:","content":"The Time Frame does not appear specific or in the correct format."}],"pom_b":[{"label":"1.","content":"Number of Participants With Pathologic Complete Response (pCR) Using American Joint Committee on Cancer (AJCC) Staging System in ITT Population[ Time Frame: After neoadjuvant study treatment and surgery, up to data cut-off on 03 ApriI 2020 ]Number of participants with Pathologic Complete Response (pCR) Using American Joint Committee on Cancer (AJCC) Staging System in ITT Population. pCR is defined as eradication of invasive tumor from both breast and lymph nodes (ypT0/is ypN0). pCR was evaluated for each participant after neoadjuvant study treatment and surgery. Participants whose pCR assessment was missing will be counted as not achieving a pCR."},{"label":"2.","content":"Number of Participants With pCR in Subpopulation With PD-L1-Positive Tumor Status (Tumor-infiltrating Immune Cell [IC] 1/2/3) Using AJCC Staging System[ Time Frame: After neoadjuvant study treatment and surgery, up to data cut-off on 03 ApriI 2020 ]Number of participants with Pathologic Complete Response (pCR) Using American Joint Committee on Cancer (AJCC) Staging System in the subpopulation with programmed death-ligand1 (PD-L1)-positive tumor status(tumor-infiltrating immune cell [IC] IC1/2/3) . pCR is defined as eradication of invasive tumor from both breast and lymph nodes (ypT0/is ypN0). pCR was evaluated for each participant after neoadjuvant study treatment and surgery. Participants whose pCR assessment was missing will be counted as not achieving a pCR."}],"start_date":"July 24, 2017","primary_completion_date":"April 3, 2020","completion_date":"September 26, 2022","first_posted":"June 23, 2017","results_first_posted":"June 2, 2021","last_update_posted":"September 16, 2022"},{"nctid":"NCT03665441","version_a":6,"version_b":7,"version_a_date":"2021-02-10","version_b_date":"2022-07-26","pom_a":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: 1 year after last patient randomized ]To determine whether the addition of eryaspase to chemotherapy improves OS when compared to chemotherapy alone"}],"pom_b":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: 1 year after last patient randomized ]To determine whether the addition of eryaspase to chemotherapy improves OS when compared to chemotherapy alone"},{"label":"Quality Control Review Comment provided by the National Library of Medicine:","content":"There does not appear to be sufficient information to understand the Time Frame."}],"start_date":"September 15, 2018","primary_completion_date":"August 2021","completion_date":"October 2021","first_posted":"September 11, 2018","last_update_posted":"February 15, 2021"},{"nctid":"NCT03665441","version_a":7,"version_b":8,"version_a_date":"2022-07-26","version_b_date":"2022-08-18","pom_a":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: 1 year after last patient randomized ]To determine whether the addition of eryaspase to chemotherapy improves OS when compared to chemotherapy alone"},{"label":"Quality Control Review Comment provided by the National Library of Medicine:","content":"There does not appear to be sufficient information to understand the Time Frame."}],"pom_b":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: ~12 months ]To determine whether the addition of eryaspase to chemotherapy improves OS when compared to chemotherapy alone"}],"start_date":"September 15, 2018","primary_completion_date":"August 2021","completion_date":"October 2021","first_posted":"September 11, 2018","last_update_posted":"February 15, 2021"},{"nctid":"NCT01862874","version_a":30,"version_b":31,"version_a_date":"2017-10-05","version_b_date":"2018-07-30","pom_a":[{"label":"1.","content":"Combined Incidence of HPV 6-, 11-, 16-, or 18-Related Persistent Infection[ Time Frame: Up to 36 months ]"},{"label":"2.","content":"Percentage of Participants with an Adverse Event (AE)[ Time Frame: Up to 14 days after any vaccination ]"},{"label":"3.","content":"Percentage of Participants with Vaccine-Related Serious Adverse Events (SAEs)[ Time Frame: Up to 36 Months ]"}],"pom_b":[{"label":"1.","content":"Combined Incidence of HPV Type 6, 11, 16, or 18-related Persistent Infection[ Time Frame: Up to Month 36 ]Persistent infection was defined as 1) polymerase chain reaction (PCR) positive to HPV Type 6, 11, 16, or 18 in 2 consecutive anogenital or biopsy samples collected \u22654 months apart, or 2) Pathology Panel consensus diagnosis of condyloma acuminate, penile/perianal/perineal intraepithelial neoplasia (PIN), penile, perianal, or perineal cancer and PCR detection of HPV Type 6, 11, 16, or 18 in an adjacent section and PCR positive for the same HPV type at a separate adjacent visit. The combined incidence of HPV Type 6, 11, 16, or 18 persistent infection detected in samples from \u22652 consecutive visits \u22656 months apart was assessed."},{"label":"2.","content":"Percentage of Participants With Maximum Temperature \u226537.5\xb0C Reported on the Vaccination Report Card[ Time Frame: Up to 5 days after any vaccination ]Body temperature (oral or oral equivalent) was recorded on the Vaccination Report Card (VRC). The percentage of participants with a maximum temperature \u226537.5\xb0C was summarized."},{"label":"3.","content":"Percentage of Participants With an Injection-site Adverse Event Prompted on the Vaccination Report Card[ Time Frame: Up to 5 days after any vaccination ]An adverse event (AE) is defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with study drug. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study drug or a protocol-specified procedure, whether or not considered related to the study drug or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the study drug or protocol-specified procedure is also an AE. The percentage of participants with an injection-site AE prompted on the VRC (erythema, pain, and swelling) was summarized."},{"label":"4.","content":"Percentage of Participants With a Systemic Adverse Event[ Time Frame: Up to 15 days after any vaccination ]An adverse event (AE) is defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with study drug. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study drug or a protocol-specified procedure, whether or not considered related to the study drug or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the study drug or protocol-specified procedure is also an AE. The percentage of participants with a systemic AE was summarized."},{"label":"5.","content":"Percentage of Participants With a Vaccine-related Systemic Adverse Event[ Time Frame: Up to 15 days after any vaccination ]An adverse event (AE) is defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with study drug. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study drug or a protocol-specified procedure, whether or not considered related to the study drug or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the study drug or protocol-specified procedure is also an AE. Vaccine-related AEs are those that were deemed possibly, probably, or definitely related to vaccine administration by the investigator. The percentage of participants with a vaccine-related systemic AE was summarized."}],"start_date":"June 27, 2013","primary_completion_date":"August 30, 2017","completion_date":"August 30, 2017","first_posted":"May 27, 2013","results_first_posted":"August 31, 2018","last_update_posted":"April 2, 2019"},{"nctid":"NCT00252564","version_a":9,"version_b":10,"version_a_date":"2008-02-27","version_b_date":"2010-04-08","pom_a":[],"pom_b":[{"label":"1.","content":"Progression-Free Survival (PFS)[ Time Frame: at 12-months ]"}],"start_date":"September 2005","primary_completion_date":"June 2007","completion_date":"June 2009","first_posted":"November 11, 2005","results_first_posted":"March 14, 2011","last_update_posted":"February 15, 2019"},{"nctid":"NCT00252564","version_a":10,"version_b":11,"version_a_date":"2010-04-08","version_b_date":"2011-02-15","pom_a":[{"label":"1.","content":"Progression-Free Survival (PFS)[ Time Frame: at 12-months ]"}],"pom_b":[{"label":"1.","content":"Progression-Free Survival (PFS)[ Time Frame: (no pre-determined maximum time) ]From randomization to first progression or death, whichever comes first (event); or first new anti-cancer treatment if before or without progression / death (censoring); or last follow-up date otherwise (censoring).Kaplan-Meier median PFS time and PFS rate (at 12 months)"},{"label":"2.","content":"Progression-free Survival (PFS)[ Time Frame: (no pre-determined maximum time. PFS rate at 12 months) ]From randomization to first progression or death, whichever comes first (event); or first new anti-cancer treatment if before or without progression / death (censoring); or last follow-up date otherwise (censoring).Kaplan-Meier median PFS time and PFS rate at 12 months."}],"start_date":"September 2005","primary_completion_date":"June 2007","completion_date":"June 2009","first_posted":"November 11, 2005","results_first_posted":"March 14, 2011","last_update_posted":"February 15, 2019"},{"nctid":"NCT00252564","version_a":11,"version_b":12,"version_a_date":"2011-02-15","version_b_date":"2018-09-27","pom_a":[{"label":"1.","content":"Progression-Free Survival (PFS)[ Time Frame: (no pre-determined maximum time) ]From randomization to first progression or death, whichever comes first (event); or first new anti-cancer treatment if before or without progression / death (censoring); or last follow-up date otherwise (censoring).Kaplan-Meier median PFS time and PFS rate (at 12 months)"},{"label":"2.","content":"Progression-free Survival (PFS)[ Time Frame: (no pre-determined maximum time. PFS rate at 12 months) ]From randomization to first progression or death, whichever comes first (event); or first new anti-cancer treatment if before or without progression / death (censoring); or last follow-up date otherwise (censoring).Kaplan-Meier median PFS time and PFS rate at 12 months."}],"pom_b":[{"label":"1.","content":"Progression-Free Survival (PFS)[ Time Frame: 12 months ]From randomization to first progression or death, whichever comes first (event); or first new anti-cancer treatment if before or without progression / death (censoring); or last follow-up date otherwise (censoring).Kaplan-Meier median PFS time and PFS rate (at 12 months)"},{"label":"2.","content":"Progression-free Survival (PFS) Rate at 1 Year.[ Time Frame: 12 months ]From randomization to first progression or death, whichever comes first (event); or first new anti-cancer treatment if before or without progression / death (censoring); or last follow-up date otherwise (censoring)."}],"start_date":"September 2005","primary_completion_date":"June 2007","completion_date":"June 2009","first_posted":"November 11, 2005","results_first_posted":"March 14, 2011","last_update_posted":"February 15, 2019"},{"nctid":"NCT01964430","version_a":46,"version_b":47,"version_a_date":"2019-08-12","version_b_date":"2019-12-17","pom_a":[{"label":"1.","content":"Disease Free Survival (DFS)[ Time Frame: up to approximately 9 months ]Time from the date of randomization to the date of disease recurrence or death, whichever is earlier. (Disease recurrence will be determined by independent radiological review of computed tomography (CT) or magnetic resonance imaging (MRI) scans.)"}],"pom_b":[{"label":"1.","content":"Kaplan Meier Estimate for Disease Free Survival (DFS) According to the Independent Radiological Review Committee[ Time Frame: Date of randomization up to data cut off date of 31 December 2018; median DFS follow-up time for censored participants was 22.242 months for nab-Paclitaxel and gemcitabine and 13.832 months for gemcitabine alone ]Disease free survival was defined as the time from the date of randomization to the date of disease recurrence or death, whichever occurred earlier. Disease recurrence was determined by the independent radiological review of computed tomography (CT) or magnetic resonance imaging (MRI) scans. Participants who did not have disease recurrence or did not die were censored at the last tumor assessment date with disease-free status or the randomization date if the last tumor assessment with disease-free status was missing. Disease-free status referred to a status that was neither being disease recurrent nor indeterminate or not evaluable. Participants who received new anti-cancer therapy or cancer-related surgery prior to disease recurrence or death were censored at the date of last tumor assessment with disease-free status prior to the start of new anti-cancer therapy or cancer-related surgery or the randomization date."}],"start_date":"March 28, 2014","primary_completion_date":"December 31, 2018","completion_date":"June 30, 2022","first_posted":"October 17, 2013","results_first_posted":"January 6, 2020","last_update_posted":"July 20, 2022"},{"nctid":"NCT03061812","version_a":17,"version_b":18,"version_a_date":"2018-06-14","version_b_date":"2018-07-30","pom_a":[{"label":"1.","content":"Objective response rate (ORR)[ Time Frame: Approximately 23 months ]ORR is defined as the percentage of participants whose best overall response is either complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1."},{"label":"2.","content":"Overall Survival (OS)[ Time Frame: Approximately 34 months ]Overall Survival (OS) is defined as the time from the date of randomization to the date of death from any cause."}],"pom_b":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: Approximately 34 months ]Overall Survival (OS) is defined as the time from the date of randomization to the date of death from any cause."},{"label":"2.","content":"Objective Response Rate (ORR)[ Time Frame: Approximately 34 months ]ORR is defined as the percentage of participants whose best overall response is complete response (CR) + partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1."}],"start_date":"April 11, 2017","primary_completion_date":"February 12, 2020","completion_date":"February 12, 2020","first_posted":"February 23, 2017","results_first_posted":"February 23, 2021","last_update_posted":"February 23, 2021"},{"nctid":"NCT03061812","version_a":19,"version_b":20,"version_a_date":"2018-08-30","version_b_date":"2018-09-28","pom_a":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: Approximately 34 months ]Overall Survival (OS) is defined as the time from the date of randomization to the date of death from any cause."},{"label":"2.","content":"Objective Response Rate (ORR)[ Time Frame: Approximately 34 months ]ORR is defined as the percentage of participants whose best overall response is complete response (CR) + partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1."}],"pom_b":[{"label":"1.","content":"Objective response rate (ORR)[ Time Frame: Approximately 23 months ]ORR is defined as the percentage of participants whose best overall response is either complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1."},{"label":"2.","content":"Overall Survival (OS)[ Time Frame: Approximately 34 months ]Overall Survival (OS) is defined as the time from the date of randomization to the date of death from any cause."}],"start_date":"April 11, 2017","primary_completion_date":"February 12, 2020","completion_date":"February 12, 2020","first_posted":"February 23, 2017","results_first_posted":"February 23, 2021","last_update_posted":"February 23, 2021"},{"nctid":"NCT03061812","version_a":20,"version_b":21,"version_a_date":"2018-09-28","version_b_date":"2018-10-10","pom_a":[{"label":"1.","content":"Objective response rate (ORR)[ Time Frame: Approximately 23 months ]ORR is defined as the percentage of participants whose best overall response is either complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1."},{"label":"2.","content":"Overall Survival (OS)[ Time Frame: Approximately 34 months ]Overall Survival (OS) is defined as the time from the date of randomization to the date of death from any cause."}],"pom_b":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: Approximately 34 months ]Overall Survival (OS) is defined as the time from the date of randomization to the date of death from any cause."}],"start_date":"April 11, 2017","primary_completion_date":"February 12, 2020","completion_date":"February 12, 2020","first_posted":"February 23, 2017","results_first_posted":"February 23, 2021","last_update_posted":"February 23, 2021"},{"nctid":"NCT03061812","version_a":28,"version_b":29,"version_a_date":"2020-02-18","version_b_date":"2021-01-29","pom_a":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: Approximately 34 months ]Overall Survival (OS) is defined as the time from the date of randomization to the date of death from any cause."}],"pom_b":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: From randomization until the end of study; median time on follow-up was 20 and 20.6 months for the topotecan and rovalpituzumab tesirine arms, respectively. ]OS is defined as the time from the date of randomization to the date of death from any cause. Participants were censored at the last date they were documented alive. After the End of treatment, survival information was collected at approximately 6-week intervals (or as requested by sponsor to support data analysis) continuing until the endpoint of death, the participant became lost to follow-up, AbbVie terminated the study, or until 12 February 2020. Calculated using the Kaplan-Meier product-limit method."}],"start_date":"April 11, 2017","primary_completion_date":"February 12, 2020","completion_date":"February 12, 2020","first_posted":"February 23, 2017","results_first_posted":"February 23, 2021","last_update_posted":"February 23, 2021"},{"nctid":"NCT00492752","version_a":1,"version_b":2,"version_a_date":"2007-06-26","version_b_date":"2007-12-21","pom_a":[{"label":"1.","content":"Overall Survival[ Time Frame: Dec.2007 to Apr.2008 ]"}],"pom_b":[{"label":"1.","content":"Overall Survival[ Time Frame: Dec. 2007 to Apr. 2008 ]"}],"start_date":"October 2005","primary_completion_date":"March 2007","completion_date":"July 2009","first_posted":"June 27, 2007","results_first_posted":"January 13, 2011","last_update_posted":"April 16, 2014"},{"nctid":"NCT00492752","version_a":4,"version_b":5,"version_a_date":"2008-10-20","version_b_date":"2008-12-08","pom_a":[{"label":"1.","content":"Overall Survival[ Time Frame: Dec. 2007 to Apr. 2008 ]"}],"pom_b":[{"label":"1.","content":"Overall Survival[ Time Frame: longterm follow up visit ]"}],"start_date":"October 2005","primary_completion_date":"March 2007","completion_date":"July 2009","first_posted":"June 27, 2007","results_first_posted":"January 13, 2011","last_update_posted":"April 16, 2014"},{"nctid":"NCT00492752","version_a":10,"version_b":11,"version_a_date":"2009-08-20","version_b_date":"2010-12-08","pom_a":[{"label":"1.","content":"Overall Survival[ Time Frame: longterm follow up visit ]"}],"pom_b":[{"label":"1.","content":"Overall Survival[ Time Frame: From randomization of the first subject until the data cut-off date approximately 23 months after start of randomization ]Overall Survival (OS) was defined as the time from date of randomization to death due to any cause. Subjects still alive at the time of analysis were censored at their last date of last contact."}],"start_date":"October 2005","primary_completion_date":"March 2007","completion_date":"July 2009","first_posted":"June 27, 2007","results_first_posted":"January 13, 2011","last_update_posted":"April 16, 2014"},{"nctid":"NCT00653068","version_a":147,"version_b":148,"version_a_date":"2012-11-03","version_b_date":"2013-06-10","pom_a":[{"label":"1.","content":"Event-free survival"},{"label":"2.","content":"Toxic death, defined as death primarily attributable to complications of treatment"}],"pom_b":[{"label":"1.","content":"Event-free survival[ Time Frame: Time to disease progression, disease relapse, occurrence of a second malignant neoplasm, or death from any cause, assessed up to 4 years ]For statistical evaluation and data reporting, the study cohort can be regarded as comprising four different strata. A one-sided log-rank test with 5% Type I error rate will be used for stratum I. For patients in strata II through IV, Kaplan-Meier estimates of disease control (event-free survival) and overall survival will be computed and compared to that in stratum I. The comparison with Stratum I will be largely descriptive."},{"label":"2.","content":"Overall survival (S) of patients with histologically and/or molecularly diagnosed AT/RT[ Time Frame: Time to death from any cause, assessed up to 4 years ]The outcome of very young patients (<3 years of age) on this study whose histologic diagnosis is AT/RT will be compared with infants identified as having AT/RT on POG 9233 and CCG 9921. For patients in strata II through IV, Kaplan-Meier estimates of disease control (event-free survival) and overall survival will be computed and compared to that in stratum I."},{"label":"3.","content":"Toxic death[ Time Frame: During and after completion of study treatment ]Treatment-related death is defined as death primarily attributable to complications of treatment."}],"start_date":"December 8, 2008","primary_completion_date":"September 27, 2016","completion_date":"August 30, 2023","first_posted":"April 4, 2008","results_first_posted":"February 13, 2017","last_update_posted":"March 2, 2022"},{"nctid":"NCT00653068","version_a":154,"version_b":155,"version_a_date":"2016-11-16","version_b_date":"2016-11-17","pom_a":[{"label":"1.","content":"Event-free survival[ Time Frame: Time to disease progression, disease relapse, occurrence of a second malignant neoplasm, or death from any cause, assessed up to 4 years ]For statistical evaluation and data reporting, the study cohort can be regarded as comprising four different strata. A one-sided log-rank test with 5% Type I error rate will be used for stratum I. For patients in strata II through IV, Kaplan-Meier estimates of disease control (event-free survival) and overall survival will be computed and compared to that in stratum I. The comparison with Stratum I will be largely descriptive."},{"label":"2.","content":"Overall survival (S) of patients with histologically and/or molecularly diagnosed AT/RT[ Time Frame: Time to death from any cause, assessed up to 4 years ]The outcome of very young patients (<3 years of age) on this study whose histologic diagnosis is AT/RT will be compared with infants identified as having AT/RT on POG 9233 and CCG 9921. For patients in strata II through IV, Kaplan-Meier estimates of disease control (event-free survival) and overall survival will be computed and compared to that in stratum I."},{"label":"3.","content":"Toxic death[ Time Frame: During and after completion of study treatment ]Treatment-related death is defined as death primarily attributable to complications of treatment."}],"pom_b":[{"label":"1.","content":"Event-free survival[ Time Frame: Time to disease progression, disease relapse, occurrence of a second malignant neoplasm, or death from any cause, assessed up to 4 years ]For statistical evaluation and data reporting, the study cohort can be regarded as comprising four different strata. Stratum I: Infants (<36 months of age) with tumor histology and immunohistochemical analysis diagnostic of AT/RT; Stratum II: Infants with INI1 mutation only based diagnosis (histology is not consistent with AT/RT); Stratum III: Older children (greater than 36 months of age) with tumor histology and immunohistochemical analysis diagnostic of AT/RT; and Stratum IV: Older children with INI1 mutation only based diagnosis. A one-sided log-rank test with 5% Type I error rate will be used for stratum I. For patients in strata II through IV, Kaplan-Meier estimates of disease control (event-free survival) and overall survival will be computed and compared to that in stratum I. The comparison with Stratum I will be largely descriptive."},{"label":"2.","content":"Overall survival (S) of patients with histologically and/or molecularly diagnosed AT/RT[ Time Frame: Time to death from any cause, assessed up to 4 years ]For statistical evaluation and data reporting, the study cohort can be regarded as comprising four different strata: Stratum I: Infants (<36 months of age) with tumor histology and immunohistochemical analysis diagnostic of AT/RT; Stratum II: Infants with INI1 mutation only based diagnosis (histology is not consistent with AT/RT); Stratum III: Older children (greater than 36 months of age) with tumor histology and immunohistochemical analysis diagnostic of AT/RT; and Stratum IV: Older children with INI1 mutation only based diagnosis. The outcome of stratum 1 patients will be compared with infants identified as having AT/RT on POG 9233 and CCG 9921. For patients in strata II through IV, Kaplan-Meier estimates of disease control (event-free survival) and overall survival will be computed and compared to that in stratum I."},{"label":"3.","content":"Toxic death[ Time Frame: During and after completion of study treatment ]Treatment-related death is defined as death primarily attributable to complications of treatment."}],"start_date":"December 8, 2008","primary_completion_date":"September 27, 2016","completion_date":"August 30, 2023","first_posted":"April 4, 2008","results_first_posted":"February 13, 2017","last_update_posted":"March 2, 2022"},{"nctid":"NCT00653068","version_a":156,"version_b":157,"version_a_date":"2016-11-18","version_b_date":"2016-12-20","pom_a":[{"label":"1.","content":"Event-free survival[ Time Frame: Time to disease progression, disease relapse, occurrence of a second malignant neoplasm, or death from any cause, assessed up to 4 years ]For statistical evaluation and data reporting, the study cohort can be regarded as comprising four different strata. Stratum I: Infants (<36 months of age) with tumor histology and immunohistochemical analysis diagnostic of AT/RT; Stratum II: Infants with INI1 mutation only based diagnosis (histology is not consistent with AT/RT); Stratum III: Older children (greater than 36 months of age) with tumor histology and immunohistochemical analysis diagnostic of AT/RT; and Stratum IV: Older children with INI1 mutation only based diagnosis. A one-sided log-rank test with 5% Type I error rate will be used for stratum I. For patients in strata II through IV, Kaplan-Meier estimates of disease control (event-free survival) and overall survival will be computed and compared to that in stratum I. The comparison with Stratum I will be largely descriptive."},{"label":"2.","content":"Overall survival (S) of patients with histologically and/or molecularly diagnosed AT/RT[ Time Frame: Time to death from any cause, assessed up to 4 years ]For statistical evaluation and data reporting, the study cohort can be regarded as comprising four different strata: Stratum I: Infants (<36 months of age) with tumor histology and immunohistochemical analysis diagnostic of AT/RT; Stratum II: Infants with INI1 mutation only based diagnosis (histology is not consistent with AT/RT); Stratum III: Older children (greater than 36 months of age) with tumor histology and immunohistochemical analysis diagnostic of AT/RT; and Stratum IV: Older children with INI1 mutation only based diagnosis. The outcome of stratum 1 patients will be compared with infants identified as having AT/RT on POG 9233 and CCG 9921. For patients in strata II through IV, Kaplan-Meier estimates of disease control (event-free survival) and overall survival will be computed and compared to that in stratum I."},{"label":"3.","content":"Toxic death[ Time Frame: During and after completion of study treatment ]Treatment-related death is defined as death primarily attributable to complications of treatment."}],"pom_b":[{"label":"1.","content":"Event-free Survival[ Time Frame: Up to 4 years after study enrollment ]Time to disease progression, disease relapse, occurrence of a second malignant neoplasm, or death from any cause."},{"label":"2.","content":"Overall Survival (OS)[ Time Frame: Up to 4 years after study enrollment ]Time to death from any cause."},{"label":"3.","content":"Toxic Death[ Time Frame: During and after completion of study treatment ]Toxic death is defined to be death primarily attributable to complications of treatment."}],"start_date":"December 8, 2008","primary_completion_date":"September 27, 2016","completion_date":"August 30, 2023","first_posted":"April 4, 2008","results_first_posted":"February 13, 2017","last_update_posted":"March 2, 2022"},{"nctid":"NCT00653068","version_a":157,"version_b":158,"version_a_date":"2016-12-20","version_b_date":"2017-02-13","pom_a":[{"label":"1.","content":"Event-free Survival[ Time Frame: Up to 4 years after study enrollment ]Time to disease progression, disease relapse, occurrence of a second malignant neoplasm, or death from any cause."},{"label":"2.","content":"Overall Survival (OS)[ Time Frame: Up to 4 years after study enrollment ]Time to death from any cause."},{"label":"3.","content":"Toxic Death[ Time Frame: During and after completion of study treatment ]Toxic death is defined to be death primarily attributable to complications of treatment."}],"pom_b":[{"label":"1.","content":"Event-free Survival[ Time Frame: Up to 4 years after study enrollment ]Estimated 4-year EFS where EFS is calculated as the time from study enrollment to disease progression, disease relapse, occurrence of a second malignant neoplasm, death from any cause or last follow-up whichever occurs first. Kaplan-Meier method is used for estimation. Patients without an event are censored at last contact."},{"label":"2.","content":"Overall Survival (OS)[ Time Frame: Up to 4 years after study enrollment ]Estimated 4-year survival, where survival is calculated as the time from study enrollment to death from any cause or last follow-up alive whichever occurs first. Kaplan-Meier method is used for estimation. Patients alive at last contact are censored."},{"label":"3.","content":"Toxic Death[ Time Frame: During and after completion of study treatment up to 1 year after enrollment. ]The number of patients who experience death that is considered to be primarily attributable to complications of treatment."}],"start_date":"December 8, 2008","primary_completion_date":"September 27, 2016","completion_date":"August 30, 2023","first_posted":"April 4, 2008","results_first_posted":"February 13, 2017","last_update_posted":"March 2, 2022"},{"nctid":"NCT01438112","version_a":2,"version_b":3,"version_a_date":"2011-10-05","version_b_date":"2011-11-11","pom_a":[{"label":"1.","content":"Durable Complete Response Rate[ Time Frame: 6 months (Phase II) ]The 6 months durable complete response rate will be measured by complete response lasting 6 months or longer with negative cytology, cystoscopy, and biopsy. Durable Complete Response Rate at 6 months [Time Frame: 6 months following first treatment] [Designated as safety issue: No]"},{"label":"2.","content":"Disease Free Survival w/o Cystectomy[ Time Frame: 18 months (Phase III) ]The 18 months disease free survival rate w/o cystectomy will be measured by patients who exhibit a complete response lasting 18 month or longer confirmed by negative cytology, cystoscopy, and biopsy.\u2022 Disease Free Survival Rate (\\"DFS\\") w/o Cystectomy at 18 months [Time Frame: 18 months post randomization] [Designated as a safety issue: No]"}],"pom_b":[{"label":"1.","content":"Durable Complete Response Rate[ Time Frame: 6 to 9 months (Phase II) ]Durable \'CR\' Rate is confirmed by negative biopsy, cystoscopy, cytology (in the case of \\"pending CR\\" following first treatment and to allow for TURBT rendered CR which needs confirmation by a re-TURBT) If first assessment shows only positive urine cytology and negative biopsy, a \\"pending CR\\" is allocated for a second assessment of urine cytology, which if negative together with a negative biopsy will confirm a delayed CR. TURBT rendered CR is only allowed if it is followed by a confirming re-TURBT in 4wks."},{"label":"2.","content":"Disease Free Survival w/o Cystectomy[ Time Frame: 18 months (Phase III) ]The disease free survival rate w/o cystectomy will be confirmed by negative cytology, cystoscopy, and biopsy. If the 1st assessment shows only positive urine cytology and negative biopsy, a \\"pending CR\\" is allocated (no cystectomy) for a 2nd assessment of urine cytology, which if negative together with a negative biopsy will confirm a delayed CR. TURBT rendered CR is only allowed if it is followed by a confirming re-TURBT in 4 weeks."}],"start_date":"March 2014","primary_completion_date":"June 2016","completion_date":"June 2016","first_posted":"September 21, 2011","last_update_posted":"April 14, 2021"},{"nctid":"NCT01438112","version_a":3,"version_b":4,"version_a_date":"2011-11-11","version_b_date":"2011-12-15","pom_a":[{"label":"1.","content":"Durable Complete Response Rate[ Time Frame: 6 to 9 months (Phase II) ]Durable \'CR\' Rate is confirmed by negative biopsy, cystoscopy, cytology (in the case of \\"pending CR\\" following first treatment and to allow for TURBT rendered CR which needs confirmation by a re-TURBT) If first assessment shows only positive urine cytology and negative biopsy, a \\"pending CR\\" is allocated for a second assessment of urine cytology, which if negative together with a negative biopsy will confirm a delayed CR. TURBT rendered CR is only allowed if it is followed by a confirming re-TURBT in 4wks."},{"label":"2.","content":"Disease Free Survival w/o Cystectomy[ Time Frame: 18 months (Phase III) ]The disease free survival rate w/o cystectomy will be confirmed by negative cytology, cystoscopy, and biopsy. If the 1st assessment shows only positive urine cytology and negative biopsy, a \\"pending CR\\" is allocated (no cystectomy) for a 2nd assessment of urine cytology, which if negative together with a negative biopsy will confirm a delayed CR. TURBT rendered CR is only allowed if it is followed by a confirming re-TURBT in 4 weeks."}],"pom_b":[{"label":"1.","content":"Durable Complete Response Rate[ Time Frame: 6 to 9 months (Phase II) ]Durable \'CR\' Rate is confirmed by negative biopsy, cystoscopy, cytology (in the case of \\"pending CR\\" following first treatment and to allow for TURBT rendered CR which needs confirmation by a re-TURBT) If first assessment shows only positive urine cytology and negative biopsy, a \\"pending CR\\" is allocated for a second assessment of urine cytology, which if negative together with a negative biopsy will confirm a delayed CR. TURBT rendered CR is only allowed if it is followed by a confirming re-TURBT in 4wks."},{"label":"2.","content":"Disease Free Survival[ Time Frame: 24 months (Phase III) ]The disease free survival rate will be confirmed by negative cytology, cystoscopy, and biopsy. If the 1st assessment shows only positive urine cytology and negative biopsy, a \\"pending CR\\" is allocated (no cystectomy) for a 2nd assessment of urine cytology, which if negative together with a negative biopsy will confirm a delayed CR. TURBT rendered CR is only allowed if it is followed by a confirming re-TURBT in 4 weeks. All patients with cystectomies or do not have a complete response after treatment with CG0070 or the control regimen are classfied as treatment failures."}],"start_date":"March 2014","primary_completion_date":"June 2016","completion_date":"June 2016","first_posted":"September 21, 2011","last_update_posted":"April 14, 2021"},{"nctid":"NCT01438112","version_a":4,"version_b":5,"version_a_date":"2011-12-15","version_b_date":"2012-02-07","pom_a":[{"label":"1.","content":"Durable Complete Response Rate[ Time Frame: 6 to 9 months (Phase II) ]Durable \'CR\' Rate is confirmed by negative biopsy, cystoscopy, cytology (in the case of \\"pending CR\\" following first treatment and to allow for TURBT rendered CR which needs confirmation by a re-TURBT) If first assessment shows only positive urine cytology and negative biopsy, a \\"pending CR\\" is allocated for a second assessment of urine cytology, which if negative together with a negative biopsy will confirm a delayed CR. TURBT rendered CR is only allowed if it is followed by a confirming re-TURBT in 4wks."},{"label":"2.","content":"Disease Free Survival[ Time Frame: 24 months (Phase III) ]The disease free survival rate will be confirmed by negative cytology, cystoscopy, and biopsy. If the 1st assessment shows only positive urine cytology and negative biopsy, a \\"pending CR\\" is allocated (no cystectomy) for a 2nd assessment of urine cytology, which if negative together with a negative biopsy will confirm a delayed CR. TURBT rendered CR is only allowed if it is followed by a confirming re-TURBT in 4 weeks. All patients with cystectomies or do not have a complete response after treatment with CG0070 or the control regimen are classfied as treatment failures."}],"pom_b":[{"label":"1.","content":"Durable Complete Response Rate[ Time Frame: 6 to 9 months (Phase II) ]Durable \'CR\' Rate is confirmed by negative biopsy, cystoscopy, cytology (in the case of \\"pending CR\\" following first treatment and to allow for TURBT rendered CR which needs confirmation by a re-TURBT) If first assessment shows only positive urine cytology and negative biopsy, a \\"pending CR\\" is allocated for a second assessment of urine cytology, which if negative together with a negative biopsy will confirm a delayed CR. TURBT rendered CR is only allowed if it is followed by a confirming re-TURBT in 4wks."},{"label":"2.","content":"Hazard Ratio (treatment:control)[ Time Frame: 24 months (Phase III) ]The hazard ratio will compare the rates of experiencing disease recurrence at 24 months, which will be monitored by negative cytology, cystoscopy, and biopsy. If 1st assessment shows only pos. urine cytology and neg. biopsy, a \\"pending CR\\" is allocated for a 2nd assessment of urine cytology, which if negative together with a neg. biopsy will confirm a delayed CR. TURBT rendered CR is only allowed if followed by a confirming re-TURBT in 4 weeks. All patients with cystectomies or those who do not achieve complete response after treatment or control regimens are classified as treatment failures."}],"start_date":"March 2014","primary_completion_date":"June 2016","completion_date":"June 2016","first_posted":"September 21, 2011","last_update_posted":"April 14, 2021"},{"nctid":"NCT01438112","version_a":5,"version_b":6,"version_a_date":"2012-02-07","version_b_date":"2012-04-12","pom_a":[{"label":"1.","content":"Durable Complete Response Rate[ Time Frame: 6 to 9 months (Phase II) ]Durable \'CR\' Rate is confirmed by negative biopsy, cystoscopy, cytology (in the case of \\"pending CR\\" following first treatment and to allow for TURBT rendered CR which needs confirmation by a re-TURBT) If first assessment shows only positive urine cytology and negative biopsy, a \\"pending CR\\" is allocated for a second assessment of urine cytology, which if negative together with a negative biopsy will confirm a delayed CR. TURBT rendered CR is only allowed if it is followed by a confirming re-TURBT in 4wks."},{"label":"2.","content":"Hazard Ratio (treatment:control)[ Time Frame: 24 months (Phase III) ]The hazard ratio will compare the rates of experiencing disease recurrence at 24 months, which will be monitored by negative cytology, cystoscopy, and biopsy. If 1st assessment shows only pos. urine cytology and neg. biopsy, a \\"pending CR\\" is allocated for a 2nd assessment of urine cytology, which if negative together with a neg. biopsy will confirm a delayed CR. TURBT rendered CR is only allowed if followed by a confirming re-TURBT in 4 weeks. All patients with cystectomies or those who do not achieve complete response after treatment or control regimens are classified as treatment failures."}],"pom_b":[{"label":"1.","content":"Durable Complete Response Rate[ Time Frame: 9 months (Phase II) ]Durable \'CR\' Rate is confirmed by negative biopsy, cystoscopy, cytology weekly times 2 with the first assessment three months after last intravesical treatment and then assessed again at 9 month post randomization. Two consectutive positive urine cytologies to confirm a persistent or recurrent disease if visual and biopsy is negative. Random biopsy mandatory at the first assessment in the trigone, bladder dome, right, left , anterior and posterior of the bladder wall."},{"label":"2.","content":"Recurrence Free Survival or RFS[ Time Frame: 18 months (Phase III) ]RFS will be calculated by log rank test with a minimal follow up period of 18 months. All patients who did not have a completer response at first assessment will have the RFS event at time zero, the time of randomization. RFS will be defined as the time from randomization to local recurrence, distant metastasis or death."}],"start_date":"March 2014","primary_completion_date":"June 2016","completion_date":"June 2016","first_posted":"September 21, 2011","last_update_posted":"April 14, 2021"},{"nctid":"NCT01438112","version_a":6,"version_b":7,"version_a_date":"2012-04-12","version_b_date":"2012-05-04","pom_a":[{"label":"1.","content":"Durable Complete Response Rate[ Time Frame: 9 months (Phase II) ]Durable \'CR\' Rate is confirmed by negative biopsy, cystoscopy, cytology weekly times 2 with the first assessment three months after last intravesical treatment and then assessed again at 9 month post randomization. Two consectutive positive urine cytologies to confirm a persistent or recurrent disease if visual and biopsy is negative. Random biopsy mandatory at the first assessment in the trigone, bladder dome, right, left , anterior and posterior of the bladder wall."},{"label":"2.","content":"Recurrence Free Survival or RFS[ Time Frame: 18 months (Phase III) ]RFS will be calculated by log rank test with a minimal follow up period of 18 months. All patients who did not have a completer response at first assessment will have the RFS event at time zero, the time of randomization. RFS will be defined as the time from randomization to local recurrence, distant metastasis or death."}],"pom_b":[{"label":"1.","content":"Complete Response Proportion (CR)[ Time Frame: 9 months (Phase II) ]\'CR\' Proportion is confirmed by negative biopsy, cystoscopy, cytology weekly times 2 with the first assessment three months after first intravesical treatment and then assessed again at 9 month. Two consectutive positive urine cytologies to confirm a persistent or recurrent disease if visual and biopsy is negative. Random biopsy mandatory at the first assessment in the trigone, bladder dome, right, left , anterior and posterior of the bladder wall."},{"label":"2.","content":"Durable Complete Response Proportion (DCR)[ Time Frame: 15 months (Phase III) ]DCR proportion of DCR lasting 12 months or longer will be conducted after a follow up period of 15 months for each patient. The first complete response assessment will be at 3 month."}],"start_date":"March 2014","primary_completion_date":"June 2016","completion_date":"June 2016","first_posted":"September 21, 2011","last_update_posted":"April 14, 2021"},{"nctid":"NCT01438112","version_a":16,"version_b":17,"version_a_date":"2015-05-12","version_b_date":"2016-07-27","pom_a":[{"label":"1.","content":"Complete Response Proportion (CR)[ Time Frame: 9 months (Phase II) ]\'CR\' Proportion is confirmed by negative biopsy, cystoscopy, cytology weekly times 2 with the first assessment three months after first intravesical treatment and then assessed again at 9 month. Two consectutive positive urine cytologies to confirm a persistent or recurrent disease if visual and biopsy is negative. Random biopsy mandatory at the first assessment in the trigone, bladder dome, right, left , anterior and posterior of the bladder wall."},{"label":"2.","content":"Durable Complete Response Proportion (DCR)[ Time Frame: 15 months (Phase III) ]DCR proportion of DCR lasting 12 months or longer will be conducted after a follow up period of 15 months for each patient. The first complete response assessment will be at 3 month."}],"pom_b":[{"label":"1.","content":"Complete Response Proportion (CR)[ Time Frame: 9 months (Phase II) ]\'CR\' Proportion is confirmed by negative biopsy, cystoscopy, cytology weekly times 2 with the first assessment three months after first intravesical treatment and then assessed again at 9 month. Two consecutive positive urine cytologies to confirm a persistent or recurrent disease if visual and biopsy is negative. Random biopsy mandatory at the first assessment in the trigone, bladder dome, right, left , anterior and posterior of the bladder wall."},{"label":"2.","content":"Durable Complete Response Proportion (DCR)[ Time Frame: 15 months (Phase III) ]DCR proportion of DCR lasting 12 months or longer will be conducted after a follow up period of 15 months for each patient. The first complete response assessment will be at 3 month."}],"start_date":"March 2014","primary_completion_date":"June 2016","completion_date":"June 2016","first_posted":"September 21, 2011","last_update_posted":"April 14, 2021"},{"nctid":"NCT00617669","version_a":21,"version_b":22,"version_a_date":"2011-07-18","version_b_date":"2012-04-26","pom_a":[{"label":"1.","content":"Overall survival[ Time Frame: while receving docetaxel study visits will be aligned with its adminstration ie every 3 weeks, after 12 weeks and completion of docetaxel therapy study may be every 12 weeks ]"}],"pom_b":[{"label":"1.","content":"Overall Survival[ Time Frame: Patients were followed for survival up to 40 months ]Median time (in months) from randomisation until death using the Kaplan-Meier method."}],"start_date":"January 2008","primary_completion_date":"May 2011","completion_date":"July 2011","first_posted":"February 18, 2008","results_first_posted":"May 31, 2012","last_update_posted":"September 10, 2012"},{"nctid":"NCT02197416","version_a":111,"version_b":112,"version_a_date":"2019-11-20","version_b_date":"2020-05-29","pom_a":[{"label":"1.","content":"Recurrence of venous thromboembolism (VTE)[ Time Frame: 6 and 12 months ]"},{"label":"2.","content":"Major and minor (including clinically relevant non-major (CRNM)) bleeding events[ Time Frame: 6 and 12 months ]"},{"label":"3.","content":"Mortality overall and related to thrombotic or thromboembolic events[ Time Frame: 6 and 12 months ]"}],"pom_b":[{"label":"1.","content":"Event-free Probability of Recurrence of Venous Thromboembolism (VTE) at 6 and 12 Months[ Time Frame: At month 6 (Week 26) and 12 (Week 52) of on treatment period ]The event-free probability of first recurrence of VTE were provided by Kaplan-Meier estimation with its 95% confidence intervals (CIs) at 6 and 12 months.Patients who did not experience recurrent VTE at the time of analysis, dropped out from the trial early, were lost to follow-up, or had died from non-VTE related cause were considered as non-events and censored. On treatment period was from first DE administration to 3 days of residual effect period after last DE administration."},{"label":"2.","content":"Event-free Probability of Major or Minor (Including Clinically Relevant Non-major (CRNM)) Bleeding Events at 6 and 12 Months[ Time Frame: At month 6 (Week 26) and month 12 (Week 52) of on treatment period ]The event-free probability of major or minor (including CRNM) bleeding event were provided by Kaplan-Meier estimation with its 95% confidence intervals (CIs) at 6 and 12 months.Patients who did not experience major or minor (including CRNM) bleeding event at the time of analysis, dropped out from the trial early, were lost to follow-up, or had died from non-bleeding related cause were considered as non-events and censored. On treatment period was from first DE administration to 3 days of residual effect period after last DE administration."},{"label":"3.","content":"Event-free Probability of Mortality Overall and Related to Thrombotic or Thromboembolic Events at 6 and 12 Months[ Time Frame: At month 6 (Week 26) and 12 (Week 52) of on treatment period ]The event-free probability of mortality overall and related to thrombotic or thromboembolic events were provided by Kaplan-Meier estimation with its 95% confidence intervals (CIs) at 6 and 12 months.Patients who did not experience mortality overall and related to thrombotic or thromboembolic events at the time of analysis, dropped out from the trial early, were lost to follow-up, were considered as non-events and censored. On treatment period was from first DE administration to 3 days of residual effect period after last DE administration."}],"start_date":"September 29, 2014","primary_completion_date":"October 16, 2019","completion_date":"November 19, 2019","first_posted":"July 22, 2014","results_first_posted":"June 4, 2020","last_update_posted":"June 4, 2020"},{"nctid":"NCT02348489","version_a":33,"version_b":34,"version_a_date":"2019-08-06","version_b_date":"2020-12-21","pom_a":[{"label":"1.","content":"Complete response (CR)[ Time Frame: 3 years ]"},{"label":"2.","content":"Overall survival[ Time Frame: 3 years ]"}],"pom_b":[{"label":"1.","content":"Number of Participants With a Complete Response (CR)[ Time Frame: Up to 38 months (median follow-up of 25.5 months) ]Number of participants with a best response of CR assessed based on International Working Group 2003 acute myeloid leukemia (AML) response criteria by a blinded independent pathologist."},{"label":"2.","content":"Overall Survival[ Time Frame: At 676 death events (up to 38 months) ]Survival time was defined as the number of days from the day the participant was randomly assigned to study treatment to the date of death, regardless of cause."}],"start_date":"March 19, 2015","primary_completion_date":"May 31, 2018","completion_date":"June 17, 2019","first_posted":"January 28, 2015","results_first_posted":"January 14, 2021","last_update_posted":"January 14, 2021"},{"nctid":"NCT00091351","version_a":28,"version_b":29,"version_a_date":"2006-04-05","version_b_date":"2007-02-20","pom_a":[],"pom_b":[{"label":"1.","content":"Progression-free survival at 5 years"}],"start_date":"August 2004","primary_completion_date":"February 2006","completion_date":"February 2006","first_posted":"September 9, 2004","last_update_posted":"July 6, 2016"},{"nctid":"NCT00091351","version_a":35,"version_b":36,"version_a_date":"2009-02-06","version_b_date":"2015-07-14","pom_a":[{"label":"1.","content":"Progression-free survival at 5 years"}],"pom_b":[{"label":"1.","content":"Progression-free survival at 5 years[ Time Frame: at 5 years ]"}],"start_date":"August 2004","primary_completion_date":"February 2006","completion_date":"February 2006","first_posted":"September 9, 2004","last_update_posted":"July 6, 2016"},{"nctid":"NCT02369835","version_a":14,"version_b":15,"version_a_date":"2019-03-01","version_b_date":"2019-09-09","pom_a":[{"label":"1.","content":"Proportion of patients who experience grade 3 radiation dermatitis as defined by the Stanford Radiation Dermatitis Scoring System[ Time Frame: Up to 10 weeks after completion of radiation treatment ]Will be assessed and graded in each arm by the treating physician, a radiation oncologist, who will give an individual score of the irradiated area at baseline, once weekly during radiation treatment course, at the end of the radiation treatment course +/- 10 days, and at the patient\'s follow up visit 6-10 weeks after completion of the radiation treatment course. The final grading for each time point will be subjected to inter-rater reliability processes. A multiple logistic regression model will be used controlling for type of chemotherapy (cisplatin, cetuximab, none)."}],"pom_b":[{"label":"1.","content":"Radiation Dermatitis[ Time Frame: From first radiation treatment up to 10 weeks after completion of radiation treatment. Because much of the study data was not provided by the prior investigator to the current Responsible Party, it is not possible to be more precise than stated. ]Participants were assessed for radiation dermatitis on the arms according to the Stanford Radiation Dermatitis Scoring System (SRDSS), at baseline and through their treatment course. The outcome is reported by treatment group as the number and proportion of participants that experience SRDSS Grade E or greater radiation dermatitis through 10 weeks after completion of radiation treatment, a number without dispersion.SRDSS, by grade:A. No skin changeB. Faint, barely detectable erythemaC. Follicular rash, hyperpigmentation, evolving erythemaD. Dry desquamation, brisk erythemaE. Moist desquamationF. Bleeding, ulceration, and/or infectionSRDSS Grade E is roughly equivalent to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 Grade 3 radiation dermatitis, \\"Moist desquamation in areas other than skin folds and creases; bleeding induced by minor trauma or abrasion\\""}],"start_date":"May 2015","primary_completion_date":"July 18, 2018","completion_date":"July 18, 2018","first_posted":"February 24, 2015","results_first_posted":"September 17, 2019","last_update_posted":"September 17, 2019"},{"nctid":"NCT00223171","version_a":3,"version_b":4,"version_a_date":"2007-02-28","version_b_date":"2013-07-18","pom_a":[{"label":"1.","content":"Specific survival"},{"label":"2.","content":"Overall survival"},{"label":"3.","content":"Treatment morbidity induced versus quality of life based on duration of hormonal therapy"}],"pom_b":[{"label":"1.","content":"Specific survival[ Time Frame: 10 years ]"},{"label":"2.","content":"Overall survival[ Time Frame: 10 years ]"},{"label":"3.","content":"Treatment morbidity induced versus quality of life based on duration of hormonal therapy[ Time Frame: 10 years ]"}],"start_date":"October 2000","primary_completion_date":"December 31, 2023","completion_date":"December 31, 2023","first_posted":"September 22, 2005","last_update_posted":"May 26, 2022"},{"nctid":"NCT00455936","version_a":2,"version_b":3,"version_a_date":"2007-05-08","version_b_date":"2007-12-04","pom_a":[{"label":"1.","content":"To examine whether gefitinib monotherapy would improve overall survival of never-smokers with adenocarcinoma of lung as compared with standard chemotherapy"}],"pom_b":[{"label":"1.","content":"To examine whether gefitinib monotherapy would improve overall survival of never-smokers with adenocarcinoma of lung as compared with standard chemotherapy[ Time Frame: from the date of randomisation to the date of death from any cause ]"}],"start_date":"October 2005","primary_completion_date":"November 2009","completion_date":"March 2010","first_posted":"April 4, 2007","last_update_posted":"October 25, 2010"},{"nctid":"NCT00455936","version_a":6,"version_b":7,"version_a_date":"2008-08-25","version_b_date":"2008-12-26","pom_a":[{"label":"1.","content":"To examine whether gefitinib monotherapy would improve overall survival of never-smokers with adenocarcinoma of lung as compared with standard chemotherapy[ Time Frame: from the date of randomisation to the date of death from any cause ]"}],"pom_b":[{"label":"1.","content":"To examine whether gefitinib monotherapy would improve overall survival of never-smokers with adenocarcinoma of lung as compared with standard chemotherapy[ Time Frame: from the date of randomization to the date of death from any cause ]"}],"start_date":"October 2005","primary_completion_date":"November 2009","completion_date":"March 2010","first_posted":"April 4, 2007","last_update_posted":"October 25, 2010"},{"nctid":"NCT00455936","version_a":9,"version_b":10,"version_a_date":"2010-03-23","version_b_date":"2010-10-22","pom_a":[{"label":"1.","content":"To examine whether gefitinib monotherapy would improve overall survival of never-smokers with adenocarcinoma of lung as compared with standard chemotherapy[ Time Frame: from the date of randomization to the date of death from any cause ]"}],"pom_b":[{"label":"1.","content":"overall survival[ Time Frame: every 12 weeks ]"}],"start_date":"October 2005","primary_completion_date":"November 2009","completion_date":"March 2010","first_posted":"April 4, 2007","last_update_posted":"October 25, 2010"},{"nctid":"NCT01821963","version_a":4,"version_b":5,"version_a_date":"2014-03-04","version_b_date":"2015-02-23","pom_a":[{"label":"1.","content":"Undetectable Viral Load[ Time Frame: 48 weeks ]The primary endpoint is undetectable viral load at 12 weeks post-transplant (Post-transplant virological response - PTVR). In order to have undetectable HCV RNA viral load after transplant, patients need to have undetectable viral load before the liver transplant. Primary analysis for undetectable viral load at 12 weeks post-transplant response rate based on the modified intent-to-treat (ITT) population. The modified ITT population defined as those patients who have achieved an undetectable HCV-RNA level before the transplant. If patients drop out the study early due to severe toxicity or treatment failure including treatment-related death, they will be counted as non-responders when evaluating the response rate."}],"pom_b":[{"label":"1.","content":"Number of Participants With Undetectable Viral Load 12 Weeks Post-transplant[ Time Frame: 12 weeks post-transplant, up to 48 weeks for overall monitoring ]The primary endpoint is number of participants with undetectable viral load at 12 weeks post-transplant (Post-transplant virological response, (PTVR)) which is defined as undetectable Hepatitis C Virus ribonucleic acid (HCV-RNA) 12 weeks after liver transplantation). In order to have undetectable HCV RNA viral load after transplant, participants need to have undetectable viral load before the liver transplant.Response rate based on the modified intent-to-treat (ITT) population where ITT population is defined as those patients who have achieved an undetectable HCV-RNA level before the transplant. If patients drop out the study early due to severe toxicity or treatment failure including treatment-related death, they will be counted as non-responders when evaluating the response rate."}],"start_date":"April 2013","primary_completion_date":"February 2014","completion_date":"February 2014","first_posted":"April 1, 2013","results_first_posted":"March 6, 2015","last_update_posted":"September 24, 2020"},{"nctid":"NCT01009593","version_a":15,"version_b":16,"version_a_date":"2011-06-08","version_b_date":"2011-10-12","pom_a":[{"label":"1.","content":"Overall Survival[ Time Frame: From randomization until patient death; monthly ]"}],"pom_b":[{"label":"1.","content":"Overall Survival[ Time Frame: From randomization until patient death; assessed monthly ]"}],"start_date":"January 2010","primary_completion_date":"July 2012","completion_date":"July 2012","first_posted":"November 6, 2009","last_update_posted":"September 10, 2012"},{"nctid":"NCT00322452","version_a":7,"version_b":8,"version_a_date":"2009-04-22","version_b_date":"2010-04-21","pom_a":[{"label":"1.","content":"To compare gefitinib with carboplatin/paclitaxel doublet chemotherapy given as first line treatment in terms of progression free survival."}],"pom_b":[{"label":"1.","content":"Median Progression Free Survival (PFS) in Months[ Time Frame: Tumour assessments as per RECIST were performed at baseline and then every 42 days \xb1 7 days from randomization until data cut off (14th April 2008). ]PFS was defined as the interval from the date of randomization to the date of objective disease progression (as per RECIST) or the date of death (from any cause) in the absence of objective disease progression. The median PFS in months is presented here."}],"start_date":"March 2006","primary_completion_date":"April 2008","completion_date":"June 2010","first_posted":"May 8, 2006","results_first_posted":"May 17, 2010","last_update_posted":"November 7, 2013"},{"nctid":"NCT00500240","version_a":1,"version_b":2,"version_a_date":"2007-07-11","version_b_date":"2008-06-05","pom_a":[],"pom_b":[{"label":"1.","content":"To determine if aggressive management of hyperglycemia results in longer overall survival in patients with ALL, Burkitts lymphoma, or lymphoblastic lymphoma treated with HyperCVAD or variants of the HyperCVAD regimen.[ Time Frame: April 2009 ]"}],"start_date":"April 2004","primary_completion_date":"April 2012","completion_date":"April 2012","first_posted":"July 12, 2007","results_first_posted":"August 7, 2014","last_update_posted":"June 3, 2015"},{"nctid":"NCT00500240","version_a":2,"version_b":3,"version_a_date":"2008-06-05","version_b_date":"2009-08-18","pom_a":[{"label":"1.","content":"To determine if aggressive management of hyperglycemia results in longer overall survival in patients with ALL, Burkitts lymphoma, or lymphoblastic lymphoma treated with HyperCVAD or variants of the HyperCVAD regimen.[ Time Frame: April 2009 ]"}],"pom_b":[{"label":"1.","content":"Overall Survival[ Time Frame: Interval from date of randomization to date of death or last follow-up. ]"}],"start_date":"April 2004","primary_completion_date":"April 2012","completion_date":"April 2012","first_posted":"July 12, 2007","results_first_posted":"August 7, 2014","last_update_posted":"June 3, 2015"},{"nctid":"NCT00500240","version_a":6,"version_b":7,"version_a_date":"2011-04-25","version_b_date":"2011-04-27","pom_a":[{"label":"1.","content":"Overall Survival[ Time Frame: Interval from date of randomization to date of death or last follow-up. ]"}],"pom_b":[{"label":"1.","content":"Overall Survival[ Time Frame: Baseline (date of randomization) to date of death or last follow-up (weekly during treatment then every 2 months post study treatment). ]Overall survival defined as the time from date of randomization to date of death due to any cause or last follow up."}],"start_date":"April 2004","primary_completion_date":"April 2012","completion_date":"April 2012","first_posted":"July 12, 2007","results_first_posted":"August 7, 2014","last_update_posted":"June 3, 2015"},{"nctid":"NCT00500240","version_a":9,"version_b":10,"version_a_date":"2012-05-07","version_b_date":"2014-07-14","pom_a":[{"label":"1.","content":"Overall Survival[ Time Frame: Baseline (date of randomization) to date of death or last follow-up (weekly during treatment then every 2 months post study treatment). ]Overall survival defined as the time from date of randomization to date of death due to any cause or last follow up."}],"pom_b":[{"label":"1.","content":"1-Year Progression Free Survival (PFS)[ Time Frame: 1 Year ]PFS calculated as number of participants out of total participants with no disease progression at one year."},{"label":"2.","content":"1-Year Overall Survival Rate[ Time Frame: 1 year ]The overall survival rate defined as percentage of participants in each treatment group who are still alive at 12 months."}],"start_date":"April 2004","primary_completion_date":"April 2012","completion_date":"April 2012","first_posted":"July 12, 2007","results_first_posted":"August 7, 2014","last_update_posted":"June 3, 2015"},{"nctid":"NCT00500240","version_a":10,"version_b":11,"version_a_date":"2014-07-14","version_b_date":"2015-06-02","pom_a":[{"label":"1.","content":"1-Year Progression Free Survival (PFS)[ Time Frame: 1 Year ]PFS calculated as number of participants out of total participants with no disease progression at one year."},{"label":"2.","content":"1-Year Overall Survival Rate[ Time Frame: 1 year ]The overall survival rate defined as percentage of participants in each treatment group who are still alive at 12 months."}],"pom_b":[{"label":"1.","content":"1-Year Overall Survival Rate[ Time Frame: 1 year ]The overall survival rate defined as percentage of participants in each treatment group who are still alive at 12 months."},{"label":"2.","content":"Overall Survival[ Time Frame: Baseline (date of randomization) to date of death or last follow-up (weekly during treatment then every 2 months post study treatment) up to 6 years ]Overall survival (OS) defined as the interval between the date of randomization and the date of death. Calculation of period was from baseline (date of randomization) to the death or last follow-up."},{"label":"3.","content":"Progression Free Survival (PFS)[ Time Frame: Date of complete remission to disease progression, assessed for approximately 6 years ]PFS was defined as the time interval between the date of complete remission and the date of relapse detection or death. Complete Remission (CR) defined as granulocyte count >1.0 \xd7 10^9/L, platelet count >100 \xd7 10^9/L, no abnormal peripheral blasts, and <5% blasts in normocellular or hypercellular bone marrow."}],"start_date":"April 2004","primary_completion_date":"April 2012","completion_date":"April 2012","first_posted":"July 12, 2007","results_first_posted":"August 7, 2014","last_update_posted":"June 3, 2015"},{"nctid":"NCT00459771","version_a":1,"version_b":2,"version_a_date":"2007-04-11","version_b_date":"2007-06-20","pom_a":[{"label":"1.","content":"The occurrence of cardiotoxicity during the one-year trastuzumab therapy and during the 26 weeks after discontinuation of trastuzumab treatment, defined as a decline in LVEF (MUGA) of more than 15% or a decrease to an"},{"label":"2.","content":"absolute value below 45%."}],"pom_b":[{"label":"1.","content":"The occurrence of cardiotoxicity, defined as a decline in LVEF (MUGA) of more than 15% or a decrease of less than 15% to an absolute value below 45%.[ Time Frame: during 1 year trastuzumab therapy and during 26 weeks after discontinuation of trastuzumab ]"}],"start_date":"June 2007","primary_completion_date":"December 2013","completion_date":"December 2014","first_posted":"April 12, 2007","last_update_posted":"December 2, 2014"},{"nctid":"NCT03762018","version_a":16,"version_b":17,"version_a_date":"2020-10-02","version_b_date":"2020-11-27","pom_a":[{"label":"1.","content":"Progression-free Survival (PFS) according to the mRECIST v1.1[ Time Frame: From date of randomisation until documented progression or death, if progression is not documented, assessed up to 67 months ]A co-primary endpoint, defined as the time from the date of randomisation until documented progression (according to the mRECIST v1.1) or death, if progression is not documented. Censoring (for participants without a PFS/death event) will occur at the last tumour assessment if the patient is lost to follow-up or refuses further documentation of follow-up."},{"label":"2.","content":"Overall Survival (OS)[ Time Frame: From date of randomisation until death from any cause, assessed up to 67 months ]The second co-primary endpoint, overall survival, is defined as the time from the date of randomisation until death from any cause. Censoring will occur at the last follow-up date."}],"pom_b":[{"label":"1.","content":"Progression-free Survival (PFS) according to the mRECIST v1.1[ Time Frame: From date of randomisation until documented progression or death, if progression is not documented, assessed up to 67 months ]A co-primary endpoint, defined as the time from the date of randomisation until documented progression (according to the mRECIST v1.1) or death, if progression is not documented. Censoring (for participants without a PFS/death event) will occur at the last tumour assessment if the patient is lost to follow-up or refuses further documentation of follow-up."},{"label":"2.","content":"Overall Survival (OS)[ Time Frame: From date of randomisation until death from any cause, assessed up to 67 months ]The other co-primary endpoint, overall survival, is defined as the time from the date of randomisation until death from any cause. Censoring will occur at the last follow-up date."}],"start_date":"April 30, 2019","primary_completion_date":"January 31, 2024","completion_date":"January 31, 2024","first_posted":"December 3, 2018","last_update_posted":"August 24, 2022"},{"nctid":"NCT03762018","version_a":18,"version_b":19,"version_a_date":"2021-02-12","version_b_date":"2021-04-30","pom_a":[{"label":"1.","content":"Progression-free Survival (PFS) according to the mRECIST v1.1[ Time Frame: From date of randomisation until documented progression or death, if progression is not documented, assessed up to 67 months ]A co-primary endpoint, defined as the time from the date of randomisation until documented progression (according to the mRECIST v1.1) or death, if progression is not documented. Censoring (for participants without a PFS/death event) will occur at the last tumour assessment if the patient is lost to follow-up or refuses further documentation of follow-up."},{"label":"2.","content":"Overall Survival (OS)[ Time Frame: From date of randomisation until death from any cause, assessed up to 67 months ]The other co-primary endpoint, overall survival, is defined as the time from the date of randomisation until death from any cause. Censoring will occur at the last follow-up date."}],"pom_b":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: From date of randomisation until death from any cause, assessed up to 58 months ]Overall survival is defined as the time from the date of randomisation until death from any cause. Data for patients who are not reported as having died at the date of analysis will be censored at the date when they were last known to be alive. Data for patients without post-baseline information will be censored at the date of randomization (plus 1 day)."}],"start_date":"April 30, 2019","primary_completion_date":"January 31, 2024","completion_date":"January 31, 2024","first_posted":"December 3, 2018","last_update_posted":"August 24, 2022"},{"nctid":"NCT02100696","version_a":47,"version_b":48,"version_a_date":"2016-10-03","version_b_date":"2016-10-31","pom_a":[{"label":"1.","content":"Remission as determined by the Mayo Clinic Score (MCS)[ Time Frame: At Week 14 ]"},{"label":"2.","content":"Remission maintenance among patients with remission at Week 14. Measured by MCS[ Time Frame: At Week 66 ]"}],"pom_b":[{"label":"1.","content":"Percentage of Participants With Remission as Determined by the Mayo Clinic Score (MCS)[ Time Frame: Week 14 ]"},{"label":"2.","content":"Percentage of Participants With Remission at Week 66 Among Randomized Participants in Clinical Remission at Week 14, as Determined by the MCS[ Time Frame: Week 66 ]"}],"start_date":"May 21, 2014","primary_completion_date":"April 16, 2020","completion_date":"April 16, 2020","first_posted":"April 1, 2014","results_first_posted":"June 15, 2021","last_update_posted":"August 13, 2021"},{"nctid":"NCT02100696","version_a":62,"version_b":63,"version_a_date":"2019-02-11","version_b_date":"2019-04-24","pom_a":[{"label":"1.","content":"Percentage of Participants With Remission as Determined by the Mayo Clinic Score (MCS)[ Time Frame: Week 14 ]"},{"label":"2.","content":"Percentage of Participants With Remission at Week 66 Among Randomized Participants in Clinical Remission at Week 14, as Determined by the MCS[ Time Frame: Week 66 ]"}],"pom_b":[{"label":"1.","content":"Induction Phase: Percentage of Participants with Remission at Week 14, as Determined by the Mayo Clinic Score (MCS)[ Time Frame: Week 14 ]"},{"label":"2.","content":"Maintenance Phase: Percentage of Participants with Remission at Week 66 Among Participants Who Had Achieved a Clinical Response at Week 14, as Determined by the MCS[ Time Frame: Week 66 ]"}],"start_date":"May 21, 2014","primary_completion_date":"April 16, 2020","completion_date":"April 16, 2020","first_posted":"April 1, 2014","results_first_posted":"June 15, 2021","last_update_posted":"August 13, 2021"},{"nctid":"NCT02100696","version_a":68,"version_b":69,"version_a_date":"2020-05-07","version_b_date":"2021-05-20","pom_a":[{"label":"1.","content":"Induction Phase: Percentage of Participants with Remission at Week 14, as Determined by the Mayo Clinic Score (MCS)[ Time Frame: Week 14 ]"},{"label":"2.","content":"Maintenance Phase: Percentage of Participants with Remission at Week 66 Among Participants Who Had Achieved a Clinical Response at Week 14, as Determined by the MCS[ Time Frame: Week 66 ]"}],"pom_b":[{"label":"1.","content":"Induction Phase: Percentage of Participants With Remission at Week 14, as Determined by the Mayo Clinic Score (MCS)[ Time Frame: Week 14 ]The Mayo Clinic Score (MCS) ranges from 0 to 12 and is a composite of 4 assessments (each rated from 0-3): stool frequency, rectal bleeding, endoscopy, and physician\'s global assessment. Higher scores represent greater disease severity. Remission was defined as MCS less than or equal to (\u2264)2 with individual subscores \u22641 and a rectal bleeding subscore of 0."},{"label":"2.","content":"Maintenance Phase: Percentage of Participants With Remission at Week 66 Among Participants Who Had Achieved a Clinical Response at Week 14, as Determined by the MCS[ Time Frame: Week 66 ]The MCS ranges from 0 to 12 and is a composite of 4 assessments (each rated from 0-3): stool frequency, rectal bleeding, endoscopy, and physician\'s global assessment. Higher scores represent greater disease severity. Remission was defined as MCS less than or equal to (\u2264)2 with individual subscores \u22641 and a rectal bleeding subscore of 0. Clinical Response is MCS with \u22653-point decrease and 30% reduction from baseline as well as \u22651-point decrease in rectal bleeding subscore or an absolute rectal bleeding score of 0 or 1."}],"start_date":"May 21, 2014","primary_completion_date":"April 16, 2020","completion_date":"April 16, 2020","first_posted":"April 1, 2014","results_first_posted":"June 15, 2021","last_update_posted":"August 13, 2021"},{"nctid":"NCT04921358","version_a":1,"version_b":2,"version_a_date":"2021-06-07","version_b_date":"2021-06-10","pom_a":[{"label":"1.","content":"Overall survival (OS)[ Time Frame: From first randomization up to 35 months, approximately ]"},{"label":"2.","content":"Progression-free survival (PFS) as assessed by Independent Review Committee (IRC)[ Time Frame: From first randomization up to 35 months, approximately ]defined as the time from randomization to the first occurrence of disease progression as determined by the IRC based on RECIST v1.1, or death from any cause, whichever occurs first"}],"pom_b":[{"label":"1.","content":"Overall survival (OS)[ Time Frame: From first randomization up to 35 months, approximately ]OS is defined as the time from first study drug administration to the date of death due to any reason."},{"label":"2.","content":"Progression-free survival (PFS) as assessed by Independent Review Committee (IRC)[ Time Frame: From first randomization up to 35 months, approximately ]defined as the time from randomization to the first occurrence of disease progression as determined by the IRC based on RECIST v1.1, or death from any cause, whichever occurs first"}],"start_date":"July 27, 2021","primary_completion_date":"June 30, 2024","completion_date":"June 30, 2024","first_posted":"June 10, 2021","last_update_posted":"August 25, 2022"},{"nctid":"NCT04921358","version_a":5,"version_b":6,"version_a_date":"2022-03-08","version_b_date":"2022-04-13","pom_a":[{"label":"1.","content":"Overall survival (OS)[ Time Frame: From first randomization up to 35 months, approximately ]OS is defined as the time from first study drug administration to the date of death due to any reason."},{"label":"2.","content":"Progression-free survival (PFS) as assessed by Independent Review Committee (IRC)[ Time Frame: From first randomization up to 35 months, approximately ]defined as the time from randomization to the first occurrence of disease progression as determined by the IRC based on RECIST v1.1, or death from any cause, whichever occurs first"}],"pom_b":[{"label":"1.","content":"Overall survival (OS)[ Time Frame: From first randomization up to 35 months, approximately ]OS is defined as the time from randomization to the date of death due to any reason."},{"label":"2.","content":"Progression-free survival (PFS) as assessed by Independent Review Committee (IRC)[ Time Frame: From first randomization up to 35 months, approximately ]defined as the time from randomization to the first occurrence of disease progression as determined by the IRC based on RECIST v1.1, or death from any cause, whichever occurs first"}],"start_date":"July 27, 2021","primary_completion_date":"June 30, 2024","completion_date":"June 30, 2024","first_posted":"June 10, 2021","last_update_posted":"August 25, 2022"},{"nctid":"NCT02775435","version_a":44,"version_b":45,"version_a_date":"2018-09-18","version_b_date":"2019-03-18","pom_a":[{"label":"1.","content":"Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by a blinded central imaging vendor[ Time Frame: Up to approximately 2 years ]"},{"label":"2.","content":"Overall Survival (OS)[ Time Frame: Up to approximately 2 years ]"}],"pom_b":[{"label":"1.","content":"Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)[ Time Frame: Up to approximately 19 months (Database cutoff date of 03-Apr-2018) ]PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per Response Criteria in Solid Tumors version 1.1 (RECIST 1.1), PD was defined as \u226520% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of \u22655 mm. Note: The appearance of \u22651 new lesions was also considered PD. PFS as assessed by blinded independent central review per RECIST 1.1 is presented."},{"label":"2.","content":"Overall Survival (OS)[ Time Frame: Up to approximately 19 months (Database cutoff date of 03-Apr-2018) ]OS was defined as the time from randomization to death due to any cause. OS is presented."}],"start_date":"June 9, 2016","primary_completion_date":"April 3, 2018","completion_date":"March 21, 2023","first_posted":"May 17, 2016","results_first_posted":"April 10, 2019","last_update_posted":"August 19, 2022"},{"nctid":"NCT02371369","version_a":9,"version_b":10,"version_a_date":"2016-10-14","version_b_date":"2016-10-17","pom_a":[{"label":"1.","content":"percentage of subjects achieving complete or partial response[ Time Frame: week 25 ]The proportion of subjects who achieve a complete response (CR) or partial response (PR) at the Week 25 visit based on centrally read MRI scans and RECIST 1.1."}],"pom_b":[{"label":"1.","content":"Percentage of participants achieving complete or partial response[ Time Frame: week 25 ]The percentage of participants who achieved a complete response (CR) or partial response (PR) at the Week 25 visit based on centrally read MRI scans and RECIST 1.1."}],"start_date":"May 11, 2015","primary_completion_date":"March 27, 2017","completion_date":"April 30, 2021","first_posted":"February 25, 2015","results_first_posted":"January 10, 2020","last_update_posted":"May 11, 2022"},{"nctid":"NCT02371369","version_a":11,"version_b":12,"version_a_date":"2016-10-20","version_b_date":"2017-04-13","pom_a":[{"label":"1.","content":"Percentage of participants achieving complete or partial response[ Time Frame: week 25 ]The percentage of participants who achieved a complete response (CR) or partial response (PR) at the Week 25 visit based on centrally read MRI scans and RECIST 1.1."}],"pom_b":[{"label":"1.","content":"Percentage of participants achieving complete or partial response[ Time Frame: to the end of the trial, assessed up to an estimated total of 36 months ]The percentage of participants who achieved a complete response (CR) or partial response (PR) at the Week 25 visit based on centrally read MRI scans and RECIST 1.1."}],"start_date":"May 11, 2015","primary_completion_date":"March 27, 2017","completion_date":"April 30, 2021","first_posted":"February 25, 2015","results_first_posted":"January 10, 2020","last_update_posted":"May 11, 2022"},{"nctid":"NCT02371369","version_a":17,"version_b":18,"version_a_date":"2017-10-13","version_b_date":"2017-11-07","pom_a":[{"label":"1.","content":"Percentage of participants achieving complete or partial response[ Time Frame: to the end of the trial, assessed up to an estimated total of 36 months ]The percentage of participants who achieved a complete response (CR) or partial response (PR) at the Week 25 visit based on centrally read MRI scans and RECIST 1.1."}],"pom_b":[{"label":"1.","content":"Percentage of participants achieving complete or partial response at Week 25[ Time Frame: at Week 25 ]The percentage of participants who achieved a complete response (CR) or partial response (PR) at the Week 25 visit based on centrally read MRI scans and RECIST 1.1."},{"label":"2.","content":"Percentage of participants achieving complete or partial response by the end of the trial[ Time Frame: at the end of the trial, assessed up to an estimated total of 36 months ]The percentage of participants who achieved a complete response (CR) or partial response (PR) by the end of the trial based on centrally read MRI scans and RECIST 1.1."}],"start_date":"May 11, 2015","primary_completion_date":"March 27, 2017","completion_date":"April 30, 2021","first_posted":"February 25, 2015","results_first_posted":"January 10, 2020","last_update_posted":"May 11, 2022"},{"nctid":"NCT02371369","version_a":18,"version_b":19,"version_a_date":"2017-11-07","version_b_date":"2018-03-13","pom_a":[{"label":"1.","content":"Percentage of participants achieving complete or partial response at Week 25[ Time Frame: at Week 25 ]The percentage of participants who achieved a complete response (CR) or partial response (PR) at the Week 25 visit based on centrally read MRI scans and RECIST 1.1."},{"label":"2.","content":"Percentage of participants achieving complete or partial response by the end of the trial[ Time Frame: at the end of the trial, assessed up to an estimated total of 36 months ]The percentage of participants who achieved a complete response (CR) or partial response (PR) by the end of the trial based on centrally read MRI scans and RECIST 1.1."}],"pom_b":[{"label":"1.","content":"Percentage of participants achieving complete or partial response at Week 25[ Time Frame: at Week 25 ]The percentage of participants who achieved a complete response (CR) or partial response (PR) at the Week 25 visit based on centrally read MRI scans and RECIST 1.1."},{"label":"2.","content":"Percentage of participants achieving complete or partial response by the end of the trial[ Time Frame: by the end of the trial, estimated at 46 months ]The percentage of participants who achieved a complete response (CR) or partial response (PR) by the end of the trial based on centrally read MRI scans and RECIST 1.1."}],"start_date":"May 11, 2015","primary_completion_date":"March 27, 2017","completion_date":"April 30, 2021","first_posted":"February 25, 2015","results_first_posted":"January 10, 2020","last_update_posted":"May 11, 2022"},{"nctid":"NCT02371369","version_a":22,"version_b":23,"version_a_date":"2019-01-20","version_b_date":"2020-01-06","pom_a":[{"label":"1.","content":"Percentage of participants achieving complete or partial response at Week 25[ Time Frame: at Week 25 ]The percentage of participants who achieved a complete response (CR) or partial response (PR) at the Week 25 visit based on centrally read MRI scans and RECIST 1.1."},{"label":"2.","content":"Percentage of participants achieving complete or partial response by the end of the trial[ Time Frame: by the end of the trial, estimated at 46 months ]The percentage of participants who achieved a complete response (CR) or partial response (PR) by the end of the trial based on centrally read MRI scans and RECIST 1.1."}],"pom_b":[{"label":"1.","content":"Percentage of Participants With Symptomatic, Locally Advanced Tenosynovial Giant Cell Tumor (TGCT) Achieving Complete or Partial Response to Pexidartinib Compared With That of Placebo Per Response Evaluation Criteria in Solid Tumors Version 1.1 at Week 25[ Time Frame: Week 25 ]Complete response (CR) and partial responses (PR) were assessed based on centrally-read magnetic resonance imaging (MRI) scans and Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1). A CR was defined as disappearance of all tumors and a PR was defined as at least a 30% decrease in the sum of diameters of target tumors using the baseline sum diameters as the reference."}],"start_date":"May 11, 2015","primary_completion_date":"March 27, 2017","completion_date":"April 30, 2021","first_posted":"February 25, 2015","results_first_posted":"January 10, 2020","last_update_posted":"May 11, 2022"},{"nctid":"NCT00353496","version_a":3,"version_b":4,"version_a_date":"2007-02-08","version_b_date":"2007-07-23","pom_a":[{"label":"1.","content":"Time to either disease progression or death within 96 weeks after the first study drug administration."}],"pom_b":[{"label":"1.","content":"Time to either disease progression or death[ Time Frame: Within 96 weeks after the first study drug administration ]"}],"start_date":"June 2006","primary_completion_date":"April 2013","completion_date":"April 2013","first_posted":"July 18, 2006","results_first_posted":"February 18, 2015","last_update_posted":"March 6, 2015"},{"nctid":"NCT00353496","version_a":24,"version_b":25,"version_a_date":"2013-08-29","version_b_date":"2015-02-17","pom_a":[{"label":"1.","content":"Time to either disease progression or death[ Time Frame: Within 96 weeks after the first study drug administration ]"}],"pom_b":[{"label":"1.","content":"Progression-Free Survival (PFS)[ Time Frame: From randomisation up to the last tumour assessment (scheduled at 96 weeks). Radiological scans were performed every 12 weeks during the first year and every 24 weeks during the second year ]Time from randomization to first documentation of disease progression, or death. Disease progression centrally assessed using Response Evaluation Criteria in Solid Tumours (RECIST) v1.0"}],"start_date":"June 2006","primary_completion_date":"April 2013","completion_date":"April 2013","first_posted":"July 18, 2006","results_first_posted":"February 18, 2015","last_update_posted":"March 6, 2015"},{"nctid":"NCT02715804","version_a":35,"version_b":36,"version_a_date":"2018-11-28","version_b_date":"2019-01-30","pom_a":[{"label":"1.","content":"Progression-Free Survival (PFS)[ Time Frame: Approximately 12 months ]"},{"label":"2.","content":"Overall Survival (OS)[ Time Frame: Approximately 24 months ]"}],"pom_b":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: Approximately 24 months ]"}],"start_date":"March 14, 2016","primary_completion_date":"November 4, 2019","completion_date":"November 4, 2019","first_posted":"March 22, 2016","results_first_posted":"July 14, 2020","last_update_posted":"July 14, 2020"},{"nctid":"NCT02715804","version_a":41,"version_b":42,"version_a_date":"2019-12-02","version_b_date":"2020-06-30","pom_a":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: Approximately 24 months ]"}],"pom_b":[{"label":"1.","content":"Overall Survival[ Time Frame: From randomization until death from any cause (maximum exposure: 150.1 weeks for PAG, and 83.9 weeks for AG) ]Overall survival was defined as the time from randomization until death from any cause. Overall survival was analyzed using Kaplan-Meier methods."}],"start_date":"March 14, 2016","primary_completion_date":"November 4, 2019","completion_date":"November 4, 2019","first_posted":"March 22, 2016","results_first_posted":"July 14, 2020","last_update_posted":"July 14, 2020"},{"nctid":"NCT00056160","version_a":1,"version_b":2,"version_a_date":"2005-06-23","version_b_date":"2007-07-27","pom_a":[],"pom_b":[{"label":"1.","content":"Time to tumor progression (TTP)"}],"start_date":"January 1, 2003","primary_completion_date":"November 1, 2005","completion_date":"October 1, 2008","first_posted":"March 7, 2003","results_first_posted":"March 3, 2010","last_update_posted":"October 19, 2017"},{"nctid":"NCT00056160","version_a":3,"version_b":4,"version_a_date":"2009-05-18","version_b_date":"2009-09-21","pom_a":[{"label":"1.","content":"Time to tumor progression (TTP)"}],"pom_b":[{"label":"1.","content":"Time to tumor progression (TTP)[ Time Frame: randomization to progression ]"}],"start_date":"January 1, 2003","primary_completion_date":"November 1, 2005","completion_date":"October 1, 2008","first_posted":"March 7, 2003","results_first_posted":"March 3, 2010","last_update_posted":"October 19, 2017"},{"nctid":"NCT00056160","version_a":4,"version_b":5,"version_a_date":"2009-09-21","version_b_date":"2010-02-02","pom_a":[{"label":"1.","content":"Time to tumor progression (TTP)[ Time Frame: randomization to progression ]"}],"pom_b":[{"label":"1.","content":"Time to Tumor Progression (TTP)[ Time Frame: 60 weeks (median Time To Progression of CC-5013/Dex treatment group) ]Time to progression (TTP) was calculated as the time from randomization to the first documentation of progressive disease based on the myeloma response determination criteria developed by Blade, et. al."}],"start_date":"January 1, 2003","primary_completion_date":"November 1, 2005","completion_date":"October 1, 2008","first_posted":"March 7, 2003","results_first_posted":"March 3, 2010","last_update_posted":"October 19, 2017"},{"nctid":"NCT00056160","version_a":5,"version_b":6,"version_a_date":"2010-02-02","version_b_date":"2010-03-10","pom_a":[{"label":"1.","content":"Time to Tumor Progression (TTP)[ Time Frame: 60 weeks (median Time To Progression of CC-5013/Dex treatment group) ]Time to progression (TTP) was calculated as the time from randomization to the first documentation of progressive disease based on the myeloma response determination criteria developed by Blade, et. al."}],"pom_b":[{"label":"1.","content":"Time to Tumor Progression (TTP)[ Time Frame: 60 weeks (median Time To Progression of CC-5013/Dex treatment group) ]Time to progression (TTP) was calculated as the time from randomization to the first documentation of progressive disease based on the myeloma response determination criteria developed by Blad\xe9 et. al., Br J Haematol 1998; 102:1115-1123."}],"start_date":"January 1, 2003","primary_completion_date":"November 1, 2005","completion_date":"October 1, 2008","first_posted":"March 7, 2003","results_first_posted":"March 3, 2010","last_update_posted":"October 19, 2017"},{"nctid":"NCT00005648","version_a":8,"version_b":9,"version_a_date":"2008-07-23","version_b_date":"2010-09-30","pom_a":[],"pom_b":[{"label":"1.","content":"Overall survival of patients with advanced pancreatic cancer after treatment with gemcitabine with or without R115777.[ Time Frame: From the date of randomization to the date of death or to the last followup date for patients who were still alive at the clinical cutoff date (ie, for up to 5 years) ]"}],"start_date":"November 1999","completion_date":"November 2003","first_posted":"May 21, 2004","last_update_posted":"May 19, 2011"},{"nctid":"NCT02531516","version_a":1,"version_b":2,"version_a_date":"2015-08-21","version_b_date":"2015-12-23","pom_a":[{"label":"1.","content":"Metastasis-free survival[ Time Frame: 72 Months ]"}],"pom_b":[{"label":"1.","content":"Metastasis-free survival[ Time Frame: 84 Months ]"}],"start_date":"November 19, 2015","primary_completion_date":"December 30, 2022","completion_date":"October 6, 2026","first_posted":"August 24, 2015","last_update_posted":"August 3, 2022"},{"nctid":"NCT02531516","version_a":65,"version_b":66,"version_a_date":"2022-04-21","version_b_date":"2022-06-02","pom_a":[{"label":"1.","content":"Metastasis-free survival[ Time Frame: 84 Months ]"}],"pom_b":[{"label":"1.","content":"Metastasis-free survival[ Time Frame: 108 Months ]Metastasis-free survival is defined as the time from randomization to the date of the first occurrence of radiographic bone or soft tissue distant metastasis based on conventional imaging by blinded independent central review (BICR), histopathologic diagnosis of distant metastasis, or death from any cause, whichever occurs first."}],"start_date":"November 19, 2015","primary_completion_date":"December 30, 2022","completion_date":"October 6, 2026","first_posted":"August 24, 2015","last_update_posted":"August 3, 2022"},{"nctid":"NCT00152256","version_a":5,"version_b":6,"version_a_date":"2007-04-10","version_b_date":"2007-06-29","pom_a":[{"label":"1.","content":"The percent of subjects who demonstrate a clinically meaningful improvement in bleeding and do not have surgical/invasive intervention during the treatment period or who discontinue treatment because of planned surgical/invasive intervention"}],"pom_b":[{"label":"1.","content":"The percent of subjects who demonstrate a clinically meaningful improvement in bleeding and do not have surgical/invasive intervention during the treatment period or who discontinue treatment because of planned surgical/invasive intervention[ Time Frame: Month 3 ]"}],"start_date":"September 2003","primary_completion_date":"February 2005","completion_date":"February 2005","first_posted":"September 9, 2005","last_update_posted":"May 29, 2008"},{"nctid":"NCT00152256","version_a":7,"version_b":8,"version_a_date":"2007-10-01","version_b_date":"2008-01-03","pom_a":[{"label":"1.","content":"The percent of subjects who demonstrate a clinically meaningful improvement in bleeding and do not have surgical/invasive intervention during the treatment period or who discontinue treatment because of planned surgical/invasive intervention[ Time Frame: Month 3 ]"}],"pom_b":[{"label":"1.","content":"Cumulative percent of subjects achieving amenorrhea.[ Time Frame: Month 3 ]"}],"start_date":"September 2003","primary_completion_date":"February 2005","completion_date":"February 2005","first_posted":"September 9, 2005","last_update_posted":"May 29, 2008"},{"nctid":"NCT01321554","version_a":7,"version_b":8,"version_a_date":"2012-01-31","version_b_date":"2012-02-02","pom_a":[{"label":"1.","content":"To compare the Progression-free Survival (PFS) of subjects with 131IRefractory differentiated thyroid cancer (DTC) with radiographic evidence of disease progression within the prior 12 months treated with E7080 versus Placebo.[ Time Frame: Date of randomization to the date of disease progression (measured every 8 weeks) or death (whichever occurs first) as determined by blinded independent imaging review ]"}],"pom_b":[{"label":"1.","content":"To compare the Progression-free Survival (PFS) of subjects with 131IRefractory differentiated thyroid cancer (DTC) with radiographic evidence of disease progression within the prior 12 months treated with lenvatinib versus Placebo.[ Time Frame: Date of randomization to the date of disease progression (measured every 8 weeks) or death (whichever occurs first) as determined by blinded independent imaging review ]"}],"start_date":"March 17, 2011","primary_completion_date":"November 15, 2013","completion_date":"March 19, 2019","first_posted":"March 23, 2011","results_first_posted":"December 12, 2016","last_update_posted":"April 2, 2020"},{"nctid":"NCT01321554","version_a":19,"version_b":20,"version_a_date":"2014-12-18","version_b_date":"2016-10-19","pom_a":[{"label":"1.","content":"To compare the Progression-free Survival (PFS) of subjects with 131IRefractory differentiated thyroid cancer (DTC) with radiographic evidence of disease progression within the prior 12 months treated with lenvatinib versus Placebo.[ Time Frame: Date of randomization to the date of disease progression (measured every 8 weeks) or death (whichever occurs first) as determined by blinded independent imaging review ]"}],"pom_b":[{"label":"1.","content":"Progression Free Survival (PFS)[ Time Frame: Date of randomization to the date of disease progression or death (whichever occurred first), assessed up to data cutoff date (15 Nov 2013) or up to approximately 2.5 years ]PFS was defined as the time from the date of randomization to the date of first documentation of disease progression or death (whichever occurred first), as determined by blinded independent imaging review (IIR) using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 for the double-blind treatment period (Randomization Phase). Disease progression per RECIST v1.1 was defined as at least a 20% relative increase and 5 mm absolute increase in the sum of diameters of target lesions (taking as reference the smallest sum on study), recorded since the treatment started or the appearance of 1 or more new lesions."}],"start_date":"March 17, 2011","primary_completion_date":"November 15, 2013","completion_date":"March 19, 2019","first_posted":"March 23, 2011","results_first_posted":"December 12, 2016","last_update_posted":"April 2, 2020"},{"nctid":"NCT01321554","version_a":28,"version_b":29,"version_a_date":"2019-04-25","version_b_date":"2020-03-18","pom_a":[{"label":"1.","content":"Progression Free Survival (PFS)[ Time Frame: Date of randomization to the date of disease progression or death (whichever occurred first), assessed up to data cutoff date (15 Nov 2013) or up to approximately 2.5 years ]PFS was defined as the time from the date of randomization to the date of first documentation of disease progression or death (whichever occurred first), as determined by blinded independent imaging review (IIR) using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 for the double-blind treatment period (Randomization Phase). Disease progression per RECIST v1.1 was defined as at least a 20% relative increase and 5 mm absolute increase in the sum of diameters of target lesions (taking as reference the smallest sum on study), recorded since the treatment started or the appearance of 1 or more new lesions."}],"pom_b":[{"label":"1.","content":"Progression Free Survival (PFS)[ Time Frame: Date of randomization to the date of disease progression or death (whichever occurred first), assessed up to data cutoff date (15 Nov 2013) or up to approximately 2.5 years ]PFS was defined as the time from the date of randomization to the date of first documentation of disease progression or death (whichever occurred first), as determined by blinded IIR using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 for the double-blind treatment period (Randomization Phase). Disease progression per RECIST v1.1 was defined as at least a 20 percent (%) relative increase and 5 millimeter (mm) absolute increase in the sum of diameters of target lesions (taking as reference the smallest sum on study), recorded since the treatment started or the appearance of 1 or more new lesions."}],"start_date":"March 17, 2011","primary_completion_date":"November 15, 2013","completion_date":"March 19, 2019","first_posted":"March 23, 2011","results_first_posted":"December 12, 2016","last_update_posted":"April 2, 2020"},{"nctid":"NCT00054392","version_a":23,"version_b":24,"version_a_date":"2006-11-08","version_b_date":"2006-11-21","pom_a":[],"pom_b":[{"label":"1.","content":"Comparison of overall survival"}],"start_date":"September 2001","primary_completion_date":"September 2001","completion_date":"September 2001","first_posted":"February 6, 2003","last_update_posted":"July 11, 2013"},{"nctid":"NCT00054392","version_a":24,"version_b":25,"version_a_date":"2006-11-21","version_b_date":"2006-12-06","pom_a":[{"label":"1.","content":"Comparison of overall survival"}],"pom_b":[{"label":"1.","content":"Survival"}],"start_date":"September 2001","primary_completion_date":"September 2001","completion_date":"September 2001","first_posted":"February 6, 2003","last_update_posted":"July 11, 2013"},{"nctid":"NCT01578239","version_a":21,"version_b":22,"version_a_date":"2017-07-13","version_b_date":"2017-08-29","pom_a":[{"label":"1.","content":"Progression Free survival (PFS)[ Time Frame: 12+/- 1 weeks ]Primary efficacy endpoint is PFS as measured by objective tumour response, centrally assessed according to RECIST Criteria.CT/MRI tumour assessment in both arms will be performed every 12\xb11 weeks from the first treatment date."}],"pom_b":[{"label":"1.","content":"Progression Free Survival (PFS)[ Time Frame: after 74 centrally confirmed cases disease progression or death ]Primary efficacy endpoint is PFS as measured by objective tumour response, centrally assessed according to RECIST Criteria.CT/MRI tumour assessment in both arms will be performed every 12\xb11 weeks from the first treatment date."}],"start_date":"September 6, 2012","primary_completion_date":"July 31, 2015","completion_date":"January 18, 2021","first_posted":"April 16, 2012","results_first_posted":"October 2, 2017","last_update_posted":"April 4, 2022"},{"nctid":"NCT01578239","version_a":22,"version_b":23,"version_a_date":"2017-08-29","version_b_date":"2017-11-10","pom_a":[{"label":"1.","content":"Progression Free Survival (PFS)[ Time Frame: after 74 centrally confirmed cases disease progression or death ]Primary efficacy endpoint is PFS as measured by objective tumour response, centrally assessed according to RECIST Criteria.CT/MRI tumour assessment in both arms will be performed every 12\xb11 weeks from the first treatment date."}],"pom_b":[{"label":"1.","content":"Progression Free Survival (PFS)[ Time Frame: after 74 centrally confirmed cases disease progression or death ]Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.CT/MRI tumour assessment in both arms are performed every 12\xb11 weeks from the first treatment date."}],"start_date":"September 6, 2012","primary_completion_date":"July 31, 2015","completion_date":"January 18, 2021","first_posted":"April 16, 2012","results_first_posted":"October 2, 2017","last_update_posted":"April 4, 2022"},{"nctid":"NCT01578239","version_a":26,"version_b":27,"version_a_date":"2019-10-29","version_b_date":"2020-01-07","pom_a":[{"label":"1.","content":"Progression Free Survival (PFS)[ Time Frame: after 74 centrally confirmed cases disease progression or death ]Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.CT/MRI tumour assessment in both arms are performed every 12\xb11 weeks from the first treatment date."}],"pom_b":[{"label":"1.","content":"Progression Free Survival (PFS)[ Time Frame: after 74 centrally confirmed cases disease progression or death ]Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. CT/MRI tumour assessment in both arms are performed every 12\xb11 weeks from the first treatment date."}],"start_date":"September 6, 2012","primary_completion_date":"July 31, 2015","completion_date":"January 18, 2021","first_posted":"April 16, 2012","results_first_posted":"October 2, 2017","last_update_posted":"April 4, 2022"},{"nctid":"NCT01578239","version_a":29,"version_b":30,"version_a_date":"2021-07-22","version_b_date":"2021-09-14","pom_a":[{"label":"1.","content":"Progression Free Survival (PFS)[ Time Frame: after 74 centrally confirmed cases disease progression or death ]Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. CT/MRI tumour assessment in both arms are performed every 12\xb11 weeks from the first treatment date."}],"pom_b":[{"label":"1.","content":"Progression Free Survival (PFS)[ Time Frame: From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first until Primary Analysis cutoff date reached on 24July2015, assessed up to approximately 34 months ]Progression Free Survival (PFS) was defined as the time from randomization to documented centrally assessed disease progression, as evaluated by the Independent Review Committee (IRC), or death due to any cause. If a participant had no centrally assessed progression and had not died at the time of the primary endpoint analysis, the participant was regarded as censored in the context of a time to event analysis at the date of last evaluable tumor assessment. Disease progression was determined by objective tumor response status using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1)."}],"start_date":"September 6, 2012","primary_completion_date":"July 31, 2015","completion_date":"January 18, 2021","first_posted":"April 16, 2012","results_first_posted":"October 2, 2017","last_update_posted":"April 4, 2022"},{"nctid":"NCT02472145","version_a":12,"version_b":13,"version_a_date":"2016-01-21","version_b_date":"2016-02-10","pom_a":[{"label":"1.","content":"Event-Free Survival[ Time Frame: Up to 1 year after last participant enrolled ]Time from randomization to treatment failure, relapse from CR (complete response) or CRi (complete response with incomplete recovery), or death of any causes."}],"pom_b":[{"label":"1.","content":"Complete Response Rate[ Time Frame: Disease assessment will continue until treatment failure or relapse or clinical cut-off (Approximately up to 4 years after first participant enrollment) ]Percentage of participants reaching complete response (CR)."},{"label":"2.","content":"Overall Survival[ Time Frame: Approximately up to 4 years after first participant enrollment ]Overall survival will be defined as the time between randomization to death from any cause."}],"start_date":"August 4, 2015","primary_completion_date":"January 25, 2018","completion_date":"January 25, 2018","first_posted":"June 15, 2015","results_first_posted":"February 28, 2019","last_update_posted":"March 19, 2019"},{"nctid":"NCT02472145","version_a":41,"version_b":42,"version_a_date":"2018-04-23","version_b_date":"2019-02-27","pom_a":[{"label":"1.","content":"Complete Response Rate[ Time Frame: Disease assessment will continue until treatment failure or relapse or clinical cut-off (Approximately up to 4 years after first participant enrollment) ]Percentage of participants reaching complete response (CR)."},{"label":"2.","content":"Overall Survival[ Time Frame: Approximately up to 4 years after first participant enrollment ]Overall survival will be defined as the time between randomization to death from any cause."}],"pom_b":[{"label":"1.","content":"Part B: Percentage of Participants Who Achieved Complete Response (Complete Response Rate) Based on Investigator Assessment[ Time Frame: Approximately up to 2.5 years ]Complete response rate defined as percentage of participants who achieved complete response as per modified International Working Group (IWG) criteria. CR: Bone marrow blasts less than (<)5 percent (%); absence of blasts with Auer rods; absence of extramedullary disease; absolute neutrophil count greater than (>)1.0*10^9/liter (L) (1000/micro liter [mcL]); platelet count >100*10^9/L (100 000/mcL); independence of red cell transfusions. This endpoint is reported here for Part B only as per the planned analysis."},{"label":"2.","content":"Part B: Overall Survival[ Time Frame: Approximately up to 2.5 years ]Overall Survival (OS) was defined as the time from the date of randomization to date of death from any cause. Median Overall Survival was estimated by using the Kaplan-Meier method. This endpoint is reported here for Part B only as per the planned analysis."}],"start_date":"August 4, 2015","primary_completion_date":"January 25, 2018","completion_date":"January 25, 2018","first_posted":"June 15, 2015","results_first_posted":"February 28, 2019","last_update_posted":"March 19, 2019"},{"nctid":"NCT01713946","version_a":2,"version_b":3,"version_a_date":"2013-01-24","version_b_date":"2013-02-19","pom_a":[{"label":"1.","content":"European Medicine Agency (EMA): Response rate[ Time Frame: Baseline, Week 6 ]Response means at least a 50% reduction from baseline in partial-onset seizure frequency"},{"label":"2.","content":"European Medicine Agency (EMA): Response rate[ Time Frame: Baseline, Week 12 ]Response means at least a 50% reduction from baseline in partial-onset seizure frequency"},{"label":"3.","content":"Food & Drug Administration (FDA): Percentage reduction in partial onset seizure frequency[ Time Frame: Baseline, Week 6 ]"},{"label":"4.","content":"Food & Drug Administration (FDA): Percentage reduction in partial onset seizure frequency[ Time Frame: Baseline, Week 12 ]"}],"pom_b":[{"label":"1.","content":"European Medicine Agency (EMA): Response rate[ Time Frame: Baseline, Week 12 ]Response means at least a 50% reduction from baseline in partial-onset seizure frequency"},{"label":"2.","content":"Food & Drug Administration (FDA): Percentage reduction in partial onset seizure frequency[ Time Frame: Baseline, Week 12 ]Percentage reduction from baseline in partial onset seizure frequency during maintenance period of the core phase."}],"start_date":"April 29, 2013","primary_completion_date":"October 25, 2017","completion_date":"October 25, 2017","first_posted":"October 25, 2012","results_first_posted":"November 7, 2018","last_update_posted":"November 7, 2018"},{"nctid":"NCT01713946","version_a":29,"version_b":30,"version_a_date":"2018-01-31","version_b_date":"2018-11-06","pom_a":[{"label":"1.","content":"European Medicine Agency (EMA): Response rate[ Time Frame: Baseline, Week 12 ]Response means at least a 50% reduction from baseline in partial-onset seizure frequency"},{"label":"2.","content":"Food & Drug Administration (FDA): Percentage reduction in partial onset seizure frequency[ Time Frame: Baseline, Week 12 ]Percentage reduction from baseline in partial onset seizure frequency during maintenance period of the core phase."}],"pom_b":[{"label":"1.","content":"Core Phase: European Medicine Agency (EMA): Seizure Frequency Response Rate[ Time Frame: Baseline (8-week period before randomization), Week 7 to 18 (12-week maintenance period of the core phase) ]Comparison of response rates in the everolimus low-trough treatment arm (3-7 ng/mL), high-trough treatment arm (9-15 ng/mL) and placebo arm. Response means at least a 50% reduction from baseline in partial-onset seizure frequency during the maintenance period of the core phase."},{"label":"2.","content":"Core Phase: Food & Drug Administration (FDA): Percentage Change From Baseline in Partial Onset-seizure Frequency[ Time Frame: Baseline (8-week period before randomization), Week 7 to 18 (12-week maintenance period of the core phase) ]Comparison of median percent change from baseline in weekly seizure frequency in the everolimus low-trough treatment arm (3-7 ng/mL), high-trough treatment arm (9-15 ng/mL) and placebo arm during maintenance period of the core phase. Percentage change from baseline in average weekly seizure frequency during the maintenance period of the Core phase (SFcfb) = 100 \xd7 (SFB - SFM) \xf7 SFB where:SFB is the average weekly seizure frequency in the Baseline phase SFM is the average weekly seizure frequency in the maintenance period of the Core phase A positive percentage change from baseline (SFcfb) means a reduction in seizure frequency whereas a negative percentage change from baseline (SFcfb) means an increase in seizure frequency."}],"start_date":"April 29, 2013","primary_completion_date":"October 25, 2017","completion_date":"October 25, 2017","first_posted":"October 25, 2012","results_first_posted":"November 7, 2018","last_update_posted":"November 7, 2018"},{"nctid":"NCT00706121","version_a":11,"version_b":12,"version_a_date":"2011-04-09","version_b_date":"2013-01-03","pom_a":[{"label":"1.","content":"Effect of selenium on colorectal adenoma (CRA) occurrence and colorectal cancer (CRC) incidence"},{"label":"2.","content":"Effect of selenium on number, location, size, histologic type, and degree of dysplasia of CRA"}],"pom_b":[{"label":"1.","content":"Effect of selenium on colorectal adenoma (CRA) occurrence and colorectal cancer (CRC) incidence[ Time Frame: Occurence of a colorectal procedure in which CRA or CRC could be evaluated is collected every 6 months ]"},{"label":"2.","content":"Effect of selenium on number, location, size, histologic type, and degree of dysplasia of CRA[ Time Frame: Occurence of a colorectal procedure in which CRA or CRC could be evaluated is collected every 6 months ]"}],"start_date":"June 2008","primary_completion_date":"October 2015","completion_date":"January 2018","first_posted":"June 27, 2008","results_first_posted":"April 4, 2017","last_update_posted":"December 16, 2019"},{"nctid":"NCT00706121","version_a":16,"version_b":17,"version_a_date":"2015-11-16","version_b_date":"2017-02-15","pom_a":[{"label":"1.","content":"Effect of selenium on colorectal adenoma (CRA) occurrence and colorectal cancer (CRC) incidence[ Time Frame: Occurence of a colorectal procedure in which CRA or CRC could be evaluated is collected every 6 months ]"},{"label":"2.","content":"Effect of selenium on number, location, size, histologic type, and degree of dysplasia of CRA[ Time Frame: Occurence of a colorectal procedure in which CRA or CRC could be evaluated is collected every 6 months ]"}],"pom_b":[{"label":"1.","content":"Effect of Selenium on Colorectal Adenoma (CRA) Occurrence[ Time Frame: Occurence of a colorectal procedure in which CRA could be evaluated is collected every 6 months ]"},{"label":"2.","content":"Effect of Selenium on Advanced Neoplasia[ Time Frame: Occurence of a colorectal procedure in which CRA or CRC could be evaluated is collected every 6 months ]Adenomas with diameter >=1cm or any adenoma with villous features or high-grade dysplasia"},{"label":"3.","content":"Effect of Selenium and/or Vitamin E on Colorectal Cancer (CRC) Incidence[ Time Frame: Occurence of a colorectal procedure in which CRC could be evaluated is collected every 6 months ]"},{"label":"4.","content":"Effect of Selenium on Occurrences of Multiple (>2) Adenomas[ Time Frame: Occurence of a colorectal procedure in which CRA could be evaluated is collected every 6 months ]"}],"start_date":"June 2008","primary_completion_date":"October 2015","completion_date":"January 2018","first_posted":"June 27, 2008","results_first_posted":"April 4, 2017","last_update_posted":"December 16, 2019"},{"nctid":"NCT00706121","version_a":17,"version_b":18,"version_a_date":"2017-02-15","version_b_date":"2017-05-23","pom_a":[{"label":"1.","content":"Effect of Selenium on Colorectal Adenoma (CRA) Occurrence[ Time Frame: Occurence of a colorectal procedure in which CRA could be evaluated is collected every 6 months ]"},{"label":"2.","content":"Effect of Selenium on Advanced Neoplasia[ Time Frame: Occurence of a colorectal procedure in which CRA or CRC could be evaluated is collected every 6 months ]Adenomas with diameter >=1cm or any adenoma with villous features or high-grade dysplasia"},{"label":"3.","content":"Effect of Selenium and/or Vitamin E on Colorectal Cancer (CRC) Incidence[ Time Frame: Occurence of a colorectal procedure in which CRC could be evaluated is collected every 6 months ]"},{"label":"4.","content":"Effect of Selenium on Occurrences of Multiple (>2) Adenomas[ Time Frame: Occurence of a colorectal procedure in which CRA could be evaluated is collected every 6 months ]"}],"pom_b":[{"label":"1.","content":"Effect of Selenium on Colorectal Adenoma (CRA) Occurrence, Analyzed by Active Selenium vs. Selenium Placebo[ Time Frame: From 1 year post randomization through study completion ]"},{"label":"2.","content":"Effect of Selenium on Advanced Neoplasia, Analyzed by Active Selenium vs. Selenium Placebo[ Time Frame: From 1 year post randomization through study completion ]Adenomas with diameter >=1cm or any adenoma with villous features or high-grade dysplasia"},{"label":"3.","content":"Effect of Selenium and/or Vitamin E on Colorectal Cancer (CRC) Incidence[ Time Frame: From 1 year post randomization through study completion ]"},{"label":"4.","content":"Effect of Selenium on Occurrences of Multiple (>2) Adenomas[ Time Frame: From 1 year post randomization through study completion ]"}],"start_date":"June 2008","primary_completion_date":"October 2015","completion_date":"January 2018","first_posted":"June 27, 2008","results_first_posted":"April 4, 2017","last_update_posted":"December 16, 2019"},{"nctid":"NCT00128531","version_a":2,"version_b":3,"version_a_date":"2005-08-23","version_b_date":"2005-08-25","pom_a":[{"label":"1.","content":"Efficacy:"},{"label":"2.","content":"1. To determine the proportion of patients achieving castration levels of plasma testosterone (defined as <0.5 ng/mL) 4 weeks after the first administration."},{"label":"3.","content":"2. To determine the proportion of patients maintaining castration levels of plasma testosterone from week 4 to study end."},{"label":"4.","content":"3. To determine the proportion of patients showing acute rises in plasma testosterone levels upon repeated dosing from week 4 to study end."},{"label":"5.","content":"Safety:"},{"label":"6.","content":"Evaluation of the safety of the new formulation based on AEs, local tolerability, vital signs, ECGs, and clinical parameters."}],"pom_b":[{"label":"1.","content":"Efficacy: to determine the proportion of patients achieving castration levels of plasma testosterone (defined as <0.5 ng/mL) 4 weeks after the first administration"},{"label":"2.","content":"to determine the proportion of patients maintaining castration levels of plasma testosterone from week 4 to study end"},{"label":"3.","content":"to determine the proportion of patients showing acute rises in plasma testosterone levels upon repeated dosing from week 4 to study end"},{"label":"4.","content":"Safety: evaluation of the safety of the new formulation based on adverse events (AEs), local tolerability, vital signs, electrocardiograms (ECGs), and clinical parameters"}],"start_date":"September 2005","completion_date":"November 2007","first_posted":"August 10, 2005","last_update_posted":"November 14, 2007"},{"nctid":"NCT03176238","version_a":1,"version_b":2,"version_a_date":"2017-06-01","version_b_date":"2017-06-16","pom_a":[{"label":"1.","content":"Safety and tolerability profile of everolimus[ Time Frame: Up to 5 years (Baseline, regularly scheduled visits up to last patient las visit) ]Incidence of adverse events (AEs) by grade (CTCAE, version 4.03), serious adverse events (SAEs), changes from baseline in vital signs and laboratory results (hematology, blood chemistry, lipid profile) qualifying as AEs."}],"pom_b":[{"label":"1.","content":"Incidence of treatment emergent adverse events (Safety and tolerability)[ Time Frame: Up to 5 years (Baseline, regularly scheduled visits up to last patient las visit) ](AEs) by grade (CTCAE, version 4.03), serious adverse events (SAEs), changes from baseline in vital signs and laboratory results (hematology, blood chemistry, lipid profile) qualifying as AEs."}],"start_date":"March 29, 2013","primary_completion_date":"January 29, 2019","completion_date":"January 29, 2019","first_posted":"June 5, 2017","results_first_posted":"April 7, 2020","last_update_posted":"April 7, 2020"},{"nctid":"NCT03176238","version_a":11,"version_b":12,"version_a_date":"2019-10-14","version_b_date":"2020-04-06","pom_a":[{"label":"1.","content":"Incidence of treatment emergent adverse events (Safety and tolerability)[ Time Frame: Up to 5 years (Baseline, regularly scheduled visits up to last patient las visit) ](AEs) by grade (CTCAE, version 4.03), serious adverse events (SAEs), changes from baseline in vital signs and laboratory results (hematology, blood chemistry, lipid profile) qualifying as AEs."}],"pom_b":[{"label":"1.","content":"Summary of Number of Participants With Treatment Emergent Adverse Events (TEAE) - All Grades[ Time Frame: Baseline up to approximately 43 weeks for Asian countires and 32 weeks for Non-Asian countries including a 30 day post treatment follow up period ]Adverse events (AEs), serious adverse events (SAEs), changes from baseline in vital signs and laboratory results (hematology, blood chemistry, lipid profile) qualifying and reported as AEs. Although a patient might had two or more adverse events the patient is only counted once in a category. The same patient might appear in different categories. AESI: Adverse events of special interest."}],"start_date":"March 29, 2013","primary_completion_date":"January 29, 2019","completion_date":"January 29, 2019","first_posted":"June 5, 2017","results_first_posted":"April 7, 2020","last_update_posted":"April 7, 2020"},{"nctid":"NCT00680901","version_a":91,"version_b":92,"version_a_date":"2010-07-15","version_b_date":"2010-12-16","pom_a":[{"label":"1.","content":"Progression-free survival to be compared between patients treated with CapeOx plus lapatinib vs CapeOx plus placebo; Progression will be evaluated according to RECIST criteria and at regular intervals"}],"pom_b":[{"label":"1.","content":"Overall survival to be compared between patients treated with CapeOx plus lapatinib vs CapeOx plus placebo[ Time Frame: until end of study approxamately 18 months from last subject randomized ]"},{"label":"2.","content":"Overall survival to be assessed on all randomized subjects[ Time Frame: Overall survival will be assessed from time of randomization until death due to any cause ]"}],"start_date":"June 4, 2008","primary_completion_date":"September 24, 2012","completion_date":"December 30, 2022","first_posted":"May 20, 2008","results_first_posted":"October 29, 2013","last_update_posted":"July 15, 2022"},{"nctid":"NCT00680901","version_a":147,"version_b":148,"version_a_date":"2013-02-07","version_b_date":"2013-08-22","pom_a":[{"label":"1.","content":"Overall survival to be compared between patients treated with CapeOx plus lapatinib vs CapeOx plus placebo[ Time Frame: until end of study approxamately 18 months from last subject randomized ]"},{"label":"2.","content":"Overall survival to be assessed on all randomized subjects[ Time Frame: Overall survival will be assessed from time of randomization until death due to any cause ]"}],"pom_b":[{"label":"1.","content":"Overall Survival[ Time Frame: From randomization until death due to any cause (average of 51 weeks) ]Overall Survival is defined as the time from randomization until death due to any cause. Participants who had not died were censored at the follow-up visit as either follow-up ended or follow-up ongoing."},{"label":"2.","content":"Overall Survival in All Randomized Participants[ Time Frame: From randomization until death due to any cause (average of 51 weeks) ]Overall Survival is defined as the time from randomization until death due to any cause. Participants who had not died were censored at the follow-up visit as either follow-up ended or follow-up ongoing."}],"start_date":"June 4, 2008","primary_completion_date":"September 24, 2012","completion_date":"December 30, 2022","first_posted":"May 20, 2008","results_first_posted":"October 29, 2013","last_update_posted":"July 15, 2022"},{"nctid":"NCT01245062","version_a":56,"version_b":57,"version_a_date":"2012-11-21","version_b_date":"2013-02-14","pom_a":[{"label":"1.","content":"Progression Free Survival[ Time Frame: from time of randomization to time of disease progression (approx. 7 months) ]"}],"pom_b":[{"label":"1.","content":"Progression-free Survival in BRAF V600E Mutation-positive Participants Without a History of Brain Metastases as Assessed by the Investigator and Independent Review[ Time Frame: Day 1 until the earliest date of disease progression or death due to any cause (average of 4.8 months) ]Progression-free survival (PFS) is defined as the time from randomization to the first documented occurrence of disease progression or death. PFS for investigator-assessed and blinded, independent, central review committee (BRIC)-assessed responses was summarized per Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1, which is a set of published rules defining when cancer patients improve (respond), stay the same (stabilize), or worsen (progress) during treatment. Disease progression is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 millimeters (mm) or the appearance of at least 1 new lesion, or the worsening of non-target lesions significant enough to require study treatment discontinuation."}],"start_date":"November 22, 2010","primary_completion_date":"October 26, 2011","completion_date":"December 16, 2016","first_posted":"November 22, 2010","results_first_posted":"March 15, 2013","last_update_posted":"April 5, 2018"},{"nctid":"NCT01245062","version_a":62,"version_b":63,"version_a_date":"2017-09-23","version_b_date":"2018-03-09","pom_a":[{"label":"1.","content":"Progression-free Survival in BRAF V600E Mutation-positive Participants Without a History of Brain Metastases as Assessed by the Investigator and Independent Review[ Time Frame: Day 1 until the earliest date of disease progression or death due to any cause (average of 4.8 months) ]Progression-free survival (PFS) is defined as the time from randomization to the first documented occurrence of disease progression or death. PFS for investigator-assessed and blinded, independent, central review committee (BRIC)-assessed responses was summarized per Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1, which is a set of published rules defining when cancer patients improve (respond), stay the same (stabilize), or worsen (progress) during treatment. Disease progression is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 millimeters (mm) or the appearance of at least 1 new lesion, or the worsening of non-target lesions significant enough to require study treatment discontinuation."}],"pom_b":[{"label":"1.","content":"Progression-free Survival in BRAF V600E Mutation-positive Participants Without a History of Brain Metastases as Assessed by the Investigator and Independent Review[ Time Frame: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months) ]Progression-free survival (PFS) is defined as the time from randomization to the first documented occurrence of disease progression (PD) or death. PFS for investigator-assessed and blinded, independent, central review committee (BRIC)-assessed responses was summarized per Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1, which is a set of published rules defining when cancer participants improve (respond), stay the same (stabilize), or worsen (progress) during treatment. Disease progression is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 millimeters (mm) or the appearance of at least 1 new lesion, or the worsening of non-target lesions significant enough to require study treatment discontinuation. Primary Efficacy Population included all participants with BRAF V600E mutation-positive melanoma without a history of brain metastases."}],"start_date":"November 22, 2010","primary_completion_date":"October 26, 2011","completion_date":"December 16, 2016","first_posted":"November 22, 2010","results_first_posted":"March 15, 2013","last_update_posted":"April 5, 2018"},{"nctid":"NCT03315364","version_a":1,"version_b":2,"version_a_date":"2017-10-16","version_b_date":"2018-06-04","pom_a":[{"label":"1.","content":"[Phase II] Overall Response Rate (ORR)[ Time Frame: Participants will be followed every 6 weeks until progression, an expected average of 9 months. ]Overall Response Rate (ORR) is defined by Response Evaluation Criteria in Solid Tumors (RECIST) (v.1.1) criteria."},{"label":"2.","content":"[Phase III] Progression Free Survival (PFS)[ Time Frame: From date of randomization, assessed up to 18 months. ]Progression Free Survival (PFS) is defined as the time from date of randomization until the date of first documented progression or death"}],"pom_b":[{"label":"1.","content":"[Phase II] Objective Response Rate (ORR)[ Time Frame: Participants will be followed every 6 weeks until progression, an expected average of 9 months. ]Objective Response Rate (ORR) is defined by Response Evaluation Criteria in Solid Tumors (RECIST) (v.1.1) criteria."},{"label":"2.","content":"[Phase III] Progression Free Survival (PFS)[ Time Frame: From date of randomization, assessed up to 18 months. ]Progression Free Survival (PFS) is defined as the time from date of randomization until the date of first documented progression or death"}],"start_date":"December 18, 2017","primary_completion_date":"December 31, 2020","completion_date":"March 31, 2022","first_posted":"October 20, 2017","last_update_posted":"March 12, 2020"}]}'),X=n(1184);var Y=e.createContext(),ee=n(5878);function te(e){return(0,C.Z)("MuiGrid",e)}var ne=["auto",!0,1,2,3,4,5,6,7,8,9,10,11,12],re=(0,ee.Z)("MuiGrid",["root","container","item","zeroMinWidth"].concat((0,j.Z)([0,1,2,3,4,5,6,7,8,9,10].map((function(e){return"spacing-xs-".concat(e)}))),(0,j.Z)(["column-reverse","column","row-reverse","row"].map((function(e){return"direction-xs-".concat(e)}))),(0,j.Z)(["nowrap","wrap-reverse","wrap"].map((function(e){return"wrap-xs-".concat(e)}))),(0,j.Z)(ne.map((function(e){return"grid-xs-".concat(e)}))),(0,j.Z)(ne.map((function(e){return"grid-sm-".concat(e)}))),(0,j.Z)(ne.map((function(e){return"grid-md-".concat(e)}))),(0,j.Z)(ne.map((function(e){return"grid-lg-".concat(e)}))),(0,j.Z)(ne.map((function(e){return"grid-xl-".concat(e)}))))),ae=re,oe=["className","columns","columnSpacing","component","container","direction","item","rowSpacing","spacing","wrap","zeroMinWidth"];function ie(e){var t=parseFloat(e);return"".concat(t).concat(String(e).replace(String(t),"")||"px")}function se(e){var t=e.breakpoints,n=e.values,r="";Object.keys(n).forEach((function(e){""===r&&0!==n[e]&&(r=e)}));var a=Object.keys(t).sort((function(e,n){return t[e]-t[n]}));return a.slice(0,a.indexOf(r))}var le=(0,M.ZP)("div",{name:"MuiGrid",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState,r=n.container,a=n.direction,o=n.item,i=n.spacing,s=n.wrap,l=n.zeroMinWidth,u=n.breakpoints,c=[];r&&(c=function(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:{};if(!e||e<=0)return[];if("string"===typeof e&&!Number.isNaN(Number(e))||"number"===typeof e)return[n["spacing-xs-".concat(String(e))]];var r=[];return t.forEach((function(t){var a=e[t];Number(a)>0&&r.push(n["spacing-".concat(t,"-").concat(String(a))])})),r}(i,u,t));var d=[];return u.forEach((function(e){var r=n[e];r&&d.push(t["grid-".concat(e,"-").concat(String(r))])})),[t.root,r&&t.container,o&&t.item,l&&t.zeroMinWidth].concat((0,j.Z)(c),["row"!==a&&t["direction-xs-".concat(String(a))],"wrap"!==s&&t["wrap-xs-".concat(String(s))]],d)}})((function(e){var t=e.ownerState;return(0,r.Z)({boxSizing:"border-box"},t.container&&{display:"flex",flexWrap:"wrap",width:"100%"},t.item&&{margin:0},t.zeroMinWidth&&{minWidth:0},"wrap"!==t.wrap&&{flexWrap:t.wrap})}),(function(e){var t=e.theme,n=e.ownerState,r=(0,X.P$)({values:n.direction,breakpoints:t.breakpoints.values});return(0,X.k9)({theme:t},r,(function(e){var t={flexDirection:e};return 0===e.indexOf("column")&&(t["& > .".concat(ae.item)]={maxWidth:"none"}),t}))}),(function(e){var t=e.theme,n=e.ownerState,r=n.container,a=n.rowSpacing,o={};if(r&&0!==a){var i,s=(0,X.P$)({values:a,breakpoints:t.breakpoints.values});"object"===typeof s&&(i=se({breakpoints:t.breakpoints.values,values:s})),o=(0,X.k9)({theme:t},s,(function(e,n){var r,a=t.spacing(e);return"0px"!==a?(0,_.Z)({marginTop:"-".concat(ie(a))},"& > .".concat(ae.item),{paddingTop:ie(a)}):null!=(r=i)&&r.includes(n)?{}:(0,_.Z)({marginTop:0},"& > .".concat(ae.item),{paddingTop:0})}))}return o}),(function(e){var t=e.theme,n=e.ownerState,r=n.container,a=n.columnSpacing,o={};if(r&&0!==a){var i,s=(0,X.P$)({values:a,breakpoints:t.breakpoints.values});"object"===typeof s&&(i=se({breakpoints:t.breakpoints.values,values:s})),o=(0,X.k9)({theme:t},s,(function(e,n){var r,a=t.spacing(e);return"0px"!==a?(0,_.Z)({width:"calc(100% + ".concat(ie(a),")"),marginLeft:"-".concat(ie(a))},"& > .".concat(ae.item),{paddingLeft:ie(a)}):null!=(r=i)&&r.includes(n)?{}:(0,_.Z)({width:"100%",marginLeft:0},"& > .".concat(ae.item),{paddingLeft:0})}))}return o}),(function(e){var t,n=e.theme,a=e.ownerState;return n.breakpoints.keys.reduce((function(e,o){var i={};if(a[o]&&(t=a[o]),!t)return e;if(!0===t)i={flexBasis:0,flexGrow:1,maxWidth:"100%"};else if("auto"===t)i={flexBasis:"auto",flexGrow:0,flexShrink:0,maxWidth:"none",width:"auto"};else{var s=(0,X.P$)({values:a.columns,breakpoints:n.breakpoints.values}),l="object"===typeof s?s[o]:s;if(void 0===l||null===l)return e;var u="".concat(Math.round(t/l*1e8)/1e6,"%"),c={};if(a.container&&a.item&&0!==a.columnSpacing){var d=n.spacing(a.columnSpacing);if("0px"!==d){var p="calc(".concat(u," + ").concat(ie(d),")");c={flexBasis:p,maxWidth:p}}}i=(0,r.Z)({flexBasis:u,flexGrow:0,maxWidth:u},c)}return 0===n.breakpoints.values[o]?Object.assign(e,i):e[n.breakpoints.up(o)]=i,e}),{})}));var ue=function(e){var t=e.classes,n=e.container,r=e.direction,a=e.item,o=e.spacing,i=e.wrap,s=e.zeroMinWidth,l=e.breakpoints,u=[];n&&(u=function(e,t){if(!e||e<=0)return[];if("string"===typeof e&&!Number.isNaN(Number(e))||"number"===typeof e)return["spacing-xs-".concat(String(e))];var n=[];return t.forEach((function(t){var r=e[t];if(Number(r)>0){var a="spacing-".concat(t,"-").concat(String(r));n.push(a)}})),n}(o,l));var c=[];l.forEach((function(t){var n=e[t];n&&c.push("grid-".concat(t,"-").concat(String(n)))}));var d={root:["root",n&&"container",a&&"item",s&&"zeroMinWidth"].concat((0,j.Z)(u),["row"!==r&&"direction-xs-".concat(String(r)),"wrap"!==i&&"wrap-xs-".concat(String(i))],c)};return(0,k.Z)(d,te,t)},ce=e.forwardRef((function(t,n){var o=(0,a.Z)({props:t,name:"MuiGrid"}),i=(0,V.Z)(m.Z).breakpoints,s=U(o),l=s.className,u=s.columns,c=s.columnSpacing,d=s.component,f=void 0===d?"div":d,h=s.container,v=void 0!==h&&h,y=s.direction,b=void 0===y?"row":y,g=s.item,_=void 0!==g&&g,T=s.rowSpacing,C=s.spacing,k=void 0===C?0:C,A=s.wrap,x=void 0===A?"wrap":A,F=s.zeroMinWidth,R=void 0!==F&&F,P=(0,w.Z)(s,oe),E=T||k,O=c||k,N=e.useContext(Y),I=v?u||12:N,M={},z=(0,r.Z)({},P);i.keys.forEach((function(e){null!=P[e]&&(M[e]=P[e],delete z[e])}));var D=(0,r.Z)({},s,{columns:I,container:v,direction:b,item:_,rowSpacing:E,columnSpacing:O,wrap:x,zeroMinWidth:R,spacing:k},M,{breakpoints:i.keys}),L=ue(D);return(0,p.jsx)(Y.Provider,{value:I,children:(0,p.jsx)(le,(0,r.Z)({ownerState:D,className:(0,S.Z)(L.root,l),as:f,ref:n},z))})})),de=ce,pe=n(2065);function fe(e){return(0,C.Z)("MuiPaper",e)}(0,ee.Z)("MuiPaper",["root","rounded","outlined","elevation","elevation0","elevation1","elevation2","elevation3","elevation4","elevation5","elevation6","elevation7","elevation8","elevation9","elevation10","elevation11","elevation12","elevation13","elevation14","elevation15","elevation16","elevation17","elevation18","elevation19","elevation20","elevation21","elevation22","elevation23","elevation24"]);var me=["className","component","elevation","square","variant"],he=function(e){return((e<1?5.11916*Math.pow(e,2):4.5*Math.log(e+1)+2)/100).toFixed(2)},ve=(0,M.ZP)("div",{name:"MuiPaper",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,t[n.variant],!n.square&&t.rounded,"elevation"===n.variant&&t["elevation".concat(n.elevation)]]}})((function(e){var t,n=e.theme,a=e.ownerState;return(0,r.Z)({backgroundColor:(n.vars||n).palette.background.paper,color:(n.vars||n).palette.text.primary,transition:n.transitions.create("box-shadow")},!a.square&&{borderRadius:n.shape.borderRadius},"outlined"===a.variant&&{border:"1px solid ".concat((n.vars||n).palette.divider)},"elevation"===a.variant&&(0,r.Z)({boxShadow:(n.vars||n).shadows[a.elevation]},!n.vars&&"dark"===n.palette.mode&&{backgroundImage:"linear-gradient(".concat((0,pe.Fq)("#fff",he(a.elevation)),", ").concat((0,pe.Fq)("#fff",he(a.elevation)),")")},n.vars&&{backgroundImage:null==(t=n.vars.overlays)?void 0:t[a.elevation]}))})),ye=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiPaper"}),o=n.className,i=n.component,s=void 0===i?"div":i,l=n.elevation,u=void 0===l?1:l,c=n.square,d=void 0!==c&&c,f=n.variant,m=void 0===f?"elevation":f,h=(0,w.Z)(n,me),v=(0,r.Z)({},n,{component:s,elevation:u,square:d,variant:m}),y=function(e){var t=e.square,n=e.elevation,r=e.variant,a=e.classes,o={root:["root",r,!t&&"rounded","elevation"===r&&"elevation".concat(n)]};return(0,k.Z)(o,fe,a)}(v);return(0,p.jsx)(ve,(0,r.Z)({as:s,ownerState:v,className:(0,S.Z)(y.root,o),ref:t},h))}));function be(e){return(0,C.Z)("MuiCard",e)}(0,ee.Z)("MuiCard",["root"]);var ge=["className","raised"],_e=(0,M.ZP)(ye,{name:"MuiCard",slot:"Root",overridesResolver:function(e,t){return t.root}})((function(){return{overflow:"hidden"}})),we=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiCard"}),o=n.className,i=n.raised,s=void 0!==i&&i,l=(0,w.Z)(n,ge),u=(0,r.Z)({},n,{raised:s}),c=function(e){var t=e.classes;return(0,k.Z)({root:["root"]},be,t)}(u);return(0,p.jsx)(_e,(0,r.Z)({className:(0,S.Z)(c.root,o),elevation:s?8:void 0,ref:t,ownerState:u},l))}));function Se(e){return(0,C.Z)("MuiCardContent",e)}(0,ee.Z)("MuiCardContent",["root"]);var Te=["className","component"],Ce=(0,M.ZP)("div",{name:"MuiCardContent",slot:"Root",overridesResolver:function(e,t){return t.root}})((function(){return{padding:16,"&:last-child":{paddingBottom:24}}})),ke=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiCardContent"}),o=n.className,i=n.component,s=void 0===i?"div":i,l=(0,w.Z)(n,Te),u=(0,r.Z)({},n,{component:s}),c=function(e){var t=e.classes;return(0,k.Z)({root:["root"]},Se,t)}(u);return(0,p.jsx)(Ce,(0,r.Z)({as:s,className:(0,S.Z)(c.root,o),ownerState:u,ref:t},l))}));function Ae(e){return(0,C.Z)("MuiTypography",e)}(0,ee.Z)("MuiTypography",["root","h1","h2","h3","h4","h5","h6","subtitle1","subtitle2","body1","body2","inherit","button","caption","overline","alignLeft","alignRight","alignCenter","alignJustify","noWrap","gutterBottom","paragraph"]);var xe=["align","className","component","gutterBottom","noWrap","paragraph","variant","variantMapping"],Fe=(0,M.ZP)("span",{name:"MuiTypography",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,n.variant&&t[n.variant],"inherit"!==n.align&&t["align".concat((0,I.Z)(n.align))],n.noWrap&&t.noWrap,n.gutterBottom&&t.gutterBottom,n.paragraph&&t.paragraph]}})((function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({margin:0},n.variant&&t.typography[n.variant],"inherit"!==n.align&&{textAlign:n.align},n.noWrap&&{overflow:"hidden",textOverflow:"ellipsis",whiteSpace:"nowrap"},n.gutterBottom&&{marginBottom:"0.35em"},n.paragraph&&{marginBottom:16})})),Re={h1:"h1",h2:"h2",h3:"h3",h4:"h4",h5:"h5",h6:"h6",subtitle1:"h6",subtitle2:"h6",body1:"p",body2:"p",inherit:"p"},Pe={primary:"primary.main",textPrimary:"text.primary",secondary:"secondary.main",textSecondary:"text.secondary",error:"error.main"},Ee=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiTypography"}),o=function(e){return Pe[e]||e}(n.color),i=U((0,r.Z)({},n,{color:o})),s=i.align,l=void 0===s?"inherit":s,u=i.className,c=i.component,d=i.gutterBottom,f=void 0!==d&&d,m=i.noWrap,h=void 0!==m&&m,v=i.paragraph,y=void 0!==v&&v,b=i.variant,g=void 0===b?"body1":b,_=i.variantMapping,T=void 0===_?Re:_,C=(0,w.Z)(i,xe),A=(0,r.Z)({},i,{align:l,color:o,className:u,component:c,gutterBottom:f,noWrap:h,paragraph:y,variant:g,variantMapping:T}),x=c||(y?"p":T[g]||Re[g])||"span",F=function(e){var t=e.align,n=e.gutterBottom,r=e.noWrap,a=e.paragraph,o=e.variant,i=e.classes,s={root:["root",o,"inherit"!==e.align&&"align".concat((0,I.Z)(t)),n&&"gutterBottom",r&&"noWrap",a&&"paragraph"]};return(0,k.Z)(s,Ae,i)}(A);return(0,p.jsx)(Fe,(0,r.Z)({as:x,ref:t,ownerState:A,className:(0,S.Z)(F.root,u)},C))})),Oe=n(5682),Ne=["component","direction","spacing","divider","children"];function Ie(t,n){var r=e.Children.toArray(t).filter(Boolean);return r.reduce((function(t,a,o){return t.push(a),o<r.length-1&&t.push(e.cloneElement(n,{key:"separator-".concat(o)})),t}),[])}var Me=(0,M.ZP)("div",{name:"MuiStack",slot:"Root",overridesResolver:function(e,t){return[t.root]}})((function(e){var t=e.ownerState,n=e.theme,a=(0,r.Z)({display:"flex",flexDirection:"column"},(0,X.k9)({theme:n},(0,X.P$)({values:t.direction,breakpoints:n.breakpoints.values}),(function(e){return{flexDirection:e}})));if(t.spacing){var o=(0,Oe.hB)(n),i=Object.keys(n.breakpoints.values).reduce((function(e,n){return("object"===typeof t.spacing&&null!=t.spacing[n]||"object"===typeof t.direction&&null!=t.direction[n])&&(e[n]=!0),e}),{}),s=(0,X.P$)({values:t.direction,base:i}),l=(0,X.P$)({values:t.spacing,base:i});"object"===typeof s&&Object.keys(s).forEach((function(e,t,n){if(!s[e]){var r=t>0?s[n[t-1]]:"column";s[e]=r}}));a=(0,B.Z)(a,(0,X.k9)({theme:n},l,(function(e,n){return{"& > :not(style) + :not(style)":(0,_.Z)({margin:0},"margin".concat((r=n?s[n]:t.direction,{row:"Left","row-reverse":"Right",column:"Top","column-reverse":"Bottom"}[r])),(0,Oe.NA)(o,e))};var r})))}return a=(0,X.dt)(n.breakpoints,a)})),ze=e.forwardRef((function(e,t){var n=U((0,a.Z)({props:e,name:"MuiStack"})),o=n.component,i=void 0===o?"div":o,s=n.direction,l=void 0===s?"column":s,u=n.spacing,c=void 0===u?0:u,d=n.divider,f=n.children,m=(0,w.Z)(n,Ne),h={direction:l,spacing:c};return(0,p.jsx)(Me,(0,r.Z)({as:i,ownerState:h,ref:t},m,{children:d?Ie(f,d):f}))})),De=ze,Le=n(1774),Ze=n.n(Le);var je=function(e){var t=e.datum,n=e.datumNumber,r=e.results,a=(e.setResults,t.pom_a),o=t.pom_b,i=t.version_a_date,s=t.version_b_date;console.log({datum:t});var l=function(e,t){return e.map((function(e){return(0,p.jsx)(we,{children:(0,p.jsx)(ke,{children:(0,p.jsxs)(Ee,{children:[(0,p.jsx)("b",{children:e.label})," ",e.content]})})},e.content)}))};return(0,p.jsxs)(de,{container:!0,spacing:2,children:[(0,p.jsx)(de,{item:!0,xs:12,children:(0,p.jsx)(we,{children:(0,p.jsx)(ke,{children:(0,p.jsxs)(de,{container:!0,children:[(0,p.jsxs)(de,{item:!0,xs:4,children:[(0,p.jsxs)(Ee,{variant:"h6",children:["Comparison Number ",n+1," of ",r.length]}),(0,p.jsxs)(Ee,{variant:"h4",children:["Trial ",t.nctid]})]}),(0,p.jsxs)(de,{item:!0,xs:4,children:[t.first_posted?(0,p.jsxs)(Ee,{children:["First Posted: ",t.first_posted]}):null,t.start_date?(0,p.jsxs)(Ee,{children:["Start Date: ",t.start_date]}):null]}),(0,p.jsxs)(de,{item:!0,xs:4,children:[t.primary_completion_date?(0,p.jsxs)(Ee,{children:["Primary Completion Date: ",t.primary_completion_date]}):null,t.last_update_posted?(0,p.jsxs)(Ee,{children:["Last Update Posted : ",t.last_update_posted]}):null]})]})})})}),(0,p.jsx)(de,{item:!0,xs:6,children:(0,p.jsx)(we,{children:(0,p.jsxs)(ke,{children:[(0,p.jsxs)(Ee,{variant:"h6",children:["Primary Outcomes for Version ",t.version_a,": ",i]}),(0,p.jsx)(Ee,{variant:"caption"}),(0,p.jsx)(De,{spacing:1,children:l(t.pom_a)})]})})}),(0,p.jsx)(de,{item:!0,xs:6,children:(0,p.jsx)(we,{children:(0,p.jsxs)(ke,{children:[(0,p.jsxs)(Ee,{variant:"h6",children:["Primary Outcomes for Version ",t.version_b,": ",s]}),(0,p.jsx)(De,{spacing:1,children:l(t.pom_b)})]})})}),(0,p.jsx)(de,{item:!0,xs:12,children:(0,p.jsx)(we,{children:(0,p.jsxs)(ke,{children:[(0,p.jsx)(Ee,{variant:"h6",children:"Compare the Raw Text"}),(0,p.jsx)(Ze(),{oldValue:JSON.stringify(a,void 0,4),newValue:JSON.stringify(o,void 0,4),splitView:!0,compareMethod:Le.DiffMethod.WORDS,styles:{variables:{light:{codeFoldGutterBackground:"#6F767E",codeFoldBackground:"#E2E4E5"}}},leftTitle:"Version ".concat(t.version_a),rightTitle:"Version ".concat(t.version_b)})]})})})]})};function Be(e){return(0,C.Z)("MuiAppBar",e)}(0,ee.Z)("MuiAppBar",["root","positionFixed","positionAbsolute","positionSticky","positionStatic","positionRelative","colorDefault","colorPrimary","colorSecondary","colorInherit","colorTransparent"]);var We=["className","color","enableColorOnDark","position"],Je=function(e,t){return"".concat(null==e?void 0:e.replace(")",""),", ").concat(t,")")},Ue=(0,M.ZP)(ye,{name:"MuiAppBar",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,t["position".concat((0,I.Z)(n.position))],t["color".concat((0,I.Z)(n.color))]]}})((function(e){var t=e.theme,n=e.ownerState,a="light"===t.palette.mode?t.palette.grey[100]:t.palette.grey[900];return(0,r.Z)({display:"flex",flexDirection:"column",width:"100%",boxSizing:"border-box",flexShrink:0},"fixed"===n.position&&{position:"fixed",zIndex:(t.vars||t).zIndex.appBar,top:0,left:"auto",right:0,"@media print":{position:"absolute"}},"absolute"===n.position&&{position:"absolute",zIndex:(t.vars||t).zIndex.appBar,top:0,left:"auto",right:0},"sticky"===n.position&&{position:"sticky",zIndex:(t.vars||t).zIndex.appBar,top:0,left:"auto",right:0},"static"===n.position&&{position:"static"},"relative"===n.position&&{position:"relative"},!t.vars&&(0,r.Z)({},"default"===n.color&&{backgroundColor:a,color:t.palette.getContrastText(a)},n.color&&"default"!==n.color&&"inherit"!==n.color&&"transparent"!==n.color&&{backgroundColor:t.palette[n.color].main,color:t.palette[n.color].contrastText},"inherit"===n.color&&{color:"inherit"},"dark"===t.palette.mode&&!n.enableColorOnDark&&{backgroundColor:null,color:null},"transparent"===n.color&&(0,r.Z)({backgroundColor:"transparent",color:"inherit"},"dark"===t.palette.mode&&{backgroundImage:"none"})),t.vars&&(0,r.Z)({},"default"===n.color&&{"--AppBar-background":n.enableColorOnDark?t.vars.palette.AppBar.defaultBg:Je(t.vars.palette.AppBar.darkBg,t.vars.palette.AppBar.defaultBg),"--AppBar-color":n.enableColorOnDark?t.vars.palette.text.primary:Je(t.vars.palette.AppBar.darkColor,t.vars.palette.text.primary)},n.color&&!n.color.match(/^(default|inherit|transparent)$/)&&{"--AppBar-background":n.enableColorOnDark?t.vars.palette[n.color].main:Je(t.vars.palette.AppBar.darkBg,t.vars.palette[n.color].main),"--AppBar-color":n.enableColorOnDark?t.vars.palette[n.color].contrastText:Je(t.vars.palette.AppBar.darkColor,t.vars.palette[n.color].contrastText)},{backgroundColor:"var(--AppBar-background)",color:"inherit"===n.color?"inherit":"var(--AppBar-color)"},"transparent"===n.color&&{backgroundImage:"none",backgroundColor:"transparent",color:"inherit"}))})),Ve=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiAppBar"}),o=n.className,i=n.color,s=void 0===i?"primary":i,l=n.enableColorOnDark,u=void 0!==l&&l,c=n.position,d=void 0===c?"fixed":c,f=(0,w.Z)(n,We),m=(0,r.Z)({},n,{color:s,position:d,enableColorOnDark:u}),h=function(e){var t=e.color,n=e.position,r=e.classes,a={root:["root","color".concat((0,I.Z)(t)),"position".concat((0,I.Z)(n))]};return(0,k.Z)(a,Be,r)}(m);return(0,p.jsx)(Ue,(0,r.Z)({square:!0,component:"header",ownerState:m,elevation:4,className:(0,S.Z)(h.root,o,"fixed"===d&&"mui-fixed"),ref:t},f))}));function $e(e){return(0,C.Z)("MuiToolbar",e)}(0,ee.Z)("MuiToolbar",["root","gutters","regular","dense"]);var He=["className","component","disableGutters","variant"],Ge=(0,M.ZP)("div",{name:"MuiToolbar",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,!n.disableGutters&&t.gutters,t[n.variant]]}})((function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({position:"relative",display:"flex",alignItems:"center"},!n.disableGutters&&(0,_.Z)({paddingLeft:t.spacing(2),paddingRight:t.spacing(2)},t.breakpoints.up("sm"),{paddingLeft:t.spacing(3),paddingRight:t.spacing(3)}),"dense"===n.variant&&{minHeight:48})}),(function(e){var t=e.theme;return"regular"===e.ownerState.variant&&t.mixins.toolbar})),qe=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiToolbar"}),o=n.className,i=n.component,s=void 0===i?"div":i,l=n.disableGutters,u=void 0!==l&&l,c=n.variant,d=void 0===c?"regular":c,f=(0,w.Z)(n,He),m=(0,r.Z)({},n,{component:s,disableGutters:u,variant:d}),h=function(e){var t=e.classes,n={root:["root",!e.disableGutters&&"gutters",e.variant]};return(0,k.Z)(n,$e,t)}(m);return(0,p.jsx)(Ge,(0,r.Z)({as:s,className:(0,S.Z)(h.root,o),ref:t,ownerState:m},f))})),Ke=n(792),Qe=n(6702),Xe=n(2763);function Ye(e,t){return t||(t=e.slice(0)),Object.freeze(Object.defineProperties(e,{raw:{value:Object.freeze(t)}}))}function et(e,t){return et=Object.setPrototypeOf?Object.setPrototypeOf.bind():function(e,t){return e.__proto__=t,e},et(e,t)}var tt=e.createContext(null);function nt(t,n){var r=Object.create(null);return t&&e.Children.map(t,(function(e){return e})).forEach((function(t){r[t.key]=function(t){return n&&(0,e.isValidElement)(t)?n(t):t}(t)})),r}function rt(e,t,n){return null!=n[t]?n[t]:e.props[t]}function at(t,n,r){var a=nt(t.children),o=function(e,t){function n(n){return n in t?t[n]:e[n]}e=e||{},t=t||{};var r,a=Object.create(null),o=[];for(var i in e)i in t?o.length&&(a[i]=o,o=[]):o.push(i);var s={};for(var l in t){if(a[l])for(r=0;r<a[l].length;r++){var u=a[l][r];s[a[l][r]]=n(u)}s[l]=n(l)}for(r=0;r<o.length;r++)s[o[r]]=n(o[r]);return s}(n,a);return Object.keys(o).forEach((function(i){var s=o[i];if((0,e.isValidElement)(s)){var l=i in n,u=i in a,c=n[i],d=(0,e.isValidElement)(c)&&!c.props.in;!u||l&&!d?u||!l||d?u&&l&&(0,e.isValidElement)(c)&&(o[i]=(0,e.cloneElement)(s,{onExited:r.bind(null,s),in:c.props.in,exit:rt(s,"exit",t),enter:rt(s,"enter",t)})):o[i]=(0,e.cloneElement)(s,{in:!1}):o[i]=(0,e.cloneElement)(s,{onExited:r.bind(null,s),in:!0,exit:rt(s,"exit",t),enter:rt(s,"enter",t)})}})),o}var ot=Object.values||function(e){return Object.keys(e).map((function(t){return e[t]}))},it=function(t){var n,a;function o(e,n){var r,a=(r=t.call(this,e,n)||this).handleExited.bind(function(e){if(void 0===e)throw new ReferenceError("this hasn't been initialised - super() hasn't been called");return e}(r));return r.state={contextValue:{isMounting:!0},handleExited:a,firstRender:!0},r}a=t,(n=o).prototype=Object.create(a.prototype),n.prototype.constructor=n,et(n,a);var i=o.prototype;return i.componentDidMount=function(){this.mounted=!0,this.setState({contextValue:{isMounting:!1}})},i.componentWillUnmount=function(){this.mounted=!1},o.getDerivedStateFromProps=function(t,n){var r,a,o=n.children,i=n.handleExited;return{children:n.firstRender?(r=t,a=i,nt(r.children,(function(t){return(0,e.cloneElement)(t,{onExited:a.bind(null,t),in:!0,appear:rt(t,"appear",r),enter:rt(t,"enter",r),exit:rt(t,"exit",r)})}))):at(t,o,i),firstRender:!1}},i.handleExited=function(e,t){var n=nt(this.props.children);e.key in n||(e.props.onExited&&e.props.onExited(t),this.mounted&&this.setState((function(t){var n=(0,r.Z)({},t.children);return delete n[e.key],{children:n}})))},i.render=function(){var t=this.props,n=t.component,r=t.childFactory,a=(0,w.Z)(t,["component","childFactory"]),o=this.state.contextValue,i=ot(this.state.children).map(r);return delete a.appear,delete a.enter,delete a.exit,null===n?e.createElement(tt.Provider,{value:o},i):e.createElement(tt.Provider,{value:o},e.createElement(n,a,i))},o}(e.Component);it.propTypes={},it.defaultProps={component:"div",childFactory:function(e){return e}};var st=it;var lt=function(t){var n=t.className,r=t.classes,a=t.pulsate,o=void 0!==a&&a,i=t.rippleX,s=t.rippleY,l=t.rippleSize,u=t.in,c=t.onExited,d=t.timeout,f=e.useState(!1),m=(0,g.Z)(f,2),h=m[0],v=m[1],y=(0,S.Z)(n,r.ripple,r.rippleVisible,o&&r.ripplePulsate),b={width:l,height:l,top:-l/2+s,left:-l/2+i},_=(0,S.Z)(r.child,h&&r.childLeaving,o&&r.childPulsate);return u||h||v(!0),e.useEffect((function(){if(!u&&null!=c){var e=setTimeout(c,d);return function(){clearTimeout(e)}}}),[c,u,d]),(0,p.jsx)("span",{className:y,style:b,children:(0,p.jsx)("span",{className:_})})};var ut,ct,dt,pt,ft,mt,ht,vt,yt=(0,ee.Z)("MuiTouchRipple",["root","ripple","rippleVisible","ripplePulsate","child","childLeaving","childPulsate"]),bt=["center","classes","className"],gt=d(ft||(ft=ut||(ut=Ye(["\n  0% {\n    transform: scale(0);\n    opacity: 0.1;\n  }\n\n  100% {\n    transform: scale(1);\n    opacity: 0.3;\n  }\n"])))),_t=d(mt||(mt=ct||(ct=Ye(["\n  0% {\n    opacity: 1;\n  }\n\n  100% {\n    opacity: 0;\n  }\n"])))),wt=d(ht||(ht=dt||(dt=Ye(["\n  0% {\n    transform: scale(1);\n  }\n\n  50% {\n    transform: scale(0.92);\n  }\n\n  100% {\n    transform: scale(1);\n  }\n"])))),St=(0,M.ZP)("span",{name:"MuiTouchRipple",slot:"Root"})({overflow:"hidden",pointerEvents:"none",position:"absolute",zIndex:0,top:0,right:0,bottom:0,left:0,borderRadius:"inherit"}),Tt=(0,M.ZP)(lt,{name:"MuiTouchRipple",slot:"Ripple"})(vt||(vt=pt||(pt=Ye(["\n  opacity: 0;\n  position: absolute;\n\n  &."," {\n    opacity: 0.3;\n    transform: scale(1);\n    animation-name: ",";\n    animation-duration: ","ms;\n    animation-timing-function: ",";\n  }\n\n  &."," {\n    animation-duration: ","ms;\n  }\n\n  & ."," {\n    opacity: 1;\n    display: block;\n    width: 100%;\n    height: 100%;\n    border-radius: 50%;\n    background-color: currentColor;\n  }\n\n  & ."," {\n    opacity: 0;\n    animation-name: ",";\n    animation-duration: ","ms;\n    animation-timing-function: ",";\n  }\n\n  & ."," {\n    position: absolute;\n    /* @noflip */\n    left: 0px;\n    top: 0;\n    animation-name: ",";\n    animation-duration: 2500ms;\n    animation-timing-function: ",";\n    animation-iteration-count: infinite;\n    animation-delay: 200ms;\n  }\n"]))),yt.rippleVisible,gt,550,(function(e){return e.theme.transitions.easing.easeInOut}),yt.ripplePulsate,(function(e){return e.theme.transitions.duration.shorter}),yt.child,yt.childLeaving,_t,550,(function(e){return e.theme.transitions.easing.easeInOut}),yt.childPulsate,wt,(function(e){return e.theme.transitions.easing.easeInOut})),Ct=e.forwardRef((function(t,n){var o=(0,a.Z)({props:t,name:"MuiTouchRipple"}),i=o.center,s=void 0!==i&&i,l=o.classes,u=void 0===l?{}:l,c=o.className,d=(0,w.Z)(o,bt),f=e.useState([]),m=(0,g.Z)(f,2),h=m[0],v=m[1],y=e.useRef(0),b=e.useRef(null);e.useEffect((function(){b.current&&(b.current(),b.current=null)}),[h]);var _=e.useRef(!1),T=e.useRef(null),C=e.useRef(null),k=e.useRef(null);e.useEffect((function(){return function(){clearTimeout(T.current)}}),[]);var A=e.useCallback((function(e){var t=e.pulsate,n=e.rippleX,r=e.rippleY,a=e.rippleSize,o=e.cb;v((function(e){return[].concat((0,j.Z)(e),[(0,p.jsx)(Tt,{classes:{ripple:(0,S.Z)(u.ripple,yt.ripple),rippleVisible:(0,S.Z)(u.rippleVisible,yt.rippleVisible),ripplePulsate:(0,S.Z)(u.ripplePulsate,yt.ripplePulsate),child:(0,S.Z)(u.child,yt.child),childLeaving:(0,S.Z)(u.childLeaving,yt.childLeaving),childPulsate:(0,S.Z)(u.childPulsate,yt.childPulsate)},timeout:550,pulsate:t,rippleX:n,rippleY:r,rippleSize:a},y.current)])})),y.current+=1,b.current=o}),[u]),x=e.useCallback((function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},n=arguments.length>2?arguments[2]:void 0,r=t.pulsate,a=void 0!==r&&r,o=t.center,i=void 0===o?s||t.pulsate:o,l=t.fakeElement,u=void 0!==l&&l;if("mousedown"===(null==e?void 0:e.type)&&_.current)_.current=!1;else{"touchstart"===(null==e?void 0:e.type)&&(_.current=!0);var c,d,p,f=u?null:k.current,m=f?f.getBoundingClientRect():{width:0,height:0,left:0,top:0};if(i||void 0===e||0===e.clientX&&0===e.clientY||!e.clientX&&!e.touches)c=Math.round(m.width/2),d=Math.round(m.height/2);else{var h=e.touches&&e.touches.length>0?e.touches[0]:e,v=h.clientX,y=h.clientY;c=Math.round(v-m.left),d=Math.round(y-m.top)}if(i)(p=Math.sqrt((2*Math.pow(m.width,2)+Math.pow(m.height,2))/3))%2===0&&(p+=1);else{var b=2*Math.max(Math.abs((f?f.clientWidth:0)-c),c)+2,g=2*Math.max(Math.abs((f?f.clientHeight:0)-d),d)+2;p=Math.sqrt(Math.pow(b,2)+Math.pow(g,2))}null!=e&&e.touches?null===C.current&&(C.current=function(){A({pulsate:a,rippleX:c,rippleY:d,rippleSize:p,cb:n})},T.current=setTimeout((function(){C.current&&(C.current(),C.current=null)}),80)):A({pulsate:a,rippleX:c,rippleY:d,rippleSize:p,cb:n})}}),[s,A]),F=e.useCallback((function(){x({},{pulsate:!0})}),[x]),R=e.useCallback((function(e,t){if(clearTimeout(T.current),"touchend"===(null==e?void 0:e.type)&&C.current)return C.current(),C.current=null,void(T.current=setTimeout((function(){R(e,t)})));C.current=null,v((function(e){return e.length>0?e.slice(1):e})),b.current=t}),[]);return e.useImperativeHandle(n,(function(){return{pulsate:F,start:x,stop:R}}),[F,x,R]),(0,p.jsx)(St,(0,r.Z)({className:(0,S.Z)(yt.root,u.root,c),ref:k},d,{children:(0,p.jsx)(st,{component:null,exit:!0,children:h})}))})),kt=Ct;function At(e){return(0,C.Z)("MuiButtonBase",e)}var xt,Ft=(0,ee.Z)("MuiButtonBase",["root","disabled","focusVisible"]),Rt=["action","centerRipple","children","className","component","disabled","disableRipple","disableTouchRipple","focusRipple","focusVisibleClassName","LinkComponent","onBlur","onClick","onContextMenu","onDragLeave","onFocus","onFocusVisible","onKeyDown","onKeyUp","onMouseDown","onMouseLeave","onMouseUp","onTouchEnd","onTouchMove","onTouchStart","tabIndex","TouchRippleProps","touchRippleRef","type"],Pt=(0,M.ZP)("button",{name:"MuiButtonBase",slot:"Root",overridesResolver:function(e,t){return t.root}})((xt={display:"inline-flex",alignItems:"center",justifyContent:"center",position:"relative",boxSizing:"border-box",WebkitTapHighlightColor:"transparent",backgroundColor:"transparent",outline:0,border:0,margin:0,borderRadius:0,padding:0,cursor:"pointer",userSelect:"none",verticalAlign:"middle",MozAppearance:"none",WebkitAppearance:"none",textDecoration:"none",color:"inherit","&::-moz-focus-inner":{borderStyle:"none"}},(0,_.Z)(xt,"&.".concat(Ft.disabled),{pointerEvents:"none",cursor:"default"}),(0,_.Z)(xt,"@media print",{colorAdjust:"exact"}),xt)),Et=e.forwardRef((function(t,n){var o=(0,a.Z)({props:t,name:"MuiButtonBase"}),i=o.action,s=o.centerRipple,l=void 0!==s&&s,u=o.children,c=o.className,d=o.component,f=void 0===d?"button":d,m=o.disabled,h=void 0!==m&&m,v=o.disableRipple,y=void 0!==v&&v,b=o.disableTouchRipple,_=void 0!==b&&b,T=o.focusRipple,C=void 0!==T&&T,A=o.LinkComponent,x=void 0===A?"a":A,F=o.onBlur,R=o.onClick,P=o.onContextMenu,E=o.onDragLeave,O=o.onFocus,N=o.onFocusVisible,I=o.onKeyDown,M=o.onKeyUp,z=o.onMouseDown,D=o.onMouseLeave,L=o.onMouseUp,Z=o.onTouchEnd,j=o.onTouchMove,B=o.onTouchStart,W=o.tabIndex,J=void 0===W?0:W,U=o.TouchRippleProps,V=o.touchRippleRef,$=o.type,H=(0,w.Z)(o,Rt),G=e.useRef(null),q=e.useRef(null),K=(0,Ke.Z)(q,V),Q=(0,Xe.Z)(),X=Q.isFocusVisibleRef,Y=Q.onFocus,ee=Q.onBlur,te=Q.ref,ne=e.useState(!1),re=(0,g.Z)(ne,2),ae=re[0],oe=re[1];h&&ae&&oe(!1),e.useImperativeHandle(i,(function(){return{focusVisible:function(){oe(!0),G.current.focus()}}}),[]);var ie=e.useState(!1),se=(0,g.Z)(ie,2),le=se[0],ue=se[1];e.useEffect((function(){ue(!0)}),[]);var ce=le&&!y&&!h;function de(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:_;return(0,Qe.Z)((function(r){return t&&t(r),!n&&q.current&&q.current[e](r),!0}))}e.useEffect((function(){ae&&C&&!y&&le&&q.current.pulsate()}),[y,C,ae,le]);var pe=de("start",z),fe=de("stop",P),me=de("stop",E),he=de("stop",L),ve=de("stop",(function(e){ae&&e.preventDefault(),D&&D(e)})),ye=de("start",B),be=de("stop",Z),ge=de("stop",j),_e=de("stop",(function(e){ee(e),!1===X.current&&oe(!1),F&&F(e)}),!1),we=(0,Qe.Z)((function(e){G.current||(G.current=e.currentTarget),Y(e),!0===X.current&&(oe(!0),N&&N(e)),O&&O(e)})),Se=function(){var e=G.current;return f&&"button"!==f&&!("A"===e.tagName&&e.href)},Te=e.useRef(!1),Ce=(0,Qe.Z)((function(e){C&&!Te.current&&ae&&q.current&&" "===e.key&&(Te.current=!0,q.current.stop(e,(function(){q.current.start(e)}))),e.target===e.currentTarget&&Se()&&" "===e.key&&e.preventDefault(),I&&I(e),e.target===e.currentTarget&&Se()&&"Enter"===e.key&&!h&&(e.preventDefault(),R&&R(e))})),ke=(0,Qe.Z)((function(e){C&&" "===e.key&&q.current&&ae&&!e.defaultPrevented&&(Te.current=!1,q.current.stop(e,(function(){q.current.pulsate(e)}))),M&&M(e),R&&e.target===e.currentTarget&&Se()&&" "===e.key&&!e.defaultPrevented&&R(e)})),Ae=f;"button"===Ae&&(H.href||H.to)&&(Ae=x);var xe={};"button"===Ae?(xe.type=void 0===$?"button":$,xe.disabled=h):(H.href||H.to||(xe.role="button"),h&&(xe["aria-disabled"]=h));var Fe=(0,Ke.Z)(te,G),Re=(0,Ke.Z)(n,Fe);var Pe=(0,r.Z)({},o,{centerRipple:l,component:f,disabled:h,disableRipple:y,disableTouchRipple:_,focusRipple:C,tabIndex:J,focusVisible:ae}),Ee=function(e){var t=e.disabled,n=e.focusVisible,r=e.focusVisibleClassName,a=e.classes,o={root:["root",t&&"disabled",n&&"focusVisible"]},i=(0,k.Z)(o,At,a);return n&&r&&(i.root+=" ".concat(r)),i}(Pe);return(0,p.jsxs)(Pt,(0,r.Z)({as:Ae,className:(0,S.Z)(Ee.root,c),ownerState:Pe,onBlur:_e,onClick:R,onContextMenu:fe,onFocus:we,onKeyDown:Ce,onKeyUp:ke,onMouseDown:pe,onMouseLeave:ve,onMouseUp:he,onDragLeave:me,onTouchEnd:be,onTouchMove:ge,onTouchStart:ye,ref:Re,tabIndex:h?-1:J,type:$},xe,H,{children:[u,ce?(0,p.jsx)(kt,(0,r.Z)({ref:K,center:l},U)):null]}))})),Ot=Et;function Nt(e){return(0,C.Z)("MuiIconButton",e)}var It=(0,ee.Z)("MuiIconButton",["root","disabled","colorInherit","colorPrimary","colorSecondary","edgeStart","edgeEnd","sizeSmall","sizeMedium","sizeLarge"]),Mt=["edge","children","className","color","disabled","disableFocusRipple","size"],zt=(0,M.ZP)(Ot,{name:"MuiIconButton",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,"default"!==n.color&&t["color".concat((0,I.Z)(n.color))],n.edge&&t["edge".concat((0,I.Z)(n.edge))],t["size".concat((0,I.Z)(n.size))]]}})((function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({textAlign:"center",flex:"0 0 auto",fontSize:t.typography.pxToRem(24),padding:8,borderRadius:"50%",overflow:"visible",color:(t.vars||t).palette.action.active,transition:t.transitions.create("background-color",{duration:t.transitions.duration.shortest})},!n.disableRipple&&{"&:hover":{backgroundColor:t.vars?"rgba(".concat(t.vars.palette.action.activeChannel," / ").concat(t.vars.palette.action.hoverOpacity,")"):(0,pe.Fq)(t.palette.action.active,t.palette.action.hoverOpacity),"@media (hover: none)":{backgroundColor:"transparent"}}},"start"===n.edge&&{marginLeft:"small"===n.size?-3:-12},"end"===n.edge&&{marginRight:"small"===n.size?-3:-12})}),(function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({},"inherit"===n.color&&{color:"inherit"},"inherit"!==n.color&&"default"!==n.color&&(0,r.Z)({color:(t.vars||t).palette[n.color].main},!n.disableRipple&&{"&:hover":{backgroundColor:t.vars?"rgba(".concat(t.vars.palette[n.color].mainChannel," / ").concat(t.vars.palette.action.hoverOpacity,")"):(0,pe.Fq)(t.palette[n.color].main,t.palette.action.hoverOpacity),"@media (hover: none)":{backgroundColor:"transparent"}}}),"small"===n.size&&{padding:5,fontSize:t.typography.pxToRem(18)},"large"===n.size&&{padding:12,fontSize:t.typography.pxToRem(28)},(0,_.Z)({},"&.".concat(It.disabled),{backgroundColor:"transparent",color:(t.vars||t).palette.action.disabled}))})),Dt=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiIconButton"}),o=n.edge,i=void 0!==o&&o,s=n.children,l=n.className,u=n.color,c=void 0===u?"default":u,d=n.disabled,f=void 0!==d&&d,m=n.disableFocusRipple,h=void 0!==m&&m,v=n.size,y=void 0===v?"medium":v,b=(0,w.Z)(n,Mt),g=(0,r.Z)({},n,{edge:i,color:c,disabled:f,disableFocusRipple:h,size:y}),_=function(e){var t=e.classes,n=e.disabled,r=e.color,a=e.edge,o=e.size,i={root:["root",n&&"disabled","default"!==r&&"color".concat((0,I.Z)(r)),a&&"edge".concat((0,I.Z)(a)),"size".concat((0,I.Z)(o))]};return(0,k.Z)(i,Nt,t)}(g);return(0,p.jsx)(zt,(0,r.Z)({className:(0,S.Z)(_.root,l),centerRipple:!0,focusRipple:!h,disabled:f,ref:t,ownerState:g},b,{children:s}))})),Lt=n(2156),Zt=n(5129);n(8472),(0,G.Z)({palette:{neutral:{main:"#fff",contrastText:"#000"}}});function jt(e){var t=e.datumNumber,n=e.setDatumNumber,r=e.numComparisons,a=(e.outputData,e.batchNum),o=function(){n(t-1)},i=function(){n(t+1)};return(0,p.jsx)(K,{sx:{flexGrow:1},children:(0,p.jsx)(Ve,{position:"static",children:(0,p.jsxs)(qe,{children:[(0,p.jsxs)(Ee,{component:"div",variant:"h6",sx:{flexGrow:1},children:["Compare Trial Versions for Batch ",a]}),(0,p.jsxs)(Ee,{component:"div",children:[t>0?(0,p.jsx)(Dt,{color:"inherit",variant:"text",onClick:o,children:(0,p.jsx)(Lt.Z,{})}):null,t<r-1?(0,p.jsx)(Dt,{color:"inherit",variant:"text",onClick:i,children:(0,p.jsx)(Zt.Z,{})}):null]})]})})})}for(var Bt=JSON.parse('{"1":"Add endpoint to composite endpoint","2":"Add endpoint","3":"Change endpoint","4":"Change endpoint, add endpoint","5":"Change in endpoint in a composite endpoint","6":"Change method of analysis","7":"Change number of events","8":"Change population","9":"Change readers","10":"Change timepoint","11":"Error","12":"From nothing to something","13":"Refine definition","14":"Remove endpoint","15":"Shuffle Endpoints","16":"Syntax","":""}'),Wt=[],Jt=Q.e,Ut=Q.C,Vt=Ut.length,$t=0;$t<Vt;$t++)Wt.push("");var Ht=function(){var t=(0,e.useState)(0),n=(0,g.Z)(t,2),r=n[0],a=n[1],o=(0,e.useState)(Ut[r]),i=(0,g.Z)(o,2),s=i[0],l=i[1],u=(0,e.useState)(Wt),c=(0,g.Z)(u,2),d=c[0],f=c[1],m=(0,e.useState)([]),h=(0,g.Z)(m,2),v=h[0],y=h[1];return(0,e.useEffect)((function(){l(Ut[r])}),[r]),(0,e.useEffect)((function(){for(var e=[],t=0;t<Vt;t++){var n={};n.nctid=Ut[t].nctid,n.version_a=Ut[t].version_a,n.version_b=Ut[t].version_b,n.classification_number=d[t],n.classification_meaning=Bt[d[t]],e.push(n)}y(e)}),[d]),(0,p.jsxs)(e.Fragment,{children:[(0,p.jsx)(jt,{datumNumber:r,setDatumNumber:a,numComparisons:Vt,outputData:v,batchNum:Jt}),(0,p.jsx)(D,{children:(0,p.jsx)(K,{sx:{flexGrow:1,m:1},children:(0,p.jsx)(je,{datum:s,datumNumber:r,results:d,setResults:f})})})]})};t.createRoot(document.getElementById("root")).render((0,p.jsxs)(e.StrictMode,{children:[(0,p.jsx)(b,{}),(0,p.jsx)(Ht,{})]}))}()}();
//# sourceMappingURL=main.3b845206.js.map